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8  |  CHAPTER 1 
INTRODUCTION 
The immune system protects the body against pathogens by recognizing dangerous 
invasive organisms and subsequently eliminating them. Different parts of the immune 
system cooperate to achieve this, including the innate immune system, which is able to 
recognize pathogens based on repetitive signals associated with danger, and the 
adaptive immune system, which is able to improve recognition over time and to 
memorize this recognition (1). Mast cells and basophils are immune cells mainly 
considered as part of the innate immune system, although recent evidence has 
suggested they might be at the basis of certain adaptive immune responses as well.  
MAST CELL DISCOVERY 
Mast cells were discovered more than a century ago, by Paul Erlich, who based his 
discoveries on immunohistochemical studies of “Mastzellen”, cells in connective 
tissue containing granules which stained with basic aniline dyes, and supposedly had 
a feeding or nutritional function. He used similar techniques to describe granulocytes 
in blood, and discovered basophils based on their staining with basophilic dyes. In 
the 1950’s, these granules were found to contain histamine, and thus, mast cells and 
basophils were hypothesized to participate in allergic reactions by releasing their 
granular contents (2).  
Mast cell granules contain several mediators besides histamine, including the enzymes 
tryptase and chymase, discovered in the 1980’s. In both human and mouse, these 
enzymes have a heterogeneous expression pattern, allowing for the identification of 
two main mast cell subsets in different tissues. In humans, mucosal mast cells express 
only tryptase (MCT), whereas skin and submucosal tissue mast cell granules contain 
both tryptase and chymase (MCTC).  
As mast cell granules contain several mediators that could cause wheal-and-flare 
reactions when administered locally or anaphylactic shock when administered 
systemically, mast cells were long considered in the context of these allergic reactions.  
However, the physiological role of mast cells was not clear, and it was questioned why 
these cells with potent detrimental effects to the host existed without obvious benefits 
in terms of physiological function. It was not until the last two decades, that our 
perception of mast cell and basophil function has been broadened to other immune 
responses as well, and now, these cell types are thought to play a role in various 
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MAST CELL MEDIATORS 
Besides releasing their granule content, mast cells can release several other mediators, 
including membrane-derived lipid mediators, and cytokines and chemokines which are 
produced de novo (Figure 1).  
 
Figure 1: Mediator release by mast cells. Upon activation, mast cells have the ability to degranulate within 
seconds, thereby releasing pre-formed molecules residing in their granules. Lipid mediators, derived from 
fatty acids in membranes through arachidonic acid, are synthesized through enzymatic reactions inside the 
cell and can be released within minutes after activation. De novo transcription and translation leads to 
secretion of cytokines and chemokines within hours after activation. 
GRANULE MEDIATORS 
Mast cell granules are structures within the cell which contain inflammatory mediators, 
which can be released rapidly (within seconds) upon activation of the cell. The granule 
structure serves mainly two functions: First of all, the granules contents contain very high 
concentrations of mediators allowing their rapid release into extracellular space. Second, 
these mediators are often destructive to the intracellular environment (such as proteolytic 
enzymes), and therefore need to be contained in a separate structure. They are initially 
produced as inactive precursor proteins (pre-pro-enzymes), after which they are processed 
through the ER-golgi pathway. Once they enter the granule, they are cleaved into the active 
protein. This is important, as it allows for immediate proteolytic activity in the affected 
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The granule-resident mediators can be divided into different functional groups. As 
mentioned, histamine is an important mast cell mediator associated with allergic 
symptoms. Four different histamine receptors exist, which each lead to different 
downstream effects, including increased vascular permeability and chemotaxis, each 
enhancing influx of immune cells into the affected tissue.  
Next, proteases such as tryptase, chymase (both serine proteases) and 
carboxypeptidase (zinc-containing metalloprotease) are the most abundantly 
expressed proteins in mast cells, constituting 25-50% of the total proteins (3, 4). 
Release of these proteases can lead to pro- and anti-inflammatory effects, depending 
on the extracellular substrates that are being cleaved. For, example, these proteases 
can cleave pro-inflammatory cytokines into active forms, or in contrast, degrade pro-
inflammatory cytokines or other molecules (5). Furthermore, they can degrade toxic 
substance, such as derived from snake and bee venoms or endogenous toxins released 
upon injury (see below).  
Proteoglycans are another major constituent of granules. These are mainly serglycin 
proteoglycans that contain heparin and/or chondroitin sulfate chains. They form 
complexes with mast cell proteases in the granules, which is essential for correct 
storage and release of these proteases (6). The heparin which is released upon 
degranulation also serves as anti-coagulant. 
A fourth type of mediator which has been suggested to be present in granules are 
cytokines, such as TNF-ɑ (7). However, it is not clearly established whether human 
mast cell granules also contain cytokines, in particular TNF-ɑ.  
LIPID-DERIVED MEDIATORS 
The second wave of mediators released by mast cells consists of eicosanoids, or 
arachidonic acid metabolites, which are released within minutes after activation. 
Arachidonic acid is released from membrane phospholipids by phospholipase A2, and 
subsequently converted to leukotrienes and prostaglandins by arachidonate 5-lipoxygenase 
(5-LO) and cyclooxygenases (COX) enzymes respectively. Leukotrienes induce 
bronchoconstriction, increased vascular permeability and neutrophil chemotaxis, and can 
induce anaphylactic shock when present in excess. Prostaglandins, and in particular PGD2 
released by mast cells, leads to recruitment of Th2 cells, eosinophils, and basophils, as well 
as vasodilation and bronchoconstriction.  
Together, these early mast cell-derived molecules induce an early inflammatory reaction, 
allowing other immune cells to enter the tissue. 
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CYTOKINES AND CHEMOKINES 
Upon activation, transcription factors induce de novo transcription and production of 
several molecules, including secretion of cytokines and chemokines. The production 
and release of these molecules takes several hours, and this response is therefore 
sometimes referred to as the late phase response, especially in the context of allergic 
inflammation. Although the release of pre-formed and lipid derived mediators leads to 
general inflammation, the release of cytokines and chemokines can lead to more 
versatile functions, as different mast cell triggers can induce the differential production 
of cytokines, probably through inducing different transcription factors.  
Mast cells can produce cytokines affecting many different cell types. For example, 
several cytokines are most known for their effects on stromal or parenchymal cells. 
Likewise, the effect of mast cell-derived IL-13 on non-immune cells can lead to parasite 
expulsion through increased mucous production, epithelial cell turnover, and 
contraction by intestinal muscle. Mast cell-derived cytokines can also affect various 
immune cells, both from innate and adaptive immune system, as discussed below. 
These include IL-3, which can activate T cells, IL-5, which can recruit and activate 
eosinophils, and GM-CSF, which can affect neutrophil and monocyte expansion and 
function.  
Chemokines produced by mast cells lead to recruitment of different cell types, with 
neutrophils and other granulocytes as main responder cell types being attracted to the 
site of injury by mast cell-derived chemokines, such as IL-5, IL-8, MIP1ɑ (CCL3), TNF-ɑ. 
However, these and other chemokines, such as CCL2/MCP-1, can also attract T cells, 
monocytes and natural killer cells. This suggests that the mast cell chemokine response 
can lead to potent influx of a variety of other immune cells. 
MAST CELL MEDIATORS AS IMMUNOSUPPRESSORS 
In contrast to the pro-inflammatory role that mast cells play during injury and 
infection, mast cell derived cytokines and granule-derived mediators can also induce 
regulatory responses. Examples of such cytokines are IL-10 and TGFβ. In particular 
mast cell-derived IL-10 has been shown to be involved in immune regulation (8-10). 
In addition, mast cell proteases can cleave proinflammatory cytokines, and thereby 
limit inflammation. Many cytokines can be cleaved by chymase (at least in the mouse), 
sometimes leading to inactivation of the cytokines and alarmins, such as IL -3, IL-6, SCF, 
HSP70 and IL-33 (5, 11-13). Therefore, the response of mast cells can modulate the 
immune system towards anti-inflammatory responses as well. 
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MAST CELL ACTIVATION 
The most well-known receptor for activation of mast cells and basophils is the high affinity 
receptor for IgE, FcεRI. Due to its high affinity, IgE from the circulation is constantly bound 
to the cell surface, and upon antigen recognition, this receptor is crosslinked causing the 
full-blown mast cell response characterized by degranulation and production of lipid 
derived mediators, cytokines and chemokines.  As the IgE is already bound to the receptor, 
minute amounts of antigen are needed for activation, and activation can occur within 
seconds after antigen recognition. Therefore, this is a very potent mast cell response.  
Several other pathways for mast cell activation have been described. These include Fcγ 
receptors, complement receptors and innate receptors, such as Toll like receptors. In 
addition, mast cells can be activated by various cytokines or growth factors, which often 
influence their proliferation as well.  
APPROACHES TO STUDY MAST CELL FUNCTION 
Human 
Mast cells are not present in blood, and are therefore a difficult cell type to obtain for 
functional studies. Several mast cell-lines exist, such as LAD-2 and HMC-1, however, each of 
these have several molecular abnormalities compared to tissue mast cells, including low 
expression of FcεRI, dysfunction of ckit (receptor for stem cell factor; SCF), and lack of 
granules. These features constitute a limitation of studies employing these cell lines. 
Therefore, most studies of mast cell function in the human rely on in vitro expansion of 
stem cells or tissue mast cells, such as using hematopoietic stem cells from peripheral or 
cord blood. Although some discrepancies have been described, these have been shown to 
closely resemble tissue mast cells in most characteristics, such as granule constituents, 
expression of FcεRI and degranulation. 
In vivo approaches in humans include immunohistochemistry or measurement of mast cell 
specific mediators in serum or other body fluids. Although useful, these studies can merely 
be used for descriptive studies. Due to the low frequency of mast cells in most tissues, 
characterization of tissue mast cells in humans is still difficult, but new technologies, such 
as next generation sequencing, are likely to give us more insight into the exact function of 
mast cells in different tissues.  
Mouse 
In the mouse, several in vivo models for mast cell function are being used. The most 





which display profound mast cell-deficiency. However, the mutation in kit in these mice 
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affects some other cell types as well. This includes neutropenia observed in kit
W/Wv
 
mice and neutrophilia in kit
Wsh/sh
 mice (14, 15). Therefore, mast cell reconstitution 
using mast cells derived from bone marrow of wildtype mice is usually required to 
confirm that the phenotype is mast cell-specific.  
In the last years, several novel mouse strains have been developed which target mast 
cell molecules, including carboxypeptidase A3 (cpa3), and mast cell proteases (such as 
Mcpt5) (16-19). Several findings using kit mutant mice with knockin mast cells, have 
been recently challenged using the more specific mast cell deficient mice (15, 17, 20). 
Therefore, these new mast cell deficient mouse models might change the paradigms 
on the contribution of mast cells to various immune responses.  
Differences between mouse and human mast cells 
It is important to note that mouse mast cells and human mast cells differ considerably. 
Their constitution of granules is different, as in humans there is only one chymase 
gene, whereas in mice, several different chymases can be expressed at the same time 
(21). Their origin and development also differs considerable: in humans the 
proliferation and differentiation is thought to mainly depend on SCF, whereas in mice, 
IL-3 alone can induce differentiation and proliferation of mast cells from stem cells 
(22). Also, the expression of activating receptors such as TLR and FcγR might differ 
between these species.  
Importantly, several cytokines which have been shown to be crucial for certain mast 
cell functions in the mouse (TNF-ɑ and IL-4) were not found in human mast cells (22, 
23). So, although mouse studies are very important to obtain understanding of mast 
cell function in vivo, caution needs to be applied for extrapolation of these results to 
human conditions. As it is difficult and expensive to obtain functional human mast 
cells, there is a lack of translation of the findings in mice to human disease, and this is 
therefore an important area of research.  
PHYSIOLOGICAL FUNCTIONS OF MAST CELLS 
The presence and homology of mast cells between different species suggests that they 
are essential to our survival. In support of this notion, mast cell -deficient persons have 
not been identified. Mast cells are located in strategic locations where they can 
encounter pathogens upon entry of the body. The following paragraphs describe the 
protective immune responses in which mast cells play an important role.  
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THE ROLE OF MAST CELLS IN INNATE IMMUNE RESPONSES 
Venoms 
A physiological role for mast cell degranulation has recently emerged, hypothesizing that 
such an immune response has evolved as a protective mechanism against venoms which 
need to be eradicated in a quick manner.  Besides direct toxicity of venom contents, 
venoms can induce toxic endogenous (neuro-) peptides, such as endothelin-1, neurotensin 
and vasoactive intestinal polypeptide (VIP) (24-26). Granule-derived mast cell enzymes 
have been shown to detoxify or degrade several venom-derived toxins as well as 
endogenous peptides produced in response to venoms (26-28), giving protection to the 
host (Figure 2).  
Venom-induced mast cell degranulation is usually triggered by innate recognition, but their 
receptors are not known. Nonetheless, as venoms resemble neuropeptides, they might act 
on mast cells through similar G protein coupled receptors. Besides activation of mast cells 
via innate receptors, a recent study has demonstrated that IgE memory can also contribute 
to venom-induced mast cell activation (29). In this mouse model, IgE was produced after 
sensitization with bee venom, which later mediated resistance to a lethal dose of the same 
venom in a mast cell-dependent manner.  
These mast cell responses to venoms are a good example on how immune responses need 
to be tightly balanced. As described above, both innate and IgE-mediated responses can 
contribute to protection against these dangerous venoms through release of mast cell 
proteases. However, uncontrolled mast cell degranulation in allergic individuals can lead to 
anaphylaxis such as during severe reactions to bee and wasp stings in sensitized individuals.  
Parasites 
Another type of innate immune response in which mast cells have been shown to play a 
role is the protection against various parasites, in particular intestinal helminths. These are 
multicellular pathogens, and can therefore not be controlled or eliminated by traditional 
immune responses such as phagocytosis or cytotoxicity. Helminth parasites are well-known 
for their induction of Th2 immune responses (30), but they also have several immune 
evasion strategies, including upregulation of Tregs and anti-inflammatory cytokines such as 
IL-10 (31, 32).  
Parasites trigger TLRs and other pattern recognition receptors, generally leading to Th2 
responses (33-37). Due to their Th2-skewing properties, parasitic infection often promote 
production of both total and parasite-specific IgE.(38-40) In addition, the helminth parasite 
Schistosoma mansoni has been shown to directly crosslink non-specific IgE/FcεRI in an 
antigen-independent manner (41). The contribution of IgE antibodies or FcεRI to protective 
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immunity is not completely clear, and seems to depend on the type of parasites and the 
site of infection (42-44). 
Mast cells are also thought to contribute to immunity during primary helminth infections in 
mice (45, 46). The mast cell effector molecules during protective responses against 
parasites are IL-4, IL-13, TNF-ɑ, histamine and mast cell proteases, such as mouse MCP-1, -
2 and -6 (Figure 2) (47-50). These cytokines play different roles; IL-13 specifically has been 
suggested to induce goblet cell hyperplasia, causing increased mucus production, leading to 
trapping of parasites in the mucus as well as enhancing expulsion of the parasites (51). 
Mast cell proteases can enhance intestinal permeability, thereby directly contributing to 
parasite expulsion (46, 52). The other cytokines and proteases are mainly thought to 
contribute to intestinal inflammation, for example through recruitment of eosinophils (49). 
Although most of these cytokines are also produced by Th2 cells, IL-4 and IL-13 derived 
from innate cells was shown to be most important for worm clearance during infection 
with N Brasiliensis (51). 
Recent data suggest a non-redundant role for basophils in the context of secondary 
parasite infection. Basophils were shown to be important in the secondary immune 
response against diverse intestinal helminthes (N. brasiliensis, H. polygyrus, T. muris) and 
ticks, probably by activation through parasite-specific IgE (44, 53, 54). 
Together, these observations suggests that whereas mast cells are potent effector cells to 
prevent parasites from entering the body in a primary infection, basophils may be more 
potent during IgE-dependent secondary responses against parasites. 
Bacteria 
The first study to show an important role for mast cells in protection against bacteria 
originated in 1996, when mast cell-derived TNF-ɑ was shown to confer protection against 
E. Coli (55). Several studies have since then shown a protective role of mast cells against 
various bacteria, including K. pneumoniae, M. pneumoniae, and C difficile (56-59).  In most 
of these models, the crucial mechanism of mast cell-mediated protection is recruitment of 
immune effector cells, mainly neutrophils (Figure 2). Due to their ability to rapidly 
degranulate, mast cells are thought to be the first cell to initiate an inflammatory response 
upon bacterial invasion of a tissue. Such an acute response is characterized by increased 
vascular permeability mediated by histamine and proteases, and recruitment of effector 
cells by release of lipid-derived mediators (LTB4) and cytokines or chemokines present in 
granules (TNF) (7, 60). This early response is important, as mast cell-deficient mice have a 
wider spread of bacterial infection, suggesting that mast cells can contain infections to a 
local tissue, such as lung or skin (55, 56, 61). 
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In addition to their role in acute infection, mast cell may initiate adaptive immune 
responses to bacteria as well. Mast cell derived TNF was shown to regulate recruitment of T 
cells to draining lymph nodes during intradermal infection with E. Coli (62). Furthermore, 
DCs were recruited to the infected tissue by mast cells, followed by their migration to 
draining lymph nodes (63, 64). Therefore, mast cells may orchestrate T cell activation 
during bacterial infection by regulating the migration and activation of both T cells and 
antigen presenting cells. 
Different receptors have been shown to contribute to mast cell activation during bacterial 
infections, including complement receptors (CR1, CR2) and TLR4 (65-67). In addition, 
bacterial toxins may directly activate mast cells through yet unknown receptors (68). The 
exact receptors inducing mast cell degranulation upon bacterial infection are not known, 
but can consist of a variety of bacterial products and endogenous ligands released upon 
invasion of the body. 
Mast cells are not crucial for protection against all bacteria strains. However, a recent study 
suggested that this may originate from evasion strategies employed by bacteria to prevent 
mast cell activation. At least two bacterial strains, Salmonella Typhimurium and Yersinia 
Pestis, were capable of such mast cell inhibition (69).  
These studies show that mast cell play a non-redundant role in protection against a variety 
of bacteria, although some bacteria have developed immune evasion strategies. 
Other pathogens 
Although fewer studies have been performed evaluating the role of mast cells to viruses 
and fungi, some studies suggest they can also contribute to protective immunity against 
these pathogens. For example, mast cells were shown to induce migration and activation of 
CD8
+
 T cells and NK cells in the context of viral infections (70-75). 
Not much is known about the role of mast cells in fungal infections, but the overlapping 
mechanisms in protection against bacteria, parasites and fungi (such as TLR recognition), 
suggest that mast cells potentially play a role against fungi as well (76). 
THE ROLE OF MAST CELLS IN TISSUE HOMEOSTASIS 
Mast cells are usually associated with acute responses due to their potent degranulation 
mechanism; however, they may be an important effector cell in the context of tissue 
homeostasis. Several findings implicate a role for mast cells in tissue remodeling. Mast cell 
numbers are often associated with tissue remodeling processes, such as during scarring 
and fibrosis and pathologic conditions such as bullous pemphigus and scleroderma (77-79). 
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Figure 2: The role of mast cells in protective immunity. Mast cells have been shown to contribute to 
protection against a variety of pathogens. During parasitic infection, mast cell-derived proteases can lead to 
intestinal permeability. Cytokines contribute to recruitment of eosinophils and other granulocytes to the 
site of parasitic infection, and IL-13 specifically can induce the production of mucous; together these 
processes contribute to expulsion of intestinal parasites. Upon exposure to venoms or toxins, mast cell-
derived proteases can degrade or detoxify these molecules, thereby protecting the host. Upon bacterial 
infection, tissue-resident mast cells are one of the first cell types to respond by releasing proteases, lipid 
mediators and chemokines. These mast cell-derived molecules increase vascular permeability and 
recruitment of immune effector cells, including neutrophils. 
In addition, mast cells can produce a variety of mediators involved in tissue remodeling, 
including proteases which can activate several matrix metalloproteinases (MMPs), 
thereby contributing to breakdown of extracellular matrix proteins (80, 81). Mast cells 
can activate fibroblasts through various growth factors and cytokines and induce TGF β-
dependent collagen production by fibroblasts through a variety of mechanisms (82-85). 
These studies indicate that mast cells can contribute to extracellular matrix turnover by 
both production and breakdown of extracellular matrix constituents.  
Mast cells were also thought to contribute to wound healing and fibrosis in the skin. 
Mast cells accumulate at the site of skin injury, and some studies using kit-mutant mice 
showed a functional role for mast cells in fibrosis (78, 86). However, some studies using 
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in wound healing and fibrosis in the skin (87), indicating that more research is needed to 
understand the role of mast cells in tissue remodeling (87-90). Furthermore, most studies 
have only addressed the role of mast cells during acute wound healing responses, 
whereas tissue remodeling during chronic inflammatory responses has only been 
sparsely studied.  As mast cell-mediated tissue remodeling could be detrimental in the 
context of chronic inflammation, this is an important area of research. 
THE ROLE OF MAST CELLS IN PATHOGENIC PROCESSES 
Although the physiological role of mast cells and basophils is being more acknowledged 
in recent years, and as it is now generally accepted that these cells play important roles 
in the first line of defense against a number of pathogens, the route that mediates the 
recognition of pathogens, is not firmly established.  For example, there is a lack of 
knowledge concerning expression of Toll-like receptors and the specific response that is 
generated by ligands for these receptors, especially in human mast cells and basophi ls. 
Activation through such receptors is important, not only for their role in protective 
immunity, but also during pathogenic processes, as described below. 
MAST CELLS IN ALLERGIC REACTIONS 
Mast cells are classically associated with allergic responses, in particular type I 
hypersensitivity responses, related to IgE. Allergic reactions consist of two phases, the 
early and late reaction, of which the exact symptoms depend on the location where the 
body comes in contact with the allergen.  The early reaction in the lungs is characterized 
by bronchoconstriction, edema and mucus production, whereas in the skin it leads to 
redness, edema and itching. The late phase reaction in all tissues is associated with influx 
of eosinophils, other granulocytes and lymphocytes. Basophils and mast cells are the 
main cell types expressing FcεRI, but because mast cells are already present in tissues 
where allergens are first encountered, and basophils need to be recruited from the 
blood, mast cells are usually considered as the main cell type in the early phase reaction. 
Their mediators histamine, proteases, leukotrienes and prostaglandins can directly 
induce the early allergic symptoms (Figure 3) (91). Through their release of cytokines, 
such as IL-5 and IL-13, mast cells can also contribute to the late phase reaction, in 
particular by recruiting and activating eosinophils (through IL-5), and inducing mucus 
production (through IL-13) (92-95). 
Besides the early and late responses to allergen exposure in sensitized individuals, allergy 
often leads to chronic inflammation, associated with tissue remodeling. The most well -
known example is chronic atopic asthma, which is thought to be driven at least partially 
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by repeated FcεRI triggering. During chronic asthma, several tissue remodeling processes 
occur, including fibrosis, matrix deposition, vascular remodeling and mucus secretion. 
Mast cells are thought to contribute to these processes through their release of 
proteases (tryptase, chymase), angiogenic factors (VEGF, IL-8), and cytokines (IL-13). 
However, the role of mast cells in such chronic IgE-mediated responses is not clearly 
understood (96).  
 
Figure 3: Role of mast cells in allergy. Once specific IgE recognizing allergens (red Y) has been formed, and 
mast cells have been sensitized, re-exposure to the allergen leads to activation of mast cells, characterized 
by degranulation, release of lipid mediators and production of cytokines, including type 2 cytokines, IL-5 
and IL-13. Degranulation of mast cells during acute allergic reactions in the lung can lead to 
bronchoconstriction and increased vascular permeability. Production of leukotrienes and chemokines then 
leads to recruitment of granulocytes and T cells, which further increase allergic symptoms. During the late 
phase reaction, IL-13 and other mast cell products can increase mucous production and 
bronchoconstriction in the lung, thereby contributing to further narrowing of the bronchial tubes.  
MAST CELLS IN AUTOIMMUNE DISEASE 
Mast cells have been correlated to several autoimmune diseases, including T cell -
dependent type IV hypersensitivity, and antibody-dependent type II and type III 
hypersensitivities (97). However, in most cases, this association is mainly correlative, 
depending on the findings of increased mast cell numbers or evidence of mast cell 
activation in the affected tissues in human disease. For example, increased mast cell 
numbers and levels of their mediators have been found in the synovium of rheumatoid 
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sclerosis patients, salivary glands of Sjögren’s syndrome, as well as the skin of 
scleroderma patients (98-102).  
Although this provides some suggestion for mast cell involvement, mast cell activation in 
these tissues is sometimes regarded as merely a consequence of tissue inflammation, 
rather than playing an important role in the pathogenesis of autoimmune disease. The 
functional contribution of mast cells to autoimmune disease is difficult to verify in 
humans, as currently, no specific mast cell inhibitors are available for clinical studies. 
Therefore, such studies rely on the use of animal models, which in most autoimmune 
diseases do not fully reflect human disease, but rather, just one component of the 
disease (103). For example, immunization models for arthritis are used to study the 
initiation of autoreactive T- and B-cell responses, whereas serum transfer models are 
used to study the effect of autoantibodies and chronic inflammation in arthritis. Next to 
variable models to study disease, there are now several models for mast cell deficiency, 
together resulting in seemingly contradictory results on the role pathogenic role of mast 
cells in autoimmune disease.  
The role of mast cells in T cell-dependent autoimmunity has only been studied sparsely. A 
recent study on collagen induced arthritis showed that mast cell deficient mice display 
reduced arthritis severity and reduced numbers of collagen-specific Th1 and Th17 cells. 
Furthermore, mast cell numbers in draining lymph nodes were markedly increased upon 
immunization in wildtype mice, suggesting a direct role for mast cells in activation of 
autoreactive T cells (104). In contrast, mast cell deficiency in the diabetic NOD mouse, 




 T cells had no effect on disease pathogenesis (105). 
However, it is unclear to which extent the NOD mouse model reflects the autoreactive T 
cell response that occurs in type 1 diabetes patients (106).  
In experimental autoimmune encephalitis, contrasting results have been obtained; 
whereas mast cells have been shown to contribute to autoreactive CD8
+
 T cell responses, 
disease severity and recruitment of T cells to the CNS, another study reported no effect 
of mast cell deficiency on disease severity in the EAE model (17, 107-109). As described 
above, mast cells can contribute to T cell responses in various ways, including T cell 
activation and recruitment to lymph nodes, so it is conceivable that mast cells indeed 
play a role in these responses. More research into the function of human mast cells in 
the priming and activation of T cells is needed to get a better understanding of their 
capacity to contribute to T cell-dependent autoimmunity.  
Autoantibodies 
A major effector function thought to contribute to pathogenesis of autoimmune 
diseases is mediated by autoantibodies. An important group of autoantibodies in 
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rheumatoid arthritis targets citrullinated proteins (anti-citrullinated protein antibodies; 
ACPA). These antibodies recognize a variety of proteins or peptides in which the am ino 
acid arginine is modified into citrulline through a posttranslational modification 
process mediated by Peptidyl Arginine Deiminase (PAD) enzymes. PAD enzymes are 
normally present inside cells and can be activated by high calcium levels when cells, 
such as neutrophils, undergo apoptosis, an event readily occurring during inflammation  
(110). PAD enzymes that are transported to the outside of cells can citru llinate 
extracellular proteins, although intracellular citrullinated proteins can also be released 
into extracellular space (111). 
ACPA show a very high specificity for rheumatoid arthritis, and are present in the 
majority (~70%) of rheumatoid arthritis patients (112, 113). When ACPA antibodies are 
adoptively transferred into mice with a low-level synovial inflammation caused by anti-
collagen antibodies, ACPA (reactive with citrullinated fibrinogen or collagen II) could 
enhance arthritis, implicating their direct involvement in the inflammatory process  
(114, 115). 
There is not much evidence for a role of mast cells in the initiation of autoantibody 
production. In most immunization models, mast cell-deficient mice have similar levels 
of autoantibodies (104). However, mast cells express a variety of Fc receptors and 
complement receptors, making them an important effector cell type in the propagation 
of autoantibody-mediated inflammation. In mice, C5aR and Fcγ receptors on mast cells 
have been shown to play an important role in antibody-mediated arthritis and bullous 
pemphigoid (116-119). In these models, mast cells were shown to play an important 
role in recruitment of leukocytes, in particular of neutrophils. This is in line with their 
function observed in the Arthus reaction, where passive transfer of IgG antibodies and 
antigen lead to a mast cell-dependent neutrophil infiltration of the affected tissue 
(120-122). In contrast, some studies did not observe any effect of mast cell deficiency 
on autoantibody-mediated tissue inflammation (17, 104, 123). 
Importantly, the expression of Fcγ receptors differs considerably between mouse and 
human mast cells (124-127), and, as a consequence, not much is known about the 
capacity of human mast cells to respond to immune complexes, especially in the 
context of autoimmune disease. Studies on the role of human mast cells in antibody -
mediated inflammation may therefore provide more insight into the potential role of 
mast cells in autoimmune disease. As activation of immune cells through Fcγ receptors 
is an important effector mechanism of autoantibodies in autoimmune disease, it will be 
important to understand the capacity of mast cells to respond to Fcγ triggering. In the 
mouse, activation of mast cells through Fcγ receptors is known to lead to neutrophil 
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recruitment, however, not much is known about the role of Fcγ receptor activation of 
mast cells in autoimmune disease in humans. 
 
Figure 4: Potential role of mast cells in autoimmune disease. Mast cells have been implicated in T cell 
responses, therefore they could contribute to T cell-mediated autoimmune disease. Although not much is 
known about the interaction between mast cells and CD4+ T cells in the human, there are suggestions that 
mast cells can function as antigen presenting cells, providing the 3 signals crucial for T cell activation: 1) 
Antigen presentation through HLA class II; 2) Co-stimulation, such as through CD28 or other molecules; 3) 
Skewing of T helper responses through production of cytokines.  
CHRONIC INFLAMMATION 
Repeated or continuous activation of the immune system can occur in a variety of 
conditions, including allergy and autoimmunity. In the case of allergy, after sensitization has 
occurred, repeated exposure to allergens, such as during yearly pollen season, can quickly 
induce reactivation of memory T cells and activation of innate immune cells through 
allergen-specific IgE. In the case of autoimmunity, release of self-antigens can lead to a 
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sustained activation of autoreactive T and B cells, as well as innate immune cells through 
antibody effector mechanisms. When the self-antigen or allergen cannot be eliminated, 
such responses can become chronic. Furthermore, the immune system contains 
amplification mechanisms to enhance inflammatory responses, and epitope spreading can 
contribute to further loss of tolerance in autoimmunity and allergy (128-132). 
Not much is known about what exactly drives the incessant cycle of inflammation during 
these diseases, but it is likely that a proinflammatory cytokine environment, TLR ligands, 
antibodies and cellular effector mechanisms all cooperate to maintain chronicity. The 
danger model, as proposed by Matzinger, hypothesizes that self-antigen in itself is not 
enough to trigger autoimmunity, but that it needs to be accompanied by danger signals, 
such as occurring through tissue damage (133). In this context, it is interesting that most 
autoantibodies involved in chronic autoimmune disease have specificities for damage 
associated molecular patterns (DAMPs) (which I discuss in Chapter 12). This indicates that 
in autoimmune disease recognition of non-self through adaptive signals (e.g. antibodies) 
and innate danger signals often coincide, as they can be present even in the same molecule 
(134). In allergy, the danger signals can originate from infection (e.g. during asthma 
exacerbations) or tissue damage (during tissue remodeling in chronic allergy), although 
some allergens may also directly activate TLRs similar to self-antigens in autoimmune 
disease (135). Together, recognition of non-self in combination with danger signals can lead 
to a sustained response when tissue damage leads to additional release of DAMPs 
recognized by autoantibodies and TLRs (136).  
The contribution of mast cells in the induction of tissue damage has not been widely 
studied. Although mast cells are not immediately viewed as a main cell type exhibiting 
cellular cytotoxicity, one study showed that mast cells can kill opsonized parasites, 
through release of tryptase (137). In addition, some studies have shown that mast cells 
exhibit cellular cytotoxicity, presumably through releasing their granule constituents 
such as TNF-ɑ, granzyme B and possibly active caspase-3 (138-142). In addition, mast 
cell granule enzymes granzyme B, tryptase and chymase have been shown to degrade 
extracellular matrix proteins directly as well as indirectly through activating MMPs (81, 
143, 144). Together, these processes may contribute to tissue and cellular damage, 
thereby inducing additional release of DAMPs and self-antigens which can be 
recognized by autoantibodies.  
Furthermore, mast cells may directly release DAMPs upon cell death, for exam ple 
through the formation of extracellular traps, or through necrosis  (145-148). Besides 
direct effects of mast cells on tissue damage, their role in recruitment of neutrophils, 
activation of T cells and other immune cells can also contribute to inflammatory 
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responses, local cell death and release of DAMPs and self-antigens, thereby potentially 
contributing to the continuous amplification of local inflammatory responses.  
However, not much is known about mast cell activation pathways in chronic inflammation, 
including their activation through TLRs, Fcγ receptors, as well as their intrinsic capacities to 
respond to these triggers in the context of continuous or repeated activation. 
THIS THESIS 
Although the studies mentioned above reveal a pivotal role for mast cells in a variety of 
immune responses, their role in autoimmunity has been studied sparsely. The objective of 
this PhD thesis is to understand mast cell (and basophil) functions and their role in 
autoimmune disease by focusing on three main aims: 
1. To characterize the interaction between innate and Fc receptor triggers on mast 
cell and basophil function 
2. To analyze the interaction between mast cells and CD4
+
 T cells 
3. To understand the function of mast cells in chronic inflammation 
INNATE SIGNALS AND FC RECEPTOR TRIGGERING 
First, it is important to characterize the specific pathways leading to mast cell 
activation, especially those pathways that operate in autoimmune diseases. The 
functional responses of human mast cells to triggering of Fcγ receptors, Toll -like 
receptors, or cytokines, have only sparsely been scrutinized. Furthermore, it is 
unknown how different activation pathways cooperate in the context of antibody -
mediated responses. Such interactions are relevant for a variety of immune responses, 
including protective responses against pathogens, allergic reactions, as well as 
autoimmunity. Therefore, the first part of this thesis focuses on the interaction of 
these pathways. In Chapter 2 and 3, the activation of human basophils by TLRs and IL-
33 was studied, in particular in combination with FcεRI-mediated activation. 
Furthermore, in these chapters, the effects of basophil activation on T helper cell 
skewing as well as monocyte activation are described. As basophils have recently 
emerged as important immunomodulatory cells, these studies will provide insight into 
their function, in particular in the context of IgE-mediated responses. 
In Chapter 4-6, we describe the studies into the effect of the combined activation by 
innate signals (TLR, IL-33) and Fc receptor triggering in mast cells. In Chapter 4, the 
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cytokine profile of mast cells upon different TLR ligands in combination with FcεRI 
triggering is described, providing insight into the specific TLR ligands that could 
contribute to mast cell responses in allergy. In Chapter 5, I evaluated the activation of 
mast cells by anti-citrullinated protein antibodies, DAMPs and other TLR ligands. This 
study therefore aimed to gain understanding of activation pathways that contribute to 
synovial inflammatory responses in RA patients. In Chapter 6, we aimed to evaluate the 
role of IL-33 on mast cell activation, and the subsequent mast cell-monocyte 
interaction.  
MAST CELL-T CELL INTERACTIONS 
As mast cells are present at strategic locations of the environment/host interface 
where they can encounter pathogens, they have been implicated in the regulation of 
adaptive immune responses and the regulation of T cell immunity.  
Besides their role in recruiting T cells to lymph nodes during bacterial infection, mast 
cells themselves were shown to be capable of migrating from the skin to the draining 
lymph nodes in murine models of contact hypersensitivity  and UV radiation (149, 150), 
suggesting they may directly be involved in antigen presentation. Thus far, little 
information is available on the antigen-presenting capacity of human mast cells. 
Therefore, in Chapter 7 and 8 we studied whether mast cells possess the required 
molecular make-up, such as HLA-DR and costimulatory molecules, to activate T-cells 
through antigen presentation and co-stimulation.  
As mast cells produce a variety of cytokines which can act on T cells, they have also 
been implicated in skewing of specific T cell responses. The effect of human mast cells 
on skewing of T helper cell responses and the effect of different modes of mast cell 
activation has not been elucidated. In Chapter 9 we therefore evaluated the effect of 
mast cells on Th cell responses. 
CHRONIC INFLAMMATION 
Finally, although mast cells are very potent cells in the context of acute inflammatory 
responses, only little is known about their function in the context of chronic 
inflammation. First of all, they are very long-lived (estimated >10 months in rats with 
a lifespan of 30-36 months) and therefore, can be influenced by inflammatory stimuli 
that are present during that time (50, 151). Further, as they enter a tissue as 
immature cell, their maturation depends on growth factors and cytokines in the 
tissue, allowing mast cell plasticity under the influence of local inflammatory 
conditions (152, 153).  
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However, as mast cells are usually considered in acute responses, not much is known 
about mast cell function under the influence of prolonged inflammatory stimulation or 
chronic infections. Therefore, the studies described in Chapter 10 were aimed at 
understanding mast cell function upon chronic Fc receptor triggering, providing 
detailed insight into changes in the mast cell transcriptome related to chronic allergy. 
Chapters 11 provides an overview of the role of mast cells in rheumatic disease, and 
Chapter 12 and 13 describe how autoantibodies are initiated and how chronic 
inflammation is propagated in autoimmune disease, also providing a perspective on 
novel therapeutic targets for the treatment of these diseases.  
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ABSTRACT 
Basophils are mostly known for their involvement in allergic reactions. Recent studies in 
mice indicate a role for basophils in the induction of adaptive immunity, especially T helper 
2 (Th2) responses. Therefore, it would be highly important to understand how basophils 
respond to pathogen-associated molecules, such as ligands for Toll-Like Receptors (TLRs), 
and if the basophils could promote Th2 responses via these stimuli. To this end, the 
activation of basophils via TLRs in combination with activation via IgE was studied, as well 
as its effect on T helper cell skewing.  
Using quantitative PCR, we demonstrated the presence of mRNA for TLRs 1–8 in human 
basophils. Basophils responded to TLR triggering with differential cytokine production, but 
not with degranulation. Simultaneous triggering of TLRs and IgE led to synergy in 
production of IL-4, IL-8, IL-13, and RANTES. Furthermore, the synergistic effects on 
basophils mediated by IgE and TLR-4 triggering allowed robust Th2 skewing upon activation 
of naïve human CD4
+
 T cells.  
Our data show that human basophils respond to TLR ligands in synergy with IgE-mediated 
activation and that the cytokines produced can promote Th2 differentiation. These results 
indicate a role for basophils in the regulation of T -cell responses in humans.  
INTRODUCTION 
Basophils are circulating granulocytes that can migrate to tissues when inflammation or 
other triggers are present locally. Activation of basophils through crosslinking of FcεRI via 
antigen-specific IgE causes the release of granule contents (histamine, proteoglycans), lipid-
derived mediators (leukotrienes), and cytokines. Due to their potent activation via IgE-
bound antigens and their production of T helper 2 (Th2) type cytokines such as IL-4 and IL-
13, basophils are often considered important innate effector cells in IgE-mediated immune 
responses. Besides activation through IgE, several other pathways have been described to 
activate basophils, including activation through complement receptors and Toll-Like 
Receptors (TLR). Although information about TLR protein expression and the response of 
basophils to TLR ligands is scarce, human basophils express mRNA of several TLRs, and 
protein of TLR-2 and -4. However, the functional response of basophils to ligation of most 
TLRs is unknown (1-4). 
Basophil responses to TLR ligands may be important, as it is not understood how pathogens 
and allergens may lead to induction of Th2 responses. As TLR ligation of dendritic cells most 
often induces type 1 responses through production of IL-12, it is not understood whether 
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and how Th2 cells can be induced via TLR. IL-4 production is known to be an important 
factor for induction of Th2 responses (5), and therefore, the notion has arisen that Th2 
induction would be driven by the combination of DCs that present antigen in the context of 
MHC class II and accessory cells that provide an early source of IL-4 in the LN (6). Additional 
cytokines able to enhance Th2 responses have been identified, including IL-25, IL-33, and 
thymic stromal lymphopoietin, which may either act directly on the T cells or change the 
maturation of APCs to drive Th2 responses (7).  
Since basophils are a known early source of IL-4 and other cytokines associated with Th2 
responses, they have been proposed to play a prominent role in the induction of such 
responses (8). In mice, it was suggested that basophils play a crucial role in responses 
against Th2-associated helminth parasites and in protease allergens (9-11). Basophils were 
proposed to function as APCs in these studies and were also shown to be present in LNs in 
models of allergy and helminth infection (12-14). However, the function of basophils as 
APCs during the priming phase of Th2 responses in mice has been challenged by others (13, 
15, 16), and human basophils could not present antigens to CD4
+
 T cells (11, 17, 18). 
Therefore, it seems unlikely that human basophils function as APCs. However, by providing 
an early IL-4 signal that facilitates Th2 skewing after T-cell activation by APCs, basophils 
could play an important role in skewing of Th2 responses as accessory cells. Indeed, in a 
mouse model for papain-induced Th2 responses, both DCs and basophils were important 
for Th2 skewing (19). 
Since several allergens and helminth parasites can activate TLRs (20-22), it would be of high 
importance to know whether human basophils can be activated via TLR triggering, and if so, 
which cytokines are released. Until now, little information on these aspects is available for 
human basophils. Furthermore, as allergic responses and helminth infections may induce 
IgE responses (23), it would be important to know whether these pathways would interact 
and promote the establishment of a Th2 cytokine milieu. Therefore, in this study, we aimed 
to understand the activation of basophils by TLR ligands, and to subsequently determine 
whether this activation could influence Th2 responses. 
RESULTS 
EXPRESSION OF TLR 
To determine the expression of TLR1 to TLR10 and other molecules involved in TLR 
signaling pathways, a real-time PCR array was performed on mRNA of basophils isolated 
from peripheral blood of three different donors. Isolated basophils were defined by 
expression of CD123, FcεRI and CD203c (Fig. 1A). mRNA encoding TLR1 to TLR8 was found 
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in the basophil populations from all three donors (Fig. 1B). TLR9 and TLR10 mRNA were 
only detected in one of the three donors, but were readily detected in PBMCs and the 
monocytic cell-line THP-1 (data not shown). 
 
 
Figure 1. Expression of TLRs by human basophils. (A) Basophils were isolated from peripheral blood 
leukocytes by negative magnetic isolation. Representative examples of leukocytes before isolation of 
basophils and the isolated basophil population are shown on the top and bottom, respectively, as analyzed 
by flow cytometric staining for either CD123 or CD203c with FcεRI. The plots show cells from a live gate 
based on FSC/SSC characteristics. (B) Total mRNA was isolated from peripheral blood basophils of three 
different donors. Relative mRNA expression of TLRs (left) and molecules involved in TLR signaling (right), 
normalized to HPRT1 expression as housekeeping gene, is shown. Data are shown as the mean +SEM 
pooled from three independent basophil donors. The dotted line indicates the detection limit of the PCR 
assay. #: mRNA for TLR-9 and -10 was only detected in one out of three donors. (C) Flow cytometric staining 
of PBMCs for TLR-2 (top) and TLR-4 (bottom). Basophils were gated as shown in (A) and monocytes were 
gated based on FSC/SSC characteristics. A representative example from three experiments with n = 5 
independent donors is shown. 
Basophils also expressed mRNA for several molecules associated with TLR signaling, such as 
MyD88, TICAM1 (TRIF), TICAM2, and BTK and MD-2. Expression of TLRs by basophils was 
confirmed on the protein level by flow cytometric staining for TLR-2 and TLR-4 (Fig. 1C). 
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Expression of TLR-4 by basophils was slightly less than monocytes, but was clearly higher 
than the isotype control, and higher than other cells in the total PBMC population, 
confirming the specificity of the staining. These data indicate that human basophils can 




Figure 2. Cytokine production by human basophils in response to TLR ligands. (A) Isolated 
basophils were stimulated with TLR ligands for 24 h, after which cytokines were measured in 
supernatant by Luminex assay. Stimulation index was calculated by dividing the amount of 
cytokine produced after stimulation by the amount of cytokine in the supernatant of 
unstimulated basophils. Results are shown as a summary of ten experiments performed with 
basophils from ten different donors. The boxplots show the mean (line), 25 –75 percentile (box) 
and minimum-maximum (whiskers). *p < 0.05, increase in stimulation index (above 1), one-
sample t-test. (B) Intracellular flow cytometry staining for IL -8 and matching isotype control after 
overnight stimulation of isolated basophils with anti -IgE and LPS in the presence of brefeldin A. 
Basophils were gated as FcεRI+CD203c+ cells, as shown in Fig. 1. A representative example from 
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CYTOKINE PRODUCTION AFTER BASOPHIL ACTIVATION WITH TLR LIGANDS 
To examine whether the mRNA expression of TLRs could be related to functional 
responses, cytokine production by basophils was measured 24 h after stimulation with TLR 
ligands. Basophils respond to TLR ligands with production of various cytokines (Fig. 2A, 
Supplementary Fig. 1 and Supporting Information Table 1 online). Although IL-8 was 
produced in response to most of the TLR ligands (except TLR-3), production of IL-4 and IL-
13 was mainly restricted to ligands for TLR-2/2, -4, and -6/2, and production of RANTES was 
restricted to the virus-associated TLR ligands PolyI:C (TLR-3) and CpG (TLR-9). These results 
suggest that the response to TLR ligands was different depending on the TLR that was being 
triggered. IL-10 production was only observed after ligation of TLR-2 and -4, and had p 
values >0.005 (not significant after correction for multiple testing). As no ligands are known 
for TLR-10, the absence of mRNA expression for this TLR could not be confirmed by 
functional assays. The differences in cytokines produced with different TLR ligands were 
confirmed by a titration of the TLR ligands (data not shown), indicating that the differential 
response that was seen was not merely a result of different degrees of activation with the 
TLR ligands. 
Intracellular cytokine staining confirmed that IL-8 production in response to TLR ligands was 
derived from basophils (Fig. 2B). Altogether, these results indicate that basophils respond 
to all TLR triggers with cytokine production and interestingly, that basophils produce 
different cytokines depending on the TLR that is triggered. 
DEGRANULATION AND LEUKOTRIENE RELEASE AFTER BASOPHIL ACTIVATION WITH TLR 
LIGANDS 
Besides cytokine production, one of the main effector functions of basophils is mediated 
via release of granules containing several proinflammatory mediators. Therefore, 
degranulation of basophils in response to TLR triggering was analyzed by determination of 
histamine release in supernatant and flow cytometric staining for CD63, which is 
upregulated on the surface of degranulated basophils (Fig. 3A and B). As expected, 
basophils released histamine in response to the positive controls anti-IgE and fMLP within 1 
h (Fig. 3C). Likewise, CD63 was upregulated on the surface of degranulated basophils.  
Although activation of basophils by ligands for TLR-7 and TLR-8 led to small increases in 
CD63 upregulation and histamine release (TLR-7 only), these responses were low compared 
with anti-IgE and fMLP and were statistically not significant. No degranulation of basophils 
was observed following activation by other TLR ligands. Furthermore, no CD63 upregulation 
was found in response to TLR ligands after 24 h of incubation (data not shown).  
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Figure 3. Basophil degranulation and leukotriene 
production in response to TLR ligands. (A–D) 
Isolated basophils were stimulated for 1 h with 
anti-IgE, fMLP, or TLR ligands, after which cells 
were stained for flow cytometry to determine 
expression of (A and B) CD63, and supernatant was 
assayed by ELISA to determine the release of (C) 
histamine and (D) leukotriene C4. (A) 
Representative data for CD63 expression in 
unstimulated basophils (dotted line) or basophils 
stimulated with anti-IgE (shaded histogram) or LPS 
(straight line) are shown. Basophils were gated as 
CD123+FcεRI++CD203c+ cells, as shown in Fig. 1. (B) 
The delta percentage of CD63 that is shown was 
determined by subtracting the percentage of PE+ 
cells in the isotype control from the percentage of 
CD63-PE+ cells for each indicated ligand. (B–D) 
*p<0.05 compared with unstimulated basophils, 
repeated measures ANOVA with Bonferroni's 
posthoc test. Results are shown as a summary of 
five independent experiments, with the line across 
the dots representing the median, and each 
symbol representing an individual donor. 
To further examine basophil responses to 
TLR ligands, we analyzed the release of 
lipid-derived mediators of basophils by 
measuring Leukotriene C4 in supernatant. 
Basophils only responded with leukotriene 
C4 release after activation with anti-IgE and 
fMLP and not after activation with TLR 
ligands (Fig. 3D). Therefore, TLR ligands 
induce a different response compared with 
IgE-mediated activation, characterized by 
production of cytokines and chemokines in 
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Figure 4 (left). Synergy in cytokine 
production after combined TLR- and IgE-
mediated stimulation. Basophils were 
stimulated with TLR ligands alone or in 
combination with anti-IgE for 24 h, after 
which degranulation was measured by flow 
cytometric staining of CD63 and cytokines 
were measured in supernatant by Luminex 
assay. (A and B) Examples of additive effects 
on IL-8 production in response to 
stimulation with anti-IgE and either TLR-2 or 
-5 ligands. (C and D) Examples of synergistic 
effects on cytokine production in response 
to stimulation with anti-IgE and either TLR-4 
or -9 ligands. Percentage of CD63+ basophils 
on gated CD123+FcεRI++CD203c+ cells, as 
shown in Fig. 1. The delta percentage of 
CD63 that is shown was determined by 
subtracting the percentage of PE+ cells in the 
isotype control from the percentage of 
CD63-PE+ cells for each indicated ligand. (A–
D) Data are shown as mean + SEM pooled 
from four independent experiments with 
basophils from four donors. (E–I) Summaries 
of CD63 expression and cytokine production 
for all TLR ligands in combination with anti-
IgE are shown as ratio of percentage of 
CD63+ cells or cytokine production in 
response to combined triggering divided by 
the sum of CD63+ cells or cytokine 
production following stimulation with anti-
IgE and TLR ligands separately, with each 
symbol representing an independent 
experiment and basophil donor. *p<0.05 
compared with the additive cytokine 
production, one-sample t-tests. 
SYNERGY BETWEEN TLR- AND FCεRI-
MEDIATED ACTIVATION 
It has been described that certain cytokines 
such as IL-3 can enhance the response of 
basophils upon IgE-mediated stimulation. 
However, it is not known whether a similar 
interaction is present between TLR- and IgE-
mediated triggering of basophils. Therefore, 
we next studied the effects of combined 
TLR- and FcεRI-triggering by combining the 
different TLR ligands with anti-IgE. 
No influence of TLR ligands on IgE-mediated 
degranulation (CD63 upregulation) was 
found. A representative example is shown 
for LPS (TLR-4 ligand) in Figure 4C. Although 
only additive effects on cytokine production 
were observed when TLR-1/2, -2/2, -3, -5, -
6/2, and -7 ligands were combined with anti-
IgE (Fig. 4A and B), combination of ligands 
for TLR-4 and -9 led to a fivefold increase in 
IL-4/IL-13 production and IL-4/RANTES 
production, respectively (Fig. 4C–I), as 
compared with the combined amounts of 
cytokines found after separate TLR and FcεRI 
triggering. 
These results indicate that the combined 
stimulation of basophils with ligands for TLR-
4 and -9 and anti-IgE induce a synergy in 
cytokine production by basophils. 
SYNERGY WITH ALLERGEN-MEDIATED ACTIVATION OF BASOPHILS 
As simultaneous activation of basophils from allergic individuals through allergen-specific 
IgE and TLRs could possibly underlie exacerbations of asthma symptoms during pulmonary 
infection, for example, we next evaluated whether the synergy is also present when 
basophils of allergic individuals are activated via LPS and allergens.  
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Although LPS only led to a small increase in degranulation of basophils (Fig. 5A), cytokine 
production was greatly enhanced when the basophils were stimulated by both LPS and 
allergen (Fig. 5B), indicating that synergy in cytokine production is also present when TLR 
triggering is combined with activation via allergen-specific IgE. 
 
 
Figure 5. Synergy in cytokine production after combined TLR- and allergen-specific IgE-mediated 
stimulation. Basophils isolated from two allergic individuals were stimulated with TLR ligands alone or in 
combination with allergens for 24 h, after which degranulation was measured by CD63 upregulation and 
cytokines were measured in supernatant by ELISA. (A) CD63 upregulation when allergen-induced 
stimulation was combined with LPS. Basophils were gated as CD123+FcεRI++CD203c+ cells. (B) Production of 
IL-4 and IL-8 after stimulation of basophils with allergen and LPS. Data are shown as individual experiments 
with basophils from two donors. 
SYNERGY IN BASOPHIL ACTIVATION CAN ENHANCE T HELPER 2 (TH2) RESPONSES VIA IL-4 
As basophils respond to combined triggering via TLR-4 and anti-IgE with greatly enhanced 
cytokine production, we next analyzed the relevance of this synergistic response by 
evaluating the influence of the cytokine production by basophils on the skewing of naive 
Th cells. To this end, naive CD4
+
 T cells were stimulated with anti-CD3 and -CD28 in the 
presence or absence of basophil supernatant for 5 days, after which cytokine production 
by T cells was analyzed. When T cells were cultured in the presence of supernatant from 
basophils triggered by the combination of anti-IgE and LPS, the percentage of IL-13
+
 cells 
was greatly enhanced (Fig. 6A and B). In contrast, only a relatively small increase in the 
percentage of IFN-γ
+
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toward a Th2 phenotype. To confirm that the intracellular staining of IL-13 reflected 
enhanced skewing toward Th2 cells, we also measured T -cell cytokines in supernatant 
(Fig. 6C). Enhanced release of the typical Th2 cytokines IL-4, IL-5, and IL-13 was found 
when T cells were cultured in the presence of basophil supernatant stimulated with LPS 
and anti-IgE. Only a relatively slight increase in the production of IFN-γ was found in two 
out of three donors when supernatant of activated basophils was used. Together, our 
results indicate that basophils activated by anti-IgE in combination with the TLR-4 ligand 
LPS can promote the skewing toward Th2 cells. 
As IL-4 is able to induce skewing of naive T cells toward Th2 cells and basophils were 
shown to produce relatively high amounts of IL-4 in response to anti-IgE and LPS, we 
investigated whether the effects of basophils on Th2 skewing were mediated via IL -4 by 
using blocking antibodies. Blocking IL-4 in basophil supernatant diminished the 
percentage of IL-13
+
 T cells, and the effect of basophil supernatant on Th2 induction 
was completely reversed (Fig. 6D). These results indicate that synergy in IL-4 
production by basophils in response to anti-IgE and LPS can promote the skewing 
toward Th2 cells. 
DISCUSSION 
In this study, we extensively analyzed basophil responses to TLR ligands. Although a few 
studies report cytokine production by basophils in response to TLR-2 and -4 ligands (2-4), 
functional responses toward other TLR ligands have not been reported. Furthermore, the 
effect of the TLR-4 ligand LPS on basophil activation showed inconsistent results among the 
different studies. Whereas two studies reported absence of CD11b upregulation and 
cytokine production (2, 3), one study reported production of cytokines in response to LPS 
(4), which is in agreement with our findings. We found that mRNA expression of TLR-4 was 
relatively high compared with the other TLRs. Furthermore, LPS induced the broadest 
cytokine production profile among the TLR ligands studied, and we were able to show a 
large shift in intracellular IL-8 in basophils treated with LPS, suggesting that basophils can 
indeed respond functionally to the TLR-4 ligand LPS.  
By using sensitive multiplex assays, we detected cytokine production by basophils in 
response to ligands for TLR-1 to -9. There was a very small amount of BDCA-2 positive cells 
in the isolated basophil fraction in some donors (maximally 0.3%), whereas in other donors, 
no BDCA-2 positive cells were detected at all (data not shown). However, typical DC 
cytokines were not detected in response to TLR ligation, suggesting that the cytokine 
production we observed was not derived from contaminating DCs. 
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Figure 6. Influence of basophil activation by LPS and anti-IgE on Th-cell skewing. Naive CD4+ T cells were 
cultured for 5 days in the presence of anti-CD3 and anti-CD28, with or without basophil supernatant, 
indicated as “basophil sup” or “stimuli only”, respectively. T cells were restimulated with PMA/ionomycin to 
evaluate cytokine production by intracellular staining and by Luminex assay. (A) Representative example 
from five independent experiments of intracellular flow cytometric staining for IL-13 in the absence or 
presence of basophil supernatant from unstimulated or LPS- and anti-IgE-stimulated cells. Gating strategy is 
shown (top). (B) Percentages of IL-13+ and IFN-γ+ T cells derived from intracellular flow cytometry from five 
independent experiments performed using supernatants from six independent basophil donors and five 
independent T-cell donors. The delta percentage of cytokines was calculated by subtracting the percentage 
of positive cells in the isotype control from the percentage of cytokine-positive cells for each condition. *p < 
0.05 increase in percentage of IL-13+ T cells when supernatant from LPS- and anti-IgE-stimulated basophils 
was compared with that of basophils stimulated with only anti-IgE, paired samples t-test. (C) T-cell cytokine 
production as measured in supernatant. Data were pooled from three experiments with three independent 
basophil and T-cell donors. n.d.: not detected. (D) Intracellular staining of IL-13 in cultured naive CD4+ T 
cells stimulated with basophil supernatant incubated with either an IL-4-blocking antibody or matching 
isotype control. Summary pooled from three experiments with three independent basophil and T-cell 
donors. *p < 0.05 decrease when basophil supernatant was treated with anti-IL-4 blocking antibody 
compared with the isotype control, paired samples t-test. The boxplots show the mean (line), 25–75 
percentile (box) and minimum-maximum (whiskers). 
Live gate
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We observed different patterns of cytokine production depending on the TLR that was 
being triggered. Interestingly, the virus-associated TLRs induced different responses than 
the bacterial-associated TLRs, indicating that basophils can respond in diverse ways to 
these different types of pathogens. Such different cytokine production profiles have 
previously been reported for dendritic cells, where different cytokines produced in 
response to bacterial- or viral -associated TLR ligands were shown to induce different types 
of immune responses (24, 25). Therefore, the different cytokines produced by basophils in 
response to TLR ligands may also alter the immune response that is elicited upon infection 
by viruses or parasites. 
The synergy we observed when both TLR-4 or -9 and FcεRI were triggered indicates that 
TLR triggering could enhance IgE-mediated responses, such as in allergy or parasitic 
infection. The effects of TLR ligands are somewhat comparable to the effects that cytokines 
have on the priming of basophil responses. For example, IL-3 and IL-33 have both been 
shown to enhance degranulation and IL-4 and IL-13 production by basophils in response to 
anti-IgE (26, 27). TLR triggering did not influence IgE-mediated degranulation, indicating 
that the effects of TLR triggering and priming by cytokines on IgE-mediated basophil 
activation are distinct. In mice, synergy in TNF-α production by mast cells upon TLR and 
FcεRI triggering has been shown to depend on synergistic activation of protein kinases (28). 
Although TLRs and FcεRI use different molecules for their intracellular signaling (e.g. MyD88 
and Syk), they can activate similar transcription factors via mitogen-activated protein 
kinases, such as p38, Erk, and JNK (29). Therefore, the synergy in cytokine production by 
basophils in our system may have been induced via a similar mechanism. 
This synergy in cytokine production of basophils might occur in vivo when both specific IgE 
and TLR ligands are present, such as during parasitic infections, autoimmune diseases, and 
allergic reactions. Although parasites can induce specific IgE and activate TLRs through 
pathogen-associated molecular patterns, chronic allergic inflammation may lead to 
activation of TLR by damage-associated molecular patterns (30, 31). In addition, certain 
viral and bacterial infections have been associated with asthma exacerbations (32, 33), and 
the presence of endotoxin (TLR-4 ligand) was demonstrated in house dust, and was related 
to severity of allergic reactions against house dust mite (21), Our data indicate that 
activation of basophils may contribute to these processes by enhanced cytokine production 
when both specific IgE and TLR ligands are present. The fact that basophil responses to TLR 
ligands could greatly enhance the IgE-mediated activation suggests that these responses 
mainly play a role in memory or chronic immune responses, when specific IgE has already 
been generated. However, since certain allergen and helminth antigens may directly 
crosslink FcεRI on basophils without the need for specific IgE (34-36), these responses may 
also be enhanced by the presence of TLR ligands at the same time, and TLR activation of 
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basophils may thus contribute to enhanced cytokine production in primary immune 
responses against helminths as well.  
Our results indicate that TLR ligation of basophils may induce IL-4 production as well as 
other Th2-like cytokines, and may therefore provide an early IL-4 signal when specific IgE is 
not (yet) present. As such, basophils may function as accessory cell providing IL-4 signals to 
naïve T cells in the presence of APCs. Two recent studies reported that human basophils 
could enhance Th2 and Th17 memory responses, through TCR-independent pathways (37). 
Furthermore, in mice, IL-4-producing basophils were shown to enhance DC-driven antigen-
specific induction of Th2 cells in the LN, suggesting that basophils can indeed function as 
accessory cells to provide the IL-4 signal to naive T cells in vivo (37). Our results showed 
that TLR triggering of human basophils may contribute to the induction or expansion of Th2 
responses in a similar way. 
In this study, we chose to evaluate the effect of synergistic cytokine production by 
basophils on T -cell skewing, but similar effects may be observed when evaluating the effect 
of basophil-derived cytokines on other immune cells or on tissue-resident cells, as, for 
example, IL-4 and IL-13 have been shown to induce mucus production and parasite 
expulsion, two important processes in parasite infection and allergic responses (38, 39). In 
addition, release of IL-4 and IL-13 by basophils may induce alternatively activated 
macrophages, which in turn play a role in tissue homeostasis and repair (40, 41). Therefore, 
synergy in cytokine production by basophils may amplify Th2-type immune responses via T 
cell-dependent and -independent mechanisms.  
In conclusion, we found cytokine production by basophils in response to ligands for TLR-1 
to -9. The type of TLR ligand determined the cytokine profile being produced, which 
suggests that basophils could play different roles in the immune response depending on 
the pathogens present. Furthermore, increased cytokine production by basophils in 
response to ligation of TLR and FcεRI at the same time could have important implications 
for their role in Th2 responses. Altogether these results suggest nonredundant roles for 
basophils in the immune response against pathogens via TLRs, and for the first time suggest 
that TLR-activated basophils can enhance Th2 responses. 
MATERIALS AND METHODS 
CELL ISOLATION 
Buffy coats from healthy volunteers were obtained from the blood bank (Sanquin, The 
Netherlands). For isolation of basophils, total leukocytes were first isolated using HetaSep 
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(StemCell). Basophils were then isolated by negative magnetic bead isolation using the 
Basophil Enrichment Kit (StemCell), using the manufacturer's instructions. The purity of 
isolated basophils was determined by flow cytometric analysis of FcεRI, CD203c, and 
CD123. The purity of isolated basophils was above 95% in each experiment.  
For isolation of CD4
+




 T cells were isolated from PBMCs by 
negative magnetic bead isolation (Miltenyi Biotec). The purity of isolated naive CD4
+
 T cells 










 cells. The purity of isolated naive 
CD4
+
 T cells was above 95% in each experiment.  
REAL-TIME POLYMERASE CHAIN REACTION 
Basophil lysate was prepared using TRIzol reagent (Invitrogen). RNA isolation was 
performed using TRIzol following manufacturer's instructions, including removal of 
proteoglycans using a high-salt buffer. A cDNA library was constructed using the RT
2
 first 
strand kit (SA Biosciences) following manufacturer's instructions.  
Expression of TLRs by basophils was assessed by real-time PCR. The Toll-Like Receptor 
Signaling Pathway PCR Array (SA Biosciences) was performed to assess the expression of 
the several genes, including the following: TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, 
TLR9, TLR10, BTK, MD-2, MYD88, TICAM1, and TICAM2. Relative expression of these genes 
was normalized toward expression of the housekeeping gene HPRT1.  
BASOPHIL ACTIVATION 
Basophils were cultured in Iscove's Modified Dulbecco's Media containing 10% FCS at a cell 
concentration of 1 × 106 cells/mL in all experiments, unless indicated otherwise. For TLR-
mediated activation, basophils were stimulated using 1 μg/mL Pam3csk, 10
8
 cells/mL heat 
killed Listeria monocytogenes (HKLM), 10 μg/mL Poly I:C, 10 μg/mL LPS, 1 μg/mL Flagellin, 1 
μg/mL FSL-1, 10 μg/mL Imiquimod, 10 μg/mL ssRNA40, and 5 uM CpG (all from InVivoGen). 
IgE- or fMLP-mediated activation of basophils was induced using 10 μg/mL goat-anti-
human IgE (Nordic) or 1 μg/mL fMLP (Sigma), respectively.  
For combined activation with TLR ligands and anti-IgE, basophils were stimulated with 0.1 
μg/mL Pam3csk, 10
7
 cells/mL HKLM, 2.5 μg/mL Poly I:C, 50 ng/mL LPS, 0.2 μg/mL 
Flagellin, 0.05 μg/mL FSL-1, 0.5 μg/mL Imiquimod, 5 μg/mL ssRNA40, and 5 uM CpG with 
or without 0.2 μg/mL anti-IgE.  
After 24 h, basophil activation was measured using flow cytometry, multiplex assays, and 
ELISA. For analysis of degranulation by FACS and release of histamine and leukotrienes, 
basophils were stimulated for 1 h in Tyrode's buffer (137 mM NaCl, 2.7 mM KCl, 0.4 mM 
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NaH2PO4, 1.4 mM CaCl2, 0.5 mM MgCl2, 5.6 mM glucose, 100 mM Hepes, and 0.1% BSA 
in 50% H2O and 50% D2O). To assess the total histamine content of basophils to 
calculate the percentage of release, basophils were lysed with 1% Triton X-100 in 
Tyrode's buffer. 
For intracellular cytokine staining, basophils were cultured in the presence of 3 μg/mL 
brefeldin A for 18 h, after which cells were used for flow cytometry.  
ALLERGEN-INDUCED BASOPHIL ACTIVATION 
Heparinized peripheral blood was obtained from individuals allergic to house-dust mite 
allergen or cat epithelia. Leukocytes and basophils were isolated as described above. 
Basophils were incubated with 0.25 U/mL Dermatophagoides pteronissymus (HAL Allergy) 
or 25 U/mL Epithelia Felis catus (HAL Allergy), respectively, with or without LPS (5 ng/mL). 
After 24 h, basophil activation was measured using flow cytometry and ELISA.  
EFFECT OF BASOPHIL SUPERNATANT ON TH -CELL SKEWING 
Basophil supernatant was collected after culture as described above in the presence of 
anti-IgE and/or LPS. As control, medium with the same concentration of anti-IgE and/or LPS 
was used. Naive CD4
+
 T cells were activated using 5 μg/mL plate-bound anti-CD3 
(eBioscience; clone: OKT3) and 1 μg/mL soluble anti-CD28 (Sanquin; clone: CLB-CD28/1, 
15E8) in the presence of absence of basophil supernatant that was diluted twice in the 
culture medium.  
After 5 days of incubation, T cells were harvested, washed, and split over two wells. One 
well of each condition was left unstimulated, whereas the other well was restimulated 
using 50 ng/mL PMA (Sigma) and 500 ng/mL Ionomycin (Sigma). Cells were restimulated for 
5 h in the presence of 10 μg/mL brefeldin A (Sigma) for intracellular cytokine staining of 
IFN-γ and IL-13, or left overnight without brefeldin A to determine cytokine levels in 
supernatant.  
For blocking experiments, basophil supernatant was incubated with 10 μg/mL anti-IL-4 
(clone MP4–25D2, eBioscience) or rat IgG1 isotype control (eBRG1, eBioscience), for 1 h at 
37°C before adding the supernatant to the T cells. 
FLOW CYTOMETRY 
The following antibodies were obtained from BD Biosciences: CD123-PerCpCy5.5 (clone 
7G3), CD63-PE (H5C6), CD14-PECy7 (M5E2), CD3-Pacific Blue (UCHT1), CD45RA-FITC (L48), 
CD45RO-PE (UCHL1), IL-8-PE (G265–8), IFN-γ-FITC (25723.11), IFN-γ-PE (4S.B3), IL-13-
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allophycocyanin (JES10–6A2), mIgG1-APC (MOPC-21), mIgG2b-FITC (27–35), rIgG1-
allophycocyanin (R3-R4), streptavidin-allophycocyanin. The following were obtained from 
eBioscience: FcεRI-FITC (AER-37), TLR-2-biotin (TL2.1), TLR-4-biotin (HTA125), mIgG1-PE 
(P3.6.2.8.1), mIgG2b-PE (eBMG2b), mIgG2a-biotin (eBM2a), and the following were 
obtained from Miltenyi: CD203c-allophycocyanin and -PE (FR3–16A11), BDCA-2-
allophycocyanin (AC144), and Biolegend: CD4-AlexaFluor700 (OKT4). For surface staining, 
cells were incubated with fluorochrome-conjugated antibodies diluted in PBS 0.5% BSA at 
4°C for 30 min.  
For staining of TLR-2 and -4, cells were incubated for 15 min with 50 ug/mL human IgG 
(Jackson Immunoresearch) to block Fc receptors, prior to addition of the primary 
antibodies. After washing, cells were incubated with strep-allophycocyanin at 4°C for 30 
min. For intracellular cytokine staining, basophils and T cells were incubated with anti-
bodies against surface antigens as described above, after which they were permeabilized 
using CytoFix CytoPerm Kit (BD Biosciences). After washing, basophils were incubated with 
antibodies against intracellular cytokines and incubated at 4°C for 30 min. 
After washing, cells were suspended in 1% paraformaldehyde until flow cytometric 
aquisition on an FACS Calibur (BD) or LSR-II (BD). Analysis was performed using FACS Diva 
(BD) and FlowJo software. 
CYTOKINE, HISTAMINE, AND LEUKOTRIENE C4 PRODUCTION 
Quantitative immunoassays for EGF, Eotaxin, FGF-2, Flt-3 Ligand, Fractalkine, G-CSF, GM-
CSF, GRO, IFN-α2, IFN-γ, IL-1ra, IL-1α, IL-1β, IL-2, sIL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, 
IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MCP-3, MDC, MIP-1α, MIP-
1β, PDGF-AA, PDGF-AB/BB, RANTES, sCD40L, TGF-α, TNF-α, TNF-β, and VEGF in basophil 
culture supernatants were performed using Milliplex assays (Millipore). Quantitative 
immunoassays for GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12(p70), IL-13, IL-
15, IL-17A, IL-17E/IL-25, IL-17F, IL-21, IL-22, IL-23, IL-27, IL-28A, IL-31, IL-33, MIP-3α/CCL20, 
TNF-α, TNF-β in T -cell culture supernatants were performed using Milliplex assays 
(Millipore). Additionally, IL-4, IL-8, and IL-13 production was evaluated using ELISA (from 
Sanquin and eBioscience). Histamine and Leukotriene C4 were analyzed using competitive 
ELISA kits (Neogen). 
STATISTICAL ANALYSIS 
Results are expressed as mean ± SEM. For detection of TLR mRNA expression, one-sample 
T-test was performed. For differences between multiple groups, a repeatedmeasures 
ANOVA was performed, with Bonferroni's posthoc test. Paired-sample T-test was 
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performed to analyze differences between two groups. Synergy was calculated as a ratio 
dividing the cytokine production induced by combined TLR and anti-IgE stimulation by the 
sum of the cytokine production induced by the separate stimuli (value(TLR + a-
IgE)/(value(TLR) + value(a-IgE), after which one-sample T-test was performed. Statistical 
analysis was performed using SPSS PASW 17.0 and GraphPad Prism 4. P values of <0.05 
were considered statistically significant. 
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Supplementary Figure 1. Cytokine production by human basophils in response to TLR ligands. (A-D) Isolated 
basophils were stimulated with TLR ligands for 24 hours, after which cytokines were measured in 
supernatant by Luminex assay. Paired graphs showing cytokine production by basophils left unstimulated 
(ctr) or stimulated with ligands for the indicated TLR ligands or anti-IgE (aIgE).Results are shown as a 
summary of 10 experiments performed with basophils from 10 different donors, with each line indicating 
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ABSTRACT 
Basophils are circulating granulocytes, best known as effector cells in allergic reactions. 
Recent studies in mice suggest that they might also participate in the suppression of 
chronic inflammation. The aim of this study was to assess the ability of purified human 
basophils to modulate monocyte responses upon IL-33 and IgE triggering.  
Activation of human basophils with IL-33 induced the production of IL-4 and the release of 
histamine, and enhanced their IgE-mediated activation. In addition, basophils triggered 
with IL-33 and anti-IgE significantly suppressed the LPS-induced production of the 
proinflammatory cytokine TNF-α and the upregulation of the costimulatory molecule CD80 
by monocytes. These effects were mainly explained by the release of histamine, as they 
could be inhibited by the histamine receptor 2 antagonist ranitidine, with a smaller 
contribution of IL-4. In contrast, basophil-derived IL-4 and histamine had opposing effects 
on the expression of the inhibitory Fc γ receptor IIb and the production of IL-10 by 
monocytes.  
Our data show that basophils can influence monocyte activation and suggest a previously 
unrecognized role for human basophils in the modulation of monocyte-mediated immune 
responses, through the balanced secretion of histamine and IL-4. 
INTRODUCTION 
Basophils are circulating granulocytes, representing less than 1% of peripheral blood 
leukocytes. They are classically known for their involvement as effector cells in allergic 
reactions (1-3). Because of their paucity and the difficulty in isolating them, there is still 
relatively little information available on their functions and potential immunomodulatory 
effects (4). Studies in mice suggest a possible role for basophils in the induction of 
adaptive immunity in the context of Th2 responses, where they have been shown to be 
the major producers of IL-4 (5), although their function as antigen presenting cells and 
their dispensability in the induction of Th2 responses are still under debate (6, 7).  
In addition, recent experimental data showed how these rare leukocytes might also exert 
anti-inflammatory effects in the context of autoimmune and allergic inflammation. In a 
mouse model of arthritis, basophils have been implicated in the immunosuppressive  
response mounted upon injection of intravenous immunoglobulin (IVIG) (8). Briefly, the 
authors proposed the following scenario to elucidate IVIG-mediated immune 
suppression: myeloid-derived cells, in response to the sialylated fraction of IVIG, release 
IL-33, which, in turn, activates basophils to produce IL-4. Finally, basophil-derived IL-4 
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induces the upregulation of the inhibitory Fc γ Receptor (FcγRIIb) on inflammatory 
macrophages, leading to the suppression of antibody-dependent inflammation. Thus, IL-
33 was shown to be involved in the suppression of arthritis through its action on 
basophils. Even though the role of the sialylated fraction of IVIG or basophils in the 
immunomodulatory effects of IVIG therapy has recently been challenged (9), another 
study using an experimental model of IgE-mediated chronic allergic inflammation, 
showed that mouse basophils, through IL-4, drive the differentiation of monocytes into 
anti-inflammatory macrophages, thereby regulating chronic allergic skin inflammation in 
vivo (10). 
Human basophils, which can significantly differ from their mouse counterparts (1, 3, 11), 
have been known for a long time to produce IL-4 (12), and have been recently shown to 
induce Th2 skewing of naïve helper T cells in vitro (13, 14). On the other hand, the 
function as antigen presenting cells, still debated in mice, has been ruled-out for human 
basophils by several groups (15-17). In addition to well-known basophil triggers like IgE or 
IL-3, IL-33 also activates human basophils, inducing the production of several cytokines, 
including IL-4 (18-20).  
IL-33 is a member of the IL-1 cytokine family that plays an important role in the induction 
and effector phases of type 2 immune responses (21), suspected to be involved in the 
pathogenesis of several allergic and autoimmune diseases (22), where it can have both 
protective and deleterious effects in different settings (23). For example, in the 
aforementioned arthritis model (8), IL-33 production was critically involved in the 
suppression of arthritis upon IVIG administration, specifically through its effects on 
basophils. Since IL-33, as an alarmin (22), is released in any inflamed tissue and reaches 
high levels locally but also in the sera of patients with several allergic and autoimmune 
conditions, such basophil-driven anti-inflammatory network could be active, 
independently from exogenous stimuli like IVIG, in any condition in which IL-33 is 
released upon cell necrosis. Therefore, it would be of invaluable interest to verify 
whether IL-33 is able to induce anti-inflammatory responses through the activation of 
human basophils. 
To this end, we investigated the interaction of IL-33-stimulated human basophils with 
monocytes. We found that purified human basophils, triggered via FcεRI ligation and IL -
33, suppressed LPS-induced monocyte activation. Unexpectedly, only little of this effect 
could be attributed to IL-4. Instead, basophil-derived histamine was found to be the main 
factor involved. Overall, our data show that human basophils are able to influence 
monocyte activation via the balanced secretion of IL-4 and histamine, and suggest that 
they play an important role in the regulation of the immune responses.  
62  |  CHAPTER 3 
RESULTS 
IL-33 ACTIVATES HUMAN BASOPHILS 
To determine basophil activation upon IL-33 triggering, we performed in vitro stimulation 
of purified human basophils. Basophils were identified by the expression of CD123 (IL-3 
receptor), FcεRI (Fig. 1A), and CD203c (Fig. 1B). To exclude contamination with 




), also known to express low levels of 
FcεRI (24), we verified that the isolated fractions, while positive for the basophil marker 
CD203c, did not contain BDCA2
+
 cell (Fig. 1B). IL-4 levels were measured after 24 h of 
stimulation with different doses of IL-33 or with two classical basophil stimuli, i.e. IgE-
mediated cross-linking of the FcεRI and IL-3 (Fig. 1C). In addition, IL-4 production upon 
combined stimulation of basophils with IL-33 and anti-IgE or IL-3 was evaluated (Fig. 1D). 
These data show that IL-33 alone induced low but detectable amounts of IL-4, which is in 
line with previous literature (20). Additionally, as shown in Figure 1D, IL-33, at 100 ng/mL, 
significantly increased IL-4 production upon IgE or IL-3 triggering. 
To further study basophil activation, we measured the membrane expression of CD63, as a 
marker of degranulation (25). IL-33, as expected, did not induce degranulation when used 
alone, but significantly enhanced IgE-mediated degranulation of basophils (Fig. 1E and 1F). 
In addition, histamine release was evaluated (Fig. 1G). In line with CD63 expression, 
histamine was released by basophils upon IgE cross-linking. In addition to a spontaneous 
secretion of histamine in unstimulated basophils, we observed a significant induction of 
histamine release upon IL-33 triggering. Such histamine release was independent from 
CD63, which is possibly in line with previous reports of spontaneous and degranulation-
independent release of histamine by human basophils (26, 27). 
These data indicate that IL-33 can activate human basophils, inducing the production of IL-
4 and the release of histamine. Furthermore, IL-33 can enhance IgE-mediated basophil 
degranulation, histamine release and cytokine production. 
ACTIVATED HUMAN BASOPHILS MODULATE MONOCYTE ACTIVATION 
To evaluate whether human basophils can modulate monocyte activation, monocytes were 
incubated with supernatants of basophils or control media (containing the stimuli originally 
used to trigger basophils) and activated with LPS. As shown in Figure 2A, TNF-α production 
was significantly suppressed when monocytes were conditioned with basophils 
supernatants. Unstimulated basophils partially inhibited TNF-α production by monocytes, 
but a significantly stronger inhibition of TNF-α production by monocytes was induced by 
supernatants of basophils triggered with anti-IgE together with IL-33.  
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Figure 1. Activation 
of human basophils. 




healthy donors by 
immune-magnetic 
negative selection. 
Cells were analyzed 
by FACS to verify 
purity. A repre-
sentative example is 




After gating out 
debris using 
FSC/SSC, basophils 




analyzed for the 
expression of 
CD203c and BDCA2. 
Total cells from the 
live gate are shown. 
(C) Isolated 
basophils were 
stimulated with the 
indicated concen-
trations of anti-IgE, 
IL-3, or IL-33 for 
24 h and IL-4 
production was measured by ELISA in the supernatants after harvesting. (D) IL-4 production after 24 h of 
incubation of isolated basophils with IL-3 or anti-IgE + indicated concentrations of IL-33. (E, F) Flow 
cytometric expression of CD63 by isolated basophils after 24 h of stimulation with anti-IgE (0.5 μg/mL), 
IL-33 (100 ng/mL), or both. A representative example is shown in (E) and the summary of all donors in 
(F). (G) Histamine release, measured by ELISA, after 24 h of incubation with the indicated stimuli. (A, B, 
and E) Data shown are representative of five independent experiments performed. (C, D, F, and G) Data 
are shown as mean + SEM and are pooled from (C, D) three independent experiments (n = 3 basophil 
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Figure 2. Effects of basophil supernatants on LPS-induced activation of monocytes. (A–C) Monocytes were 
isolated by positive selection using CD14 immunomagnetic beads, incubated with the supernatants of 
basophils (black bars) or with control media (white bars) and activated with LPS (5 ng/mL). The stimuli used 
to activate basophils and also present in the control media are indicated on the x axis. (A) TNF-α and (B) IL-
10 were measured by ELISA in the supernatants of LPS-stimulated monocytes after overnight incubation (18 
h). (C) Monocyte expression of CD80 was evaluated by (D) flow cytometry after FSC/SSC gating and 
exclusion of dead cells with DAPI. (A–C) Data are shown as mean + SEM from five independent experiments 
(n = 5 monocyte donors). (D) Data shown are representative of five independent experiments performed. * 
p < 0.05; for comparison of each basophil supernatant with its own control, Student t-test was performed. 
For multiple comparisons between basophil supernatants ANOVA with Bonferroni's post-test was 
performed. 
IL-10 production by monocytes was not influenced, indicating that monocytes were still 
equally able to produce cytokines, and that they were still viable (Fig. 2B). Indeed, the 
percentages of live monocytes were similar in all conditions, confirming that the observed 
reduction of TNF-α was not due to impaired survival of monocytes (data not shown), but 
rather to a suppression of TNF-α production upon exposure to basophil supernatants. To 
confirm that TNF-α and IL-10 were derived from monocytes, the cytokine levels were also 
measured in basophil supernatants, and were below detection limit (data not shown). 
Together, these results indicate that basophils significantly suppress LPS-induced TNF-α, 
without affecting the production of IL-10, thereby modulating the proinflammatory 
responses of monocytes. 
To further study monocytes activation, we analyzed surface markers by flow cytometry. 
While the expression of several markers, including activating and inhibitory Fc γ receptors 
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shown), basophils supernatants reduced the percentage of monocytes expressing the 
costimulatory molecule CD80 upon LPS stimulation (Fig. 2C and D). Although this effect was 
statistically significant only for the combined activation of basophils with IgE and IL-33, 
these data further confirm the ability of basophils to modulate monocyte function, by 
influencing their expression of costimulatory molecules. 
Together, these data show that basophil supernatants significantly modulate monocyte 
proinflammatory activation, by inhibiting the LPS-induced production of TNF-α and 
upregulation of CD80. 
BASOPHIL-DERIVED IL-4 AND HISTAMINE MODULATE CYTOKINE PRODUCTION BY 
MONOCYTES 
We next sought to identify the mechanism by which basophils affected monocyte cytokine 
production and speculated that IL-4 might play a role in this process. Indeed, IL-4 did inhibit 
the LPS-elicited TNF-α production by monocytes to a similar extent as activated basophil 
supernatants (Fig. 3A). Nonetheless, IL-4 blocking in the supernatants of anti-IgE and IL-33 
activated basophils only slightly reverted the inhibition of TNF-α (Fig. 3B), indicating that 
this effect was mainly mediated by other factors. Among other mediators produced by 
basophils, histamine has been shown to modulate monocytes responses to LPS (28). 
Accordingly, exogenously added histamine could suppress LPS-induced TNF-α production 
and, when used together with IL-4, the suppression of TNF-α was almost complete, as 
shown in Figure 3A. Additional experiments (not shown) confirmed that this effect of 
histamine is specifically mediated by the interaction with histamine 2 receptor (H2R) as it 
could be inhibited by H2R antagonist ranitidine and not by H1R antagonist cetirizine or H3–
4R antagonist thioperamide (at doses from 10−6 to 10−4 M). In line with these 
observations, preincubation of monocytes with ranitidine significantly prevented the 
inhibitory effects of activated basophil supernatants, while concomitant blocking of IL-4 in 
the supernatants showed almost no additional effect (Fig. 3B). These data indicate that 
basophil-derived histamine is predominantly responsible for suppressing LPS-induced TNF-
α production by monocytes. 
We next analyzed the influence of exogenous histamine and IL-4 on LPS-induced IL-10 
production and, intriguingly, observed opposite effects, as shown in Figure 3C. 
Consequently, only when IL-4 was blocked in basophil supernatants, the IL-10 inducing 
effects of histamine could be revealed. The enhanced IL-10 production observed after 
blocking IL-4 could be reverted by the addition of ranitidine, showing it was mediated by 
histamine via H2R (Fig. 3D). Together, these data indicate that IL-4 and histamine in 
basophils supernatants have opposite effects with respect to IL-10 production. 
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In order to further confirm that basophil 
derived histamine and IL-4, at the levels found 
in the supernatants, are relevant mediators 
involved in the inhibitory effect on TNF-α 
production, we performed a titration 
experiment (Supplementary Fig. 1). Both 
histamine and IL-4 suppressed LPS-induced 
TNF-α at very low concentrations (as low as 1 × 
10−9 M of histamine and 1 pg/mL of IL-4).  
Moreover, additional suppression of TNF-α 
could be obtained by combining histamine and 
IL-4 at these low concentrations (data not 
shown). This confirms that low levels of 
histamine and IL-4 can modulate monocyte 
responses to LPS triggering. 
 
Figure 3. Basophil-derived mediators and the 
modulation of LPS-induced cytokine production by 
monocytes. (A) TNF-α in the supernatants of 
monocytes conditioned with IL-4 and histamine. Briefly, 
isolated monocytes were stimulated with LPS (5 ng/mL) 
with or without IL-4 (10 ng/mL) and/or histamine (10−5 
M). Blocking was performed by preincubation with 
anti-IL4 antibody and matching isotype control or with 
histamine receptor 2 antagonist ranitidine. (B) Blocking 
experiments, as described above, were also performed 
using anti-IgE + IL-33 activated basophil supernatants. 
TNF-α produced by basophil-conditioned monocytes 
was compared with the amount produced by 
monocytes incubated with control media, and is shown 
as percentage over control. Monocytes stimulated with 
LPS alone correspond to 100% of TNF-α production. 
Direct effects of anti-IL-4 and ranitidine on monocytes 
were excluded by adding them to the respective 
control media. (C, D) IL-10 concentration was 
measured in the supernatants, as described in (A, B). 
(A–D) Data are shown as mean + SEM pooled from five 
independent experiments (n = 5 monocyte donors). * p 
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Altogether, these results show that basophil-derived IL-4 and histamine can differently 
modulate the response of human monocytes to TLR4-triggering, where opposing 
effects are observed regarding IL-10-production. In contrast, both molecules, but 
mainly histamine, contribute to the suppression of LPS-induced TNF-α production by 
monocytes. 
IL-4 AND HISTAMINE SUPPRESS CD80 BUT HAVE OPPOSITE EFFECTS ON THE EXPRESSION OF 
FCγRIIB BY MONOCYTES 
Having established that IL-4 and histamine can have different effects on the modulation of 
cytokine production by monocytes, we next studied their influence on the expression of 
monocyte surface markers by flow cytometry. As expected, IL-4 induced the expression of 
the inhibitory FcγRIIb in monocytes (Fig. 4A). Intriguingly, when histamine was added to IL-4 
this effect was lost. Therefore, we speculated that histamine could be responsible for 
inhibiting the upregulation of FcγRIIb by basophils supernatants. Accordingly, when 
histamine effects were blocked with ranitidine, basophil supernatants did induce an 
upregulation of FcγRIIb on monocytes (Fig. 4B).  
The upregulation of FcγRIIb was lost when IL-4 present in the basophil supernatant was 
blocked (data not shown), confirming our hypothesis that basophil-derived histamine 
masked the FcγRIIb induction by basophil-derived IL-4. In contrast, exogenously added 
histamine and IL-4 synergized in the inhibition of the LPS-induced CD80-expression on 
monocytes (Fig. 4C). Accordingly, inhibition of basophil supernatants with ranitidine and 
anti-IL-4 significantly reverted the inhibitory effect of basophil supernatants on CD80 
expression, although the contribution of basophil-derived histamine appeared to be 
prevalent (Fig. 4D). 
Taken together, these results indicate that basophil derived IL-4 and histamine can have 
combined effects, as shown for the inhibition of the costimulatory molecule CD80, but also 
contrasting effects. Remarkably, histamine was shown to modulate the ability of basophil-
derived IL-4 to upregulate the inhibitory FcγRIIb on monocytes. 
BASOPHILS DIRECTLY INHIBIT MONOCYTE ACTIVATION IN COCULTURE 
We showed how basophil supernatants inhibit monocyte activation, with a contribution of 
IL-4 and histamine, two of the main mediators produced by basophils. Nonetheless, the 
release of mediators by basophils is known to be differentially regulated over time, with an 
immediate release of high amounts of granule-stored mediators (including histamine) upon 
IgE cross-linking, followed by an active production of cytokines and other mediators in the 
later phase of basophil activation.  
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Therefore, to better reproduce this physiological time course, and to verify possible 
additional effects dependent on cell-to-cell contact, we performed experiments in which 
basophils and monocytes were cocultured. LPS-induced TNF-α production by monocytes 
was inhibited in the presence of basophils (Fig. 5A).  
Further activation of basophils with anti-IgE 
and IL-33 significantly enhanced the inhibition 
of TNF-α production by monocytes. This effect 
could be reverted by preincubation of 
monocytes with ranitidine and only partially 
by blocking IL-4, again pointing toward a 




Figure 4. FcγRIIb and CD80 modulation by basophil 
supernatants. After 18 h of incubation with LPS (5 
ng/mL) monocytes were analyzed by flow cytometry 
for the expression of surface markers. (A) FcγRIIb 
expressed by monocytes stimulated with rIL-4 (10 
ng/mL), histamine (10−5 M), or both. (B) FcγRIIb 
expressed by monocytes conditioned with anti-IgE + 
IL-33 triggered basophil supernatants and blocked 
with H2R antagonist ranitidine. Histograms from a 
single experiment representative of five independent 
experiments are shown. (C–D) CD80 expression by 
monocytes incubated with (C) rIL-4 (10 ng/mL), and 
histamine (10−5 M) and with (D) anti-IgE + IL-33 
triggered basophil supernatants. Blocking was 
performed by preincubation with anti-IL-4 antibody 
and matching isotype control or with histamine 
receptor 2 antagonist ranitidine. DAPI+ cells were 
gated out as shown in Figure 2D. (C, D) Data are shown 
as shown as mean+SEM of percentages of CD80+ cells 
and are pooled from five independent experiments (n 
= 5 monocyte donors) * p < 0.05 determined by 
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Similar to what was observed for supernatants, LPS-induced IL-10 was significantly 
upregulated only when IL-4 was blocked (Fig. 5B). Control conditions with basophils alone 
did not produce TNF-α or IL-10, suggesting that the cytokines in the coculture were 
derived from monocytes (data not shown).Cell viability, as measured by DAPI staining, 
was comparable in all conditions (data not shown).  
Furthermore, activated basophils in coculture with monocytes significantly inhibited LPS-
induced CD80 expression with a contribution of both histamine and IL-4 (Fig. 5C and F). 
On the other hand, the expression of FcγRIIb was not influenced by the presence and 
activation of basophils, unless histamine effects were blocked by ranitidine (Fig.  5D). 
These data are similar to the results obtained with supernatants, as we could not 
observe, for the analyzed parameters, additional or different effects possibly due to cell -
to-cell contact. 
However, these results indicate that human basophils can influence monocyte responses 
when cells are being exposed to the proinflammatory stimulus at the same time, further 
confirming the immunomodulatory properties of basophil-derived soluble mediators. 
DISCUSSION 
Here, we show that human basophils, in addition to their known effector functions (29), 
can participate in immune regulation, by suppressing monocyte-mediated 
proinflammatory responses. In particular, purified human basophils, activated via FcεRI  
ligation and IL-33, inhibited the LPS-induced production of the prototypical 
proinflammatory cytokine TNF-α and the expression of the costimulatory molecule CD80 
by monocytes. In other words, monocyte activation via a strong proinflammatory 
stimulus such as LPS was dampened when they were exposed to basophil supernatants 
or cocultured with basophils. Similar results were obtained using basophil supernatants 
or coculturing basophils and monocytes, suggesting that these effects do not require cell -
to-cell contact and are mainly dependent on soluble mediators. Indeed, blocking 
experiments showed that basophil-derived IL-4 and, most of all, histamine, were 
responsible for the modulation of monocyte activity. 
These data are in line with recent findings in a mouse model of allergic inflammation, in 
which basophils, via IL-4, were shown to induce the differentiation of inflammatory 
monocytes into anti-inflammatory macrophages (10). Likewise, in a mouse model of 
arthritis, basophils, by producing IL-4 in response to IL-33, were essential to mediate the 
immunosuppressive effects of IVIG (8). 
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Figure 5 (left). Monocytes and 
basophils coculture. Isolated 
autologous basophils and 
monocytes were cultured alone or 
together, in the presence or 
absence of LPS (5 ng/mL) and anti-
IgE (0.5 μg/mL) + IL-33 (100 
ng/mL) for 18 h. The 
concentration of (A) TNF-α and (B) 
IL-10 in the supernatants of 
monocytes cocultured with 
basophils (black bars) or 
monocytes alone (white bars), 
followed by the activation with 
LPS and blocking by preincubation 
of cells with anti-IL4 antibody, 
matching isotype control, and 
ranitidine, was measured by ELISA. 
The cytokines in conditions with 
basophils alone were below 
detection limit and are not shown. 
(C, D) The percentages of (C) CD80 
and (D) FcγRIIb in monocytes and 
monocytes cocultured with 
basophils are shown, as described 
in (A and B). (E) Example of gating 
strategy. (F) Histograms of CD80 
expression by monocytes. Data 
from one donor representative of 
three independent experi-ments. 
(A–D) Data are shown as mean + 
SEM (n = 3 donors) and are pooled 
from three independent 
experiments.* p < 0.05; for 
comparison between two groups, 
Student t test was performed. For 
multiple comparisons of coculture 
conditions, ANOVA was used with 
Bonferroni's post-test. 
We now provide evidence, for the first time, that 
basophils can mediate similar immunomodulatory 
effects in human settings. Because of the 
aforementioned studies in mice (8, 10), we expected 
basophil-derived IL-4 to be the main factor responsible 
for the anti-inflammatory effects of human basophils. 
Instead, our results show that histamine, specifically 
via H2R, is also involved in the modulation of the 
monocyte response. The interaction of basophil-
derived histamine and IL-4 proved to be more complex 
regarding the modulation of the expression of the 
inhibitory FcγRIIb and the production of IL-10, which 
were differently regulated by histamine and IL-4. 
In particular, histamine dampened the upregulation of 
the FcγRIIb by basophil-derived IL-4. A very recent 
publication offers an intriguing in vivo model to 
reproduce these findings in humans (30). Studying 
patients with primary immune deficiency, it was found 
that IVIG therapy suppresses dendritic cell function via 
IL-33-mediated induction of IL-4 and IL-13. Similar to 
our in vitro findings with monocytes, the authors did 
not observe an upregulation of the inhibitory FcγRIIb 
on dendritic cells, but on the contrary, an inhibition of 
the activating FcγRIIa. Our data, although not directly 
related to IVIG treatment, provides additional 
immunological insights and an alternative mechanism, 
suggesting that basophil-derived histamine is able to 
inhibit the IL-4 dependent upregulation of FcγRIIb, 
without influencing, in the short term, the expression 
of FcγRIIa. Overall, the involvement of histamine in the 
immunomodulatory ability of basophils has been 
apparently underestimated by previous studies, both 
in mice and humans, and most definitely warrants 
more attention. 
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To further show the relevance of histamine-mediated immune modulation, we provide 
evidence that very low concentrations of histamine still influence LPS-induced cytokine 
production by monocytes (Supplementary Fig. 1). Accordingly, very low amounts of IL-4 
(as low as 1 pg/mL) could further modulate the histamine-induced responses (and vice 
versa), suggesting a balance between these two mediators in tuning monocyte 
responses. 
The immunomodulatory properties of histamine have been investigated over the past 
years, showing both pro- and anti-inflammatory effects (31). As an example, in line with our 
observations, histamine via H2R, has been shown to inhibit the cytokine response to 
microbial products of monocytes (28, 32) and dendritic cells (33). Differentiation of 
monocytes into macrophages, on the other hand, induces the preferential expression of 
H1R over H2R (34), leading to increased production of IL-8 upon exposure to histamine 
(35). Therefore, the response to histamine can greatly vary among different cells, 
depending on expression profile of histamine receptors and among different individuals, 
possibly depending on genetic variation of histamine receptors (36). Our data further 
underline the relevance of histamine in immune regulation, showing that, among basophil-
derived mediators, histamine represents a prominent factor responsible for the modulation 
of monocyte activation. 
As for the intracellular mechanisms involved in the influence of basophil-derived histamine 
on TLR4 signaling, cAMP, induced upon histamine triggering of H2R (31), is known to inhibit 
NF-kB and therefore TNF-α production (37), while enhancing IL-10 (38). IL-4, on the other 
hand, via STAT-6, is able to inhibit both NF-kB activation (39) and IL-10 production (40). 
Overall, these intracellular pathways explain the effects on TLR4 signaling we observed 
when monocytes were exposed simultaneously to basophil-derived histamine and IL-4. 
While extensively studied independently, very little is known about the combined effects of 
these mediators on immune cells. In particular, our findings suggest for the first time 
histamine as an important player, which contribution has been so far underestimated, in 
the cross-talk between basophils and monocytes. 
Although difficult to directly show in a human setting, our data argue for a basophil- and 
histamine-dependent contribution to immunomodulation in vivo. Plasma levels of 
histamine in healthy subjects are known to be less than 1 × 10−8 M (41). We found that the 
suppressive effects of histamine on LPS-induced TNF-α production by monocytes were 
present up to a histamine concentration of 10−9 M. Although other cells are able to secrete 
histamine, in the peripheral blood the amounts produced by basophils are estimated to be 
100× to 1000× higher than the amounts produced by other leukocytes (42), suggesting 
that, even with their relatively low percentage, most of the circulating histamine is likely to 
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originate from basophils. Basophils can also infiltrate tissues, as shown in several 
inflammatory conditions (43, 44). Upon activation by local stimuli (exogenous and 
endogenous TLRs ligands, IL-33 etc.) basophil could, potentially, influence monocyte 
activation locally, as was shown in the previously discussed mouse model of allergic 
inflammation (10). 
Unexpectedly, we observed the presence of histamine in basophil cultures in which the 
basophils remained unstimulated or were stimulated with IL-33 only. Although we can't 
exclude that histamine release is partially due to in vitro culture conditions, these findings 
are in line with previous studies showing histamine release by a mechanism defined as 
"piecemeal’’ degranulation (45). While it would be tempting to speculate that the 
described IL-33-induced histamine release by human basophils and subsequent immune 
regulation are also operative in IgE-independent inflammatory conditions, further studies 
will be needed to address the relevance of the IgE-independent histamine release by 
basophils. 
In conclusion, our data show that IL-33 significantly enhances IgE-mediated activation of 
basophils, inducing the production of IL-4 and the release of histamine. These basophil-
derived mediators, in turn, were found to modulate monocyte responses, by suppressing 
their LPS-induced activation. Histamine, in particular, played a central role in basophil-
mediated immune modulation. Overall, our observations show that human basophils are 
able to inhibit monocyte proinflammatory activation and point to a previously 
unrecognized role for human basophils, through the balanced secretion of IL-4 and 
histamine, in the regulation of the immune response. 
MATERIALS AND METHODS 
CELL ISOLATION 
Buffy coats from healthy volunteers were obtained from the blood bank (Sanquin, NL). 
For isolation of basophils, leukocyte-rich plasma was first prepared with HetaSep 
(StemCell Technologies) and basophils were then selected by negative magnetic bead 
isolation using the EasySep™ Human Basophil Enrichment Kit (StemCell Technologies), 
according to the manufacturers’ instructions. The purity of enriched basophils (mean 
98%) was determined by flow cytometric analysis of FcεRI, CD123 , and CD203c, using 
BDCA-2 to exclude the presence of contaminating pDC. For monocyte isolation, PBMCs 
were isolated from buffy coats and CD14
+
 monocytes were selected using magnetic-
labeled anti-CD14 beads (Miltenyi Biotec), according to the manufacturer's instructions 
(mean purity 96%). 
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BASOPHIL ACTIVATION 
After isolation, basophils were cultured in RPMI-1640 medium containing 10% fetal calf 
serum, glutamine, penicillin, and streptomycin (Invitrogen) at 37°C in 5% CO2 atmosphere 
at a concentration of 1 × 106 cells/mL. Basophils were stimulated using 0.5 μg/mL of goat-
anti-human IgE (Nordic-MUbio), 100 ng/mL of recombinant human IL-33 (PeproTech), or 
both. After 24 h, cells were harvested, supernatants were collected and stored at –20°C 
and cells were used for flow cytometric analysis. 
MONOCYTE STIMULATION 
After isolation, monocytes were cultured in the same medium under the same 
conditions as basophils. Monocytes were incubated with basophil supernatants 
(diluted 1:4 in normal medium) or control media (containing the same stimuli used for 
basophil activation to exclude their direct effects on monocytes). In parallel, 
monocytes were incubated with recombinant human IL-4 (PeproTech) at a 
concentration of 10 ng/mL and histamine (Sigma-Aldrich) at a concentration of 10−5 
M. Monocytes were stimulated with LPS from Salmonella typhosa (Sigma-Aldrich) at a 
concentration of 5 ng/mL. After overnight (18 h) incubation cells were harvested, 
supernatants collected and stored at –20°C for further analysis and cells were 
resuspended in PBS with 2 mM EDTA (Sigma-Aldrich) for 15 min on ice. Cells were 
detached by vigorously pipetting, washed, and resuspended in PBS 0.5% BSA for flow 
cytometric analysis.  
For blocking experiments, supernatants of anti-IgE and IL-33 activated basophils were 
used. They were preincubated with anti-IL-4 antibody or matching isotype control rat 
IgG1 (both from eBioscience) at a concentration of 20 μg/mL for 30 min at 37°C in 5% 
CO2 atmosphere, prior to addition to the monocytes. For inhibition of his tamine, 
monocytes were preincubated for 30 min at 37°C with histamine receptor 2 antagonist 
ranitidine at a concentration of 10−4 M. For blocking experiments with exogenous 
histamine in addition to ranitidine, histamine receptor 1 antagonist cetirizine and  
histamine receptor 3/4 antagonist thioperamide (Sigma-Aldrich) were used, at 
concentrations from 10−6 to 10−4 M. 
BASOPHILS AND MONOCYTES COCULTURE 
Isolated autologous basophils and monocytes were cultured alone or together at 1 × 106 
cells/mL in a ratio 1:2, in the presence or absence of LPS and anti-IgE/IL-33 at the same 
concentrations mentioned above, for 16–18 h. Supernatants were collected and stored 
at –20°C for further analysis, monocytes were detached with PBS 2 mM EDTA as 
previously indicated and cells were used for flow cytometric analysis. 
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FLOW CYTOMETRY 
For standard surface staining, cells were incubated with fluorochrome-conjugated 
antibodies diluted in PBS 0.5% BSA at 4ºC for 30 min. After washing, cells were suspended 
in PBS 0.5% BSA. To exclude dead cells, cells were suspended in PBS/0.5%BSA and just prior 
to flow cytometric acquisition, 0.2 μM DAPI (Invitrogen) was added. 
Cells were acquired on a LSR-II (BD Biosciences) and analysis was performed using FlowJo 
software (Tree Star, Inc). The following antibodies (clone) were used: CD123-PerCpCy5.5 
(clone 7G3), CD63-PE (H5C6), HLA DR-FITC (L243), CD80-PE (L307.4), CD16-FITC (3G8), 
CD64 PE (10.1), mIgG2b-FITC (27–35), IgG2ak-FITC (X39). IgG2ak-allophycocyanin (MOPC-
21) from BD Biosciences; FcεRI-FITC (AER-37), CD14-PerCP-Cy5.5 (61D3), mIgG1-PE 
(P3.6.2.8.1), mIgG2b-PE (eBMG2b), mIgG2b-PerCP-Cy5.5 (MOPC-21) from eBioscience; 
BDCA2-PE (AC144) and CD203c (FR 3–16A11) from Miltenyi and CD32-FITC (IV.3) from 
Stemcell. AlexaFluor488-CD32b (ch2b6-N297Q) and corresponding isotype control 
(ch4420-N297Q) were generously provided by Macrogenics (46, 47). 
MEASUREMENT OF CYTOKINES 
IL-4 was measured using the IL-4 Human PeliPair™ ELISA kit (Sanquin Reagents), TNF-α and 
IL-10 were measured using the Human TNF ELISA set (BD Biosciences) and the IL-10 Human 
PeliPair™ ELISA kit (Sanquin Reagents), respectively. Histamine was measured using the 
Histamine ELISA kit (Neogen). All kits were used according to manufacturer's instructions. 
STATISTICAL ANALYSIS 
Data are expressed as mean + SEM. For comparisons of two groups, paired Student's t-test 
was performed. For comparisons of multiple groups, ANOVA was performed with 
Bonferroni's post-test to determine statistical significance between each group. The 
number of independent experiments is indicated in each figure legend and each 
independent experiment represents a different donor. P-values <0.05 were considered 
significant and are shown in the figures. Analyses were performed using GraphPad Prism 5 
Software (GraphPad Inc Software). 
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Supplementary Figure 1. Titration of IL-4 and histamine effects on LPS-induced activation of monocytes. 
Isolated monocytes were activated with LPS together with decreasing amount of IL-4 (A) or histamine (B). 
After over-night incubation, TNF-alpha was measured by ELISA in the supernatants. Results are expressed 
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SUMMARY 
Background Mast cells are mainly present in strategic locations, where they may have a role 
in defence against parasites and bacteria. These pathogens can be recognized by mast cells 
via Toll-like receptors (TLR). Allergic symptoms are often increased in the presence of 
pathogens at the site of allergen exposure, but it is unknown which cytokines can mediate 
such an effect. 
Objective To study whether an interaction between IgE- and TLR-mediated activation of 
human mast cells can contribute to exacerbated inflammatory responses. 
Methods Peripheral blood-derived mast cells were stimulated with TLR ligands, in the 
presence or absence of anti-IgE triggering, after which degranulation was measured using 
flow cytometry and cytokine production was evaluated by multiplex assays, and ELISA. For 
evaluation of allergen-specific responses, mast cells were sensitized with serum of allergic 
individuals or controls, after which they were stimulated using allergens in combination 
with TLR ligands. 
Results Simultaneous triggering of mast cells via IgE and TLR ligands greatly enhanced 
cytokine production but not IgE-induced degranulation. Different TLR ligands specifically 
enhanced the differential production of cytokines in conjunction with FcεRI triggering. 
Importantly, only TLR-4 and TLR-6 were able to induce robust production of IL-13, an 
important molecule in allergic reactions. 
Conclusions & Clinical Relevance These results indicate that the simultaneous presence of 
pathogen- or danger-associated signals and FcεRI triggering via specific IgE can significantly 
modify mast cell-mediated allergic reactions via synergistic production of cytokines and 
inflammatory mediators and provide an explanation of augmented allergic symptoms 
during infection. 
INTRODUCTION 
Mast cells are immune cells that reside in all tissues and are most well known for their 
role in IgE-mediated allergic responses. Mast cells are found at strategic locations 
where they can encounter pathogens, such as the skin and mucosal surfaces like the 
gut and the respiratory tract. Mast cells have been well established to play a role in the 
defence against bacteria, certain parasites (mainly intestinal helminth parasites), and 
possibly against fungal and viral infections (1-5). Recognition of pathogens via Toll-like 
receptors (TLR) has been shown to contribute to mast cell responses to pathogens (5). 
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In addition to activation via innate receptors in primary responses, IgE that is produced 
in response to parasites or other pathogens may also play an important role in 
recognition of pathogens in secondary or chronic infection (6) or, as described 
recently, in the protection against venoms upon second exposure (7). 
However, although such responses may play an important role in the protection 
against secondary exposure to pathogens or venoms, these enhanced responses can 
have detrimental effects in responses when no danger is present, such as is the case in 
allergic responses (8). Viral and bacterial infections have been associated with asthma 
exacerbations (9, 10), and the presence of the TLR-4 ligand endotoxin was 
demonstrated in house dust and was related to severity of allergic reactions against 
house dust mite (11). Furthermore, allergens have been reported to promote TLR 
signalling directly (12). Therefore, mast cell activation via TLRs may contribute to these 
processes when triggered at the same time by allergen-specific IgE. Studies using 
mouse mast cells have shown contrasting data concerning the degranulation and 
cytokine response upon combined antigen and TLR triggering (13-15). 
In human mast cells, it has been shown that prolonged pre-treatment with LPS can 
significantly enhance IgE-mediated mast cell responses (15), and it is therefore been 
hypothesized that TLR triggering of mast cells can contribute to asthma exacerbations. 
We and others have previously shown that mast cells can differentially secrete 
cytokines depending on the TLR that is triggered (16-18). However, it is unknown 
whether differential cytokine production is still present upon combined IgE -mediated 
responses. This is important, as different mast cell mediators have distinct functions in 
allergic responses. 
Therefore, we aimed to characterize human mast cell responses upon combined 
activation via (allergen-specific) IgE and TLR triggering and to analyse the specific 
cytokines induced by different TLR ligands. 
METHODS 
PERIPHERAL BLOOD-DERIVED MAST CELLS 
Buffy coats from healthy volunteers were obtained from the blood bank (Sanquin, the 
Netherlands). CD34
+
 hematopoietic stem cells were isolated from mononuclear cells with 
CD34 microbeads (Miltenyi Biotec, GmbH, Bergisch Gladbach, Germany) and were 
differentiated into mast cells as described (16). The purity of mast cells ranged from 90 to 
99%. 
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MAST CELL ACTIVATION 
Cultured mast cells were sensitized with 0.1 μg/mL hybridoma IgE (Diatec Monoclonals, 
Oslo, Norway) for a minimum of 18 h, after which they were activated with goat anti-
human IgE (Nordic-MUbio, Susteren, The Netherlands) to induce IgE-mediated activation. 
For TLR-mediated activation, mast cells were stimulated using S. aureus Peptidoglycan 
(Pgn), Poly(I:C), E. Coli K12 lipopolysaccharide (LPS), S. typhimurium flagellin, FSL-1, 
10 μg/mL ssRNA40 (all from InVivoGen, San Diego, CA, USA) for 24 h. A titration was 
performed to determine the optimal concentrations of stimuli, using the following 
concentrations (high, medium, low): aIgE: 10, 0.5, 0.05 μg/mL; Peptidoglycan: 10, 5, 
1 μg/mL; LPS: 10, 0.5, 0.05 μg/mL; Flagellin: 1, 0.1, 0.01 μg/mL; FSL-1: 1, 0.1, 0.01 μg/mL; 
ssRNA40: 10, 1, 0.1 μg/mL. 
For combined activation via IgE and TLRs, IgE-sensitized mast cells were activated with 
suboptimal and optimal concentrations of anti-IgE (10 and 0.01 μg/mL), Peptidoglycan (10 
and 5 μg/mL), LPS (10 and 0.5 μg/mL), flagellin (1 and 0.1 μg/mL), FSL-1 (1 and 0.1 μg/mL) 
and ssRNA40 (10 and 1 μg/mL). 
For allergen-specific activation, mast cells were sensitized for 18 h with serum from house 
dust mite-allergic individuals and control individuals, diluted 1 : 1 in culture medium. The 
presence of house dust mite-specific IgE was measured by ImmunoCAP (Phadia Thermo 
Fisher Scientific, Uppsala, Sweden), with 0.35 UA/mL as cutoff. Mast cells were washed 
with medium and subsequently activated with 10 μg/mL anti-IgE or 0.25 U/mL house dust 
mite allergen (Dermatoph. pteronyssinus, HAL Allergy, Leiden, The Netherlands) in the 
presence or absence of LPS. 
FLOW CYTOMETRY 
For detection of mast cell degranulation, cells were incubated with fluorochrome-
conjugated antibodies recognizing CD117, CD203c and CD63 or matching isotype controls. 
Cells were taken up in 1% paraformaldehyde until flow cytometric acquisition on a FACS 
Calibur (BD Biosciences, San Jose, CA, USA). Analysis was performed using FACS Diva 
software (BD) and FlowJo. 
CYTOKINE SECRETION 
Quantitative immunoassays for EGF, Eotaxin, FGF-2, Flt-3 Ligand, Fractalkine, G-CSF, GM-
CSF, GRO, IFN-ɑ2, IFNγ, IL-1ra, IL-1ɑ, IL-1β, IL-2, sIL-2Rɑ, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, 
IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MCP-3, MDC, MIP-1ɑ, MIP-
1β, PDGF-AA, PDGF-AB/BB, RANTES, sCD40L, TGF-ɑ, TNF-ɑ, TNF-β and VEGF in culture 
supernatants were performed using the 42-plex cytokine or custom-made Milliplex assays 
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(EMD Millipore, Billerica, MA, USA). Additionally, IL-8 and IL-13 production was evaluated 
using ELISA (eBioscience, San Diego, CA, USA). 
STATISTICAL ANALYSIS 
Results are expressed as mean + SEM. For comparison of multiple groups, one-Way ANOVA 
was performed, with Bonferroni's post-test to correct for multiple testing. For comparison 
of two groups, Student's t-test was performed. Statistical analysis was performed using 
GraphPad Prism 4 (Graphpad Software, La Jolla, CA, USA). P values of < 0.05 were 
considered statistically significant. 
RESULTS 
DIFFERENTIAL CYTOKINE PRODUCTION UPON TITRATION OF TLR LIGANDS 
We have previously shown that mast cells functionally express TLR-2, TLR-4, TLR-5, TLR-6, 
and TLR-8 (16). To determine the optimal concentrations of stimuli, the ligands for these 
TLRs were titrated, after which cytokines were measured in supernatant (Fig. 1). For most 
cytokines, the highest concentration of TLR ligands was most potent in inducing cytokine 
production. An exception is IL-8, which was also significantly up-regulated at lower 
concentrations of several TLR ligands.  
Importantly, a differential cytokine profile was observed, with LPS and FSL-1 (TLR-4 and -6 
ligands) showing a nearly similar pattern of upregulation of GM-CSF, IL-8 and IL-10, 
whereas ssRNA (TLR-8 ligand) induced IL-8, MIP-1ɑ and TNF-ɑ. As the optimal 
concentration of stimuli was different for IL-8 as most other cytokines, we decided to 
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Figure 1. Mast cells were 
stimulated with control 
medium (ctr) or different 
concentrations of anti-IgE, 
Peptidoglycan (Pgn; TLR-2), 
LPS (TLR-4), Flagellin (TLR-5), 
FSL-1 (TLR-6) and ssRNA (TLR-
8). The concentrations of 
stimuli (high, medium, low) 
used were as follows: aIgE: 10, 
0.5, 0.05 μg/mL; Peptido-
glycan: 10, 5, 1 μg/mL; LPS: 
10, 0.5 and 0.05 μg/mL; 
Flagellin: 1, 0.1, and 
0.01 μg/mL; FSL-1: 1, 0.1, 
0.01 μg/mL; ssRNA40: 10, 1 
and 0.1 μg/mL. Cytokine 
production was measured in 
supernatant after 24 h. 
Asterisks indicate significantly 
(P < 0.05) increased cytokine 
production compared to 
control medium (ctr), using 
one-way ANOVA with 
Bonferroni's post-test (n = 3 
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DIFFERENTIAL CYTOKINE PRODUCTION IS AMPLIFIED BY COMBINED TLR- AND FCεRI-
MEDIATED ACTIVATION 
We next evaluated possible interactions between triggering of FcεRI and activation via 
TLRs. FcεRI was crosslinked using anti-IgE in the presence or absence of TLR ligands for 
24 h, after which cytokine production was measured. We observed amplified cytokine 
responses upon combined stimulation by several TLR ligands and anti-IgE (Figs 2 and 3).  
The cytokines were separated based on their pattern of induction by different TLR 
ligands. The TLR-4 ligand LPS in combination with anti-IgE significantly enhanced the 
production of GM-CSF, IL-5, IL-8 (at suboptimal concentrations), IL-10 and IL-13, in 
comparison with anti-IgE alone (Fig. 2). The effect of TLR-6 ligand FSL-1 resembled this 
pattern, although with a smaller magnitude. Therefore, only IL-8 and IL-13 were 
significantly enhanced by FSL-1. In contrast to this pattern, TLR-8 ligand ssRNA 
significantly enhanced the production of several other cytokines, EGF, GRO-ɑ, MIP-1ɑ 
and TNF-ɑ (Fig. 3). 
These results suggest that the response to TLR ligands was different depending on the 
TLR that was being triggered. Importantly, when comparing the cytokine profiles of TLR 
ligands without anti-IgE to the profiles in presence of anti-IgE, there is a striking 
resemblance between the profiles, indicating that enhancement of specific cytokines by 
FcεRI triggering is defined by specific TLRs. These results indicate that the combination of 
TLR triggering and anti-IgE synergizes in cytokine production by mast cells, where the 
exact cytokine profile is defined by the TLR ligand. 
SYNERGY BETWEEN ALLERGEN-SPECIFIC IgE-MEDIATED ACTIVATION AND TLR TRIGGERING 
To confirm the synergy in production of IL-8 and IL-13 upon triggering with LPS in an 
antigen-specific system, we next evaluated mast cell activation through allergen-specific 
IgE. Mast cells were sensitized with serum of house dust mite-(HDM) allergic individuals, 
and subsequently stimulated with HDM, leading to mast cells degranulation and activation, 
as shown by upregulation of CD63 and CD203c and release of IL-8 (Figs 4a and b). In 
contrast, sensitization with serum from non-allergic individuals did not induce HDM-
induced mast cell activation. 
The presence of LPS did not affect the HDM-induced degranulation (CD63) or upregulation 
of CD203c (Fig. 4c). Intriguingly however, combining TLR-signals with FcεRI triggering via 
HDM-specific IgE led to enhanced production of IL-8 and IL-13 (Figs 4d and e). Specifically, 
IL-13 production increased twofold to eightfold upon combined activation as compared to 
the cumulative production of each stimulus alone (Figs 4d and e). 
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Figure 2. This figure shows the cytokines which are upregulated in response to TLR-4 and TLR-6 ligands. See 
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Figure 3. Mast cells were stimulated with Peptidoglycan, LPS, Flagellin, FSL-1 and ssRNA alone or in 
combination with anti-IgE at low (left) or high (right) concentrations. Low concentrations used were as 
follows: anti-IgE (0.01 μg/mL), Peptidoglycan (5 μg/mL), LPS (0.5 μg/mL), flagellin (0.1 μg/mL), FSL-1 
(0.1 μg/mL) and ssRNA40 (1 μg/mL). High concentrations used were as follows: anti-IgE (10 μg/mL), 
Peptidoglycan (10 μg/mL), LPS (10 μg/mL), flagellin (1 μg/mL), FSL-1 (1 μg/mL) and ssRNA40 (10 μg/mL). 
Cytokine production was measured in supernatant after 24 h. Asterisks indicate significantly (P < 0.05) 
increased cytokine production compared with control medium (ctr) or anti-IgE alone, as indicated in the 
figure, using one-way ANOVA with Bonferroni's post-test. Data shown are from n = 3 independent 
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Figure 4. Mast cells were 
sensitized with serum of 
house dust mite allergic 
individuals, after which they 
were stimulated for 24 h with 
house dust mite (HDM) 
allergen or anti-IgE as positive 
control. (a) Representative 
flow cytometry plots for CD63 
and CD203c, gated on CD117+ 
mast cells. (b,c) Summary of 
data of CD63 and CD203c 
surface expression as well as 
IL-8 production in super-
natant. (d) Surface expression 
of CD63 and CD203c upon 
combined activation of 
sensitized mast cells with 
HDM and LPS. (e) Production 
of IL-8 and IL-13 after 
combined activation of 
sensitized mast cells with 
HDM and LPS. (f) Relative 
increase in cytokine 
production upon combined 
activation is shown as per-
centage of cytokine pro-
duction in response to com-
bined triggering divided by 
the sum of the cytokine 
production following stimu-
lation with HDM and LPS 
separately. Asterisks indicate 
significantly (P < 0.05) in-
creased degranulation (b,c) or 
cytokine production (c–f) as 
indicated in the figure, using 
Student's t-test. Data shown are from n = 3 independent experiments and mast cell donors, using serum 
from 4 HDM-IgE-positive and 3 HDM-IgE-negative individuals. 
Together, these results show that TLR- and IgE-mediated activation of human mast cells 
can synergistically enhance their activation, leading to enhanced cytokine production by 
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DISCUSSION 
Our results show that the combination of IgE- and TLR-mediated activation greatly 
enhances cytokine production by mast cells, but not their degranulation. Whereas mast cell 
degranulation is important for acute-phase allergic responses, cytokine production is 
considered to be more important for the, more inflammation related, late-phase responses 
(19, 20). Therefore, our results suggest that the presence of TLR ligands may specifically 
enhance the late-phase responses in allergy. Our results indicate that the type of cytokine 
response that is induced depends on the TLR that is being triggered. For example, IL-13 
production was only enhanced by ligands for TLR-4 and TLR-6. The presence of endotoxin 
(TLR-4 ligand) in house dust has been associated with allergic symptoms (10), and LPS has 
been shown to enhance allergic symptoms in a mouse model of house dust mite allergy 
(21). IL-13 is an important cytokine implicated in the induction of several key symptoms in 
allergy, such as enhancing mucus hypersecretion and airway hyperresponsiveness (22). Our 
results indicate that synergy in IL-13 production by mast cells when they are exposed to LPS 
and house dust mite could contribute to endotoxin-enhanced allergic responses to house 
dust mite. 
A clear inherent limitation of our study is that we used in vitro-generated mast cells, rather 
than primary mast cells isolated from tissue. The number of mast cells obtained from 
tissues is limited, and isolation of mast cells often leads to their activation, making it 
difficult to perform functional studies evaluating cytokine production (23). We and others 
have shown that in vitro-generated mast cells resemble tissue mast cells in various aspects 
(16, 23, 24). However, we cannot exclude that cytokine production by mast cells in vivo is 
also influenced by the local tissue environment. We did not observe a response of mast 
cells to house dust mite extract as measured by CD63-upregulation, or IL-8, respectively, IL-
13-release. In contrast, this allergen only induced such a response when mast cells were 
sensitized with serum from allergic individuals, suggesting that the house dust mite extract 
did not directly activate mast cells. This is in contrast with studies in the mouse showing 
that der p 2 present in house dust mite could directly promote TLR signalling (12). Our 
results suggest that the activation of human mast cells by house dust mite allergens 
through specific IgE is much more potent than the activation through TLR.  
Other studies have evaluated TLR-mediated potentiation of IgE-dependent release of TNF-
ɑ, for example using mast cell-lines or mouse mast cells. In mouse bone marrow-derived 
mast cells, a number of cytokines were synergistically enhanced by combined FcεRI and 
TLR-2 or TLR-4 triggering, but only few cytokines were analysed (13). In the human mast 
cell line LAD2, no TNF-ɑ potentiation was observed when TLR-2 or TLR-4 ligands were 
combined with anti-IgE (25). In our study, we also did not observe significant enhancement 
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of TNF-ɑ with LPS. Rather, a group of cytokines, including TNF-ɑ, was specifically enhanced 
with the TLR-8 ligand ssRNA, and another group of cytokines, including IL-5 and IL-13, was 
enhanced by LPS. Therefore, our results suggest that potentiation of cytokine production 
depends on the specific TLR that is being triggered, and that analysis of mast cell responses 
to TLR ligands requires the measurement of multiple cytokines. We provide a technique to 
sensitize mast cells with allergen-specific IgE using serum of allergic individuals, which 
allowed us to analyse allergen-specific mast cell responses in a specific manner. 
In conclusion, our data show that IgE-mediated activation of human mast cells is 
synergistically enhanced by TLR ligands in a cytokine-specific and TLR-ligand-specific 
manner. These data could therefore contribute to further the understanding of 
exacerbations of allergic reactions during infections. 
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ABSTRACT 
Objective Mast cells may play a role in rheumatoid arthritis (RA), but activation of human 
mast cells in autoimmune settings has been little studied. Toll-like receptors (TLR) and Fcγ 
receptors (FcγR) are important receptors for cellular activation in the joint, but expression 
and stimulation of these receptors in human mast cells or the functional interplay between 
these pathways is poorly understood. Here, we analysed triggering of human mast cells via 
these receptors in the context of anti-citrullinated protein antibody-positive (ACPA+) RA.  
Methods RNA and protein expression of TLRs and FcγR was quantified using PCR and flow 
cytometry, respectively. Mast cells were stimulated with TLR ligands (including HSP70) 
combined with IgG immune complexes and IgG-ACPA.  
Results Human mast cells expressed TLRs and produced cytokines in response to TLR 
ligands. Both cultured and synovial mast cells expressed FcγRIIA, and triggering of this 
receptor by IgG immune complexes synergised with activation by TLR ligands, leading to 
two- to fivefold increased cytokine levels. Mast cells produced cytokines in response to 
ACPA immune complexes in a citrulline-specific manner, which synergised in the presence 
of HSP70.  
Conclusions Our data show that synovial mast cells express FcγRIIA and that mast cells can 
be activated by IgG-ACPA and TLR ligands. Importantly, combined stimulation via TLRs and 
immune complexes leads to synergy in cytokine production. These findings suggest mast 
cells are important targets for TLR ligands and immune complexes, and that combined 
activation of mast cells via these pathways greatly enhances inflammation in synovial tissue 
of RA patients.  
INTRODUCTION 
Rheumatoid arthritis (RA) is an autoimmune disease characterised by chronic 
inflammation of the synovial lining of the joint. Antibodies against citrullinated 
proteins (ACPA) can be found in the majority of patients with established RA (1). 
These antibodies recognise proteins in which arginine is converted into citrulline  
through a post-translational modification. ACPA are associated with disease 
progression (2) and their pathogenic potential has been shown in mice (3, 4). The 
exact way by which ACPA contribute to inflammation is not known, but ACPA immune 
complexes have been shown to allow the activation of monocytes and macrophages 
(5, 6). However, several other immune cells may contribute to ACPA -mediated 
immune responses in RA.  
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One of these cell subsets are mast cells, which comprise up to 5% of the synovial cells. 
Several findings in patients support an active role of mast cells in RA pathogenesis. Mast 
cell numbers are increased in RA synovium (7, 8). Furthermore, several mast cell mediators 
have been observed in the synovial fluid of RA patients (8, 9), and these mediators have 
been shown to have pathogenic effects on synovial fibroblasts (10, 11), suggesting that 
mast cells may play a role in inflammatory processes in RA. However, the specific pathways 
leading to mast cell activation in RA have not been shown.  
The main biological function of mast cells is considered to be protection against pathogens 
(12). Recognition of pathogens by mast cells via toll-like receptors (TLRs) may lead to 
inflammatory responses such as recruitment of neutrophils and T cells. TLR ligands can also 
be released during chronic inflammatory responses, and are thought to contribute to the 
chronicity of RA (13-17). Although studies performed in mice suggest that mast cells can be 
activated by TLR ligands, there is only limited information on TLR triggering of human mast 
cells. Some studies have shown expression of TLR-2, -3 and -4 by human mast cells, but the 
response to other TLRs and the type of response that is induced in mast cells is not clear 
(18-22). It has been suggested that the innate responses of mast cells towards pathogen-
derived or endogenous TLR ligands may be enhanced by the presence of specific 
antibodies, such as those present during a memory response to pathogens, allowing a rapid 
clearance of the infecting microbe.(12) However, in the context of autoimmunity, such an 
enhanced response can have harmful effects, and may contribute to aberrant and 
continuous activation of the immune system.  
As mast cells are present in RA synovium, a location where endogenous TLR ligands and 
citrullinated proteins have been found, combined mast cell activation via TLR and ACPA 
immune complexes could play a role in chronic immune activation in RA. Because the 
expression of TLRs and the functional response towards TLR ligands in human mast cells is 
not established, and because it is not known whether mast cells can be activated by ACPA 
immune complexes, we aimed to thoroughly analyse mast cell responses upon TLR and 
FcγR triggering as well as the interplay between TLR- and IgG-mediated responses in ACPA+ 
RA.  
METHODS 
PERIPHERAL BLOOD-DERIVED MAST CELLS 
Buffy coats from healthy volunteers were obtained from a blood bank (Sanquin, The 
Netherlands). CD34
+
 haematopoietic stem cells were isolated from peripheral blood 
mononuclear cells (PBMCs) with CD34 microbeads (Miltenyi Biotec). Isolated stem cells 
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were differentiated into mast cells as described.(23) After 6–8 weeks, the purity of mast 
cells was determined by flow cytometric analysis of CD117, FcεRI, CD203c and intracellular 
tryptase. The purity of mast cells ranged from 90% to 99%.  
REAL-TIME PCR 
One million mast cells per donor were lysed in TRIzol reagent (Invitrogen). RNA was isolated 
using TRIzol. A cDNA library was constructed using the RT2 First Strand Kit (SA Biosciences). 
Expression of mRNA for TLRs and the TLR signalling pathway was assessed by real-time PCR, 
using the Toll–Like Receptor Signaling Pathway PCR Array (SA Biosciences). Expression was 
normalised to housekeeping gene HPRT1.  
MAST CELL ACTIVATION 
Cultured mast cells were sensitised with 0.1 μg/mL IgE (Diatec) for 18 h, after which they 
were activated with 10 μg/mL goat anti-human IgE (Nordic). For TLR-mediated activation, 
mast cells were stimulated using 1 μg/mL Pam3csk, 10 μg/mL zymosan, 10 μg/mL 
Staphylococcus aureus peptidoglycan, 10 μg/mL poly(I:C), 0.1–10 μg/mL Escherichia coli 
K12 lipopolysaccharide (LPS), 1 μg/mL Salmonella typhimurium flagellin, 1 μg/mL FSL-1, 5–
10 μg/mL imiquimod, 10 μg/mL ssRNA40 and 5 μM ODN2006 (CpG) (all from InvivoGen) for 
24 h.  
For FcγR-mediated activation by plate-bound IgG (pb IgG), culture plates (U-bottom, 96 
wells) were coated with 10 μg/mL purified human IgG (Jackson ImmunoResearch) in PBS at 
37° for 1.5 h (24). For activation by soluble immune complexes, human IgG was heat 
aggregated (HA) at 63°C for 30 min, after which insoluble complexes were removed by 
centrifugation at 13 000 rpm for 5 min. Mast cells were stimulated using 100 μg/mL HA IgG 
(25).  
For blocking studies, mast cells were incubated with 20 μg/mL anti-CD32 (clone IV.3; 
Stemcell), mIgG2b isotype control (eBioscience), 10 μg/mL anti-TLR-2 (clone TL2.1; 
eBioscience) or anti-TLR-4 (clone HTA-125; eBioscience) for 1 h at 37° prior to activation, 
after which cells were diluted 1:1 in culture medium containing the indicated stimuli.  
IgG-ACPA MEDIATED MAST CELL ACTIVATION 
Biotinylated CCP2 peptide and the arginine control peptide were obtained from Dr J W 
Drijfhout, Department of Immunohematology and Bloodtransfusion, LUMC, Leiden, The 
Netherlands. Nunc MaxiSorp plates (VWR) were first coated overnight with 5 μg/mL 
streptavidin (Sigma). After washing, biotinylated CCP2 and arginine control peptides (1  
μg/mL) were coated for 1 h at room temperature, and the coated wells were 
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subsequently incubated for 1 h at 37°C with serum of ACPA-positive and ACPA-negative 
RA patients, diluted 50× in PBS/0.1% BSA. After washing, mast cells were added, and 
were cultured in the presence or absence of 10 μg/mL human HSP70 (Enzo Life 
Sciences). Alternatively, CCP2- or arginine control-coated plates were incubated with 5 
μg/mL ACPA mAb.  
The ACPA IgG monoclonal antibody used here was previously cloned by van de Stadt et al 
(26). Briefly, ACPA antibody was produced following transduction with heavy and light 
chain cDNA expressing lentiviral vectors by HEK 293 T cells (27), and antibodies were 
purified from supernatant using fast protein liquid chromatography (ÄKTA; GE Healthcare) 
equipped with HiTrap Protein A columns (GE Healthcare) (28). Following purification, the 
quantity of ACPA was assessed by standard total IgG ELISA (Bethyl Laboratories) according 
to the manufacturer's instructions.  
PATIENT SAMPLES 
Diagnoses of RA or osteoarthritis (OA) were made according to 1987 and 1986 American 
College of Rheumatology criteria, respectively (29, 30). The presence of total IgG-ACPA and 
rheumatoid factor (RF) in serum was tested by routine diagnostic ELISA. Synovial tissues 
were obtained from patients with established RA and OA who had undergone knee or hip 
replacement surgery. Synovial tissue was digested in 1 mg/mL collagenase IA (Sigma-
Aldrich) and 50 μg/mL DNAse (Sigma–Aldrich) at 37°C for 1 h, after which single cell 
suspensions were obtained using a 70 μm filter. All patients gave written informed consent, 
and the study was approved by the Leiden University Medical Center human ethics 
committee.  
FLOW CYTOMETRY 
A list of antibodies used in this study is shown in online supplementary table S1  
(online). For surface staining, cells were incubated with fluorochrome-conjugated 
antibodies diluted in PBS 0.5% BSA at 4°C for 30 min. Intracellular tryptase staining was 
performed as described.23 Flow cytometric acquisition was performed on FACSCalibur 
(BD) and LSR II (BD) flow cytometers. Analysis was performed using FACSDiva (BD) and 
FlowJo software.  
CYTOKINE AND LEUKOTRIENE C4 PRODUCTION 
Quantitative immunoassays in culture supernatants were performed using the 42-plex 
cytokine Milliplex assay (Millipore). Additionally, IL-8 production was evaluated using ELISA 
(eBioscience). Leukotriene C4 was analysed using a competitive ELISA kit (Neogen).  
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STATISTICAL ANALYSIS 
Results are expressed as mean±SEM. For detection of TLR mRNA expression, the one-
sample t test was performed. For differences between multiple groups, one-way 
ANOVA was performed, with Bonferroni's post hoc test to correct for multiple testing. 
Synergy was defined as an increase in mast cell activation with the combination of 
stimuli compared to the additive mast cell response induced by the stimuli separately, 
determined using the paired-samples t test. p Values of <0.05 were considered 
statistically significant.  
RESULTS 
EXPRESSION OF TLR 
To determine the expression of TLR1 to -10 and other molecules involved in TLR signalling 
pathways, real-time PCR was performed on the mRNA of peripheral blood-derived mast 
cells. Mast cell cultures were defined by expression of CD117, CD203c, FcεRI and 
intracellular tryptase, indicating that the culture resulted in mature mast cells (see online 
supplementary figure S1).  
mRNA encoding TLR-1 to -9 was found in all three mast cell donors (figure 1A), although 
expression of TLR-3 and -9 was low compared to the other TLRs. The relative expression 
levels of TLRs in mast cells were comparable to PBMCs and most often higher than in the 
monocyte cell line THP-1 (see online supplementary figure S2). Mast cells also expressed 
mRNA for several molecules associated with TLR signalling, such as MyD88, TICAM1 (TRIF), 
TICAM2 and BTK (figure 1B).  
These data indicate that human mast cells express TLR-1 to -9 as well as the downstream 
signalling molecules, needed for TLR signal transduction.  
MAST CELL ACTIVATION BY TLR LIGANDS 
To examine whether the expression of TLRs by mast cells could be related to functional 
responses, cytokine production in response to TLR ligands was measured. Figure 2A and 
online supplementary figure S3 show that mast cells respond to TLR ligands with the 
production of several cytokines. Cytokine responses to ligands for TLR-3 and -9 were low or 
absent, in line with their low mRNA expression. In contrast, GM-CSF, IL-8 and MIP-1α were 
produced in response to most TLR ligands, IL-10 and IL-13 were mainly produced in 
response to ligands for TLR-2, and TNF-α production was mainly restricted to ligands for 
TLR-2, -4 and -8. 
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Figure 1. Total mRNA was isolated from independent peripheral blood-derived mast cell cultures of 
different donors (n=3). Relative mRNA expression of (A) Toll-like receptors (TLRs) and (B) molecules 
involved in TLR signalling, normalised to HPRT1 expression as housekeeping gene. The dotted line indicates 
the detection limit. nd, not detected.  
Besides cytokine production, one of the main effector functions of mast cells is mediated 
via granule release and production of lipid-derived mediators. In contrast to stimulation 
with anti-IgE, these responses were absent when mast cells were activated with TLR 
ligands (figure 2B–D). Therefore, TLR ligands induce a different response as compared to 
anti-IgE, characterised by the production of several cytokines in the absence of 
degranulation or release of lipid-derived molecules. Importantly, different TLR triggers 
can induce different response modes as exemplified by different cytokines induced by 
different TLR ligands.  
ACTIVATION OF MAST CELLS BY IgG IMMUNE COMPLEXES VIA FCγRII 
As the expression of FcγRs by human mast cells and their possible activation via these 
receptors is not established, we next evaluated the potential of human mast cells to be 
activated by IgG immune complexes. First, we evaluated expression of the different FcγRs 
by flow cytometry (figure 3A,B). Mast cells were found to express FcγRIIA (CD32A) but no 
other FcγR. We next stimulated mast cells with IgG immune complexes, and found that 
mast cells produced IL-8 in response to plate-bound IgG (figure 3C). Importantly, this 
response was almost completely inhibited by blocking antibodies to FcγRIIA (figure 3D). In 
addition, mast cells produced IL-8 in response to soluble immune complexes (HA IgG), and 
this response was also blocked by anti-FcγRIIA (figure 3E). No degranulation was observed 
in response to IgG immune complexes (data not shown). Together, these data show that 
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Figure 2 (left). (A) Mast cells were 
stimulated with the indicated Toll-like 
receptor (TLR) ligands for 24 h after 
which cytokines were measured in 
supernatant. The stimulation index 
was calculated by dividing the 
amount of cytokine produced after 
stimulation by the amount of cytokine 
in the supernatant of unstimulated 
mast cells. (B–D) Mast cells were 
stimulated with TLR ligands for 1 h, 
after which cells were used for flow 
cytometry to assess degranulation 
with anti-CD63 (B,C) and supernatant 
was used for the determination of 
leukotriene C4 (LTC4) release (D). 
Data were obtained from two 
independent experiments performed 
in duplicate. Asterisks indicate 
significant increases compared to 
unstimulated mast cells (p<0.001).  
SYNERGY BETWEEN TLR- AND FCγR-MEDIATED 
ACTIVATION 
As mast cells responded to triggering of TLR as 
well as FcγRII, we next evaluated the possible 
interaction between triggering with IgG immune 
complexes and TLR ligands (figure 4A,B). No 
additional effects were observed when TLR-3 or -
9 ligands were combined with plate-bound IgG, 
which is in line with the absence of activation 
with these ligands. However, combination of 
other TLR ligands with IgG led to synergy in 
cytokine production (figure 4B). Similar to the 
results obtained with plate-bound IgG, IL-8 
production by mast cells in response to LPS was 





Figure 3. (A,B) Expression of Fcγ receptors (FcγR) by cultured mast cells was analysed by flow cytometry. 
Representative examples are shown in (A) and a summary of all donors (n=6–15) analysed is shown in (B). 
(C) IL-8 production by mast cells in response to plate-bound (pb) IgG and lipopolysaccharide (LPS) (n=13). 
(D) Inhibition of IL-8 production in response to pb IgG or LPS by anti-CD32 or isotype control (n=6), 
indicated as a percentage of total IL-8 production in stimulated mast cells without blocking antibodies. (E) 
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Figure 4 (left). Mast cells were 
stimulated with Toll-like receptor 
(TLR) ligands alone or in 
combination with plate-bound 
IgG immune complexes. (A–C) IL-
8 production was measured in 
supernatant after 24 h upon 
combined triggering with plate-
bound (pb) IgG and TLR ligands. 
(A) Summary graphs showing the 
mean±SEM of IL-8 in 
supernatant (n=3). (B) IL-8 
production for all TLR ligands in 
combination with plate-bound 
IgG is shown (closed symbols) 
compared to the sum of cytokine 
levels following stimulation with 
IgG and TLR ligands separately 
(open symbols). Each symbol 
represents an independent 
donor. Asterisks indicate 
significantly (p<0.05) increased 
cytokine production when TLR 
ligands were combined with 
anti-IgE compared to the 
cumulative effect of the stimuli 
alone. (C) IL-8 production in 
response to heat-aggregated IgG 
(HA IgG) in combination with 
lipopolysaccharide (LPS) (n=4). 
(D) IL-8 production in response 
to plate-bound IgG in 
combination with zymosan (zym) 
and LPS after blocking with anti-
CD32 or isotype control (n=2).  
Expression of FcγRs was not changed by TLR ligands 
(data not shown), indicating that the synergistic 
effect was dependent on FcγRIIA, the only FcγR that 
was expressed. Indeed, blocking of FcγRIIA led to 
almost complete inhibition of IL-8 production, 
resulting in IL-8 production comparable to the TLR 
ligands alone (figure 4D). These results indicate that 
combined stimulation of mast cells via TLR and 
FcγRIIA can markedly enhance inflammatory 
responses by mast cells.  
EXPRESSION OF FCγR BY SYNOVIAL MAST CELLS 
Although mast cells are present in synovial tissue, the 
number of cells that can be isolated in a non-
activated manner does not allow for in vitro mast cell 
activation for functional studies. Nonetheless, we 
were able to analyse the expression of FcγR by 
synovial mast cells by flow cytometry (figure 5). 
Synovial mast cells from all RA and OA donors were 
found to express FcγRII. Further analysis in three 
donors showed that FcγRIIA, and not IIB, is expressed 
by synovial mast cells. Expression of other FcγRs was 
very low or absent, except for one donor, in which 
both FcγRI and FcγRIII were detected. These results 
confirm the comparability between cultured mast 
cells and synovial mast cells regarding FcγR 
expression and indicate that the molecular make-up 
of synovial mast cells allows them to be activated by 
IgG immune complexes via FcγRIIA. 
 
SYNERGY BETWEEN TLR- AND IgG-ACPA-MEDIATED ACTIVATION OF MAST CELLS 
We next wished to evaluate whether human mast cells can respond to ACPA immune 
complexes to confirm the observed synergy between IgG- and TLR-mediated activation in 
an antigen-specific system.  
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Figure 5. (A) Representative example of mast cell gating is shown. Mast cells were gated as CD117+IgE+ or 
CD117+FcεRI+ cells within the live cells as gated based on forward (FSC) and sideward scatter (SSC). 
Representative examples of Fc receptor staining are shown in (B) and a summary of all patients analysed 
(n=6 rheumatoid arthritis patients and n=4 osteoarthritis patients) is shown in (C), with each symbol 
representing an individual patient.  
First, mast cells were stimulated with ACPA immune complexes on CCP2 -coated 
plates, resulting in IL-8 production (figure 6A,B). This activation was citrulline 
dependent, as the arginine control peptide, or the use of serum from ACPA -negative 
patients, did not induce IL-8 release. Mast cell activation was inhibited by pre-
incubating mast cells with an anti-FcγRIIA antibody (figure 6C).  
The use of RF-negative serum (figure 6D) or an ACPA monoclonal IgG antibody (figure 
6E) also induced IL-8 production, confirming that mast cell activation by ACPA 
immune complexes is not dependent on the presence of RF. These results show that 
mast cells can be activated by ACPA immune complexes, and that this is mainly 
mediated via FcγRIIA.  
Subsequently, we evaluated the activation of mast cells by the endogenous TLR 
ligand HSP70 (figure 6F). To confirm that activation with HSP70 was TLR dependent, 
mast cells were pre-incubated with blocking antibodies to TLR-2 and -4. As shown in 
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Figure 6. (A, B) Mast cells were stimulated on CCP-coated plates incubated with no serum (ctr) or serum 
of ACPA+ and ACPA− RA patients, as indicated, for 24 h, after which IL-8 production was measured in 
supernatant. Results are shown as the summary of all experiments (A) or with each symbol representing 
an individual patient serum tested (B). (C) Inhibition of IL-8 production by mast cells in response to plate-
bound ACPA, IgG or LPS by anti-CD32 antibodies or isotype control, indicated as a percentage of total IL-
8 production in stimulated mast cells without blocking antibodies. (D) Mast cells were stimulated on 
CCP-coated plates incubated with the serum of ACPA+RF− patients. Results are shown as the summary 
(mean±SEM) of three independent mast cell donors using the serum of two different patients. (E) Mast 
cells were stimulated on CCP-coated plates incubated with ACPA IgG monoclonal antibody. Results are 
shown as the summary (mean±SEM) of four independent mast cell donors. (F) IL-8 production by mast 
cells in response to endogenous TLR ligand HSP70. (G) Inhibition of IL-8 production by mast cells in 
response to HSP70, by anti-TLR-2 or anti-TLR-4 antibodies, indicated as a percentage of total IL-8 
production in stimulated mast cells. (H,I) IL-8 production by mast cells in response to combined 
triggering using plate-bound ACPA and HSP70 or their separate stimulations. Results are shown as the 
summary of all independent (n=5) experiments (H) or pairwise (I), with each symbol representing an 
individual patient serum tested. (I) IL-8 production after combined stimulation with HSP70 and ACPA 
(closed symbols) compared to the sum of IL-8 following separate stimulation with HSP70 and ACPA 
(open symbols). Asterisks indicate significant (p<0.05) differences between the indicated condition s, 
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Combined activation of mast cells by ACPA immune complexes and HSP70 led to 
considerable increases in IL-8 production as compared to the single stimulus (figure 6H). 
This increase was significantly higher than the cumulative production of the separate 
stimuli when ACPA-positive serum was used, whereas no additional IL-8 production was 
observed when ACPA-negative serum was combined with HSP70 (figure 6I). Together, 
these results show enhanced cytokine production by mast cells when exposed to ACPA 
immune complexes and endogenous TLR ligands.  
DISCUSSION 
In this study, we show that human mast cells can be activated by TLR triggering as well as 
FcγR ligation. Only limited information is available on the activation of human mast cells via 
TLR and FcγR. Here, we have extensively analysed mast cell responses towards ligands for 
all TLR ligands and found different patterns of cytokine production depending on the TLR 
that was triggered. Such different cytokine production profiles in response to TLR triggering 
have previously been reported for dendritic cells and basophils, and are thought to 
contribute different types of immune responses to different pathogens (31, 32). Our results 
therefore indicate that different cytokines produced by mast cells may further promote 
these differences.  
In addition to the response to pathogen-derived TLR ligands, we show that mast cells also 
respond to endogenous TLR ligands which are present in RA synovium. Endogenous ligands 
in synovium have been postulated to induce a positive feedback loop leading to chronic 
immune activation (13, 33). Activation of TLR may be important for several chronic 
rheumatic diseases, including RA and spondyloarthritis (SpA) (34). Since mast cells are 
relatively abundant in RA and SpA synovium (7, 8, 35), they may represent an important cell 
type involved in TLR-driven chronic inflammation.  
Besides activation of mast cells via TLR ligands, we show for the first time that human mast 
cells can be triggered by ACPA immune complexes in a citrulline-dependent manner. 
Human mast cells were activated via IgG-ACPA, mediated by FcγRIIA (36-38). FcγRI was not 
expressed by synovial mast cells in the majority of patients, which is also in line with the 
absence of FcγRI expression by mast cells in other tissues (38). As ACPA immune complexes 
activated mast cells mainly via FcγRIIA and as this receptor is expressed by synovial mast 
cells from all patients analysed, we consider it most likely that this receptor is responsible 
for mast cell activation by ACPA immune complexes. A clear limitation of our study is that it 
is not feasible to perform functional assays using mast cells isolated from synovium. 
However, although we cannot show that synovial mast cells respond in the same way as 
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cultured mast cells, the cultured mast cells generally resemble the phenotype of synovial 
mast cells in their granule composition and in their expression of FcγR.  
Importantly, we showed that combination of IgG- and TLR-mediated activation greatly 
enhanced cytokine production by human mast cells. Synergy between TLR and Fc receptor 
triggering has been previously described for basophils and dendritic cells (32, 39), and likely 
represents a physiological function of the immune system to mount an enhanced response 
when antibodies are produced after the first encounter with a pathogen. Synergy in the 
production of chemokines may dictate the type and extent of immune cells which are 
attracted to the site of inflammation (40), and may therefore also have detrimental effects 
in the context of autoimmunity. For example, IL-8 is increased in synovial fluid of RA 
patients and was shown to contribute to 30–60% of neutrophil chemoattraction by synovial 
fluid (41). Therefore, synergistic IL-8 production by mast cells in response to ACPA immune 
complexes and endogenous TLR ligands may lead to increased neutrophil recruitment, and 
thus contribute to inflammatory processes in RA.  
In conclusion, we found that human mast cells functionally express TLRs and FcγRIIA and 
that triggering of TLR via endogenous TLR ligands can synergise with IgG-ACPA-mediated 
activation, greatly increasing cytokine production. These results suggest a role for 
combined TLR and FcγRIIA triggering of mast cells in the pathogenesis of RA.  
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SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1. Characterization of mast cells. Peripheral blood-derived mast cells were cultured 
from CD34+ stem cells for 6-8 weeks.  Mast cells were identified as CD117+CD203c+FcepsilonRI+Tryptase+ 
cells (>90% pure). (A) Gating of live cells (cell debris excluded based on Forward and Sideward scatter). (B) 
CD117 expression of total live cells as gated in A. (C,D) Intracellular Tryptase and chymase expression of 
total live cells.  (E) Gating of CD117+ mast cells. (F,G) Expression of CD203c and FcepsilonRI on CD117+ mast 
cells as gated in E. Representative FACS plots are shown. 
 
 
Supplementary Figure 2. Total mRNA was isolated from  independent peripheral blood-derived mast cell 
cultures of different donors (n=3) and of the monocytic cellline THP-1 and total peripheral blood 
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Supplementary Figure 3. 
Mast cells were stimulated 
with the indicated TLR 
ligands for 24 hours after 
which production of IL-8 was 
measured in supernatant. 
Paired data of n=6 to n=10 
donors is shown. P values 
shown are derived from 
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ABSTRACT 
Objective Mast cells have been implicated in the pathogenesis of rheumatoid arthritis (RA). 
In particular, their activation by interleukin-33 (IL-33) has been linked to the development 
of arthritis in animal models. The aim of this study was to evaluate the functional responses 
of human mast cells to IL-33 in the context of RA. 
Methods Human mast cells were stimulated with IL-33 combined with plate-bound IgG or 
IgG anti–citrullinated protein antibodies (ACPAs), and their effects on monocyte activation 
were evaluated. Cellular interactions of mast cells in RA synovium were assessed by 
immunofluorescence analysis, and the expression of messenger RNA (mRNA) for mast cell–
specific genes was evaluated in synovial biopsy tissue from patients with early RA who were 
naive to treatment with disease-modifying antirheumatic drugs. 
Results IL-33 induced the up-regulation of Fcγ receptor type IIa and enhanced the 
activation of mast cells by IgG, including IgG ACPAs, as indicated by the production of 
CXCL8/IL-8. Intriguingly, mast cell activation triggered with IL-33 and IgG led to the release 
of mediators such as histamine and IL-10, which inhibited monocyte activation. Synovial 
mast cells were found in contact with CD14
+
 monocyte/macrophages. Finally, mRNA levels 
of mast cell–specific genes were inversely associated with disease severity, and IL-33 mRNA 
levels showed an inverse correlation with the levels of proinflammatory markers. 
Conclusion When human mast cells are activated by IL-33, an immunomodulatory 
phenotype develops, with human mast cells gaining the ability to suppress monocyte 
activation via the release of IL-10 and histamine. These findings, together with the presence 
of synovial mast cell–monocyte interactions and the inverse association between the 
expression of mast cell genes at the synovial level and disease activity, suggest that these 
newly described mast cell–mediated inhibitory pathways might have a functional relevance 
in the pathogenesis of RA. 
INTRODUCTION 
Mast cells are tissue-resident cells of hematopoietic origin, classically known as effector 
cells in IgE-mediated inflammation and as mediators of host antimicrobial defenses. In 
addition, mast cells have been involved in the pathogenesis of many human diseases, 
including autoimmune disorders (1). However, emerging evidence suggests that mast cells 
might also have immunoregulatory/homeostatic functions (2). Therefore, their exact role in 
the pathogenesis of autoimmune diseases, such as rheumatoid arthritis (RA), is still 
debated (3). In particular, contrasting data have been obtained from animal models of 
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arthritis (4-8), which could be attributable to the aforementioned double-edged functions 
of mast cells or to the different disease models and methods used to obtain their depletion 
in vivo (9). 
In humans, several lines of evidence point toward a contributory role of mast cells in the 
pathogenesis of RA. First, they are constitutively present in the synovial membrane (10) and 
their numbers are increased in RA (11, 12), possibly correlating with parameters of disease 
activity and progression (13). Furthermore, activation of mast cells in rheumatoid synovial 
tissue has been linked to the production of proinflammatory cytokines (14), several mast 
cell mediators have been observed in the synovial fluid of patients with RA (15), and these 
mediators have been shown to have pathogenic effects on synovial fibroblasts (16). 
Recently, we showed that mast cells are activated by immune complexes containing anti–
citrullinated protein antibodies (ACPAs), with Toll-like receptors (TLRs) augmenting the 
response of mast cells to ACPA-containing immune complexes (17). Despite these findings, 
the interaction of mast cells with other synovial immune cells has never been fully 
investigated, and their ability to influence immune responses during the course of RA is still 
uncertain. 
Among the multiple factors known to activate mast cells, interleukin-33 (IL-33), a 
member of the IL-1 cytokine family (18), has been shown to enhance the survival, 
adhesion, and differentiation of these cells, and to induce the production of several 
proinflammatory cytokines (19, 20). Furthermore, IL-33 was found to prime mouse and 
human mast cells for activation by IgG immune complexes (21, 22). In vivo, IL-33 has 
been implicated in the ability of mast cells to contribute to the development of  arthritis 
in murine experimental models (23, 24), and high levels of IL-33 have been found in the 
serum and synovial fluid of patients with RA and those with other inflammatory 
arthritides (25). In addition to these proinflammatory properties, which are consistent 
with the described role of IL-33 as an alarmin, recent evidence suggests that this cytokine 
can also mediate immunoregulatory responses in various settings, by, for example, 
promoting regulatory T and B cell activity and suppressing monocyte activation through 
its effects on basophils (26-31). Thus, similar to the findings regarding mast cells, the 
specific functions of IL-33 in the pathogenesis of autoimmune diseases, including 
arthritis, are still unclear (32, 33). 
To better understand the roles of IL-33 and mast cells in RA, we examined the effects of IL-
33 on human mast cells. We hypothesized a novel scenario in which activation of mast cells 
triggered by the alarmin IL-33 may play a homeostatic role, by contributing to the 
resolution of inflammation through a feedback system that leads to down-regulation of 
monocyte-mediated immune responses in RA synovial tissue. 
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MATERIALS AND METHODS 
PERIPHERAL BLOOD–DERIVED MAST CELLS 
Buffy coat cells were obtained from the peripheral blood of healthy volunteers, with 
samples collected from a blood bank in The Netherlands (Sanquin). CD34
+
 hematopoietic 
stem cells were isolated from peripheral blood mononuclear cells (PBMCs) using CD34 
microbeads (Miltenyi Biotec). Isolated CD34
+
 stem cells were differentiated into mast 
cells using a previously described method (34). After 6–8 weeks, the purity of the mast 
cells was determined by flow cytometry analyses for the expression of CD117 (c-Kit), Ig ɛ-
class–binding Fc receptor type I (FcɛRI), and CD203c; purity ranged from 90% to 99%. 
MAST CELL ACTIVATION 
Plate-bound IgG was used as a model to study FcγR-mediated activation of mast cells (17, 
35). Briefly, culture plates (96-well or 48-well flat-bottomed plates) were coated with 100 
μg/ml of purified human IgG (Jackson ImmunoResearch) in phosphate buffered saline (PBS) 
for 1.5 hours at 37°C and washed 2 times with PBS. Mast cells were then cultured at a 
concentration of 1 × 106/ml in RPMI 1640 medium containing 10% fetal calf serum, 
glutamine, penicillin, and streptomycin (all from Invitrogen) together with 100 ng/ml of 
stem cell factor (Tebu-Bio), without or with 100 ng/ml of recombinant human IL-33 
(PeproTech). After 24 hours, the cells were harvested and supernatants were collected and 
stored at −20°C until further analysis by flow cytometry. 
IgG ACPA-MEDIATED MAST CELL ACTIVATION 
Cyclic citrullinated peptide 2 (CCP2) peptides were obtained from Dr. J. W. Drijfhout 
(Department of Immunohematology and Blood Transfusion, Leiden University Medical 
Center, Leiden, The Netherlands). Nunc Maxisorp plates (VWR Scientific Products) were 
coated with CCP2 peptide or arginine as a control peptide, and then incubated at 37°C for 1 
hour with serum from patients with ACPA-positive RA, with the serum samples diluted 50 
times in PBS–0.1% bovine serum albumin (BSA). After washing, mast cells were added to 
the wells and cultured in the presence or absence of 100 ng/ml of recombinant human IL-
33. After 24 hours, the cells were harvested, and supernatants were collected and stored at 
−20°C. 
MONOCYTE ISOLATION AND STIMULATION 
CD14
+
 monocytes were isolated from buffy coat PBMCs using magnetic-labeled anti-CD14 
beads (Miltenyi Biotec), according to the manufacturer's instructions. Isolated monocytes 
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(purity >95%) were cultured in the same medium as used for mast cells. Monocytes were 
incubated with mast cell supernatants (diluted 1:4 in medium) or control medium, and then 
stimulated with lipopolysaccharide (LPS) from Salmonella typhosa (Sigma-Aldrich) at a 
concentration of 5 ng/ml. After overnight (18-hour) incubation, the cells were harvested 
and supernatants were collected and stored at −20°C until further analysis by flow 
cytometry.  
For blocking experiments, supernatants of activated mast cells were preincubated with 
anti–IL-10 antibody or rat IgG2a as a matched isotype control (BD Biosciences), at 10 μg/ml 
for 30 minutes at 37°C in an atmosphere of 5% CO2, prior to being incubated with the 
monocytes. For inhibition of histamine, monocytes were preincubated for 30 minutes at 
37°C with the histamine receptor 2 antagonist ranitidine (Sigma) at 10−4M (28). 
PATIENT SAMPLES 
Serum samples were obtained from patients with RA, and the presence of total IgG ACPAs 
was tested by routine diagnostic enzyme-linked immunosorbent assay (ELISA). For 
immunofluorescence analysis, synovial tissue was obtained from 3 patients with 
established ACPA-positive RA (ages 59, 70, and 76 years) who had undergone surgery. For 
messenger RNA (mRNA) sequencing, mRNA was extracted from synovial tissue samples 
obtained by ultrasound-guided biopsy from patients with early active RA (<12 months’ 
duration) who were naive to treatment with disease-modifying anti-rheumatic drugs 
(DMARDs) (n = 40), enrolled in the Pathobiology of Early Arthritis Cohort (details at 
http://www.peac-mrc.mds.qmul.ac.uk) at the Centre for Experimental Medicine and 
Rheumatology of Queen Mary University (London, UK) (36). Additional patient 
characteristics are listed in Supplementary Table 1 (online). All patients fulfilled the 
American College of Rheumatology 1987 revised criteria for RA (37). Written informed 
consent was obtained from the patients, and the study was approved by local human ethics 
committees. 
IMMUNOFLUORESCENCE ANALYSIS 
Synovial tissue samples were fixed with 4% (weight/volume) formaldehyde (Merck) in 
PBS and stored in 70% (volume/volume) ethanol. The tissue samples were then 
embedded in paraffin, in 4-μm sections. Slides were deparaffinized with xylene (Merck), 
and endogenous peroxidase activity was blocked with 1% hydrogen peroxide (Merck) in 
methanol for 10 minutes. After antigen retrieval with a Tris–EDTA solution (pH 9; Dako) 
for 30 minutes at 96°C, slides were stained with monoclonal mouse anti-human 
antibodies for tryptase (0.2 μg/ml; Millipore) or polyclonal goat anti-human antibodies 
for tryptase (8 μg/ml; Santa Cruz Biotechnology), in combination with polyclonal goat 
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anti-human CD14 antibodies (2.5 μg/ml; Abcam) or monoclonal mouse anti-human CD3 
(2.8 μg/ml) or CD20 (0.4 μg/ml) antibodies (both from Dako) in PBS–1% BSA for 1 hour. 
For control sections, matching isotype control antibodies for CD14 (normal goat IgG; 
Merck) or for CD3 and CD20 (each mouse IgG1; Dako) were used. Detection of staining 
was performed using donkey anti-mouse/goat Alexa Fluor 568 and donkey anti-
goat/mouse Alexa Fluor 488 (each 2 μg/ml; Invitrogen). All slides were mounted with 
Vectashield Hard Set mounting medium with DAPI (Vector) and visualized using a Zeiss 
Axio Scope A1 and AxioVision 4.9.1. Stained sections were scored by counting the 
number of cells in 10 high-power fields (400× magnification), with scoring performed in a 
blinded manner by 3 observers (FR, KH, and ALD). Interobserver agreement was 
evaluated using the intraclass correlation coefficient (with a cutoff value of >0.7 to 
indicate acceptable agreement). 
FLOW CYTOMETRY 
For flow cytometry staining, cells were incubated with fluorochrome-conjugated 
antibodies diluted in PBS–0.5% BSA at 4ºC for 30 minutes. To exclude dead cells, 0.2 μM 
DAPI (Invitrogen) was added. Flow cytometric acquisition was performed on an LSR-II 
flow cytometer (BD Biosciences). Analysis was performed using FACSDiva (BD 
Biosciences) and FlowJo software (Tree Star). The following (clonal) antibodies were 
used: PerCP–Cy5.5–conjugated CD14 (61D3), fluorescein isothiocyanate (FITC)–
conjugated FcɛRI (AER-37), phycoerythrin (PE)–conjugated mouse IgG1 (61D3) (all from 
eBioscience), FITC-conjugated CD16 (3G8), PE-conjugated CD63 (H5C6), PE-conjugated 
CD64 (10.1), PE-conjugated CD80 (L307.4), FITC-conjugated HLA–DR (L243), FITC-
conjugated mouse IgG2b [27-35] (all from BD Biosciences), FITC-conjugated CD32 (IV.3) 
(StemCell Technologies), and Alexa Fluor 488–conjugated CD32b (ch2b6-N297Q) and a 
corresponding isotype control (ch4420-N297Q) (Macrogenics) (38). 
MEASUREMENT OF CYTOKINES 
Quantitative immunoassays in mast cell culture supernatants were performed using a 42-
plex cytokine Milliplex assay (Millipore). In addition, the following ELISA kits were used: 
human IL-8 Ready-SET-Go! ELISA kit (eBioscience), human tumor necrosis factor (TNF) 
ELISA set (BD Biosciences), human IL-10 PeliPair ELISA kit (Sanquin Reagents), and 
histamine ELISA kit (Neogen). 
MESSENGER RNA SEQUENCING 
Total RNA from synovial tissue was extracted using a Qiagen RNeasy mini kit in 
accordance with the manufacturer's protocol, including on-column DNase digestion. 
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Quality control of samples was done to determine RNA quantity and quality, prior to 
their processing RNA sequencing. The concentration of total RNA samples was 
determined using NanoDrop 8000 (Thermo Scientific). The integrity of RNA samples 
was determined using both a 2100 Bioanalyzer and a 2200 TapeStation (Agilent 
Technologies). Where available, 1 μg of total RNA was used as an input material for 
library preparation, using an Illumina TruSeq RNA Sample Preparation kit (version 2).  
Generated libraries were amplified with 10 cycles of polymerase chain reaction (PCR). 
The size of the libraries was confirmed using a 2200 TapeStation and High Sensitivity 
D1K screen tape (Agilent Technologies), and their concentration was determined using 
a quantitative PCR–based method with a Library quantification kit (Kapa). The libraries 
were first multiplexed (5 per lane) and then sequenced on an Illumina HiSeq2500 to 
generate 50 million paired-end, 75-basepair reads (in synovial samples). For the data 
analysis, the Genomic Short-read Nucleotide Alignment Program (details available at 
http://research-pub.gene.com/gmap/) was used to map and assemble transcripts, 
using the University of California, Santa Cruz human genome reference sequence hg19 
and associated transcriptome map (available at http://genome.ucsc.edu/). 
STATISTICAL ANALYSIS 
Results are expressed as the mean ± SEM. For comparison between 2 groups, 2-sample t-
tests were performed. For differences between multiple groups, one-way analysis of 
variance was performed, with the Bonferroni post hoc test to correct for multiple testing. 
Statistical analysis was performed using GraphPad Prism software (version 5). P values less 
than 0.05 were considered significant. 
RESULTS 
MODULATION OF HUMAN MAST CELL ACTIVATION BY IL-33 
We investigated the activation of mast cells by stimuli known to be present in human 
synovium and implicated in the pathogenesis of RA, i.e., IL-33 and IgG. Stimulation of 
mast cells with plate-bound IgG mainly induced the release of CXCL8/IL-8, while 
stimulation with IL-33 induced higher amounts of histamine and IL-10 (Figure 1A).  
Likewise, only IL-33, and not plate-bound IgG, induced the up-regulation of the mast cell 
activation marker CD203c. The histamine release induced by IL-33 triggering was not 
accompanied by an up-regulation of CD63, a marker of mast cell degranulation 
(Supplementary Figure 1A). 
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Figure 1. Activation of mast cells via interleukin-33 (IL-33) and immune complexes. Mast cells were left 
unstimulated (unst) or were activated with IL-33 and/or plate-bound IgG (pbIgG) for 24 hours. A, Levels of 
CXCL8/IL-8, histamine, and IL-10 were measured by enzyme-linked immunosorbent assay (ELISA). Values 
are the mean ± SEM from 4 independent experiments (n = 4 donors). B, Synergy was assessed by comparing 
the sum concentrations of mediators (same as those in A) measured in cell supernatants with single stimuli 
(IL-33 + IgG) and the actual values measured in cell supernatants stimulated simultaneously (IL-33 & IgG). 
Each symbol joined by a line represents a single mast cell donor (n = 4 donors from 4 independent 
experiments). C, CXCL8/IL-8 levels were measured by ELISA in unstimulated or IL-33–stimulated mast cells 
after incubation with serum from 3 patients with anti–citrullinated protein antibody (ACPA)–positive 
rheumatoid arthritis bound to citrullinated (Cit) peptides or arginine (Arg) controls. Values are the 
mean ± SEM results from 6 mast cell donor samples. −= no plate coating. D, Left, Histograms show Fcγ 
receptor type IIa (FcγRIIa) expression by mast cells left unstimulated or upon stimulation with IL-33 or upon 
antibody blocking of the IL-33 receptor ST2; matched isotype was used as control. Representative results of 
4 independent experiments (n = 4 mast cell donors) are shown. Right, Expression of FcγRs was examined in 
mast cells left unstimulated or stimulated with IL-33. Results are expressed as the ratio of mean 
fluorescence intensity (MFI) relative to the values for the isotype control; data are from 5 independent 
experiments. Each symbol represents a single mast cell donor (n = 7 or more); horizontal line indicates the 
mean. ∗ = P < 0.05 by analysis of variance with Bonferroni post hoc test for multiple comparisons, and by 
Student's t-test for comparisons between 2 groups. 
Combination of the 2 stimuli led to an increased activation of mast cells, as indicated by the 
release of significantly higher amounts of CXCL8/IL-8, histamine, and IL-10 when compared 
to that observed in unstimulated mast cells or mast cells incubated with either stimulus 
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compared the sum concentration of CXCL8/IL-8, histamine, and IL-10 in cell cultures 
incubated with each stimulus alone to the actual amounts produced upon combined 
stimulation with IL-33 and plate-bound IgG (Figure 1B). This comparison showed higher 
amounts of histamine and IL-10 in cell cultures that received combined stimulation, 
indicating that IL-33–triggered mediators have a synergistic effect, whereas in the 
production of CXCL8/IL-8, only an additive effect of each stimulus was observed. 
Having found that plate-bound IgG–mediated activation of mast cells is modulated by IL-33, 
we wondered whether IL-33 would also enhance the activation of mast cells induced by IgG 
ACPAs. Similar to previous findings from our group (17), mast cell activation, evaluated by 
measurement of CXCL8/IL-8 levels, was observed upon triggering with IgG ACPA immune 
complexes, which were formed by binding of the serum of patients with ACPA-positive RA 
to citrullinated peptides (Figure 1C). Importantly, mast cells were not activated by ACPA-
positive serum incubated with the arginine control (Figure 1C) or by serum from ACPA-
negative patients (results not shown). In addition, IL-33 significantly enhanced the ACPA-
induced production of CXCL8/IL-8. 
We next sought to identify the mechanism by which IL-33 enhances mast cell activation, 
and hypothesized that IL-33 modulates the expression of FcγRs on mast cells. Indeed, IL-33 
induced a significant up-regulation of the activating FcγRIIa (Figure 1D). This effect was 
mediated by the IL-33 receptor ST2, as demonstrated by the finding that FcγRIIa expression 
could be blocked by anti-ST2 antibodies (Figure 1D). Importantly, we did not detect any 
notable changes in the expression of the other FcγR types by cultured human mast cells, 
and none of them were influenced by IL-33 stimulation (Figure 1D). 
Taken together, these results indicate that IL-33, via its receptor ST2, induces the up-
regulation of FcγRIIa, which thereby enhances the activation of mast cells upon triggering 
with plate-bound IgG, as well as IgG ACPAs, as demonstrated by the increased production 
of CXCL8/IL-8. More specifically, IL-33 induces IgG-activated mast cells to release histamine 
and IL-10, but not CXCL8/IL-8, in a synergistic manner. 
SKEWING BY IL-33 TOWARD A TH2/IMMUNOMODULATORY PHENOTYPE IN MAST CELLS 
To further support the notion that IL-33 is able to modulate mast cell activation by IgG, 
we performed a multiplex assay on mast cell supernatants. Consistent with the findings 
in previous literature [20-22], mast cells triggered with IL-33 and plate-bound IgG 
secreted a wide range of mediators. When comparing the 2 stimuli, we found that plate-
bound IgG induced higher amounts of classic proinflammatory mediators, whereas IL -33 
induced higher levels of Th2 and immunomodulatory cytokines such as IL-5, IL-10, and IL-
13 (see Supplementary Figure 1B). Interestingly, using the combination of IL-33 and 
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plate-bound IgG to trigger mast cell activation induced higher levels of these cytokines 
when compared to stimulation with IL-33 alone. In contrast, no additional effects of IL-33 
(i.e., no augmentation of the effects of IgG) on the production of proinflammatory 
mediators such as TNF or FLT-3 ligand could be observed (Figure 2A). In addition, 
consistent with the data presented in Figure 1B, the combined stimulation showed a 
synergistic effect that was only present for those mediators whose production was 
induced by IL-33 (Figures 2A and B). 
 
Figure 2. Stimulation of mast cells with IL-33 skews the cells toward an immunomodulatory phenotype. A, 
Production of various mediators in cell cultures was compared between single stimulations and combined 
stimulations with IL-33 and plate-bound IgG. Values are the mean ± SEM from 3 independent experiments in 
3 mast cell donor samples, as measured by multiplex assay. B, Synergy of the single or combined 
stimulations was assessed as described in Figure 1B. Symbols joined by lines represent individual donors. 
Only mediators exhibiting significantly increased levels upon stimulation of mast cells with either IL-33 or 
plate-bound IgG are shown. ∗ = P < 0.05 by analysis of variance with Bonferroni post hoc test in A and by 
Student's t-test in B. NS = not significant; FGF2 = fibroblast growth factor 2; G-CSF = granulocyte colony-
stimulating factor; IFN-α2 = interferon-α2; TNF = tumor necrosis factor; VEGF = vascular endothelial growth 
factor (see Figure 1 for other definitions). 
Taken together, these findings indicate that IL-33 is not simply enhancing mast cell 
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inducing the production of a specific set of Th2-associated and immunomodulatory 
mediators. 
INTERACTION OF MAST CELLS WITH MONOCYTES IN RA SYNOVIUM 
To better understand the possible consequences of mast cell activation at the synovial 
level in RA, we investigated the occurrence of cellular interactions between mast cells 
and other immune cells ex vivo, by performing immunofluorescence staining for mast 
cells reactive with tryptase, as well as staining for the monocyte/macrophage marker 
CD14, the B cell marker CD19, or the T cell marker CD3, in tissue sections from the 
synovium of patients with RA. We found numerous tryptase-positive mast cells 
scattered in the synovium of patients with RA. Interestingly, tryptase-positive cells 









Figure 3. Mast cell interaction with immune cells in rheumatoid arthritis (RA) synovial tissue. RA synovial 
tissue was analyzed by immunofluorescence staining, showing tryptase-positive mast cells (red) closely 
interacting with other immune cells (green), including CD14+ cells (A), CD3+ T cells (B), and CD20+ B cells (C). 
Nuclear staining with DAPI (blue) is also shown. Representative images from 1 of 3 donors are shown. 
Original magnification ×40. Boxed areas highlight the cellular interactions. 
To quantify these interactions, we counted the number of tryptase-positive cells in 
close contact with each cell type. As shown in Table 1, a substantial proportion of mast 
cells (mean 19.5%) was found to be in contact with CD14
+
 cells in the synovial tissue of 
3 patients with RA. Similarly, the proportion of total CD14
+
 cells interacting with mast 
cells was considerably higher than the proportion of B and T cells interacting with mast 
cells. 
These results show that mast cells in the synovial tissue of patients with RA are in clo se 
contact with immune cells. In particular, a substantial number of synovial mast cells are 
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Table 1. Interactions between mast cells (MCs) and other immune cells in RA synovia. 
 RA 1 RA 2 RA 3 Mean* 
Mast cells 31,3 11,7 30,7 24,6 
Close to CD14+ 6,7 (21,4%) 1,7 (14,6%) 6 (19,6%) 4,8 (19,5%) 
Mast cells 18,7 24 26,3 23 
Close to CD20+ 1,7 (9.1%) 3 (12,5%) 0,3 (1,1%) 1,7 (7.3%) 
Mast cells 27,3 25,6 38,3 30,4 
Close to CD3+ 3,3 (12,1%) 1,7 (6,6%) 2 (5,2%) 2,3 (7,6%) 
     
CD14+ cells 80,7 7,0 125,3 71 
Close to mast cells 8,3 (10,3%) 0,3 (4,3%) 11,0 (8,8%) 6,5 (9,2%) 
CD20+ cells 49,6 45,0 240,3 111,6 
Close to mast cells 1 (2,0%) 0,3 (0,7%) 2,3 (1%) 1,2 (1,1%) 
CD3+ cells 358,6 0 14,7 124,4 
Close to mast cells 6,7 (1,9%) 0 (0 %) 0 (0 %) 2,2 (1,8%) 
Means of the number of cells counted in 10 high power fields by 3 independent and blind observers.  RA = 
Rheumatoid arthritis, n=3. *Mean of the three patients. 
MODULATION OF MONOCYTE RESPONSES BY IL-33- AND IgG-ACTIVATED MAST CELLS 
Since a substantial proportion of mast cells were located near CD14
+
 cells in the RA 
synovium (Figure 3 and Table 1), we next examined whether IL-33–primed mast cell 
supernatants were able to influence the activation of CD14
+
 cells. To this end, LPS was 
used to boost the proinflammatory activation of CD14
+
 monocytes, acting as a model 
for TLR-4–induced activation of monocytes. Monocyte responses were evaluated in the 
presence or absence of mast cell supernatants. We used TNF production as the 
response marker because mast cells produce only minimal amounts of TNF compared 
to LPS-stimulated monocytes. As shown in Figure 4A, in the presence of supernatants 
of mast cells, the TLR-4–mediated TNF production by monocytes was inhibited. 
Activation of mast cells with IL-33 and plate-bound IgG significantly enhanced the 
inhibition of TNF production without affecting monocyte survival (as measured by DAPI  
staining) (results not shown). This effect was dependent, in part, on IL -10, since we 
found that TNF production could be partially inhibited by anti–IL-10 blocking antibodies 
(Figure 4B).  
In addition, blocking of histamine receptor 2 with ranitidine also partially reverted the 
induced production of TNF by monocytes. When both histamine and IL -10 were 
blocked, the ability of monocytes to produce TNF was retained. Importantly, the 
possibility that IL-33 may have exerted direct effects on monocytes was excluded, since 
no effect on the release of cytokines by monocytes was observed after adding this 
cytokine to the control medium. 
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Figure 4. Mast cells (MCs) modulate monocyte activation. A, Monocytes were incubated either with 
control medium containing the same stimuli as used for mast cells (i.e., interleukin-33 [IL-33]) or with 
mast cell supernatants, followed by triggering with lipopolysaccharide (LPS). Levels of tumor necrosis 
factor (TNF) in cell cultures stimulated with IL-33 and/or plate-bound IgG (pbIgG) were measured by 
enzyme-linked immunosorbent assay after 18 hours. TNF levels in mast cell supernatants were below 
the predetermined level of detection (dotted horizontal line). B, Monocytes were incubated with the 
supernatants of activated mast cells and anti–IL-10 blocking antibody, correspondent isotype control, 
the histamine receptor 2 antagonist ranitidine, or the latter two combined.  Levels of LPS-induced TNF 
are shown as a percentage of the values in control (ctr) medium, which was set at 100%. Results in A 
and B are the mean ± SEM in samples from 6 monocyte donors and 12 mast cell donors in 5 
independent experiments. C, Monocytes were left unstimulated (unstim) or were triggered with LPS 
after incubation with mast cell supernatants (IL-33 + plate-bound IgG) or control medium with IL-33 
alone, together with anti–IL-10 blocking antibody, isotype control, or ranitidine. Expression of CD80 
by monocytes was analyzed by flow cytometry (right; representative results shown) and quantified as 
the mean ± SEM percentage expression in samples from 6 monocyte donors and 8 mast cell donors in 
4 independent experiments (left). ∗ = P < 0.05 by Student's t-test for comparison between 2 groups, 
and by analysis of variance with Bonferroni post hoc test for multiple comparisons.  
Membrane markers of monocyte activation were also evaluated, and the influence of mast 
cell mediators was assessed with blocking experiments. Interestingly, the LPS-induced 
expression of the costimulatory molecule CD80 was reduced by mast cell supernatants 
(Figure 4C). This effect was mainly dependent on histamine, since the down-regulated 
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Taken together, these findings indicate that activation of mast cells triggered by IL-33 
inhibits the proinflammatory responses of monocytes, as shown by the suppression of TNF 
production and CD80 expression. This effect is presumably mediated through the release of 




Figure 5. Gene expression in the synovial tissue of patients with early rheumatoid arthritis. A and B, 
Levels of mRNA for immune cell markers and tumor necrosis factor (TNF) (A) and for mast cell –
specific genes (B) in patients with moderate disease activity (defined as a Disease Activity Score in  28 
joints [DAS28] 3.2 to ≤5.1) and those with severe disease activity (DAS28 >5.2). Symbols represent 
individual patients; horizontal lines indicate the mean. ∗ = P < 0.05 by Student's t-test. C, Correlation 
of interleukin-33 (IL-33) mRNA levels with levels of CD14, Fcγ receptor type IIa (FCGR3A), and TNF 
mRNA. Each symbol represents an individual patient (n = 40), with the regression line and the 
Pearson's correlation coefficient. CD3G = CD3 antigen, γ subunit; CD14 = monocyte differentiation 
antigen CD14; FCGR3A = Fc fragment of IgG, low affinity IIIa (receptor for CD16); KIT = c-Kit hardy-
zuckerman 4 feline sarcoma viral oncogene homolog (stem cell factor receptor); FCER1A = Fc fragment 
of IgE, high affinity I receptor for α subunit; IL1RL1 = interleukin-1 receptor–like 1 (ST2/IL-33 
receptor); MS4A2 = membrane-spanning 4 domains, subfamily a, member 2 (FcɛRIβ); 
ENPP3 = ectonucleotide pyrophosphatase/phosphodiesterase 3; HDC = histidine decarboxylase; 
TPSAB1 = tryptase, α/β-1; TPSD1 = tryptase, δ-1; CMA1 = chymase 1; CPA3 = carboxypeptidase A3, mast 
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INVERSE ASSOCIATION BETWEEN SYNOVIAL EXPRESSION OF MAST CELL-RELATED GENES 
AND DISEASE ACTIVITY IN EARLY RA 
To investigate whether the mast cell–mediated immunomodulatory/homeostatic functions 
observed in vitro might have a functional relevance in patients with RA, we analyzed the 
expression of mRNA extracted from the synovial biopsy tissue of patients with early RA (<12 
months’ duration) who were naive to DMARD therapy. As expected, the levels of mRNA for 
immune cell markers (e.g., CD3, CD14, and CD16) and TNF were significantly higher in 
patients with severe disease activity (measured as the Disease Activity Score in 28 joints 
[DAS28] (39), with severe disease activity defined as a DAS28 of >5.2) than in patients with 
moderate disease activity (defined as a DAS28 of 3.2 to ≤5.1) (Figure 5A). In contrast, the 
opposite observation was made for the mRNA expression levels of mast cell–specific genes, 
selected on the basis of a recent study describing highly specific genes for human mast cells 
(40).  
Using the mRNA levels of these genes as a proxy for the presence of mast cells, we 
observed that most of the mast cell–related genes (such as c-Kit, α/β1-tryptase, and 
chymase, among others) displayed a significantly lower expression in patients with severe 
disease activity compared to patients with moderate disease activity (Figure 5B).  
These findings are consistent with the observations made in our in vitro studies, as they 
suggest that mast cells, unlike other immune cells, are not associated with a more severe 
clinical phenotype. Finally, the levels of IL-33 mRNA showed an inverse correlation with the 
levels of proinflammatory markers, such as CD14, FcγRIIIa, and TNF (Figure 5C). 
Supplementary Table 2 (online) provides the raw RNA sequence data on the analyzed genes 
in the 40 patients with early RA. 
Taken together, these findings further support our hypothesis that IL-33–mediated 
activation of mast cells has an immunomodulatory/homeostatic role in RA and could 
potentially influence the level of disease severity in patients with RA. 
DISCUSSION 
Persistency of inflammation is the hallmark of RA. In particular, an imbalance between pro- 
and antiinflammatory signals is presumed to be the basis of the chronic inflammation 
observed in the course of RA. Among the many cells and pathways potentially involved in 
this process, we have now identified IL-33–mediated mast cell activation as a new 
mechanism leading to the down-regulation of immune responses in the context of RA. To 
examine the involvement of mast cells in the inflammatory response in RA, we investigated 
130  |  CHAPTER 6 
their activation by plate-bound immune complexes (plate-bound IgG) and found that 
activation of mast cells can be modulated by IL-33, a cytokine previously implicated in the 
ability of mast cells to contribute to experimental arthritis (23). It has been suggested 
that IL-33 induces the accumulation of proinflammatory cytokine mRNA in murine mast 
cells (21), whereas no clear mechanisms were proposed to explain the combined effects 
of IL-33 and immune complexes on human mast cells (22). Our data show that IL-33, via 
its receptor ST2, induces the expression of the activating receptor for the Fc fragment of 
IgG (FcγRIIa) in human mast cells. This, together with the observations of additional 
intracellular interactions, might explain the enhancement of IgG-mediated activation of 
mast cells in the presence of IL-33. 
We recently showed that mast cells can be activated by immune complexes formed by 
binding of ACPAs from the sera of patients with RA to citrullinated antigens, a response 
that can be augmented by the triggering effects of TLRs (17). In the present study, we 
extended these findings by showing that IL-33 augments the activation of mast cells 
induced by IgG ACPAs. Overall, these observations suggest that mast cells, activated by 
IL-33 and IgG, both of which are known to be present in the synovial compartment, might 
contribute to the inflammatory response in RA, thereby supporting the longstanding 
hypothesis that mast cells play a deleterious role in RA. By further exploring the influence 
of IL-33 on mast cell activation, we found that IL-33 induces human mast cells to release 
immunomodulatory mediators, such as IL-10 and histamine, as well as other cytokines 
associated with type 2 immune responses, such as IL-5 and IL-13. The release of these IL-
33–induced mediators was further enhanced by IgG triggering. In particular, the 
combined stimulation with IL-33 and IgG showed a synergistic effect that, intriguingly, 
was present for IL-33–induced mediators (such as IL-5, IL-10, IL-13, and histamine) and 
absent for mediators induced by IgG (such as CXCL8/IL-8). These findings are important 
because they indicate that IL-33 is able to prime mast cells toward a 
Th2/immunomodulatory phenotype, a phenotype that becomes more prominent 
following the concomitant activation of mast cells by IgG. 
Since IL-33 is found in the synovial fluid of patients with RA, we hypothesized that the 
effects of IL-33 on mast cells might be relevant in modulating the immune responses in 
RA, by, for example, influencing the behavior of other synovial immune cells. 
Immunostaining of the RA synovial tissue demonstrated that human synovial mast cells 




 T cells, and CD20
+
 B cells. 
In particular, synovial mast cells were most commonly found in proximity to CD14
+
 
monocyte/macrophages. Without implying that such interactions are specific for RA, 
these findings could nevertheless indicate that mast cell–monocyte interactions at the 
synovial level are frequent and might, therefore, have functional consequences.  
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To validate the hypothesis that IL-33 triggering of mast cell activation may exert 
immunomodulatory effects, we explored the ability of these cells to influence monocyte 
responses. Mast cells activated with IL-33 and plate-bound IgG were able to dampen the 
activation of monocytes, inhibiting both the production of the prototypic 
proinflammatory cytokine TNF and the up-regulation of the costimulatory molecule 
CD80. These effects were mediated, at least in part, by the release of IL-10 and histamine 
from mast cells. Among other mediators with known immunomodulatory functions, IL -4 
was recently shown to be responsible for mast cell–mediated inhibition of peritoneal 
macrophage phagocytosis in a mouse model of sepsis (41). However, we consider the 
involvement of mast cell–derived IL-4 in our in vitro system to be unlikely, since we could 
not detect this cytokine in the supernatants of stimulated mast cells. In our experiments, 
monocytes were stimulated with bacterial LPS, acting via TLR-4, a commonly used model 
to study monocyte activation. Independent of the effects of LPS, several endogenous 
stimuli, ligands of TLR-4, have been implicated in the pathogenesis of RA (42), suggesting 
that the inhibition of TLR-4–mediated activation of monocytes by mast cells might be 
relevant in the context of RA. 
Although several studies explored the ability of mast cells to influence both innate (41, 
43) and adaptive (44, 45) immune responses, the direct cross-talk between human mast 
cells and monocyte/macrophages has never been investigated. This study is the first to 
show that mast cells and CD14
+
 monocyte/macrophages can interact at the synovial 
level. Furthermore, mast cells triggered with stimuli known to be present in the inflamed 
synovium and classically considered to be proinflammatory (i.e., IL-33 and IgG) 
surprisingly gain the ability to suppress the activation of monocytes. 
Taken together, these findings might help to understand the contrasting observations 
obtained in animal models of arthritis, in which, upon mast cell depletion, their pro- or 
antiinflammatory functions might be revealed or balanced, depending on the specific 
experimental conditions. Moreover, considering the heterogeneity of RA, the role of 
human mast cells might be even more complex and possibly multifaceted (2). Most of the 
evidence points toward a deleterious role for mast cells in patients with RA, with some 
reports proposing the mast cell c-Kit receptor as a therapeutic target (46-49). However, 
these studies used relatively nonspecific inhibitors (multitargeted tyrosine kinase 
inhibitors), which could have effects on other receptors on different cells (50). Similarly, 
the alarmin IL-33 has been proposed as a promising treatment target for RA (51), even 
though its involvement in the pathogenesis of RA has not been clearly established (33). 
Our results indicate that mast cells, in addition to their well-known proinflammatory 
functions, are also able to mediate regulatory/homeostatic responses, in particular when 
exposed to IL-33. 
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To confirm the relevance of the latter hypothesis, we studied a cohort of patients with 
early (duration <12 months) RA who were naive to DMARD therapy. Interestingly, 
although the presence of many types of immune cells, as determined by cell-specific 
gene expression, was associated with high disease activity, the presence of mast cells 
displayed an inverse association with disease severity. At the same time, IL-33 mRNA 
levels were inversely correlated with the levels of proinflammatory markers, such as 
CD14, CD16 (FcγRIIIA), and TNF. These observations make it tempting to speculate that 
mast cells, in particular when triggered by IL-33, could function in an immunomodulatory 
manner in the synovial tissue of patients with RA. Thus, the findings provide a rationale 
for future studies aimed at unravelling the complex influence of mast cells on disease 
activity in different stages of RA. 
In conclusion, the results of this study indicate that mast cells, finely balancing between 
their well-known proinflammatory functions and their IL-33–triggered anti-inflammatory 
functions as observed herein, might play a previously unrecognized role as 
immunomodulatory/homeostatic cells in the pathogenesis of RA. 
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Supplementary Figure 1. FACS and multiplex analyses of IL-33 and pbIgG-triggered mast cells. Mast cells 
were triggered with IL-33 or plate bound IgG for 24h. A, Expression of CD203c (left) as Median Fluorescence 
Intensity (MFI) ratio to isotype, and CD63 (right), as % of positive cells. Each symbol represent a mast cell 
donor (n=12) from 5 independent experiments. *p<0.05 determined by ANOVA with Bonferroni’s post-test 
(for multiple comparisons) B, Of the 42 mediators included in the panel, the ones above minimal detection 
levels are shown**. Levels of each mediators in IL-33 and IgG-triggered mast cells were compared, black 
arrows indicate mediators which levels were significantly higher in IL-33-triggered mast cells, grey arrows 
mediators which levels were significantly higher in IgG-triggered mast cells. n=3 mast cells donors, 3 
independent experiments. *p 0.05 determined by Student’s t test, comparing IL-33 and IgG-triggered mast 
cells for each mediator. **As IL-8 levels were over the detection range, this cytokine is not shown (IL-8 
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ABSTRACT 
Mast cells (MCs) are immune cells residing in tissues where pathogens are first 
encountered. It has been indicated that MCs might also be involved in setting the outcome 
of T-cell responses. However, little is known about the capacity of human MCs to express 
MHC class II and/or to capture and present antigens to CD4
+
 T cells.  
To study the T-cell stimulatory potential of human MCs, CD34
+
 stem cell derived MCs were 
generated. These cells expressed HLA-DR when stimulated with IFN-γ, and, importantly, 
presented peptide and protein for activation of antigen-specific CD4
+
 T cells. The interplay 
between MC and T cell led to increased HLA-DR expression on MCs. MCs were present in 
close proximity to T cells in tonsil and expressed HLA-DR and CD80, indicating their ability 
to present antigens to CD4
+
 T cells in T-cell areas of human LNs.  
Our data show that MCs can present native antigens to human CD4
+
 T cells and that HLA-
DR expressing MCs are present in tonsil tissue, indicating that human MCs can directly 
activate T cells and provide a rationale to study the potential of MCs to prime and/or skew 
human T-cell responses. 
INTRODUCTION 
Mast cells (MCs) are most well known because of their role in IgE-mediated immune 
responses as they express the high-affinity FcεRI. MCs are present at strategic locations of 
the environment/host interface where they can encounter pathogens. Therefore, they have 
been implicated in the regulation of adaptive immune responses as well as in the regulation 
of T-cell immunity. Secretion of TNF by skin MCs was shown to be essential for LN 
hypertrophy and T-cell recruitment during bacterial infection (1).  
Furthermore, MCs were shown to be capable of migrating from the skin to the draining LNs 
in murine models of contact hypersensitivity and UV radiation (2, 3). In the draining LNs, 
the secretion of chemokines by MCs has been implicated in the recruitment of T cells (2, 4). 
These studies, therefore, indicate that MCs can be involved in the regulation of T-cell 
trafficking toward lymphoid organs, suggesting that MCs may have a role in the induction of 
primary and/or local memory T-cell responses. Indeed, anti-CD3-stimulated T cells 
displayed enhanced proliferation and cytokine secretion in the presence of MCs, indicating 
that MCs are capable of enhancing T-cell responses (5-7). 
A first direct demonstration that MCs can also present antigens to T cells came from mouse 
studies showing that OVA-specific TCR-transgenic CD8
+
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MHC class I (8, 9). Likewise, using OVA-specific TCR-transgenic CD4
+
 T cells, it was 
demonstrated in vitro that mouse MCs can also activate MHC class II restricted T cells when 
loaded with OVA peptide, but were less efficient in presenting OVA protein (10, 11). 
Thus far, little information is available on the antigen-presenting capacity of human MCs. 
Human MCs have also been shown to express MHC class II, especially after incubation with 
IFN-γ, which suggests their capacity to present antigen to CD4
+
 T cells (12-14). Indeed, 
activation of T-cell hybridomas with superantigens by these cells has been reported (14). 
However, T-cell activation by superantigen does not require the presentation of antigenic 
peptides by MHC molecules or the processing of protein via endogenous pathways. Human 
MCs have been reported to be present in the interfollicular area in tonsil (7), indicating that 
they may be involved in the activation of T-cell responses in lymphoid organs. However, it is 
unknown whether these MCs possess the required molecular make-up, such as HLA-DR and 
costimulatory molecules, to present antigen and activate T cells in lymphoid organs. 
As it is unclear whether human MCs are able to process and present native antigen to CD4
+
 
T cells, we aimed to study the interaction between these cells. Our data show that human 
MCs can present both peptide and entire protein antigens to CD4
+
 T cells, using two 
different antigen-specific CD4
+
 T-cell responses as read-out. Interaction of CD4
+
 T cells with 
MCs led to the enhanced expression of HLA class II molecules on MCs via release of IFN-γ 
by T cells. In addition, we show that human MCs, analyzed ex vivo from tonsil, are present 
in T-cell areas where they express HLA-DR and CD80. Together, these data indicate that 
antigen-specific MC–T cell interactions could contribute to the outcome of immune 
responses in the human. 
RESULTS 
HUMAN PERIPHERAL BLOOD DERIVED MC EXPRESS HLA-DR WHEN STIMULATED WITH 
IFN-γ 
Human MCs were generated from CD34
+
 stem cells. Typical flow cytometry plots 
identifying MCs by combined expression of CD117, CD203c (Ectoenzyme E-NPP3), FcεRI, 





) MCs. No expression of the DC markers DC-SIGN and CD1c 
(BDCA-1) was found on our cultured MCs (data not shown). Only low, but detectable, levels 
of HLA-DR were detected on resting MCs (Fig. 1B and C). 
Because it was previously shown for MC lines that IFN-γ could induce expression of HLA 
class II, we evaluated whether this could lead to upregulation of HLA-DR on our cultured 
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MCs as well. Incubation with 50 ng/mL IFN-γ for 24 h induced upregulation of HLA-DR 
(Fig. 1B and C). No induction of expression of HLA class II was found after stimulation with 
TLR ligands, anti-IgE, or recombinant IL-4 (data not shown). These results indicate that in 
the presence of IFN-γ, MCs can acquire the expression of HLA class II, and possibly the 
ability to present antigen to CD4
+
 T cells.  
Of the costimulatory molecules tested (CD80, CD86, ICOSL, OX40L, CD40L, and CD40), we 
found expression of CD80 but not CD86 or any of the other markers, as assessed by flow 
cytometry (Fig. 1D and E). Together, these data indicate that human MCs can express 
molecules required for stimulation of CD4
+
 T cells. 
 
Figure 1. Expression of HLA-class II and costimulatory molecules by human peripheral blood derived mast 
cells (MCs). (A) Representative flow cytometric plots of MC characterization after 6–8 weeks differentiation 
showing expression of CD117, intracellular tryptase, FcεRI, and CD203c. Histograms show gated live cells 
based on forward scatter (FSC) and sidescatter (SSC) characteristics as shown in the first panel. (B, C) MCs 
were cultured in the presence of 50 ng/mL IFN-γ for 24 h, after which expression of HLA-DR was assessed. 
(D, E) Expression of CD80 and CD86 in resting MCs. (B, D) Representative examples of MCs gated as CD117+ 
CD203c+. (C, E) Summaries (mean +SEM) of independent MC cultures (n = 3). Expression (MFI ratio) is 
indicated as MFI of the marker of interest (e.g. HLA-DR) divided by the MFI of the matching isotype control. 
Asterisk in (C) indicates significant (p < 0.05) increase in IFN-γ-treated cells compared with ctr MCs, using 
Student's t-test. 
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Figure 2. Antigen presentation by human mast cells (MCs) leads to activation of adenovirus-specific T 
cells. (A) Representative flow cytometric plots of TNF-α and IFN-γ production by gated CD3+CD4+ T 
cells after overnight coculture with MCs preincubated with medium (ctr), adenovirus -specific peptide 
or protein, in the presence of brefeldin A. (B, C) Summary of T-cell activation after preincubation of 
MCs with peptide and protein. Each dot shows an independent MC culture or PBMCs donor (n = 18 
and n = 9 for peptide and protein, respectively). p values comparing the  indicated conditions were 
calculated using Student's t-test. (D, E) Cytokine production by T cells after preincubation of MCs with 
blocking HLA class II antibodies (n = 3). (E) Data are shown as mean +SEM pooled from (n = 3) 
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HUMAN MC CAN PRESENT PEPTIDE AND PROTEIN TO CD4+ T CELLS 
To evaluate the potential of human MCs to present antigen to CD4
+
 T cells, MCs were 
preincubated with an adenovirus-derived peptide or hexon IID protein. Subsequently, 
MCs were cocultured with an adenovirus-specific T-cell clone recognizing the particular 
peptide. As shown by intracellular cytokine staining, MCs preincubated with peptide, in 
contrast to control MCs, were capable of inducing robust cytokine production by the T 
cells (Fig. 2A and B). The capacity of MCs to induce T-cell responses with the peptide was 
comparable to that of PBMCs. Importantly, MCs preincubated with the hexon IID protein 
were also capable of activating T cells, indicating the capacity of MCs to take up, process, 
and present native protein antigen to CD4
+
 T cells (Fig. 2A and C).  
Presentation of protein antigens by MCs appeared rather efficient, as 5  μg/mL protein, 
equivalent to 225 nM, was still able to activate adenovirus-specific T cells. Furthermore, 
although there was no difference between the T-cell responses induced by MCs 
compared with PBMCs when they were incubated with peptide, MCs were more efficient 
than PBMCs in inducing T-cell responses with the protein antigen (Fig. 2C). Similar results 
were obtained when T-cell-derived cytokine levels in supernatant were measured by 
ELISA (data not shown). 
To confirm that these T-cell responses were HLA class II dependent, MCs were next 
incubated with blocking HLA class II or isotype control antibodies. CD4
+
 T-cell 
responses induced by MCs preincubated with hexon IID protein were almost 
completely inhibited by HLA class II blocking antibodies, compared with the respective 
isotype control (Fig. 2D and E), further confirming that the MCs stimulated the T cells 
via HLA class II. 
Although the data presented above indicate that human MCs can present protein 
antigens to T cells, they do not show whether polyclonal T cells can be activated by MCs. 
To determine whether polyclonal T cells, rather than cloned T cells potentially harboring 
a high-avidity TCR to the peptide–MHC complex, are also activated by MCs, we next 
generated CD4
+
 bulk T cells expanded for 1 week with pooled tetanus toxoid, tuberculin, 
and Candida albicans. Subsequently, autologous MCs were incubated with these recall 
antigens and used as APCs for polyclonal bulk T cells. MCs were capable of activating 
autologous polyclonal CD4
+
 T cells, confirming their T-cell-activating capacity (Fig. 3). The 
response by CD4
+
 T cells that was induced by MCs was comparable to or better than our 
positive control, autologous adherent PBMCs. 
Together, these results indicate that human MCs are capable of taking up and processing 
native proteins for presentation to CD4
+









Figure 3. Antigen presentation by human mast cells (MCs) to autologous bulk CD4+ T cells. Polyclonal CD4+ 
T-cell bulks were generated by activation of PBMCs with the recall antigens tetanus toxoid, tuberculin 
purified protein derivative, and Candida albicans for 7 days. Autologous MCs or adherent PBMCs 
preincubated with medium (ctr) or these recall antigens (memory mix) were cultured overnight with the 
bulk T cells in the presence of brefeldin A. Flow cytometric plots of TNF-α production by T cells in three 
independent experiments are shown. T cells were gated based on FSC/SSC characteristics, CD14/CD117 
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CD4+ T CELLS CAN MODULATE MC VIA IFN-γ 
As the interaction between APCs and T cells can be bidirectional, the potential of CD4
+
 T 
cells to modulate MC phenotype was analyzed. To this end, MCs preincubated with peptide 
were cocultured with adenovirus-specific CD4
+
 T cells to evaluate potential effects of T-cell 
activation on the MCs. As shown in Figure 4A and B, the expression of HLA-DR by MCs was 
enhanced when T cells were activated by MCs preincubated with peptide. MCs cultured 
without T cells or MCs not preincubated with peptide did not show an increase in HLA-DR 
expression. Upregulation of HLA-DR was inhibited by blocking IFN-γ, ranging from 14 to 
100% inhibition as compared with the isotype control (Fig. 4C and D). 
These data indicate that the effect of activated T cells responsible for HLA class II 
upregulation on MCs was mainly mediated via IFN-γ. Together, these results show that MCs 
not only activate T cells, but also CD4
+
 T cells that can modulate MCs by upregulation of 
HLA class II, indicating a bidirectional interplay between MC and T cell. 
 
Figure 4. Induction of HLA class II on mast cells (MCs) through IFN-γ production by CD4+ T cells. (A, B) 
Representative flow cytometric plots and summary of HLA-DR expression by MCs preincubated with 
medium (ctr) or adenovirus-specific peptide (pept), after coculture with or without adenovirus-specific 
CD4+ T cells for the indicated time periods (n = 2). (C, D) Representative flow cytometric plots and summary 
of HLA-DR expression by MCs, after coculture for 48 h with adenovirus-specific CD4+ T cells in the presence 
of isotype control antibodies (mIgG1) or blocking antibodies to IFN-γ (n = 3). MCs are gated as CD203c+ cells 
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HUMAN TONSILS CONTAIN HLA-DR+ 
MC 
To evaluate whether HLA-DR
+
 MCs can 
also be found in vivo in T-cell areas of 
lymphoid organs, tonsil sections were 






cells and were found in all (n = 6) 
tissues analyzed (Fig. 5A). All tryptase
+
 
cells expressed CD117, whereas also 
some CD117
+
 tryptase- cells could be 
identified, indicating that CD117 alone 
cannot uniquely define tonsillar MCs. 
Tryptase
+
 MCs were most often found 
in T-cell areas characterized by 
abundant expression of CD3, and were 
commonly observed in close proximity 
to CD3
+
 T cells (Fig. 5B and C). These 
results indicate that MCs are present in 
T-cell areas of lymphoid organs and at 
locations allowing T cell–MC 
interactions. 
Figure 5. Mast cells (MCs) are present in T-cell 
areas of human tonsil. (A) MCs in tonsils are 
characterized as tryptase (tryp)+ CD117+ 
double-positive cells. (B, C) Double staining of 
tryptase and CD3. (B) MCs are mainly found in 
T-cell areas of the tonsil. “F” indicates the B-
cell follicles and “T” indicates the T-cell area, 
defined by expression of CD3. Arrowheads 
show Tryp+ MCs present in the T-cell area. (C) 
MCs are often found in close proximity to T 
cells. Arrowheads show examples of Tryp+ 
MCs in close contact with CD3+ T cells. Original 
magnifications: 20× (A, B) and 40× (C). (A–C) 
Images are representative examples of 
fluorescent stainings of tonsils from six 
independent donors. 
A. Mast cell identification in tonsil










B. Tonsil mast cells in T cell areas
10 μm
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Nonetheless, as evaluated by immunofluorescent staining of tonsil sections, we could not 
detect HLA-DR on these tryptase
+
 MCs (data not shown). As HLA-DR expression might be 
relatively low on tonsillar MCs, the detection of its expression might be obscured by the 
high HLA expression of other APCs that are abundantly present in tonsil. Therefore, we also 
analyzed MCs in tonsil cell suspensions using a more sensitive flow cytometric technique 
with antibodies recognizing CD117, CD203c, FcεRI, HLA-DR, and costimulatory molecules 
(Fig. 6). MCs were identified by their expression of high levels of CD117 and were further 
characterized by expression of the MC markers CD203c and FcεRI (Fig. 6A and B), and 
absence of the DC markers DC-SIGN and CD1c (data not shown). HLA-DR expression was 
found on MCs of all six donors analyzed, both when analyzed as percentage or mean 
fluorescence (Fig. 6C and D). The relative immunofluorescence was approximately tenfold 
lower than on other HLA-DR
+
 cells in the tonsil, which is in line with the difficulty to detect 
HLA-DR on MCs in a convincing manner by staining of tonsil sections. 
The expression of costimulatory molecules by tonsillar MCs was also evaluated (Fig. 6E and 
F). Although only low levels of CD86 were found, all four donors analyzed showed 
significant expression of CD80 compared with the isotype control, confirming the data 
obtained from MCs cultured from blood (Fig. 1C). 
Together, these results show that MCs expressing HLA-DR and costimulatory molecules are 
present in human tonsil, and that the majority of these MCs are located in close proximity 
to T cells, arguing for MC–T cell interaction in human LNs. 
DISCUSSION 
In this article, we show for the first time that cultured human MCs are capable of 
presenting native protein antigens to CD4
+
 T cells. The interaction between MCs and CD4
+
 T 
cells modulated the MC phenotype, indicating that both cell types can influence each other 
in an antigen-dependent manner. Furthermore, the interaction between these cell types 
may be physiologically relevant as the presence of MCs in proximity to T cells was also 
shown in lymphoid organs.  
A clear inherent limitation of our study is that we are unable to show the ability of MCs to 
present antigen in vivo. Likewise, there were some differences between the cultured MCs 
and their in vivo counterparts. Whereas the cultured MCs readily expressed HLA-DR after 
coculture with the T cells, the tonsil-resident MCs already expressed HLA-DR when 
evaluated directly ex vivo. This difference might be explained by the exposure of MCs to 
IFN-γ either in the tonsil or in the periphery by either T cells or innate IFN-γ-producing cells 
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Figure 6 (left). Mast cells 
(MCs) in tonsil express 
HLA-DR and CD80. (A, B) 
MC characterization in 
total tonsil cell 
suspensions by CD117, 
FcεRI, and CD203c (n = 6). 
Live cells were gated 
based on FSC/SSC 
characteristics and DAPI 
negativity and their 
expression of CD117 or 
isotype control are shown 
in the dotplots. 
Histograms show 
expression of FcεRI and 
CD203c by gated CD117hi 
cells as shown in the 
dotplots. (C, D) Expression 
of HLA-DR by MCs 
characterized as in (A) (n = 
6). (E, F) Expression of 
CD80 and CD86 by MCs 
characterized as in (A) (n = 
4). Expression (MFI ratio) 
in (D) and (F) is indicated 
as MFI of the marker of 
interest (e.g. HLA-DR and 
CD80) divided by the MFI 
of the matching isotype 
control. Dotted lines in (D) 
and (F) indicate absence 
of expression of the 
indicated marker 
compared with the 
isotype control (MFI ratio 
= 1). Data shown are 
representative of tonsils 
from four to six 
independent donors. 
Nonetheless, as the phenotype of MCs for the other markers 
evaluated (CD117, tryptase and CD80) was comparable, we 
believe that the cultured MCs are a good representation of 
their counterparts in vivo, and that the biological effects 
observed in vitro are conceivably present in vivo as well. 
The presentation of antigen to CD4
+
 T cells by human MCs 
may serve to stimulate T cells in diverse locations, such as 
lymphoid organs and peripheral tissues. As MCs can produce 
a different set of cytokines than other APCs (15-17), our 
findings could potentially have important implications for the 
skewing of T helper cells and maybe even for the outcome of 
naïve T-cell priming in LNs. Since both cultured and tonsil-
resident MCs express HLA class II and CD80, their potential in 
stimulating naïve CD4
+
 T cells cannot be excluded. Skin MCs 
have been shown to migrate from infected/allergic areas to 
draining LNs in the mouse (2, 3). Nonetheless, mouse MCs, 
although able to activate memory T cells, were not able to 
prime naïve CD4
+
 T cells, probably due to the lack of 
costimulatory molecules (10, 11).  
As MCs only comprised approximately 0.02–0.04% of total 
tonsil cells as shown in Fig. 6, and as their expression of HLA 
class II molecules was much lower than that of other 
professional APCs such as DCs, we do not consider it likely 
that MCs play a crucial role in priming of T cells in primary 
immune responses. In contrast, we consider it more likely 
that they might be more important in activation of secondary 
T cells in either LN or peripheral tissue. Especially, the latter is 
an intriguing possibility as MCs are present at several 
strategic locations where pathogens are first encountered. It 
could be very beneficial to the host to swiftly activate effector 
memory T cells that are known to reside in tissues (18), by 
MCs that are well known for their immediate and strong 
actions upon activation.  
Furthermore, MCs could produce several cytokines upon activation through activation via 
IgE and TLR, which may have an impact on T-cell activation or skewing. In addition, CD4
+
 T 
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MCs were shown to specifically enhance activation of CD4
+
 Treg cells through MHC class II 
(10), such T cell–MC interactions could also function to inhibit MC responses, such as 
observed in a murine model of anaphylaxis (19). The expression of MHC class II by MCs 
depended on the production of IFN-γ by T cells in this study, showing the ability of T cells to 
influence MC phenotype. Therefore, interaction between MCs and T cells might direct the 
responsiveness of both cell types, allowing for optimal control of both cell populations. 
We have not shown how the MCs have taken up antigen for presentation to T cells in our 
study. However, we observed no enhancement of antigen presentation when protein 
antigens were targeted to the FcεRI on the MCs via hapten-specific IgE and hapten-coupled 
protein (data not shown). The lack of enhancement of presentation by Fc-receptor-
targeted antigens by human MCs contrasts findings obtained in mice, as two studies 
reported enhanced antigen presentation by Fc-receptor-mediated uptake (11, 20). 
Nonetheless, another study using murine MCs indicated decreased antigen presentation 
when antigen was routed to IgE/FcεRI, possibly because antigens were protected from 
proteolytic degradation and subsequent presentation as peptide in MHC (10). Further 
research into this aspect is required, but our data indicate that Fc-receptor-mediated 
uptake and presentation of Ig(E)-bound antigen by human MCs, if present, is likely to be 
less efficient as compared with the ability of DCs to take up and present immune-
complexed antigens (21). 
In conclusion, our results show that cultured human MCs can function as APCs, by uptake 
and processing of protein, with subsequent presentation to CD4
+
 T cells via HLA class II. 
Furthermore, expression of HLA class II and CD80 is found on MCs isolated from human 
tonsil, where they are found in close proximity to T cells. In addition, the interaction 
between MCs and CD4
+
 T cells led to changes in the MC phenotype in an antigen-specific 
manner, indicating an intimate interaction between these two distinguished cell types. 
MATERIALS AND METHODS 
MAST CELLS 
Buffy coats from healthy volunteers were obtained from the blood bank (Sanquin, The 
Netherlands). PBMCs were isolated using a standard Ficoll procedure, after which 
CD34
+
 hematopoietic stem cells were isolated with CD34 microbeads (Miltenyi Biotec). 
Isolated CD34
+
 stem cells were differentiated into MCs using serum-free medium 
(StemPro 34 + supplement, Gibco) with 30 ng/mL IL-3, 100 ng/mL IL-6, and 100 ng/mL 
stem cell factor (SCF) at 50 000 cells/mL as described (22, 23). Half of the medium was 
replaced weekly with serum-free medium containing 100 ng/mL IL-6 and 100 ng/mL 
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SCF. All recombinant cytokines were obtained from Peprotech. After 6–8 weeks, the 
purity of MCs was determined by flow cytometric analysis of CD117 (c-kit), FcεRI and 
CD203c, and intracellular tryptase. The purity of MCs ranged from 90 to 99%.  
CD4+ T-CELL CLONE 
An adenovirus-specific CD4
+
 T-cell clone (M2.11) was used to determine antigen 
presentation by MCs (24). This clone recognizes a peptide derived from hexon protein 
II, in the context of HLA-DRB1*03:01. MCs from blood of HLA-DRB1*03:01 positive 
donors were generated as described above. MCs were incubated with 5 μg/mL peptide 
for 24 h, or 1–50 μg/mL protein (22.2 kDa polypeptide fragment D from hexon protein 
II (24)) for 6–72 h, before coculture with the CD4
+
 T cells. Before coculture with the T-
cell clone, MCs were thoroughly washed to remove all soluble protein or peptide. 
Subsequently, the MCs were added to the CD4
+
 T cells in a 1:1 ratio in RPMI with 10% 
human serum and 100 ng/mL SCF at 200 000 cells/mL. After 1 h, 5 μg/mL brefeldin A 
was added and incubated overnight. To determine the effects of activation of the T -cell 
clone on the MCs, the cells were cultured without brefeldin A for the indicated 
timepoints. 
Blocking antibodies and isotype controls for HLA class II (BD Pharmingen, clone Tü39, 
10 μg/mL) were added to the MCs, and incubated for 1 h at 37°C before the MCs were 
added to the T cells. Blocking antibodies remained present during the coculture. 
Blocking antibodies and isotype controls for IFN-γ (eBioscience, clone NIB42, 20 μg/mL) 
were added to the cocultures directly. 
CD4+ T-CELL BULK RESPONSES AGAINST RECALL ANTIGENS 
Polyclonal CD4
+
 T-cell bulks were generated by activation of PBMCs with the recall 
antigens tetanus toxoid at 0.75 Lf/mL (Netherlands Vaccine Institute), tuberculin 
purified protein derivative (0.5 μg/mL) (Netherlands Vaccine Institute), and C. albicans 
0.005% (HAL allergy) in IMDM/5% human serum for 7 days, after which antigen 
presentation by autologous MCs was evaluated. MCs or autologous PBMCs were 
incubated with the recall antigens mentioned above for 16 h, before coculture with 
autologous bulk CD4
+
 T cells. After this incubation, the cells were thoroughly washed to 
remove all soluble protein. Autologous PBMCs were used as positive control and were 
allowed to adhere to the plate at 37°C for 2 h, after which nonadherent cells were 
removed. Subsequently, the CD4
+
 T cells were added to the APCs in IMDM/5% human 
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TONSILS 
Human tonsils were obtained after tonsillectomy. A portion of these tissues were fixed with 
4% formaldehyde in PBS, stored in 70% ethanol, and embedded in paraffin for 
immunofluorescent staining of sections. The remaining part of the tonsils was washed with 
RPMI with 10% FCS and cut into small pieces. Subsequently, the tonsils were dispersed 
through a 70 μm filter to get single-cell suspensions. Cells were frozen until flow cytometric 
staining and acquisition. This study was performed in accordance with the declaration of 
Helsinki and local ethical guidelines. 
IMMUNOFLUORESCENCE 
Tonsil tissues were treated according to the method described by Schuerwegh et al. to 
deparaffinize and retrieve antigens with EDTA (25). Slides were incubated with 8 μg/mL 
goat anti-human tryptase, 26.5 μg/mL rabbit anti-human CD117, 60 μg/mL rabbit anti-
human CD3, or matching isotype controls for 1 h at room temperature. After washing, 
slides were stained with 2 μg/mL donkey α-goat AF 568 and 2 μg/mL donkey α-rabbit AF 
488 for 1 h at room temperature. After washing, slides were covered with Vectashield 
containing DAPI (Vector laboratories) to stain nuclei. Slides were analyzed on a Zeiss Axio 
ScopeA1 microscope. 
FLOW CYTOMETRY 
For detection of HLA-DR and costimulatory molecules expression by cultured MCs, cells 
were incubated with fluorochrome-conjugated antibodies recognizing CD117, CD203c, 
HLA-DR, CD80, and CD86 or matching isotype controls. Intracellular staining of tryptase was 
performed as described (26). 
For detection of expression of HLA-DR and costimulatory molecules on tonsil MCs, cells 
were incubated with fluorochrome-conjugated antibodies recognizing CD117, CD203c, 
FcεRI, HLA-DR, CD86, and CD80 or matching isotype controls for each of these antibodies. 
Just prior to flow cytometric acquisition, 0.2 μM DAPI was added for exclusion of dead cells. 
For intracellular cytokine staining by CD4
+
 T cells, the cells were incubated with 
fluorochrome-conjugated antibodies recognizing CD3 and CD4, after which they were 
permeabilized using CytoFix CytoPerm Kit (BD Biosciences). To gate out any remaining 
monocytes in the CD4
+
 T-cell bulks, antibodies to CD14 were added as well. After washing, 
cells were incubated with PE-labeled anti-IFN-γ, TNF-α, or matching isotype control. Cells 
were taken up in 1% paraformaldehyde until flow cytometric acquisition. Flow cytometry 
was performed on FACS Calibur (BD) or LSR II (BD). Analysis was performed using FACS Diva 
(BD) and FlowJo software. 
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STATISTICAL ANALYSIS 
Results are expressed as mean ± SEM. Statistical analysis was performed using SPSS PASW 
17.0 and GraphPad Prism 4. For differences between two groups, Student's t-tests were 
performed. p values of <0.05 were considered statistically significant. 
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ABSTRACT 
Mast cells are innate immune cells usually residing in peripheral tissues, where they are 
likely to activate T-cell responses. Similar to other myeloid immune cells, mast cells can 
function as antigen presenting cells. However, little is known about the capacity of human 
mast cells to co-stimulate CD4+ T cells.   
Here, we studied the T cell-stimulatory potential of human mast cells. Peripheral blood-
derived mast cells were generated and co-cultured with isolated CD4+ T cells. In the 
presence of T-cell receptor triggering using anti-CD3, mast cells promoted strong 
proliferation of T cells, which was 2-5 fold stronger than the “T-cell promoting capacity” of 
monocytes. The interplay between mast cells and T cells was dependent on cell-cell 
contact, suggesting that co-stimulatory molecules on the mast cell surface are responsible 
for the effect. However, in contrast to monocytes, the T cell co-stimulation by mast cells 
was independent of the classical co-stimulatory molecule CD28, or that of OX40L, ICOSL, or 
LIGHT.   
Our data show that mast cells can co-stimulate human CD4+ T cells to induce strong T cell 
proliferation, but that therapies aiming at disrupting the interaction of CD28 and B7 
molecules do not inhibit mast cell-mediated T-cell activation. 
INTRODUCTION 
Mast cells are innate immune cells derived from myeloid progenitors. They have been 
originally described as one of the effector cells in allergic IgE-mediated responses. More 
recently, their role in immune regulation, and specifically in regulation of adaptive 
immune responses, has been recognized.(1) For example, we and others have shown that 
mast cells can function as antigen presenting cells through cognate interactions with 
CD4
+
 T cells both in human and mouse.(2-4) CD4
+
 T cell activation in this context was 
dependent on recognition of specific antigens in the context of MHC class II. Activation 
and skewing of T cells generally requires the presence of 3 signals, consisting of antigen 
presentation through MHC, co-stimulation and specific cytokine signals.(5) Co-
stimulation is the interaction of membrane-bound receptors on T cells and antigen 
presenting cells that enhance signals through the T cell receptor, and that is necessary to 
induce full T cell activation, proliferation and survival. Classical co-stimulation consists of 
CD28-mediated signaling by B7 family members on antigen presenting cells, although 
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lymphocyte activation molecule (SLAM) family are known to regulate the balance 
between T cell death and survival as well.(6) 
We have previously shown the presence of mast cells in T cell areas of lymphoid 
organs,(2) as well as their colocalization in synovial tissue,(7) suggesting that mast cells 
could modulate T cell responses. Although mast cells have been shown to function as 
antigen presenting cells, their capacity to provide co-stimulatory signals to T-cells has 
been studied sparsely. In the mouse, TCR-stimulated T-cells displayed enhanced 
proliferation and cytokine secretion in the presence of mast cells,  indicating that mast 
cells are capable of enhancing T-cell responses.(8, 9) This effect in the mouse was directly 
mediated through TNF production by the mast cells. However, several important 
differences have been shown between mouse and human mast cells, one of which being 
the low production of TNF by human mast cells in contrast to their mouse 
counterparts.(10) 
Co-stimulation pathways are therapeutic targets, for example in autoimmune diseases. 
CTLA4-Ig, which targets the CD28-dependent interaction between T cells and antigen-
presenting cells through binding to B7 molecules on antigen presenting cells, is used as 
treatment for rheumatoid arthritis.(11) Recently, mast cells were shown to play an 
important role in T cell-dependent inflammation in a mouse model of arthritis, 
suggesting that mast cells may directly regulate T cell responses in this disease.(12) 
Therefore, it is important to understand if mast cells can regulate T cell  activation 
through co-stimulation, and if CTLA4-Ig can regulate this interaction. 
Our data show that human mast cells can induce robust proliferation responses of CD4
+
 
T-cells in the presence of T cell receptor stimulation. This interaction depends on cell -cell 
contact, but is independent of CD28. Together, these data indicate that mast cell -T cell 
interactions contribute to the outcome of adaptive immune responses in humans, and 
that these interactions are not targeted by “conventional” co-stimulation blockade.  
RESULTS 
CD4+ T CELL ACTIVATION AND PROLIFERATION IS GREATLY ENHANCED BY MAST CELLS 
To evaluate the co-stimulatory function of mast cells, isolated CD4
+
 T cells were activated 
with anti-CD3 in the presence or absence of human peripheral blood-derived mast cells. T 
cell activation was measured by evaluating the expression of activation markers CD69 and 
CD25 (Figure 1A-C). To gate out mast cells (CD117
+





 cells (Figure 1A).  
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Figure 1 (left): CD4+ T cell co-stimulation by mast cells. A-C) Isolated human CD4+ T cells were co-cultured 
with autologous peripheral blood-derived mast cells for 24 hours, in the presence or absence of anti-CD3 
and anti-CD28, after which they were stained for activation markers CD69 and CD25. T cells were gated as 
CD3+CD117- cells as shown in A. Representative flow cytometry plots of T cells in co-culture with mast cells 
and in the presence of anti-CD3 (B) and summary (C) of 3 independent experiments are shown. D-F) 
Isolated CD4+ T cells were CFSE-labeled and co-cultured with autologous mast cells for 5 days, in the 
presence or absence of anti-CD3 and anti-CD28, after which they were stained for flow cytometry. T cells 
were gated as CD3+CD117- cells as shown in panel A. Representative flow cytometry plots for CFSE (D) and 
summary of 11 independent experiments performed in duplicate with anti-CD3 (E) or anti-CD3 and anti-
CD28 (F) are shown. G) Isolated total and naïve CD4+ T cells were CFSE-labeled and co-cultured with 
autologous mast cells for 24 hours, in the presence or absence of anti-CD3 and anti-CD28, after which they 
were stained for flow cytometry. T cells were gated as CD3+CD117- cells as shown in A. Representative 
example of 2 experiments performed in duplicate is shown. The percentage of divided T cells is depicted as 
% of the input frequency, indicating how many cells from the original cell population have divided. Division 
index represents the average number of cell divisions that a cell in the original population has undergone. 
Results are expressed as mean±SEM (C,G), or as individual dots where each dot/line indicates an 
independent experiment (E,F). Asterisks indicate statistically significant difference (*p<0.05; **p<0.01; 
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Anti-CD3-stimulation led to an upregulation of these markers on T-cells.  However, the 
upregulation, in particular that of CD25, was much more pronounced when T cells were 
co-cultured with mast cells and anti-CD3, suggesting that mast cells can enhance T-cell 
activation in the presence of a TCR stimulus. 
To confirm the enhanced activation of T cells after co-culture with mast cells, we next 
analysed T cell proliferation by a CSFE-dilution assay (Figure 1D,E). As expected, in the 
absence of mast cells or other forms of co-stimulation, virtually no T cell proliferation was 
observed in response to anti-CD3 alone. In line with the requirement of co-stimulation to 
trigger full T cell activation, anti-CD28 signalling significantly enhanced T cell proliferation 
(Figure 1F). Intriguingly, an even more pronounced T-cell activation was observed in the 
presence of mast cells.  
Although CD28-signalling further enhanced T-cell proliferation in the presence of mast 
cells, the contribution of mast cells did not require the concomitant presence of a CD28-
dependent signal. However, the effect of mast cells was dependent on T cell receptor 
triggering, as no effect of mast cells was observed in the absence of anti-CD3 (Figure 1E).  
CO-STIMULATION BY MAST CELLS IS CELL-CONTACT DEPENDENT 
As co-stimulatory molecules on professional antigen presenting cells, such as dendritic 
cells, can be upregulated after their activation, the effect of stimulation of mast cells was 
evaluated. Mast cells were activated using anti-IgE and LPS, two stimuli that induce a robust 
activation of mast cells and result in degranulation and cytokine production.(13) As shown 
in Figure 2A-B, the activation of mast cells had no effect on T cell proliferation, indicating 
that resting mast cells already have the capacity to induce T cell proliferation. 
Importantly, the co-stimulatory capacity of mast cells was not dependent on crosslinking 
via FcγR (Supplementary Figure 1). Whereas IL-8 production by mast cells was significantly 
reduced in the presence of blocking FcγR antibodies (anti-CD32A), no effect on T cell 
proliferation was observed. Together these results indicate that co-stimulation by mast 
cells is independent of activation, by TLR ligands or Fc receptor crosslinking.   
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Figure 2 (left): CD4+ T cell co-stimulation by mast 
cells is cell-contact dependent. A-C) Isolated 
human CD4+ T cells were CFSE-labeled and co-
cultured with autologous mast cells or mast cell 
supernatant for 5 days, in the presence of anti-
CD3 and/or anti-CD28, after which they were 
stained for flow cytometry. T cells were gated as 
CD3+CD117- cells as shown in Figure 1A. Mast 
cells were left unstimulated (ctr) or were 
stimulated with LPS + aIgE. Summary of 3 
independent experiments is shown. A) 
Representative flow cytometry plots of T cell 
proliferation in the presence of unstimulated 
mast cells and anti-CD3 (left), mast cells 
stimulated with LPS + anti-IgE in the presence of 
anti-CD3 (middle), or mast cell supernatant in 
presence of anti-CD3 and anti-CD28 (right). B) T 
cell/mast cell coculture. Summary of 3 
independent experiments is shown. C) T cell 
culture in the presence of mast cell supernatant. 
Summary of 6 independent experiments is 
shown. D,E) Isolated CD4+ T cells were CFSE-
labeled and co-cultured in transwell plates with 
autologous mast cells for 5 days, in the presence 
of anti-CD3 and/or anti-CD28, after which they 
were stained for flow cytometry. Mast cells were 
cultured in the same well as the T cells, or were 
separated by a transwell membrane (+). D) 
Representative flow cytometry plots of T cells 
cultured in presence of anti-CD3 and in the 
presence of mast cells either together in the 
same well (left) or separated by a transwell 
(right). E) Summary of 3 independent 
experiments is shown. The percentage of divided 
T cells is depicted as % of the input frequency, 
indicating how many cells from the original cell 
population have divided. Division index 
represents the average number of cell divisions 
that a cell in the original population has 
undergone. Results are expressed as mean±SEM. 
Ns indicates no significant difference was found 
using students T-test (B,C). Asterisks indicate 
statistically significant difference (***p<0.005) 
using ANOVA with Bonferroni’s post-hoc test (E). 
To analyse whether cell-cell contact or 
mast cell-derived soluble mediators 
were responsible for the co-stimulatory 
effects, we next cultured T cells in the 
presence of mast cell supernatant. 
However, the presence supernatant 
from mast cell cultures did not result in 
enhanced proliferation, but if anything, 
the opposite (Figure 2A,C). To directly 
address the requirement for cell 
contact between mast cells and T cells, 
transwell experiments were performed. 
The effect of mast cells on T cell 
proliferation was absent when mast 
cells were separated from T cells by the 
transwell membrane (Figure 2D-E). 
These results indicate that the co-
stimulatory effect mediated by mast 
cells requires cell-cell-contact, and is 
not dependent on soluble mediators 
secreted by mast cells.  
CD4+ T CELL PROLIFERATION INDUCED BY 
MC COMPARED TO MONOCYTES 
To compare the co-stimulatory capacity 
of mast cells to other cells known to 
effectively co-stimulate T-cells, we 
compared the T cell proliferation 
induced by mast cells to that induced by 
total PBMCs (Figure 3A). At a similar 
ratio of PBMCs/mast cells to T cells, mast 
cells displayed a considerable higher 
capacity to induce T cell proliferation in 
the presence of anti-CD3 as compared to 
PBMCs. 
164  |  CHAPTER 8 
The superior co-stimulatory ability of mast cells compared to PBMCs was also observed 
in titration experiments as lower number of mast cells were required to achieve a 
similar T-cell proliferation (Figure 3B). Next, we also wished to compare the co-
stimulatory capacity of mast cells to isolated CD14
+
 monocytes. As shown in Figure 3C-
D, mast cells were also better in supporting T cell proliferation than monocytes, further 
confirming the potent co-stimulatory ability of mast cells.  
 
Figure 3: Mast cell co-stimulation compared to monocytes. A,B) Isolated human CD4+ T cells were CFSE-
labeled and co-cultured with autologous mast cells or PBMCs for 5 days, in the presence of anti-CD3, after 
which they were stained for flow cytometry. T cells were gated as CD3+CD117-CD14- cells as shown in Figure 
1A. Ratios of co-stimulatory cells (APC) to T cells was 1:1 in 3 independent experiments (A) or titrated 
ranging from 4:1 – 1:1 for PBMCs and from 1:1 – 1:4 for mast cells in 2 independent experiments (B). C,D) 
Isolated total and naïve CD4+ T cells were Cell Trace Violet (CTV) labeled and co-cultured with monocytes or 
mast cells for 5 days, in the presence or absence of anti-CD3 and CD28, after which they were stained for 
flow cytometry. C) Representative flow cytometry plots of CTV staining of T cells cultured in the presence of 
anti-CD3, gated as in Figure 1A.  D) Summary of 3 independent experiments is shown. Asterisks indicate 
statistically significant (p<0.05) differences obtained using paired-samples T test (A), or Two-way ANOVA 
with Bonferroni’s posthoc test (D). 
A. 
aCD3
T cells + PBMC
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As the co-stimulatory requirements of T cells differ between memory and naïve CD4
+
 T 
cells, with naïve T cells being more dependent on a co-stimulatory signal,(14) we also 
evaluated the contribution of mast cells to proliferation of naïve CD4
+
 T cells. As depicted in 
Ffigure 3C-D, mast cells were fully capable of inducing robust proliferation of naïve T cells in 
the presence of only anti-CD3, in contrast to monocytes which only induced minimal T cell 
proliferation. These results therefore indicate that mast cells are potent inducers of-
stimulation of CD4
+
 T cells in the presence of a TCR stimulus, also when the T-cells have a 
naïve phenotype. 
CD4+ T CELL PROLIFERATION INDUCED BY MC DOES NOT DEPEND ON CLASSICAL CO-
STIMULATION VIA CD28 
We and others have shown previously that mast cells express CD80, which is known to 
interact with CD28 on T cells to induce co-stimulation.(2, 4) Therefore, it has been 
postulated that this molecule could be responsible for a co-stimulatory signal coming from 
mast cells. We first compared the expression levels of CD80 and CD86 on mast cells and 
monocytes (Fig 4A-C). Similar to our previous findings, human mast cells express CD80 but 
no CD86. In comparison, we observed that resting monocytes express CD86, but no CD80. 
However, we have to note that the high level of autofluorescence in mast cells (due to their 
granularity) makes it difficult to directly compare expression levels between the two cell 
types. 
To analyse the contribution of this pathway to T cell co-stimulation by mast cells, we 
incubated mast cells, PBMCs or monocytes with CTLA4-Ig (Abatacept) or isotype control, 
prior to co-culture with the T cells. CTLA4-Ig remained present throughout the culture 
period. Whereas CTLA-4Ig significantly decreased T cell proliferation when T-cells were 
cultured with PBMCs or isolated monocytes, no effect of CTLA4-Ig was observed when mast 
cells were used as co-stimulatory cell (Fig 4D,E). Likewise, dilution of mast cells to achieve 
lower mast cell:T cell ratios to mimic the co-stimulatory capacity of PBMCs and monocytes 
did not lead to a detectable effect on T-cell proliferation supported by mast cells (Fig 4F).  
Our results indicate that co-stimulation by mast cells is independent of CD28, in contrast to 
the ability of PBMCs and monocytes to co-stimulate T-cells. 
We next evaluated whether other known co-stimulatory molecules were responsible for 
CD4
+
 T cell activation by mast cells. Based on published microarray databases and RNA 
sequencing results, we identified the following potential T cell co-stimulatory molecules 
expressed by human mast cells that can be blocked by neutralizing antibodies: OX40L 
(TNFSF4), ICOSL (B7H2), and LIGHT (TNFSF14).(15, 16)  
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As shown in Figure 5, co-stimulation by mast cells was not inhibited using blocking 
antibodies against OX40L, ICOSL, or LIGHT, suggesting that the activation of CD4
+
 T 
cells by mast cells was not mediated via these receptor/ligand systems and that other, 
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Figure 4 (left): Mast cell-mediated co-stimulation is 
independent of CD28A-C) Cultured mast cells and 
isolated monocytes were stained for CD80 and 
CD86 and analysed by flow cytometry. A) Debris 
and doublets were excluded based on forward and 
sideward scatter (FSC/SSC). Live monocytes were 
gated as CD14+FVD- (fixable viability dye 
eFluor506). Live mast cells were gated as 
CD117+FVD- cells. B) Representative examples of 
CD80 and CD86 expression by monocytes and mast 
cells. C) Summary expression of CD80 and CD86 by 
monocytes and mast cells. Delta-MFI was 
calculated by subtracting the MFI of isotype control 
from the MFI of CD80 or CD86 staining. D-F) 
Isolated CD4+ T cells were CFSE-labeled and co-
cultured autologous mast cells, monocytes or 
PBMCs for 5 days, after which they were stained 
for flow cytometry. Prior to co-culture, co-
stimulatory cells were treated with control 
medium, isotype control IgG, or Abatacept (CTLA4-
Ig), and these treatments remained present during 
the co-culture. D) Representative flow cytometry 
plots of CFSE staining of T cells cultured in the 
presence of anti-CD3, gated as in Figure 1A. T cells 
cultured with PBMCs as APC in a ratio 1:4 (left) and 
T cells cultured with mast cells as APC in a ratio 1:1 
(right). E,F) Summary of 5 independent 
experiments using n=5 independent mast cell 
donors, n=3 independent PBMC donors and n=2 
independent monocyte donors. E) T cell 
proliferation was normalized to control-medium 
treated PBMCs, monocytes or mast cells (T+APC 
ctr: 100%). F) T cell proliferation at different mast 
cell:T cell ratios as indicated in the axis titles. The 
percentage of divided T cells is the precursor 
frequency, indicating how many cells from the 
original cell population have divided. Division index 
is the average number of cell divisions that a cell in 
the original population has undergone. Results are 
expressed as mean±SEM. Asterisks indicate 
statistically significant difference (*p<0.05) using 
Students T-test. Ns indicates no significant 
difference was found using students T-test (E). 
DISCUSSION 
In this study we showed that mast 
cells can mediate T cell co-stimulation 
through a CD28-independent pathway. 
Although we analyzed a possible role 
for OX40L, ICOSL, and LIGHT, we have 
not identified the molecular mode of 
action explaining the ability of human 
mast cells to provide co-stimulation to 
T-cells. We also analyzed the 
contribution of FcγR crosslinking of 
mast cells by anti-CD3. Mast cells were 
activated by anti-CD3 antibodies in an 
FcγRIIA-dependent manner, but 
blocking of this receptor did not affect 
T cell proliferation induced by mast 
cells. Therefore, this activation of mast 
cells is unlikely to contribute to the T 
cell activation we observed. 
We hypothesize that classical 
members of the B7 and TNF receptor 
families are unlikely to account for the 
observed co-stimulation by mast cells. 
For example, some of the molecular 
interactions that are described to be 
involved in priming of naïve CD4
+
 T 
cells, HVEM-LIGHT, CD27-CD70 are 
either not expressed by mast cells, or 
were not inhibited by the blocking 
antibodies we used. However, there 
are many other members of the TNF 
receptor family and SLAM family, for 
which their role in co-stimulation of 
CD4
+
 T cells is currently unknown.(6) 
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Figure 5: Blocking co-stimulatory molecules in the mast cell-T cell interaction. Isolated human CD4+ T cells 
were labeled with cell trace violet (CTV) and co-cultured with mast cells for 4-5 days, in the presence of 
anti-CD3, after which they were stained for flow cytometry. Live T cells were gated as CD3+CD117-CD14- 
cells as shown in Figure 1A. As positive control, T cells were stimulated in the presence of anti-CD3 and anti-
CD28 (T+aCD28). Prior to co-culture, mast cells were treated with control medium, isotype control mIgG1 
(control for OX40L), mIgG2b (control for B7H2), goat IgG (control for LIGHT) or anti-OX40L, anti-B7H2 
(ICOSL), anti-LIGHT, and these antibodies remained present during the co-culture. A) Representative flow 
cytometry plots of cell trace violet (CTV) staining. B,C) Summary of 3 independent experiments is shown. 
The percentage of divided T cells is the precursor frequency, indicating how many T cells from the original 
cell population have divided. Division index is the average number of cell divisions that a T cell in the 
original population has undergone. Results are expressed as mean±SEM. No statistically significant 
differences between blocking antibodies and their matching isotype control antibodies were found using 
students T-test. 
Therefore, it remains to be shown which of these, or other unknown receptors, is 
responsible for co-stimulation by human mast cells. Other studies have shown T cell 
proliferation by activated mast cells was partially mediated by TNF (mouse mast cells) and 
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through TNF and OX40L/OX40 depend on mast cell activation, which is required for 
production or expression of these molecules.(8, 9)
 
Furthermore, T cell activation by these 
molecules usually only occurs in pre-activated or effector T cells. (18, 19) As we observed 
strong T cell activation in the absence of mast cell stimulation, and activation of naïve T 
cells by mast cells was as strong as that of total CD4
+
 T cells, we propose that these 
pathways are unlikely to account for the full co-stimulatory signal provided by mast cells, as 
also shown by transwell experiments and inhibition of OX40L.   
Because a redundancy of co-stimulatory molecules might be present with respect to the 
ability of human mast cells to provide co-stimulatory signals to T-cells, it might be difficult 
to identify the pathway that is responsible for the observed effect.(20) However, know-how 
on the molecular details underlying the effects observed is likely of relevance as these 
effects may have important implications for therapies aiming to block co-stimulatory 
pathways such as employed in autoimmune diseases. Whereas CTLA4-Ig is being 
successfully used as treatment for a variety of autoimmune diseases, it does not completely 
inhibit T cell activation, suggesting that CD28-independent pathways may contribute to 
autoreactive T cell responses as well.(11, 21-23) Our results suggest that this treatment 
may not inhibit mast cell-mediated, and possibly other forms of T cell activation. Indeed, 
several studies point to an important contribution of CD28-independent T cell activation in 
autoimmune disease.(24, 25) Therefore, our results suggest that CD28-independent 
inhibitors of T cell activation may prove beneficial effects against CD28-independent 
autoimmune T cell responses such as those supported by mast cells and possibly other 
cells.  
MATERIALS AND METHODS 
MAST CELL CULTURE 
Buffy coats from healthy volunteers were obtained from the blood bank (Sanquin, The 
Netherlands). PBMCs were isolated using a standard Ficoll procedure, after which CD34
+
 
hematopoietic stem cells were isolated with CD34 microbeads (Miltenyi Biotec). Isolated 
CD34
+
 stem cells were differentiated into mast cells using serum-free medium (StemPro 34 
+ supplement, Gibco) with 30 ng/mL IL-3, 100 ng/mL IL-6 and 100 ng/mL Stem Cell Factor 
(SCF) at 50.000 cells/mL as described.(26) Half of the medium was replaced weekly with 
serum-free medium containing 100 ng/mL IL-6 and 100 ng/mL SCF. All recombinant 
cytokines were obtained from Peprotech. After 6-8 weeks, the purity of mast cells was 
determined by flow cytometric analysis of CD117 (c-kit), FcεRI and CD203c and intracellular 
tryptase. The purity of mast cells ranged from 90-99%.  
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T CELL ACTIVATION 
For isolation of T cells, autologous CD45RO-negative (naïve) or total CD4
+
 T cells were 
isolated from PBMCs by negative magnetic bead isolation (Miltenyi Biotec). The purity of 
isolated T cells was above 95% in each experiment. As positive controls, total PBMCs or 
isolated CD14
+
 monocytes (Miltenyi Biotec) were used to stimulate T cells. 
Isolated T cells were labeled with Cell Trace CFSE or Cell Trace Violet (both from Invitrogen) 
to measure cell proliferation. T cells were activated in the presence or absence of 5 μg/mL 
platebound anti-CD3 (eBioscience; clone: OKT3) and/or 1 μg/mL soluble anti-CD28 
(Sanquin; clone: CLB-CD28/1, 15E8) and were cultured in the presence or absence of mast 
cells in the indicated ratios. Activation of T cells was measured after 24h by flow cytometry 
for CD25 and CD69. Proliferation and cytokine production were measured after 4-5 days of 
incubation. To this end, T cells were harvested, washed, and restimulated using 50 ng/mL 
PMA (Sigma) and 500 ng/mL Ionomycin (Sigma). Cells were restimulated for 5 hours in the 
presence of 10 μg/mL brefeldin A (Sigma) for intracellular cytokine staining.  
For mast cell activation, cells were sensitized with 0.1 µg/mL hybridoma IgE (Diatec) for a 
minimum of 18 hours, after which non-bound IgE was washed away. Mast cells were 
activated with 10 ug/mL goat anti-human IgE (Nordic) and 1 ug/mL E. Coli K12 
lipopolysaccharide (LPS; InVivoGen).  
For blocking experiments, mast cells, PBMCs or monocytes were incubated with 100 μg/mL 
CTLA4-Ig (Abatacept, Bristol-Myers Squibb), 100 μg/mL human IgG isotype control, 10 
μg/mL anti-OX40L (MAB10541-100, R&D Systems), 10 μg/mL anti-B7-H2/ICOSL (MAB165-
100, R&D Systems), 0.1 μg/mL anti-LIGHT/TNFSF14 (AF664-SP, R&D Systems), 10 μg/mL 
anti-CD32A (IV.3, StemCell), 10 μg/mL mouse IgG1 isotype control (16-4714, eBioscience), 
10 μg/mL mouse IgG2b isotype control (16-4732, eBioscience), 0.1 μg/mL polyclonal goat 
IgG isotype control (AB-108-C, R&D systems), for 30 minutes at 37 ºC prior to co-culture 
with the T cells. 
To analyse the requirement of cell-cell contact, transwell plates with 0.4 uM-pore 
membrane (Corning) were used.  
FLOW CYTOMETRY 
Antibodies to CD3, CD14, CD117, CD25 and CD69 were obtained from BD Biosciences. For 
surface staining, cells were incubated with fluorochrome-conjugated antibodies diluted in 
PBS 0,5% BSA at 4 ºC for 30 min. To exclude dead cells fixable viability dye eFluor506 
(eBioscience) was added during incubation of surface antibodies. After washing, cells were 
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or LSR-II (BD). Analysis was performed using FACS Diva (BD) and FlowJo software. Cell 
proliferation was analysed as described.(27)  The % divided cells was defined as the 
probability that a cell has divided at least once from the original population. The division 
index was defined as the average number of cell divisions that a cell in the original 
population has undergone.  
STATISTICAL ANALYSIS 
Results are expressed as mean ± SEM. Statistical analysis was performed using GraphPad 
Prism 4. For differences between two groups, student’s T tests were performed. For 
differences between more than two groups, One-way ANOVA with Bonferroni’s posthoc 
test was performed. P values of <0.05 were considered statistically significant. 
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SUPPLEMENTARY FIGURE 
Supplementary Figure 1: Blocking FcγR on mast 
cells. Isolated human CD4+ T cells were labeled 
with cell trace violet (CTV) and cocultured with 
autologous mast cells for 5 days, in the presence 
of anti-CD3, after which they were stained for 
flow cytometry. T cells were gated as 
CD3+CD117-CD14- cells as shown in Figure 1A of 
the manuscript. Prior to coculture, mast cells 
were treated with control medium, isotype 
control mIgG2b, or anti-CD32A, and these 
antibodies remained present during the 
coculture. A) Release of IL-8 in presence of 
mIgG2b or anti-CD32A was measured by ELISA. 
No IL-8 was detected in the absence of mast 
cells. IL-8 production was normalized to mIgG2b 
control (100%). Asterisk indicates statistically 
significant difference calculated using Two-way 
ANOVA and Bonferroni’s posthoc test. B,C) T cell 
proliferation in presence of mIgG2b or anti-
CD32A. T cell proliferation was normalized to 
control-medium treated mast cells (T+MC ctr: 
100%). Ns indicates no statistically significant 
differences were found using Two-way ANOVA 
and Bonferroni’s posthoc test. Results are 
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ABSTRACT 
Mast cells (MC) are most well-known for their role in innate immune responses. However, 
MC are increasingly recognized as important regulators of adaptive immune responses, 
especially in setting the outcome of T cell responses.  
In this study we determined the effect of MC on cytokine production by naive and memory 
human T helper cells. CD4
+
 T cells were cultured with MC supernatant or control medium, 
after which cytokine production by T cells was determined. Supernatant of activated MC 
specifically increased the number of IL-17 producing T cells. This enhancement of Th17 cells 
was not observed in the naive CD4
+
 T cell population suggesting MC affected memory Th 
cells. The effect of MC was inhibited for approximately 80% by blocking antibodies to IL-1β 
and the recombinant IL-1 receptor antagonist anakinra. Importantly, secretion of active IL-
1β by mast cells was independent of caspase activity indicating Th17 expansion by mast 
cells occurred through inflammasome-independent IL-1β.  
Together, these studies reveal a role for human MC in setting the outcome of T cell 
responses through release of caspase-independent IL-1β, and provide evidence for a novel 
contribution of MC in boosting the Th17-axis in mucosal immune responses. 
INTRODUCTION 
Recent research has suggested an important role for mast cells in CD4
+
 T cell responses. We 
and others have shown that human mast cells can function as antigen presenting cells, by 
taking up and processing antigens and subsequent activation of CD4
+
 T cells via HLA class II 
molecules.(1-3) Although the precise contribution of mast cells in T-cell activation is still 
controversial, mast cells often colocalize with CD4
+
 T cells, both in lymphoid organs as well 
as peripheral tissues.(2, 4) Therefore, it is conceivable that mast cells can interact with CD4
+
 
T cells and drive skewing of specific T helper cell subsets, through their secreted cytokines 
and other mediators.  
Due to their role in allergy, mast cells are often associated with Th2 responses, but recent 
data suggest they may also contribute to Th17 responses, for example through an indirect 
effect on dendritic cells, or through an OX40-mediated crosstalk with regulatory T cells 
(Tregs) as shown in mice.(5, 6) IL-9 and IL-33, two cytokines which can modulate mast cell 
responses, have been related to Th17-mediated pathology in mice.(7, 8) Furthermore, 
several mast cell derived cytokines have been implicated in Th17 skewing, including IL-6, 
TGFβ, and IL-1β.(9) 
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Importantly, mast cells are predominantly present at mucosal surfaces which are 
important sites for Th17 activation and immunity. Although Th17 cell activation at 
mucosal barriers is important in driving protection against bacteria, aberrant Th17 
responses can also contribute to pathogenic processes, such as neutrophilic inf iltration 
or airway remodeling in asthma.(10-12) 
Although studies performed in mice point to a role of mast cells in Th17 cell biology, 
little is known of the contribution of mast cells to Th17 responses in humans, also 
because the cytokines produced by MCs can differ considerably between mice and 
man.(13, 14) Understanding of the pathways that contribute to activation and 
maintenance of memory Th17 cells in humans is particularly important for 
inflammatory diseases, as Th17 memory cells are thought to be the driver of chronic 
inflammation.(15) 
Therefore, we aimed to evaluate the influence of mast cells on Thelper cell responses. 
Here, we show that activated mast cells are capable of expanding Th17 cells. Studies 
investigating the mode of action revealed that this occurred through a synergistic 
release of IL-1β upon combined TLR/FcεRI receptor triggering. Secretion of active IL -1β 
by human mast cells upon stimulation was independent of caspase activation, 
suggesting a novel mechanism of inflammasome-independent IL-1β release by mast 
cells. As allergic responses in mucosal tissue are often associated with both Th17 
responses and involvement of mast cells, these results provide a link between 
inflammasome-independent IL-1β production and pathogenic Th17 responses. 
MATERIALS AND METHODS 
MAST CELL CULTURE 
Buffy coats from healthy volunteers were obtained from the blood bank (Sanquin, The 
Netherlands). PBMCs were isolated using a standard Ficoll procedure, after which CD34
+
 
hematopoietic stem cells were isolated with CD34 microbeads (Miltenyi Biotec). Isolated 
CD34
+
 stem cells were differentiated into mast cells using serum-free medium (StemPro 
34 + supplement, Gibco) with 30 ng/mL IL-3, 100 ng/mL IL-6 and 100 ng/mL Stem Cell 
Factor (SCF) at 50.000 cells/mL as described.(16) Half of the medium was replaced 
weekly with serum-free medium containing 100 ng/mL IL-6 and 100 ng/mL SCF. All 
recombinant cytokines were obtained from Peprotech. After 6-8 weeks, the purity of 
mast cells was determined by flow cytometric analysis of CD117 (c-kit), FcεRI and CD203c 
and intracellular tryptase. The purity of mast cells ranged from 90-99% (Supplementary 
Figure 1).  
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MAST CELL ACTIVATION 
Mast cells were sensitized using 0,1 ug/mL hybridoma IgE (Diatec, clone HE-1) for a 
minimum of 18 hours. Mast cells were thoroughly washed to remove the soluble IgE, 
after which IgE was crosslinked using 10 ug/mL polyclonal goat anti -human IgE 
(Nordic). Activation of TLR was achieved using 1 ug/mL LPS (Invivogen). Activation of 
Fc-gamma receptors was achieved by using platebound IgG as described before.(17) 
Mast cells were activated in StemPro medium + supplement in the presence of 100 
ng/mL SCF for 24 hours, after which supernatant was harvested.   
For inhibition of caspase, 20 uM Z-VAD-FMK (Sigma) was added to mast cells, 15 
minutes prior to their activation, and the drug remained present throughout the 24 
hour stimulation. The levels of lactate dehydrogenease (LDH) was analysed in mast cell 
supernatant (BioAssay Systems) as a measure of cell death. 
CD4+ T CELL SKEWING 
For isolation of CD4
+
 T cells, naive (CD45RO-negative) or total CD4
+
 T cells were 
isolated from PBMCs by negative magnetic bead isolation (Miltenyi Biotec). The purity 
of isolated naive CD4
+











and the purity of total CD4
+






. The purity of 
isolated naive or total CD4
+
 T cells was above 95% in each experiment.  
Naive or total CD4
+
 T cells were activated using 5 μg/mL platebound anti-CD3 
(eBioscience; clone: OKT3) and 1 μg/mL soluble anti-CD28 (Sanquin; clone: CLB-
CD28/1, 15E8) in the presence or absence of mast cell supernatant which was diluted 
1:1 in IMDM/10% FCS. After 5 days of incubation, T cells were harvested, washed, and 
restimulated using 50 ng/mL PMA (Sigma) and 500 ng/mL Ionomycin (Sigma).  
Cells were restimulated for 5 hours in the presence of 10 μg/mL brefeldin A (Sigma) for 
intracellular cytokine staining. For analysis of proliferation, isolated CD4
+
 T cells were 
labeled with Cell Trace Violet (Invitrogen), after which they were cultured as 
mentioned above. 
For blocking experiments, mast cell supernatant was incubated with 20 μg/mL mIgG1 
isotype control (clone P3.6.2.8.1, eBioscience), IL-1RA (anakinra; kindly provided by dr. 
M Schilham), anti-IL1ɑ (Bio-Techne, Minneapolis, MN), anti-IL-1β (clone CRM56, 
eBioscience), anti-IL-6R (Tocilizumab), or anti-TNF-ɑ (Etanercept), for 1 hour at 37 ºC 
before adding the supernatant to the T cells. 
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IL-1β SECRETION AND ACTIVITY 
The amount of IL-1β in mast cell supernatant was quantified using ELISA (Biolegend). 
The amount of IL-1ɑ in mast cell supernatant was quantified using Luminex assays 
(Millipore). The IL-1 activity was measured by incubating the EL4.NOB-1 cell-line with 
mast cell supernatant or control medium as described,(18) after which secretion of 
mouse IL-2 by this cell-line was measured using ELISA (eBioscience). The NOB-1 cell-
line was kindly provided by prof. Leo Joosten, Radboud University, Nijmegen, The 
Netherlands. 
FLOW CYTOMETRY 
The following antibodies were obtained from BD Biosciences: CD3-AlexaFLuor700 (clone 
UCHT1), CD4-APC (clone SK3), IL-10-PE (clone JES3-9D7), IL-13-APC (clone JES10-6A2), 
IFNγ-FITC (clone 25723.11), TNF-ɑ-AlexaFluor488 (clone MAb11), mIgG1-FITC (clone 
X40), rIgG1-PE (clone R3-R4), mIgG1-AlexaFluor488 (clone MOPC-21); from eBioscience: 
IL-17A-AlexaFluor647 and -eFluor660 (clone eBio64CAP17), mIgG1-eF660 (clone 
P3.6.2.8.1) , mIgG1-PE (clone P3.6.2.8.1); and from R&D systems: IL-22-PE (clone 
142928). 
For surface staining, cells were incubated with fluorochrome-conjugated antibodies 
diluted in PBS 0,5% BSA at 4 ºC for 30 min. For discrimination between live and dead 
cells, cells were incubated with Fixable Viability Dye eFluor506 (eBioscience), prior to 
fixation and permeabilization. For intracellular cytokine staining, T cells were 
permeabilized using CytoFix CytoPerm Kit (BD Biosciences). After washing, cells were 
incubated with antibodies against intracellular cytokines and incubated at 4 ºC for 30 
min. After washing, cells were suspended in 1% paraformaldehyde until flow cytometric 
aquisition on a FACS Calibur (BD), LSR-II (BD), or Fortessa (BD). Analysis was performed 
using FACS Diva (BD) and FlowJo software. 
Cell proliferation was analysed as described.(19) Briefly, the % divided cells was defined 
as the probability that a cell has divided at least once from the original population. The 
division index was defined as the average number of cell divisions that a cell in the 
original population has undergone.  
STATISTICAL ANALYSIS 
Results are expressed as mean ± SEM. Statistical analysis was performed using SPSS PASW 
17.0 and GraphPad Prism 4. For differences between two groups, student’s T tests were 
performed. ANOVA with Bonferroni posthoc tests were used to analyse differences 
between multiple groups. P values of <0.05 were considered statistically significant. 
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RESULTS 
ACTIVATED HUMAN MAST CELLS INDUCE TH17 EXPANSION 
To evaluate the effect of mast cells on cytokine production by Th cells, isolated total CD4
+
 
T cells were incubated with supernatant obtained from mast cell cultures stimulated via 
TLR-4 and FcεRI. Medium containing the same concentrations of stimuli were used as 
control. After 5 days, cytokine production by T cells was analysed by intracellular flow 
cytometry upon restimulation with PMA/ionomycin (Figure 1A,B). Live CD3
+
 T cells were 
gated as shown in Supplementary Figure 2. Of the analysed cytokines produced by 
responding T-cells, mast cells most significantly enhanced Th17 responses, characterized 
by a two- to eight-fold expansion of IL-17
+
 cells (p=0.0001). Although enhancements of 
other Th cytokines like IL-22 and TNF-ɑ were observed when T cells were activated in the 
presence of supernatant from some mast cell donors, these responses were not present 
in all T cell and mast cell donors and were therefore not statistically significant.  
As enhancement of IL-17 responses could result from expansion of memory T cells or 
from de novo induction from naive Th cells, we next analysed the capacity of mast cell 
supernatant to skew IL-17 cytokine production from naive Th cells. Naive Th cells 
require specific cytokines for their differentiation into functional cytokine -producing Th 
cells. In contrast to the ability of mast cell supernatant to enhance Th17 responses 
from total Th cells, mast cells were not capable of inducing IL-17
+
 T cells from naive Th 
cells (Figure 1C).  
Together, these results indicate that activated mast cells can secrete substances that allow 
the increase of IL-17 production from T cell populations through an effect on memory Th 
cells. As only an increase in IL-17 producing T cells was noted, these results indicate a 
specific effect on IL-17 production but not on the production of other cytokines. 
EXPANSION OF TH17 CELLS BY MAST CELLS IS INDEPENDENT OF PROLIFERATION 
To address whether enhancement of Th17 responses by mast cells was driven by specific 
expansion of Th17 cells, we next analysed whether IL-17 producing T cells had undergone 
accelerated proliferation. To this end, cells were labeled with Cell Trace Violet fluorescent 
dye, and stimulated for 5 days with anti-CD3 and anti-CD28 in the presence of mast cell 
supernatant. At day 5, the proliferation history of IL-17, IFNγ, and TNF-producing cells was 
analysed. As shown in Figure 2, IL-17-producing cells had not undergone a more extensive 
proliferation compared to control, non-IL-17 producing T cells or IL-17-producing cells not 
exposed to supernatant of activated mast cells. 
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Figure 1. Supernatant of activated mast cells enhances Th17 
responses. Mast cells were left untreated, or stimulated with LPS 
and anti-IgE. Supernatant was collected after 24 hours. Isolated 
CD4+ T cells were activated with anti-CD3 and anti-CD28 in the 
presence of mast cell supernatant, or control medium containing 
the same stimuli. After 5 days, T cells were washed, and stimulated 
with PMA/ionomycin in the presence of BFA for 5 hours, to analyse 
their cytokine profile. A) Representative plots for intracellular cytokines IL-17, TNF-ɑ, and IL-22. Live T 
cells were gated as shown in Supplementary Figure 2. B) Summary of 12 independent experiments, 
with each dot indicating a different mast cell supernatant. Asterisks indicate significant increase in 
the percentage of IL-17+ T cells with supernatant from activated mast cells, as analysed using paired t-
test (***p=0,0001). C) Summary of 3 independent experiments analyzing IL -17 production using 
intracellular cytokine staining of isolated total and naïve CD4 + T cells, each treated with supernatant 
from a different mast cell donor. 
 
Similar results were obtained when T cells producing other cytokines were analysed, 
although a small decrease in proliferation of IFNγ- and TNF-producing cells was noted 
in some donors (Figure 2C,D). Therefore, we conclude that the increase in Th17 cells by 
mast cells is independent of proliferation. 
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Figure 2: Proliferation of T helper cell subsets after culture with mast cell supernatant. Mast cells were left 
untreated, or stimulated with LPS and anti-IgE. Supernatant was collected after 24 hours. Isolated CD4+ T 
cells were labeled with Cell Trace Violet and activated with anti-CD3 and anti-CD28 in the presence of mast 
cell supernatant, or control medium containing the same stimuli. After 5 days, T cells were washed, and 
stimulated with PMA/ionomycin in the presence of brefeldin A for 5 hours, to allow the analysis of 
proliferation of different T helper cell subsets based on their cytokine profile. A-E) Representative flow 
cytometry plots of Cell Trace Violet as measure of proliferation (histograms) in T helper cell subsets based 
on cytokine staining, as shown in the plots on the left. Live T cells were gated as shown in Supplementary 
Figure 2. Summary of proliferation from 5 independent experiments is shown on the right, where each dot 
and line represents a different mast cell supernatant. The percentage of divided T cells is depicted as % of 
the input frequency, indicating how many cells from the original cell population have divided. Division index 
represents the average number of cell divisions that a cell in the original population has undergone. No 
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CHARACTERIZATION OF MAST CELL-INDUCED TH17 CELLS 
Previous studies have identified different types of human Th17 cells with distinct 
effector function and differentiation requirements. Whereas memory Th17 cells have 
been shown to express IL-17 and TNF, other Th17 cell subsets co-express IFNγ, IL-22 or 
IL-10. Moreover, a substantial plasticity between these subsets has been reported, 
depending on the cytokine environment they are in.(20-23) To determine which of 
these subsets were preferentially expanded by mast cells, IL-17 staining of responding 
T cell cultures was combined with staining for TNF-ɑ and IL-22 or IFNγ and IL-10 (Figure 
3). Mast cell supernatants mainly enhanced the proportion of IL-17 single-positive 
cells, as well as the proportion of TNF-ɑ/IL-17 double-positive T cells. Only a small 
minority of IL-17 producing cells produced IFNγ or IL-10.  
Together, these results further confirm a specific effect on IL-17 production and 
suggest that mast cell-induced IL-17 producing T cells represent classical Th17 cells 
producing IL-17 and TNF, in the absence of other cytokines.  
MAST CELLS PRODUCE ACTIVE IL-1β UPON TLR/FCεRI TRIGGERING 
To better understand the mechanism responsible for strengthening of the Th17 axis by 
mast cells, we next wished to determine the role of cytokines secreted by mast cells in 
this process.  Several cytokines (IL-1, IL-6, IL-23, TNF-ɑ) have been described to 
enhance human memory Th17 responses. (9) As human mast cells are known to 
produce IL-1β, we first evaluated whether IL-1β could contribute to Th17 response 
enhancement, by using recombinant IL-1β (Fig 4A). As also noted by others, culturing T 
cells with recombinant IL-1β resulted in enhanced Th17 responses.(21) This effect 
could by blocked by the IL-1-receptor antagonist, anakinra, confirming the IL-1 
receptor-dependency (Fig 4B).  
We further wished to analyse whether mast cell supernatant contained IL -1β. As shown 
in Fig 4C, we observed increased production of IL-1β, but not IL-1ɑ, in supernatant of 
activated mast cells, as detected by ELISA. To further confirm the presence of IL -1 in 
mast cell supernatant, the IL-1 activity was measured using the cell-line NOB-1, which 
produces mouse IL-2 in response to active IL-1. This cell-line responded to supernatant 
of activated mast cells, characterized by release of mouse IL-2 (Fig 4D). Importantly, 
treatment of the mast cell supernatant with inhibitors to IL-1ɑ and IL-1β revealed a 
predominant inhibition of IL-1 activity by anti-IL-1β, suggesting that the majority of 
active IL-1 in mast cell supernatant is IL-1β (Fig 4D). 
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Figure 3. Characterization of Th17 cells induced by mast cells. Mast cells were left untreated, or were 
stimulated with LPS and anti-IgE. Supernatant was collected after 24 hours. Isolated CD4+ T cells were 
activated with anti-CD3 and anti-CD28 in the presence of mast cell supernatant, or control medium 
containing the same stimuli. After 5 days, T cells were washed, and stimulated with PMA/ionomycin in the 
presence of brefeldin A for 5 hours, to analyse their cytokine production. A) Representative flow cytometry 
dot plots of combined staining for IL-17 with IFN-gamma, IL-10, TNF-ɑ, IL-22. Live T cells were gated as 
shown in Supplementary Figure 2. B) Representative flow cytometry plots of IFN-gamma and IL-10, 
respectively TNF-ɑ and IL-22 production by a T cell population, gated on IL-17+ T cells, is shown. C) Summary 
of 7 independent experiments using mast cell supernatant from 9 different mast cell donors and T cells 
from 7 independent donors, showing the percentage of Th17 cell subsets defined by co-expression of other 
cytokines. Results are shown as mean +/- SEM. Asterisks indicate significant increase in the percentage of 
IL-17+ T cell subset with supernatant from activated mast cells, analysed using two-way ANOVA and 
Bonferroni post hoc test (*p<0,001).  
We next wished to analyse whether Th17 expansion was specific to FcεRI crosslinking or 
whether also other modes of mast cell activation induced IL-1 release and possibly a Th17-
skewing phenotype. Therefore, we obtained supernatant of mast cells activated with IgG 
immune complexes (platebound) and LPS. We have previously shown that activation of 
mast cells through FcεRI or FcγRIIA in combination with LPS leads to a synergy in cytokine 
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Figure 4. Mast cells produce active IL-1β 
upone TLR/FcεRI triggering. A,B) Isolated 
CD4+ T cells were activated with anti-CD3 
and anti-CD28 in the presence or absence 
of recombinant IL-1β and with or without 
anakinra (IL-1 receptor antagonist). After 
5 days, T cells were washed, and 
stimulated with PMA/ionomycin in the 
presence of BFA for 5 hours, to analyse 
their cytokine profile. A) Summary of 7 
independent experiments. B) 
Representative example of blocking 
experiment using anakinra. Mean +/- SEM 
is shown. C) Mast cells were left 
untreated, or stimulated with LPS and 
anti-IgE. Supernatant was collected after 
24 hours. Levels of IL-1ɑ and IL-1β in mast 
cell supernatant were measured using 
Luminex and ELISA, respectively. 
Summary of 3-5 different mast cell donors 
is shown. D) Mast cells were treated as in 
C). NOB-1 cells were cultured in the 
presence of mast cell supernatant, in 
combination of anti-IL-1ɑ, anti-IL-1β or 
isotype control antibodies for 24 hours, 
after which the secretion of mouse IL-2 by 
NOB-1 cells was measured using ELISA. 
Percentage mIL-2 release that is shown 
was calculated relative to the amount of 
mouse IL-2 released by NOB-1 cells when 
treated with supernatant from mast cells 
activated with LPS + anti-IgE in presence 
of isotype control. Mean +/- SEM from 4 
independent mast cell donors is shown. E) 
Mast cells were left untreated, stimulated 
with LPS and anti-IgE, or stimulated with 
LPS and platebound IgG immune 
complexes. T cells were cultured as in A) 
in the presence or absence of mast cell 
supernatant. Mean +/- SEM from 3 
independent mast cell donors is shown. F) 
Mast cells were treated as described in E). NOB-1 cells were cultured in the presence of mast cell 
supernatant as described in D). Mean +/- SEM from 4 independent mast cell donors is shown. Asterisks 
indicates significant difference (p<0.05), using students T-test (A, C, E, and F) or Two-way ANOVA with 
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Interestingly, mast cell activation via FcRIIA in combination with LPS did not induce 
increased Th17 responses as these were only observed when mast cells were activated 
with anti-IgE and LPS (Fig 4E). This correlated with IL-1 activity in mast cell supernatant, as 
this was only increased by stimulation through anti-IgE and LPS, and not by IgG immune 
complexes and LPS (Fig 4F). Together, these results indicate that mast cells secrete active 
IL-1β, specifically in response to anti-IgE in combination with LPS. 
IL-1β RELEASE BY MAST CELLS IS INFLAMMASOME-INDEPENDENT 
IL-1β is a cytokine that is initially produced as inactive pro-IL-1β, and therefore needs 
to be cleaved to generate the active molecule prior to secretion. The most well -known 
pathway leading to cleavage of IL-1β is the inflammasome-caspase-1 pathway. The 
specific pathways leading to IL-1β cleavage and secretion by mast cells are not known. 
Therefore, we analysed whether secretion of active IL-1β by mast cells was caspase-
dependent, using a pan-caspase inhibitor (Z-VAD). The monocyte cell-line THP-1 was 
used as positive control. These cells secrete active IL-1β upon activation with LPS, due 
to inflammasome activation by endogenous ATP.(25) As depicted in Figure 5, secretion 
of active IL-1β by the monocyte cell-line THP-1 was almost completely reversed using 
Z-VAD (Fig 5A,B; left). In contrast, no inhibition of IL-1 activity was observed using this 
inhibitor in mast cells (Fig 5A,B; right).  
Cell death can also lead to cleavage of pro-IL1β by mast cells, through aspecific release 
of pro-IL1β and chymase followed by extracellular cleavage. Therefore, LDH levels were 
quantified in mast cell supernatant as a measure of cell death. No significant increase 
in LDH levels were observed upon mast cell stimulation (Fig 5C), suggesting that th e 
inflammasome-independent cleavage of IL-1β by mast cells is not due to cell death.  
MAST CELLS INDUCE TH17 RESPONSES THROUGH INFLAMMASOME-INDEPENDENT IL-1β 
To determine the contribution of IL-1β secreted by mast cells on Th17 responses, we 
next evaluated the effect of neutralizing IL-1β in mast cell supernatant, by using IL-1 
receptor antagonist IL-1RA (anakinra) as well as a blocking antibody to IL-1β (Fig 6A-B). 
Both IL-1RA and anti-IL-1β almost completely reversed the expansion of the Th17 
response induced by supernatant from activated mast cells. This effect was specific for 
Th17 responses, as no effect of these inhibitors on TNF production by T cells was 
observed (Fig 6B, right panel).  
We next compared the blocking of IL-1β to that of potential other mast cell-derived 
cytokines described to enhance Th17 responses, IL-6 and TNF-ɑ (Fig 6C). Whereas anti-
IL-1β again led to a significant reduction in the number of Th17 cells, no effect was 
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observed with anti-IL-6R. Blocking of TNF-ɑ led to an increase in the number of Th17 
cells, indicating that TNF was not involved in the skewing towards Th17 responses by 
mast cells. As we observed that IL-1β release by mast cells was inflammasome-
independent, we wished to confirm that Th17 responses induced by mast cell 
supernatant were not affected by caspase-inhibition. Indeed, Th17 expansion by mast 
cells was not affected by the pan-caspase inhibitor Z-VAD (Fig 6D). 
Together, these results indicate that human mast cells can drive enhancement of Th17 
responses through secretion of inflammasome-independent IL-1β. 
 
Figure 5 IL-1β release by mast cells is 
inflammasome-independent. A-B) THP-1 cells 
and mast cells were left untreated, or 
stimulated with LPS or LPS + anti-IgE, 
respectively. Cells were treated with Z-VAD 15 
minutes prior to activation. Supernatant was 
collected after 24 hours. Secretion of IL-1β was 
measured using ELISA (A). NOB-1 cells were 
cultured in the presence of cell supernatant, or 
control medium containing the same stimuli for 
24 hours, after which their secretion of mouse 
IL-2 was measured using ELISA (B). 
Representative example of THP-1 cell-line is 
shown (left), and a summary (mean +/- SEM) of 
4 different mast cell donors (right). C) Analysis 
of LDH activity in mast cell supernatant. Mean 
+/- SEM from 14 independent mast cell donors 
is shown. Asterisks indicate statistically 
significant (p<0.05) differences analysed using 
student’s T-test. ns indicates no significant 
differences were found  
DISCUSSION 
In this study, we show that human mast cells can enhance Th17 responses from 
memory CD4
+
 T cells. This is in line with a recent study showing increased IL -22 
production by T cells when mast cells presented bacterial antigens. (2) Together, these 
results therefore suggest that human mast cells can contribute significantly to the 
Th17/Th22 axis. 
A. IL-1beta secretion - ELISA
ctr LPS
ctr LPS
ctr LPS + 
aIgE
THP-1 monocytes Mast cells
IL-1 activity - NOB-1
ctr LPS + 
aIgE
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Figure 6. Mast cells induce Th17 responses 
through inflammasome-independent IL-1β. A-D) 
Mast cells were left untreated, or stimulated 
with LPS and anti-IgE. Supernatant was collected 
after 24 hours. Isolated CD4+ T cells were 
activated with anti-CD3 and anti-CD28 in the 
presence of mast cell supernatant or control 
medium containing the same stimuli. After 5 
days, T cells were washed, and stimulated with 
PMA/ionomycin in the presence of brefeldin A 
for 5 hours, to analyse their cytokine profile. A-C) 
Blocking of cytokines in mast cell supernatant 
was achieved using IL-1RA or blocking antibodies 
against IL-1β, IL-6R, or TNF-ɑ. Mast cell 
supernatant or control medium was incubated 
with these inhibitors prior to addition of the 
supernatant to the isolated T cells. A) 
Representative flow cytometry plots of IL-17 
production Live T cells were gated as shown in 
Supplementary Figure 2. B) Summary of 
inhibition of IL-17 (top) and TNF-ɑ (bottom) in T 
cells in response to mast cell supernatant 
untreated (ctr), or treated with anakinra, anti-IL-
1β, or isotype control. Mean +/- SEM from 6 
independent experiments is shown. C) Summary 
of inhibition of IL-17 in T cells in response to 
mast cell supernatant treated with isotype 
control, anti-IL-6R, anti-TNF-ɑ, or anti-IL-1β. 
Mean +/- SEM from 3 independent experiments 
is shown. D) Mast cells were treated with Z-VAD, 
starting 15 minutes prior to their activation.. 
Mean +/- SEM from 5 independent experiments 
is shown. Asterisks indicate statistically 
significant (p<0.05) differences analysed using 
student’s T-test (B) or Two-way ANOVA with 
Bonferroni posthoc test (C). Ns indicates no 
significant differences were found, analysed 
using Two-way ANOVA with Bonferroni posthoc 
test (D). Percentage cytokine+ T cells that is 
shown was calculated relative to the % of 
cytokine+ T cells when treated with supernatant 
from mast cells activated with LPS + anti-IgE in 
the presence of isotype control (B, C), or in 
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Our results suggest that Th17 expansion by mast cells was induced by IL -1β. IL-1β is a 
cytokine that is produced in an inactive 31-kDa molecule residing in the cytoplasm, 
and needs to be cleaved to generate the active 17 kDa molecule, that can be 
secreted. The most well-known pathway leading to cleavage of IL-1β is the caspase-1 
pathway, which is activated upon inflammasome activation. Although inflammasome 
activation in mast cells can lead to secretion of IL-1β,(26, 27) in vivo IL-1β release 
during sterile inflammation has been shown to be at least partly independent of 
caspase-1, and mast cell- and neutrophil proteases have been suggested to 
contribute to secretion of active IL-1β.(28-32)  
Our results confirm and extend these data, by showing that IL -1β release by human 
mast cells in response to TLR/FcεRI receptor triggering is caspase-independent as 
well as that such IL-1-release can lead to boosting of Th17 responses.  
A likely candidate for cleavage of pro-IL-1β by mast cells is chymase, one of the 
granule proteases in mast cells, which has been shown to cleave pro-IL-1β in vitro 
into an active form of 18kd.(31) This would be in line with our observation that IL -1β 
release by mast cells depends on their degranulation through FcεRI crosslinking. 
However, as the amounts of IL-1β released in this study were relatively low, we were 
unable to visualize the mast cell-derived IL-1β by western blot or intracellular 
staining to analyse the mechanism of cleavage of IL -1β by mast cells. IL-1β is known 
to be active at extremely low concentrations (<1 pg/mL),(33) thereby complicating 
such analyses.  
Our results suggest a novel role of mast cells in driving Th17 responses directly through 
release of IL-1β in a caspase-independent manner. This is of particular interest in the 
context of mucosal immunity. Whereas mast cells have been shown to play beneficial 
roles in protection against bacteria at mucosal surfaces, they also contribute 
significantly to allergic responses at these same locations.(34, 35) Our results suggest 
that Th17 expansion by mast cells was dependent on FcεRI triggering. Interestingly, 
allergic responses which are classically considered to be driven by Th2 cells, are now 
increasingly recognized as also having a Th17 component.(36) Our results therefore 
provide a direct link between IgE-mediated mast cell activation and expansion of Th17 
cells in the context of allergic responses. 
Together, these studies reveal a role of human mast cells in setting the outcome of T 
cell responses through the release of inflammasome-independent IL-1β, and suggest a 
novel contribution of these cells in boosting of immune responses in mucosal barriers 
by specifically targeting the Th17-axis. 
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Supplementary Figure 1. Characterization of mast cells. Peripheral blood-derived mast cells were cultured 
from CD34+ stem cells for 6-8 weeks. Mast cells were identified as CD117+ CD203c+ FcεRI+ Tryptase+ cells 
(>90% pure). A) Gating of live cells (cell debris excluded based on Forward and Sideward scatter). B) CD117 
expression of total live cells as gated in A. C) Intracellular Tryptase expression of total live cells. D) Gating of 
CD117+ mast cells. E,F). Expression of CD203c and FcεRI on CD117+ mast cells as gated in D. Representative 
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Supplementary Figure 2. T cell 
gating strategy. Live CD3+ T cells 
were gated as follows: A) A 
lymphocyte gate was used 
based on Forward scatter (FSC) 
and Side scatter (SSC). B) Single 
cells were selected based on 
FSC-area (A) and FSC-height (H). 
C) Live cells were gated based 
on negativity for Fixable 
Viability Dye (FVD) eFluor 506. 
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ABSTRACT 
Background Activation of mast cells through FcεRI plays an important role in acute 
allergic reactions. However, little is known about the function of mast cells in chronic 
allergic inflammation, or the impact of repeated FcεRI triggering occurring in such 
responses.  
Objective We aimed to identify changes in mast cell function after repeated FcεRI 
triggering, and to correlate these changes to chronic allergic responses in tissu e. 
Methods Human cord blood-derived mast cells were treated for two weeks with anti-
IgE. The function of naive or treated mast cells was analysed by RNA sequencing, 
quantitative RT-PCR, flow cytometry, and functional assays. Protein secretion was 
measured using ELISA and multiplex assays.  
Results We observed several changes in mast cell function after repeated anti -IgE 
triggering. Whereas the acute response was dampened, we identified 289 genes 
significantly upregulated after repeated anti-IgE. Most of these genes (84%) were not 
upregulated after a single anti-IgE stimulus indicating a significantly different response 
mode, characterized by increased antigen presentation, response to bacteria, and 
chemotaxis. Changes in the mast cell function were related to changes in expression of 
transcription factors RXRA and BATF and others. Importantly, we found a substantial 
overlap between the genes upregulated after repeated anti-IgE triggering with genes 
upregulated in chronic allergic tissues, in particular chronic rhinosinusitis. 
Conclusion Our study provides evidence for intrinsic modulation of mast cell function 
upon repeated FcεRI-mediated activation. The overlap with gene expression in tissues 
is suggestive of a direct link between repeated IgE-mediated activation of mast cells 
and chronic allergy. 
KEY MESSAGES 
Repeated activation of mast cells through FcεRI leads to a modulation of their function, 
related to changes in gene expression during chronic allergy 
Chronic activation of mast cells such as occurring in chronic allergy may therefore 
contribute to changes in tissue homeostasis 
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INTRODUCTION 
Mast cells play an important role in allergic responses upon activation through the high-
affinity FcεRI. Their rapid degranulation and release of lipid-derived mediators leads to an 
immediate response, characterized by increased vascular permeability. This response can 
also lead to several tissue-specific phenomena, such as contraction of airway smooth 
muscle cells and mucus secretion in the airways, or anaphylaxis in case a systemic response 
is triggered (1, 2). Acute symptoms can occur within minutes of exposure to the associated 
allergens, and are thought to be induced through release of histamine, prostaglandins and 
leukotrienes by mast cells. During late phase responses, mast cell-derived cytokines and 
chemokines (IL-5, IL-13) also contribute to the inflammatory reactions observed in allergy, 
in particular through their effects on leukocyte infiltration and activation (3).  
However, allergic disease is often associated with repeated exposure to allergens which is 
thought to lead to chronic inflammation and changes in tissue homeostasis. In the lungs, 
these may lead to increased contractability of the smooth muscles, leading to obstruction 
of the bronchia, increased mucus production, and airway wall remodeling (1). In the skin, 
atopic dermatitis is characterized by fibrotic lesions, containing thickened dermis and 
epidermis, and accumulation of lymphocytes and mast cells (4, 5). Chronic rhinosinusitis 
(CRS) is characterized by inflammation of the upper airways. CRS is frequently divided into 
two groups based on the presence of nasal polyps. CRS with nasal polyps is associated with 
nasal obstruction and olfactory loss and is characterized by eosinophilia and Th2-related 
inflammation (6, 7).  
Importantly, these diseases are all associated with repeated antigen exposure and 
triggering through IgE. Whereas mast cells and IgE antibodies play a crucial role in acute 
symptoms of an allergic reaction, their role in chronic inflammation and tissue remodeling 
is less well-defined (8). Chronic allergic responses in tissue are the result of a complex 
interplay between different immune cells (mast cells, eosinophils, macrophages, dendritic 
cells, lymphocytes) and stromal cells. Mast cells can secrete several mediators that have 
the potential to influence tissue remodeling, such as FGF-2, VEGF and amphiregulin (9, 10). 
In some mouse models of chronic asthma, mast cells are dispensable for induction of 
eosinophilia or airway hyperresponsiveness. These models are thought to be driven by the 
Th2-derived cytokines IL-4 and IL-5 (11-14).  However, in other mouse models of chronic 
asthma, induced through repeated antigen exposure after initial sensitization, mast cells 
and activation through FcεRI are shown to be crucial for several hallmarks of chronic 
asthma, such as tissue remodeling, goblet hyperplasia and leukocyte infiltration (15-17). 
Mast cells have also been shown to play a crucial role in chronic dermatitis in mice (5, 18). 
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However, the exact changes in mast cells that occur after repeated antigen exposure are 
not well understood, especially in the context of human disease. Although mast cells alone 
are unlikely to provide all the signals leading to tissue remodeling, appreciation of the 
mechanisms contributing to their involvement in chronic inflammation can enhance our 
understanding of these diseases and thereby allow us to design novel therapeutics aimed 
at the long-term changes induced in tissues. 
As tissue-resident mast cells are long-lived cells (estimated up to months or years) (19), we 
hypothesized that mast cells will be exposed repeatedly to antigen, and that this may lead 
to intrinsic changes in mast cell function and/or biology relevant to chronic allergy. Studies 
using several pre-clinical (asthma) animal models have offered significant progress in our 
understanding of the role and function mast cell function in (chronic) allergy.  Nonetheless, 
still little is known on cell-intrinsic changes induced upon repeated antigen exposure of 
mast cells in general and human mast cells in particular.   
In this study, we modelled repeated antigen exposure of human mast cells in vitro, and 
show that mast cells respond differently after repeated- compared to acute FcεRI 
activation. We captured these changes in mast cell function using full RNA sequencing, and 
identified several novel genes specifically upregulated after repeated activation. 
Furthermore, the expression pattern of these genes related to changes in gene expression 
also observed in tissue during chronic atopic diseases, together indicating that repeated 
antigen exposure of mast cells triggers a response mode that may directly contribute to 
tissue remodeling and inflammation. 
METHODS 
EXPERIMENTAL SETUP 
Cord blood-derived mast cells were obtained as described in Supplementary Methods. 
The purity of mast cells was determined by flow cytometric analysis of CD117 (c-kit), 
FcεRI, CD203c and intracellular tryptase. The purity of mast cells ranged from 90 -99% 
(Supplementary Fig 1 A-D). Cultured mast cells were sensitized with 1 µg/mL 
hybridoma IgE (Diatec) for a minimum of 24 hours before each stimulation. Mast cells 
were cultured at 1x10
6
 cells/mL.  
For repeated anti-IgE stimulations, mast cells were stimulated once weekly with 0.2 
µg/mL goat-anti-human IgE (Nordic). After two weeks, mast cells were counted using 
Trypan Blue, and cultured again at 1x10
6
 cells/mL. Mast cells were stimulated with 
control medium or 1 µg/mL anti-IgE for 6 hours for RNA analysis, or with 0.01-10 
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µg/mL anti-IgE for 1, 6 and 24 hours for analysis of protein expression and secretion. 
For supernatant transfer experiments, sensitized mast cells were stimulated with 0.2 
µg/mL goat-anti-human IgE (Nordic) or control medium. After 24h, supernatant was 
harvested. Non-sensitized mast cells were cultured in this supernatant for two weeks. 
Supernatant was replaced after 1 week. At the end of two weeks, mast cells were 
sensitized and activated as described above for collection of RNA, and analysis of 
protein expression and cytokine secretion. 
RNA isolation, sequencing, qPCR, measurements of protein expression measurements 
and comparisons to publicly available gene expression data were performed as 
described in Supplementary methods, and samples processed for RNA-seq are shown 
in Online Repository Table E2. 
STATISTICAL ANALYSIS 
For comparison of naïve and treated mast cells, paired-samples T-test was performed. For 
differences between multiple groups, repeated measures ANOVA was performed, with 
Bonferroni’s post-hoc test to correct for multiple testing. To compare frequencies of gene 
overlap, Fisher’s Exact test was used. P values of <0.05 were considered statistically 
significant (except for the sequencing analysis, where significance was defined as described 
above). Statistical analysis was performed using GraphPad Prism 5. Venn diagrams were 
created using BioVenn (20). 
RESULTS 
REPEATED FCεRI TRIGGERING OF MAST CELLS 
We set up a model for repeated FcεRI triggering of mast cells to mimic repeated IgE-
mediated activation such as occurring during chronic allergic responses (Fig 1A). 
Human cord blood-derived mast cells were stimulated for two weeks with 0.2 µg/mL 
anti-IgE (Repeated ɑIgE) or control medium (Naive). We chose to stimulate the cells 
weekly, as more frequent stimulations with anti-IgE led to decreased FcεRI expression, 
resulting from prior stimulations (data not shown). The first stimulation led to a 
moderate level of degranulation of mast cells as well as cytokine production (Fig 1B,C). 
Twenty-four hours prior to each stimulation, mast cells were sensitized with human 
IgE. At the end of the two weeks, mast cells were either left untreated (N and R) or 
stimulated with anti-IgE (N+ɑIgE and R+ɑIgE).  
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Figure 1. Repeated mast cell stimulation through FcεRI. A) Experimental setup of repeated stimulation of 
mast cells. Human cord blood-derived mast cells were stimulated for two weeks with 0.2 µg/mL anti-IgE 
(Repeated ɑIgE) or control medium (Naive). Twenty-four hours prior to each stimulation, mast cells were 
sensitized with human IgE. At the end of the two weeks, mast cells were either left untreated (N and R) or 
stimulated with anti-IgE (N+ɑIgE and R+ɑIgE). B) Representative flow cytometry plots for CD63 of naive 
mast cells (N) or mast cells 3 hours after their first anti-IgE stimulation (R), showing their degranulation in 
response to the first anti-IgE on day 0. C) Summary of surface CD63 expression as in B) and IL-8 secretion 24 
hours after the first anti-IgE stimulation  or control medium. D, and E) Surface CD63 and CD203c expression 
in response to 24 hours of anti-IgE stimulation, in naive mast cells or mast cells exposed to two weeks of 
stimulation (Repeated ɑIgE). CD63 staining as in C, and CD203c MFI ratio calculated as in E. Data are 
represented as mean ± SEM from n=3 (C) or n=6 (D, and E) independent experiments. Ns indicates that no 
significant differences were found between naive mast cells (N) and cells exposed for two weeks to anti-IgE 
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No difference in cell number, viability, maturation, or morphology was observed between 
the different treatments (Supplementary Fig 1 E-I). After two weeks, mast cells were 
stimulated with anti-IgE to evaluate changes in mast cell function when they had been 
previously exposed to anti-IgE. No difference in degranulation (CD63 upregulation) or 
upregulation of activation marker CD203c was observed after repeated activation through 
FcεRI (Fig 1D, E).These results show that in our in vitro model, mast cells maintained the 
intrinsic capacity to respond to FcεRI triggering after repeated activation through this 
receptor, allowing the study of downstream functional changes in these cells after 
(repeated) stimulation of the FcεRI-receptor. 
DISTINCT RESPONSES TO FCεRI TRIGGERING UPON REPEATED EXPOSURE 
To capture the complete mast cell transcriptome after two weeks of stimulation through 
FcεRI, we performed deep sequencing on RNA from three independent experiments. We 
isolated RNA 6 hours after stimulation with control medium or anti-IgE at the end of the 
two weeks treatment. Quality controls are described in the Supplementary Methods, and 
results are shown in Online Repository Table E2 and Supplementary Figure 2. 
To analyse the response of mast cells after repeated anti-IgE stimulation, we first selected 
those genes that are upregulated by single anti-IgE stimulation in naïve mast cells (Fig 2A, 
Online Repository Table E4A) (21). Expression of 1919 genes (449 genes >2-fold) was 
significantly upregulated after 6 hours of single stimulation with anti-IgE. The average 
upregulation of these genes was significantly dampened in mast cells which were exposed 
repeatedly to anti-IgE for 2 weeks (R+ɑIgE) (Fig 2B,C). Of these 449 genes, 22 showed a 
significant dampening of their expression after repeated stimulation (Online Repository 
Table E5A, E6A, and Fig 2D). CSF2 and CCL4, cytokines/chemokines known to be secreted 
by mast cells, displayed the most pronounced dampened responses. We validated these 
findings by qPCR and measured secreted proteins GM-CSF (CSF2) and MIP-1β (CCL4) in 
mast cell supernatant obtained after 24h (Fig 2E-J) confirming this dampened response at 
the protein level in both GM-CSF and CCL4 (albeit a non-significant trend for CCL4). These 
results suggest a reduced responsiveness to FcεRI triggering by mast cells after repeated 
stimulation. In support of this notion, the expression of those genes that were 
downregulated by a single anti-IgE stimulation, was less downregulated after repeated 
stimulation (Supplementary Fig 3, Online Repository Table E4B), suggesting an overall 
dampening of mast cell transcriptional responses to FcεRI triggering after repeated 
stimulation. 
We did not observe changes in expression of most genes associated with arachidonic acid-
derived products (Fig 2K and Online Repository Table E7). In contrast to the decreased 
production of cytokines we observed, degranulation and release of lipid mediators LTC4 and 
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PGD2 were not affected by repeated FcεRI triggering (Fig 1H and Fig 2L,M). These results 
suggest that repeated FcεRI triggering affected the de novo transcription of FcεRI-
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Figure 2 (left). Dampened genes after repeated anti-IgE. A) 
Gene expression obtained using RNA sequencing in response 
to a single 6 hour anti-IgE stimulation (N+ɑIgE), compared to 
control mast cells (N). Log fold change (LogFC) relative to 
Naive (N) mast cells of the differentially expressed genes is 
shown. B) Genes which were significantly upregulated after a 
single anti-IgE were selected as shown in A), and compared 
to their upregulation after repeated stimulation (R+ɑIgE). 
LogFC was calculated compared to unstimulated mast cells 
at the end of the two week stimulation (N+ɑIgE/N and 
R+ɑIgE/R). C) Genes which were significantly upregulated 
after a single anti-IgE were selected as shown in A), where 
each dot indicates a different gene. Those genes significantly 
upregulated (top) and tolerized (bottom) after repeated anti-
IgE (R+ɑIgE) compared to a single anti-IgE (N+ɑIgE) 
stimulation are indicated. Data are shown as fold change 
relative to N+ɑIgE. D) Genes which are significantly 
downregulated after repeated anti-IgE, compared to single 
anti-IgE using differential expression analysis. Each line 
represents a single gene, and data is shown as relative RPKM 
normalized to single anti-IgE stimulation (N+ɑIgE). E, and H) 
Gene expression of CSF2 and CCL4, obtained using RNA 
sequencing. Data is shown as RPKM fold change relative to 
single anti-IgE stimulation (N+ɑIgE). F, and I) Gene 
expression of CSF2 and CCL4, obtained using qPCR. Data is 
shown as relative expression normalized to housekeeping 
gene RPL5, as a fold change to single anti-IgE stimulation 
(N+ɑIgE). G, and J) Protein levels of CSF2 (GM-CSF) and CCL4 
(MIP-1β) in supernatant, 24 hours after stimulation with 
anti-IgE of naive mast cells or mast cells which were exposed 
to anti-IgE for two weeks. K) Expression of genes in the 
Arachidonic Acid (AA) metabolism pathway, obtained using 
RNA sequencing in response to a single 6 hour anti-IgE 
stimulation (N+ɑIgE), compared to control mast cells (N). Log 
fold change (LogFC) relative to Naive (N) mast cells of the 
differentially expressed genes is shown. L,M) Protein levels 
of LTC4 and PGD2 in supernatant, 1 hour after stimulation 
with anti-IgE of naive mast cells or mast cells which were 
exposed to anti-IgE for two weeks. Data are represented as 
mean ± SEM from n=3 (B, E, H, and K) or n=5 (F, G, I, and J) 
or n=6 (L and M) independent experiments. Asterisks 
indicate significant differences obtained using paired T-test 
p<0.05 (B), differential expression analysis FDR<0.05 (C, E, 
and H) or repeated measures ANOVA with Bonferroni 
posthoc test p<0.05 (F, G, I, L, and M). 
Despite this dampening of 
the acute response of mast 
cells on the global level, we 
observed that 32 FcεRI-
responsive genes displayed 
increased upregulation of 
their expression after 
repeated stimulation with 
anti-IgE (Fig 2C, 
Supplementary Fig 4A, Table 
E5B, Online Repository Table 
E6B). The upregulation of the 
top three significant genes, 
TMEM45B, EMR3 and CH25H 
was confirmed using qPCR 
(Supplementary Fig 4B-G).  
Together, these results show 
that repeated anti-IgE 
triggering alters the mast cell 
response, characterized by 
overall dampening of most 
FcεRI-responsive genes, as 
well as by upregulation of a 
particular set of genes.  
To capture whether there 
were functional differences 
between the genes which 
were dampened compared 
to those that showed further 
upregulation, we analysed 
GO biological pathways 
represented by these genes 
(Online Repository Table E8).  
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Dampened responses were assigned to pathways involved in leukocyte proliferation 
and activation (6 out of 22 genes), whereas upregulated genes participated mainly in 
pathways involved in the response to bacteria (5 out of 32 genes), response to 
wounding (6 out of 32 genes), and chemotaxis (3 out of 32 genes).  
Together, these results show that mast cell function can be modulated by repeated 
FcεRI triggering resulting in a different response mode as compared to acute 
stimulations. 
DE NOVO UPREGULATION UPON REPEATED FCεRI TRIGGERING 
To capture any other changes occurring in the mast cell transcriptome after repeated 
stimulation with anti-IgE, irrespective of their responsiveness to single anti-IgE 
stimulation, we performed differential expression analysis on the total gene set. Two 
hundred eighty nine (289) genes were significantly upregulated after repeated anti -IgE 
stimulation, of which 243 genes did not respond to single anti -IgE stimulation (Online 
Repository Table E9). Upregulation of most of these genes did not increase further by 6 
hours of the additional 3
rd
 anti-IgE stimulation (R+ɑIgE), consistent with a persistent 
upregulated expression (Fig 3A,B). The 20 most strongly upregulated genes are shown 
in Online Repository Table E5C. Upregulation of TREM2, OLFM4 and CCL18 were 
confirmed using qPCR (Fig 3C-H).  
To verify the upregulation of the most highly upregulated gene CCL18 at the protein 
level, the secretion of CCL18 was measured in supernatant. Whereas secretion of 
CCL18 secretion was not detected upon acute anti-IgE activation of naive mast cells 
stimulated for 6 or 24 hours,  we observed a significant release of CCL18 after 2 weeks 
of stimulation through FcεRI (Fig 3I,J), confirming the sustained secretion of CCL18 in 
supernatant after repeated stimulation with anti-IgE. 
As a control for the specificity of anti-IgE stimulation, we have stimulated mast cells 
with IgG immune complexes at the end of the two weeks culture with anti -IgE. In 
contrast to restimulation with anti-IgE, cytokine production upon stimulation with 
platebound IgG immunecomplexes was not affected or was even increased (CCL4) 
when mast cells had been treated for two weeks with anti-IgE (Supplementary Fig 5A-
C). Furthermore, stimulation of mast cells through FcγRIIA for two weeks did not  affect 
gene expression of CSF2, CCL4 and CCL18 (Supplementary Fig 5 D-F).  
These data further confirm the specificity of FcεRI stimulation, and suggest that the 
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Figure 3. Persistent upregulation of genes after repeated anti-IgE. A) Overlap of genes upregulated after 
repeated anti-IgE, without an additional stimulation (R>N) or with an additional stimulation 
(R+ɑIgE>N+ɑIgE), obtained using differential expression ana lysis. B) Heatmap showing relative 
expression of all genes in A. Each row represents a single gene. The relative expression in 3 independent 
experiments is shown. C, E, and G) Gene expression of TREM2, OLFM4, and CCL18, obtained using RNA 
sequencing. Data is shown as RPKM fold change relative to naïve mast cells (N). D, F, and H) Gene 
expression of TREM2, OLFM4, and CCL18, obtained using qPCR. Data is shown as relative expression 
normalized to housekeeping gene RPL5, as a fold change to naïve mast cells (N) . I) Protein levels of 
CCL18 in supernatant, 24 hours after stimulation with anti-IgE of naive mast cells or mast cells which 
were exposed to anti-IgE for two weeks. J) Protein levels of CCL18 in supernatant, 6 hours after 
stimulation with anti-IgE of naive mast cells (left), or 2 weeks after stimulation with repeated anti-IgE or 
control medium (right). Data are represented as mean ± SEM from n=3 (C, E, G, and J) or n=5 (D,F, and 
H,) or n=4 (I) independent experiments. Asterisks indicate significant differences obtained using 
differential expression analysis FDR<0.05 (C, E, and G), repeated measures ANOVA with Bonferroni 
posthoc test p<0.05 (D,F, H, and I), or paired T-test p<0.05 (J). N = naive mast cells; N+ɑIgE = a single 6 
hours stimulation of naïve mast cells with anti-IgE; R = repeated anti-IgE stimulation for two weeks; 
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MODULATION OF MAST CELL FUNCTION REVEALED THROUGH PATHWAY ANALYSIS 
To confirm that the genes upregulated after repeated FcεRI triggering were not found after 
single anti-IgE stimulation, we compared them to those genes upregulated after a single 
anti-IgE stimulus in the CAGE study (22) (Supplementary Fig 6A,B). Only a small proportion 
of these genes overlapped (less than 10%), confirming that the repeated stimulation 
through FcεRI leads to changes in mast cell function, characterized by upregulation of novel 
genes. To analyse whether upregulated expression of these novel genes after repeated 
FcεRI stimulation is related to global functional changes, we performed pathway 
enrichment analysis of these genes, using GO term biological pathways in DAVID (Online 
Repository Table E10) (23).  
 
 
Figure 4. Overlap in genes and enriched pathways between repeated and single stimulation of mast cells. A, 
and B) Interaction network of GO terms enriched in genes upregulated after repeated anti-IgE (A) or single 
anti-IgE (B) stimulation. Node size reflects the significant/number of genes, and thickness of the lines 
indicates the connectivity between two GO terms. Pathways that are unique for either of the gene sets are 
highlighted in red. C, and D) Protein expression of HLA-DR, obtained using flow cytometry. Data is shown as 
delta MFI of HLA-DR compared to isotype control. Data are represented as mean ± SEM from n=5 (C) 
independent experiments. Asterisks indicate significant differences obtained using repeated measures 
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Although a substantial number of pathways overlapped, the majority (60-70%) of enriched 
pathways was uniquely enriched after repeated stimulation compared to single stimulation 
(Supplementary Fig 6 C,D). Biological pathways were then clustered using Cytoscape and 
DAVID, a clustering analysis based on the overlap of genes in closely related biological 
pathways. (Fig. 4A,B, Online Repository Table E10) (24, 25). The most prominent pathway 
clusters after repeated FcεRI triggering were “antigen processing and presentation”, 
“response to bacteria”, and “chemotaxis”. To confirm the upregulation of key genes 
involved in antigen presentation, we analysed the expression of HLA class II genes by qPCR, 
confirming the sequencing results (Supplementary Fig 7). Furthermore, protein expression 
of HLA-DR, analysed using flow cytometry showed significantly increased cell surface 
expression of HLA class II (Fig 4C,D). 
Since we observed significant pathways related to “response to bacteria” upon repeated 
triggering, we next sought out to confirm this enhanced response to bacteria in our in-vitro 
setup, using LPS to stimulate TLR-4 (Supplementary Fig 8A-C, Online Repository Table E11). 
A significant enhancement in upregulation of LPS-responsive genes was observed. 
Furthermore, the RNA expression and protein secretion of LPS-induced cytokines IL-8 and 
CCL4 were also significantly enhanced after repeated activation through FcεRI 
(Supplementary Fig 8D-I). 
Together, these results show that mast cell function after repeated anti-IgE exposure is 
modulated, and enriched for a variety of pathways including antigen processing and 
presentation, response to bacteria, and chemotaxis. 
MODULATION OF MAST CELL TRANSCRIPTOME RELATED TO CHANGES IN TRANSCRIPTION 
FACTORS RXRA AND BATF 
To analyse whether autocrine signaling of factors released by mast cells themselves could 
contribute to the changes in gene expression, we studied whether supernatant from 
activated mast cells could induce similar gene expression profiles as direct stimulation. 
Downregulation of CSF2 and CCL4 and upregulation of EMR3 were only induced by direct 
stimulation (Fig 5A-C). In contrast, upregulation of TMEM45B, TREM2, and CCL18 were also 
induced by supernatant transfer suggesting a role for autocrine signaling in the 
upregulation of these genes (Fig 5D-F). qPCR data for CSF2, CCL4 and CCL18 were 
confirmed on the protein level by ELISA (data not shown).  
These results suggest that the modulation of expression of some genes can be explained 
through autocrine signaling, although the expression of other genes is directly affected by 
repeated FcεRI-signaling. 
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Figure 5. Autocrine signaling and transcription factors. A-F) Mast cells were stimulated for two weeks 
with 0.2 µg/mL anti-IgE (Repeated ɑIgE) or control medium (Naive) through direct stimulation (left) or 
using supernatant from activated mast cells obtained 24h after activation (right). Gene expression of 
CCL4, CSF2, EMR3, TMEM45B, TREM2, and CCL18, obtained using qPCR. Data is shown as relative 
expression normalized to housekeeping gene RPL5, as a fold change to cells stimulated for 6h with 
anti-IgE (CCL4, CSF2, EMR3, TMEM45B) or to naïve mast cells (TREM2, CCL18). G-H) RNA expression 
analysis of transcription factors BATF (A) and RXRA (B) and thei r target genes as identified by Cscan 
enrichment analysis. Expression of these genes in mast cells exposed to repeated anti -IgE stimulation 
is shown as fold change relative to naive mast cells. Data in are represented as mean ± SEM from n=4 
independent experiments (A-F) or from n=3 independent experiments (G-H). Asterisks indicate 
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To analyse whether transcription factors are involved in the regulation of t ranscription 
after repeated activation of mast cells through FcεRI, we first analysed the presence of 
transcription factors in our differentially expressed genes using DAVID (Online 
Repository Table E12). We observed upregulated expression of BHLHE41, CEBPA, 
CEBPD, CEBPE, KLF2, MAFB, NFE2, RXRA, STAT4, and downregulated expression of 
BATF and NR4A1. In order to identify whether target genes of these transcription 
factors were significantly enriched in the differentially expressed genes after repeated 
FcεRI triggering, we used the analysis tools Cscan and Pscan to assesses which 
transcription factor binding sites are significantly overrepresented, providing thus hints 
on which transcription factors could be common regulators of these genes (Online 
Repository Table E13) (26, 27).  
Significantly enrichment for binding sites or predicted binding affinity to CEBPA, RXRA, 
BATF was observed in at least two of the analysis tools used. Interestingly, one of the 
transcription factors that showed decreased expression after repeated FcεRI stimulation, 
BATF, is known to be a transcriptional repressor (28). Indeed, when we analysed the gene 
expression profiles of target genes for these transcription factors as derived from Cscan 
analysis, there was an inverse relationship between expression of BATF and its target 
genes (n=73), whereas there was a positive relationship between RXRA (transcriptional 
activator) with its target genes (n=60) (Figure 5G,H and Online Repository Table E14). 
Together, these two transcription factors were found to bind the regulatory regions of 
101 of the 218 de novo upregulated genes which were analysed in Cscan. Because Pscan 
does not use experiment-derived data, and CEBPA was only present in the Pscan analysis 
tool, we could not study the expression of CEBPA target genes. 
Together, these results indicate that changes in expression of transcription factors 
RXRA, BATF and possibly others, including CEBPA, may contribute to the modified RNA 
expression profile after repeated FcεRI stimulation.  
NOVEL GENES UPON REPEATED FCεRI TRIGGERING ARE IMPLICATED IN CHRONIC ATOPIC 
TISSUES 
As some of our most highly upregulated genes, such as CCL18, have been impl icated in 
chronic atopic conditions (atopic nasal polyps, atopic asthma, and atopic dermatitis), we 
next analysed the overlap of our genes with genes upregulated in tissue of these chronic 
atopic conditions, identified using microarrays or RNA-seq (Online Repository Table E15). 
We found a striking overlap with genes associated with atopic allergies, in particular with 
tissue from nasal polyps from atopic rhinosinusitis patients (Fig 6A,B and Supplementary 
Fig 9A,B).  
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Figure 6. Association of upregulated genes with chronic allergy. A, C) Heatmap showing relative 
expression of genes upregulated in atopic allergy patients or psoriasis patients in mast cells exposed 
to repeated anti-IgE stimulation. B, D) Overlap of genes upregulated in atopic allergy patients or 
psoriasis patients with random genes (top), genes most highly expression by mast cells (2nd row), 
genes upregulated in mast cells after a single anti-IgE stimulus (3rd row), or genes upregulated in 
mast cells after repeated anti-IgE (bottom). Data are represented as mean ± SEM from n=3 (A and C) 
independent experiments. Overlap was calculated as percentage of the mast cell or random gene list. 
Asterisks indicate significant differences obtained using paired T-test p<0.05 (A and C), or Fisher’s 
exact test p<0.05 (B and D). 
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Sixty-nine out of 308 genes upregulated in chronic allergy were significantly 
upregulated upon repeated stimulation of mast cells through FcεRI, representing 24% 
of the upregulated genes after repeated stimulation (Fig 6B), a percentage  much 
higher than that with random genes (max 2%), the genes most highly expressed by 
mast cells (12%), or the genes upregulated with a single anti-IgE stimulus (9%). The 
overlap with two other atopic diseases was less pronounced, but for atopic dermatitis  
still more than obtained with random genes (Supplementary Fig 9C,D).  
As control, the same analysis was performed with genes upregulated in psoriasis (Fig 
6C,D). Whereas psoriasis genes were related to genes highly expressed by mast cells, 
possibly reflecting the increased number of mast cells in psoriasis tissue, the overlap 
did not increase when analyzing genes upregulated after repeated stimulation. These 
results suggest that chronic IgE-mediated exposure of mast cells may contribute to 
changes in tissue observed in chronic atopic conditions.  
DISCUSSION 
In this study, we aimed to characterize mast cell-intrinsic changes after repeated 
exposure to antigen, such as occurring in chronic allergy. We have used cultured 
human cord blood-derived mast cells which remain viable and stable in phenotype over 
several weeks, and showed that several changes in mast cells occur after repeated 
stimulation with anti-IgE. Obviously, in vitro stimulation is unlikely to capture all the 
changes that occur in vivo after repeated antigen exposure, as these are the result of 
interactions between a variety of cell types difficult to mimic in vitro. However, we 
hypothesized that in addition to those changes, cell-intrinsic changes as a consequence 
of repeated activation are likely to occur, and we were able to capture these changes 
using RNA sequencing.  
To our knowledge, this is the first study to evaluate the effect of repeated FcεRI 
stimulation on human mast cells. Importantly, a high proportion of upregulated genes 
after repeated FcεRI triggering were related to changes in RNA expression in tissue of 
chronic allergic disorders, in particular chronic rhinosinusitis with nasal polyps. Our 
most highly upregulated gene CCL18 is highly linked to allergy, and was found to be 
expressed by mast cells in nasal polyps (29). Whereas some studies were able to show 
increased CCL18 mRNA expression by mast cells after a single anti-IgE stimulation, 
most studies failed to show secretion of CCL18 protein in response to acute anti -IgE 
stimulation (30-32). Our data indicate that robust expression and secretion of CCL18 in 
response to anti-IgE requires repeated or prolonged activation, and may explain how 
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expression of CCL18 in mast cells is induced in chronic allergic tissue. Besides 
recruitment of Th2 cells through upregulation of chemokines, several genes involved in 
T cell activation or antigen presentation to T cells were also upregulated in mast cells 
after repeated FcεRI triggering. Although the funct ion of mast cells as antigen 
presenting cells is controversial (33), we and others have previously shown that human 
mast cells can function as antigen presenting cells through surface expression of HLA 
class II, and that tissue mast cells express HLA class II and costimulatory molecules  (34, 
35). Therefore, the upregulation of HLA class II observed after repeated FcεRI 
triggering suggests that repeated exposure to antigen may enhance this function of 
mast cells, thereby further contributing to T cell activation in chronic allergic tissue.  
The GO-term “response to bacteria” was also highly upregulated after repeated 
stimulation of mast cells. Several studies have shown that combined stimulation of 
FcεRI and TLR can induce a synergistic cytokine response in mast cells and basophils, 
suggesting that this pathway could contribute to allergic exacerbations in the presence 
of pathogens (36-39). We now show that the response of mast cells to TLR-4 triggering 
is also enhanced after repeated stimulation through FcεRI , indicating that antigen 
exposure of mast cells can lead to long-term changes in mast cells associated with 
increased responsiveness to bacteria or LPS, thereby potentially contributing to allergic 
exacerbations.  
These longterm changes in response mode of mast cells are likely regulated by 
transcription factors. Significant enrichment for target genes of CEBPA, RXRA, BATF 
were observed, suggesting that these may contribute to the modified RNA expression 
profile after repeated FcεRI stimulation. CEBPA is a  well-known transcription factor 
involved in myeloid differentiation and is known to antagonize mast cell fate at the 
progenitor stage (40, 41). Likewise, retinoic acid, which can act through RXRA in mast 
cells, was shown to reduce mast cell differentiation during the progenitor stage, but 
did not affect mast cell lineage stability after full maturation (42). The function of these 
transcription factors has not been studied widely in mature mast cells. Interestingly, 
one study showed that overexpression of CEBPA in murine mast cells increased their 
response to bacterial stimulation (43), effects that we observed in mast cells after 
repeated FcεRI triggering as well. Our results therefore warrant further investigation of 
the transcriptional regulation of the function of mature mast cells in the context of 
chronic inflammation. 
Whereas several immune-related pathways were upregulated, we observed an overall 
dampening of the FcεRI-triggered acute mast cell response after repeated triggering 
through FcεRI. Although mast cell degranulation was not affected, the expression of 
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many genes was reduced. Similar observations have also been made in the 
macrophage response to repeated LPS stimulation (44), where the gene-specific effects 
have been named tolerized genes (for genes that display a reduced expression) or non -
tolerizable (for genes that display an unaltered expression).  
Although we have not studied the mechanism of the dampened response observed in 
mast cells repeatedly exposed to FcεRI-triggering, it is interesting that several 
inhibitory receptors which can dampen FcεRI-induced mast cell activation were 
upregulated, including LAIR1, LILRB2, LILRB3, and VSTM1, providing a possible 
explanation for the dampened mast cell responses observed (45, 46). Interestingly, 
several inhibitory receptors are also upregulated in tissue from allergic patients (Online 
Repository Table E16), suggesting that dampening of inflammatory responses through 
upregulation of inhibitory receptors might represent an attempt to  maintain tissue 
homeostasis (47). 
In conclusion, our study provides a thorough analysis of mast cell -intrinsic changes 
after repeated FcεRI triggering. These changes were associated  with an increase in 
release of chemotactic factors, including CCL18, increased antigen presentation to T 
cells, and increased response to bacterium, showing that the mast cell response modes 
are modulated after repeated antigen exposure. Importantly, these changes underlie 
several pathogenic mechanisms in chronic allergy, and were associated with changes in 
tissue of chronic allergic conditions. Therefore, our study may provide insight into the 
mechanisms of mast cell involvement in chronic allergic responses.  
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SUPPLEMENTARY METHODS 
CORD BLOOD-DERIVED MAST CELLS 
Heparinized cord blood was obtained through the department of Obstetrics of the 
Leiden University Medical Center (Leiden, The Netherlands), and was performed in 
accordance with the Declaration of Helsinki. Mononuclear cells were isolated using a 
standard Ficoll procedure, after which CD34
+
 hematopoietic stem cells were isolated 
with CD34 microbeads (Miltenyi Biotec). Isolated CD34
+
 stem cells were differentiated 
into mast cells using serum-free medium (StemPro 34 + supplement, Gibco) with 5 
ng/mL IL-3, 100 ng/mL IL-6 and 100 ng/mL Stem Cell Factor (SCF) at 50,000 cells/mL as 
described (48, 49). Half of the medium was replaced weekly with serum-free medium 
containing 100 ng/mL IL-6 and 100 ng/mL SCF. In addition, 50 ng/mL SCF was added 
once weekly. When cell number exceeded 1x10
6
/mL, additional medium was added 
instead of replacing the medium.  
All recombinant cytokines were obtained from Peprotech. After six weeks, mast cells 
were incubated with the same medium containing 10% FCS for one week to induce 
maturation, and were maintained in this medium throughout the experiment. The 
purity of mast cells was determined by flow cytometric analysis of CD117 (c-kit), FcεRI, 
CD203c and intracellular tryptase. The purity of mast cells ranged from 90 -99% 
(Supplementary Fig 1A-D). Morphology of mast cells was analysed using cytospins 
stained with Toluidine blue. 
RNA ISOLATION 
RNA of four samples (donor 1) was isolated from pelleted Mast Cells cultures with a 
standard Trizol protocol, modified for samples with high proteoglycan content 
(according to manufacturers’ instructions, Life Technologies). However, increased RNA 
yields were observed if RNA was isolated with the mirVana miRNA Isolation Kit 
(Ambion). As a result, RNA from all other donors were isolated with mirVana isolation 
kit.  
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CDNA SYNTHESIS AND QPCR 
150 to 500ng RNA was used for cDNA synthesis with SuperScript® III Reverse 
Transcriptase (Life Technologies) according to manufacturer’s standard instructions in 
a total volume of 20µl. cDNA samples were diluted 1:18 in distilled water.  
The primer sequences, primer concentrations, and Melting Temperatures used for 
qPCR are shown in Online Repository Table E1. All qPCR reactions were performed with 
4µl SensiFAST™ SYBR® No-ROX (Bioline), and 3µl diluted cDNA. qPCRs were performed 
in a Biorad CFX-384 with the following protocol: 2 min 95,0°C; 45 cycles of 5s 95,0°C, 
10s Tm, 25s 72°C; followed by 10s 95,0°C; 7: Melt Curve 65,0°C to 95,0°C: Increment 
0,5°C/5s. Relative expression was calculated with ddCq method normalized to 
housekeeping gene RPL5. Similar results were obtained when normalization was done 
using B2M as housekeeping gene.  
RNA-SEQ 
Four RNA samples from donor 1 were subjected for RNA sequencing with Illumina HiSeq 
2000 at local facility LGTC (paired end, strand specific, 2x100bp). For the second and third 
donor, sixteen samples were sequenced with Illumina HiSeq 2000 at BGI, China (2x 90bp). 
Sequence libraries were prepared based on Illumina TruSeq protocol modified by the 
sequence center.  
In brief, RNA samples were DNAse treated and mRNA was selected with oligo-dT beads. 
mRNA was fragmented by heat incubation. Standard 1st strand synthesis was performed 
with Superscript III (ThermoFisher, Life Technologies) and T nucleotides and samples were 
subjected to RNAseH treatment. Second strand synthesis with U nucleotides was 
performed and dsDNA fragments were End repaired, 3’phosphorylated and dA-tailed. 
Adapters were ligated and second strand was removed by USER digest.  Libraries were pre-
amplified and sequenced on Illumina Hiseq.  
RNA-SEQ QUANTIFICATION 
Analysis of RNASeq data was done using the in-house pipeline Gentrap (version 0.4.3; 
https://git.lumc.nl/rig-framework/gentrap). In particular, adapters were detected with 
FastQC (version 0.10.1) and removed by cutadapt (version 1.1) if the overlap is greater 
than 12 base pairs. Reads were trimmed with sickle (version 1.2) using the quality 
threshold of 33 and minimum length after trimming greater than or equal to 50. Only 
cleaned and trimmed reads were used for downstream analysis. GSNAP (version 2014 -
5-15) was used to align high quality reads to the human reference genome (version 
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GCA_000001405.15_GRCh38, without alternative loci) (50). Alignment quality metrics 
were collected using Picard (http://picard.sourceforge.net version 1.86).  
A minimum of 18 million reads per sample were obtained, and at least 15 million reads 
remained after quality control (Online Repository Table E2). Greater than 94% of 
cleaned reads were mapped to the GRC38reference genome. Exon annotation was 
based on the RefSeq transcript annotation downloaded from UCSC genome browser. 
As expected for polyA
+
 RNA, >70% of mapped reads aligned to annotated exons. 
Sample to sample spearman correlation coefficient (r) ranged from 0.90 to 0.96 
between independent experiments and from 0.97-0.99 between technical replicates 
(Supplementary Fig 2 A). We observed a good correlation of gene expression in 
unstimulated samples with the expression of genes in skin MC expanded in vitro or 
analysed directly ex vivo as present in public databases(22) (R
2
 = 0.76 and 0.70 
respectively; Supplementary Fig 2 B). Furthermore, genes differentially expressed in 
anti-IgE stimulated mast cells as compared to naïve mast cells largely overlapped with 
those found in the CAGE study with skin-derived mast cells and those previously 
reported to be expressed by peripheral blood-derived mast cells (Supplementary Fig 2 
C) (51). 
Gene expression (number of reads per gene) was counted by htseq-count (HTSeq 
version 0.6.1, stranded = no, mode = intersection-nonempty, minimum alignment 
quality = 10) using RefSeq annotation including non-protein coding regions (accessed 
at 2014-09-25) (52). Due to overlapping annotations in RefSeq, genes with no unique 
features were excluded. As a result, 25,109 genes were used for RPKM (Reads per 
Kilobase per Million) calculations using EdgeR.  
DIFFERENTIAL EXPRESSION 
Genes with RPKM >3 in at least one sample for each donor (9,955 genes) were used in 
differential expression analysis to reduce noise from genes with very low expression 
levels. To identify pairwise differentially expressed genes, we used the generalized 
linear model (GLM) implemented in the EdgeR package (version 3.4.2) (21). In 
particular, both the treatment conditions and donor pairing were included in the GLM 
design to account for all systematic sources of variation. The Cox-Reid profile-adjusted 
likelihood (CR) method was used to estimate gene-wise dispersion based on the give 
GLM design. After fitting to the GLM design, the GLM likelihood ratio test was 
performed to detect differentially expressed genes. The P-value for multiple testing 
was adjusted using the Benjamini-Hochberg correction with a false discovery rate (FDR) 
of 0.05.  
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GO TERM ENRICHMENT AND VISUALIZATION 
To understand the biological functions of gene sets, we performed GO term enrichment 
analysis using DAVID.(23, 53) Enriched GO terms were then imported into the Cytoscape 
(version 3.10) plugin EnrichmentMap (version 2.0) (24, 25). Terms with FDR < 0.01 were 
visualized. The threshold for overlapping terms was set at 0.6-0.7.  
TRANSCRIPTION FACTOR ANALYSIS 
From the list of differentially expressed genes, transcription factors were identified by the 
GO term “transcription factor activity” using DAVID. In order to identify whether target 
genes of these transcription factors were significantly enriched in the differentially 
expressed genes after repeated FcεRI triggering, we used the analysis tools Cscan and 
Pscan, identifying binding sites of transcription factors (Cscan) or predicted binding affinity 
(Pscan) to promoter regions of the gene lists from mast cells (26, 27, 54, 55). Target genes 
of transcription factors for which binding has been shown in Chip-Seq experiments were 
generated using Cscan. 
MEASUREMENTS OF PROTEIN EXPRESSION 
For flow cytometry, cells were incubated with fluorochrome-conjugated antibodies for 
CD117, IgE, FcεRI,  CD63, CD203c, and HLA-DR diluted in PBS 0,5% BSA at 4 ºC for 30 min. 
Intracellular staining for tryptase and chymase was performed as described (49). Flow 
cytometric acquisition was performed on FACS Calibur (BD) and Fortessa (BD). Analysis was 
performed using FACS Diva (BD) and FlowJo software. 
Cytokines in culture supernatants were measured using Milliplex assays (Millipore) and 
ELISA for IL-8 (eBioscience), and CCL18 (R&D). Lipid mediators leukotriene C4 (LTC4) and 
Prostaglandin D2 (PGD2) were analysed by competitive ELISA (Neogen and Cayman 
Chemical respectively). 
PUBLICLY AVAILABLE GENE EXPRESSION DATA 
For comparison of gene expression in mast cells to other studies, public available RNA 
sequencing data was obtained from the FANTOM5 project deep cap analysis gene 
expression (CAGE) sequencing of skin-derived mast cells (22). Microarray data was obtained 
from a study of peripheral blood-derived mast cells (51). 
For comparison to gene expression in atopic tissues, we searched Pubmed for microarray 
or RNA sequencing studies of tissue from patients with any chronic atopic or allergic 
disease (Online Repository Table E3) (56-62). Only those studies which examined whole 
tissue (as opposed to e,g, epithelial cells) were selected. Furthermore, the selection criteria 
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included the requirement for studies that had included patients with confirmed atopy or 
allergy. Expression data from psoriasis patients was used as control (63). A list of inhibitory 
receptors was based on known expression by mast cells and additional genes derived from 
the literature (Online Repository Table E16) (64). 
SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1. Mast cell characteristics during culture. A-D) Gating strategy and purity of mast 











































































































































Live cells Dead cells
I.












































224  |  CHAPTER 10 
A) Gating of live cells (excluding debris) based on forward scatter (FSC) and side scatter (SSC). B,C) 
Expression of CD117 and intracellular tryptase in live cells, gated as in A. Dotted line indicates isotype 
control. D) Summary of the percentage of CD117 and tryptase positive cells within the live gate in n=7 
(CD117) or n=5 (tryptase) mast cell donors. E) Cell numbers after two-week culture of cord blood 
derived mast cells. Mast cells were cultured for two weeks with control medium (Naive) or anti -IgE 
(Repeated ɑIgE). The starting cell number was 1*10E6/mL medium. Numbers of live and dead cells at 
the end of two weeks stimulation were counted using Trypan Blue. Ns = no significant differences 
observed when comparing Naive mast cells versus anti-IgE-treated mast cells, analysed using paired 
samples T-test. N = 8 independent experiments with different mast cell donors.  F) Transcripts for 
mast cell maturation markers after two weeks of FcεRI stimulation. Mast cells were cultured as 
described in E. Gene expression was obtained using RNA from 3 independent experiments performed 
with different mast cell donors. Results are shown as mean +/- SEM. RPKM = Reads Per Kilobase per 
Million. G,H) Intracellular tryptase and chymase expression and cell surface FcεRI expression and IgE 
binding at the end of the two weeks in naive mast cells (N) or mast cells stimulated for two weeks 
with anti-IgE (R). Representative flow cytometry plots (H) and a summary (G) are shown. MFI ratio is 
calculated as a ratio of the median fluorescence intensity (MFI) of staining divided by  the MFI of the 
isotype control for each individual sample.I) Cytospins of mast cells were stained with Toluidine blue. 
Representative images of naive mast cells, mast cells stimulated for 1h with anti -IgE, and mast cells 
stimulated for 2 weeks with anti-IgE, Magnification: 20x (top) and 100x (bottom). Arrows indicate 
sites of degranulation. 
 
Supplementary Figure 2. Comparison of RNA sequencing results in our study with public data on mast cell 
transcriptome. 
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A) Spearman correlation of expression values (logRPKM) in biological or technical replicates. Each dot 
indicates an individual gene. B) Spearman correlation of expression values obtained in our study (CBMC) 
compared to skinMC expanded in vitro or analysed directly ex vivo, obtained through publicly available data 
from CAGE sequencing. Each dot indicates an individual gene. C) Overlap of differentially expressed genes 
upon single anti-IgE stimulation in our study, with publicly available data from CAGE sequencing (left, 
middle), or microarray (right).  Upregulated genes in skin MC (left), downregulated genes in skin MC 
(middle), or upregulated genes in PB-MC (right). The number indicated above the piechart is the number of 
genes differentially expressed in those studies. CAGE: cap analysis gene expression; CBMC: cord blood-
derived mast cells; MC: mast cells; PB-MC: peripheral blood-derived mast cells; RPKM: reads per kilobase 






Supplementary Figure 3. Dampened downregulation after repeated stimulation. A) Gene expression 
obtained using RNA sequencing in response to a single 6 hour anti -IgE stimulation (N+ɑIgE), compared 
to control mast cells (N). Log fold change (LogFC) relative to Naive (N) mast cells of the differentially 
expressed genes is shown. B) Genes which were significantly downregulated after a single anti -IgE 
were selected as shown in A), where each dot indicates a different gene. 113 genes had significantly 
less downregulation after repeated stimulation. C) Genes which had significantly dampened 
downregulation after repeated anti-IgE, compared to single anti-IgE using differential expression 
analysis. Each line represents a single gene, and data is shown as relative RPKM normalized to single 
anti-IgE stimulation (N+ɑIgE). Asterisks indicate significant differences obtained using paired T-test 
p<0.05 (B).N = naive mast cells; N+ɑIgE = a single 6 hours stimulation of naïve mast cells with anti-IgE; 
R = repeated anti-IgE stimulation for two weeks; R+ɑIgE = 6 hours stimulation with anti-IgE after 
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Supplementary Figure 4. Upregulation of 
FcεRI-responsive genes after repeated anti-
IgE. A) Genes which are significantly 
upregulated after repeated anti-IgE, 
compared to single anti-IgE using differential 
expression analysis. Each line represents a 
single gene, and data is shown as relative 
RPKM normalized to single anti-IgE 
stimulation (N+ɑIgE). B, D, and F) Gene 
expression of TMEM45B, EMR3, and CH25H, 
obtained using RNA sequencing. Data is 
shown as RPKM fold change relative to single 
anti-IgE stimulation (N+ɑIgE). C, E, and G) 
Gene expression of TMEM45B, EMR3, and 
CH25H, obtained using qPCR. Data is shown 
as relative expression normalized to 
housekeeping gene RPL5, as a fold change to 
single anti-IgE stimulation (N+ɑIgE). Data are 
represented as mean ± SEM from n=3 (B, D, 
and F) or n=5 (C, E, and G) independent 
experiments. Asterisks indicate significant 
differences obtained using differential 
expression analysis FDR<0.05 (B, D, and F) or 
repeated measures ANOVA with Bonferroni 
posthoc test p<0.05 (C, E, and G). N = naive 
mast cells; N+ɑIgE = a single 6 hours 
stimulation of naïve mast cells with anti-IgE; 
R = repeated anti-IgE stimulation for two 
weeks; R+ɑIgE = 6 hours stimulation with 
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Supplementary Figure 5. Difference between stimulation with anti-IgE and IgG immune complexes. A-C) 
Mast cells were sensitized and stimulated with anti-IgE as described in the manuscript. Mast cells were re-
stimulated at day 14 with 1 µg/mL anti-IgE or platebound IgG immune complexes. After 24 hours, mast cells 
supernatant was harvested, and cytokines were  measured using ELISA (IL-8) or multiplex assays. Mean +/- 
SEM of pooled data from 3 independent experiments with different mast cell donors, each performed in 
duplicate. Asterisks indicate significant (p<0.05) differences between naïve mast cells and those treated for 
two weeks with anti-IgE, analysed using paired samples T-test. Ns = not significant. D-F) Mast cells were 
stimulated for 2 weeks with anti-IgE (left) or with IgG immune complexes (right). At day 14, mast cells were 
re-stimulated for 6 hours with anti-IgE or IgG immune complexes respectively, after which RNA expression 
was analysed by qPCR as described in the manuscript. Mean +/- SEM of pooled data from 2 independent 
experiments with different mast cell donors each performed in duplicate. Data is shown as relative 
expression normalized to household keeping gene RPL5 as a fold change to a single aIgE stimulation 
(N+aIgE). Asterisks indicate significant (p<0.05) differences between naïve mast cells and those treated for 
two weeks with anti-IgE, analysed using Two-way ANOVA. No significant differences (ns) were observed in 
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Supplementary Figure 6. Overlap in genes and enriched pathways between repeated and single stimulation 
of mast cells. A-B) Overlap of genes upregulated after repeated anti-IgE and genes upregulated after a 
single anti-IgE stimulation identified using differential expression analysis in this study (A) or in skin-derived 
mast cells from CAGE sequencing (B). C-D) Overlap of enriched GO terms after repeated anti-IgE and genes 
upregulated after a single anti-IgE stimulation identified using differential expression analysis in this study 
(C) or in skin-derived mast cells from CAGE sequencing (D) 
 
 
Supplementary Figure 7. HLA-class II RNA expression by qPCR. A, and C) Gene expression of HLA-DRA and 
HLA-DQA1, obtained using RNA sequencing. Data is shown as RPKM fold change relative to naïve mast cells 
(N). B, and D) Gene expression of HLA-DRA and HLA-DQA1, obtained using qPCR. Data is shown as relative 
expression normalized to housekeeping gene RPL5, as a fold change to naïve mast cells (N). Data are 
represented as mean ± SEM from n=3 (A and C) or n=5 (B and D) independent experiments. Asterisks 
indicate significant differences obtained using differential expression analysis FDR<0.05 (A and C), or 
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Supplementary Figure 8. Response to LPS is enhanced after repeated activation. A) Experimental setup of 
repeated stimulation of mast cells. Human cord blood-derived mast cells were stimulated for two weeks 
with 0.2 µg/mL anti-IgE (Repeated ɑIgE) or control medium (Naive). At the end of the two weeks, mast cells 
were stimulated with LPS (N+LPS and R+LPS). B) Gene expression obtained using RNA sequencing in 
response to a single 6 hour LPS stimulation (N+LPS), compared to Naive mast cells (N). Log fold change 
(LogFC) relative to Naive (N) mast cells of the differentially expressed genes is shown. C) Genes which were 
significantly upregulated after LPS stimulation were selected as shown in B), where each dot indicates a 
different gene. Data are shown as fold change relative to N+LPS. D, and G) Gene expression of IL8 and CCL4, 
obtained using RNA sequencing, 6 hours after stimulation with LPS. Data is shown as RPKM fold change 
relative to LPS stimulation in naive mast cells (N+LPS). E, and H) Gene expression of IL8 and CCL4, obtained 
using qPCR. Data is shown as relative expression normalized to housekeeping gene RPL5, as a fold change 
LPS stimulation in naïve mast cells (N+LPS). F, and I) Protein levels of IL-8 and CCL4 (MIP-1β) in supernatant, 
24 hours after stimulation with LPS of naive mast cells or mast cells which were exposed to anti-IgE for two 
weeks. Data are represented as mean ± SEM from n=3 (D, and G) or n=5 (E, F, H, and I) independent 
experiments. Asterisks indicate significant differences obtained using differential expression analysis 
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Supplementary Figure 9. Association of upregulated genes with chronic allergic diseases. A, C, E) 
Genes upregulated in tissue of atopic rhinosinusitis with nasal polyps (A), atopic dermatitis (C) or 
atopic asthma (E) patients were selected from public databases. Relative expression of these genes in 
mast cells exposed to repeated anti-IgE stimulation is shown as heatmap. B, D, F) Overlap of genes 
upregulated in tissue of atopic rhinosinusitis with nasal polyps (B), atopic dermatitis (D) or atopic 
asthma (F) patients with random genes (top), genes highly expressed by mast cells (second row), 
genes upregulated in mast cells after a single anti-IgE stimulus (third row), or genes upregulated in 
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Supplementary Figure 9 (cont.). Overlap was calculated as percentage of the mast cell or random gene list. P 
values indicated were derived from Fisher’s exact test after correcting for multiple testing (p<0.01). The 
overlap with random genes was analysed 5 times with separate lists of random genes, and the highest 
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234  |  CHAPTER 11 
ABSTRACT 
Rheumatoid Arthritis is a chronic autoimmune disease with a complex disease pathogenesis 
leading to inflammation and destruction of synovial tissue in the joint. Several molecules 
lead to activation of immune pathways, including autoantibodies, Toll-Like Receptor ligands 
and cytokines. These pathways can cooperate to create the pro-inflammatory environment 
that results in tissue destruction. Each of these pathways can activate mast cells, inducing 
the release of a variety of inflammatory mediators, and in combination can markedly 
enhance mast cell responses.  
Mast cell-derived cytokines, chemokines, and proteases have the potential to induce 
recruitment of other leukocytes able to evoke tissue remodeling or destruction. Likewise, 
mast cells can secrete a plethora of factors that can contribute to tissue remodeling and 
fibroblast activation. Although the functional role of mast cells in arthritis pathogenesis in 
mice is not yet elucidated, the increased numbers of mast cells and mast cell-specific 
mediators in synovial tissue of rheumatoid arthritis patients suggest that mast cell 
activation in rheumatoid arthritis may contribute to its pathogenesis. 
PATHOGENIC PATHWAYS IN RHEUMATOID ARTHRITIS 
Rheumatoid arthritis is a systemic autoimmune disease characterized by chronic 
inflammation of the synovial lining of the joint, and is one of the most common 
autoimmune diseases affecting approximately 1% of the general population (1). Synovitis, 
inflammation of the synovial tissue, is mediated through leukocyte infiltration of the tissue, 
and leads to hyperplasia of fibroblast-like synoviocytes and tissue remodeling. Likewise, 
synovitis can induce cartilage destruction and bone erosion, ultimately leading to 
destruction of the joint. Clinically, synovitis induces pain and swelling of the involved joints, 
and the tissue destruction evoked can lead to disabilities if left untreated. 
It is currently believed that different cells of the immune system play a role in the 
pathogenesis of rheumatoid arthritis. However, the exact cause of rheumatoid arthritis is 
not known. Genetic risk factors (such as HLA) underlying disease susceptibility are often 
involved in T- and B-cell responses and the presence of activated B cells and T cells in the 
inflamed synovium of rheumatoid arthritis patients indicate that adaptive immunity plays a 
prominent role. Furthermore, the presence of autoantibodies in the majority of patients 
points towards an important role for B cells in rheumatoid arthritis. However, besides the 
role of adaptive immune cells in initiation of autoreactive responses, innate immune cells 
are thought to play an important role during the effector phase by sustaining inflammation. 
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Treatment is usually aimed at lowering disease activity via immunosuppression, which can 
be achieved in various ways including through the interference with B cell-mediated 
immunity, co-stimulatory pathways, and inhibition of proinflammatory cytokines, 
suggesting that these pathways play an important role in disease pathogenesis. 
AUTOANTIBODIES 
A major effector function thought to contribute to pathogenesis in rheumatoid arthritis 
is mediated by autoantibodies. The classical autoantibody system associated with 
rheumatoid arthritis is rheumatoid factor, which recognizes the Fc portion of IgG. 
However, rheumatoid factor is not specific for rheumatoid arthritis patients, as it is 
also produced in a number of other inflammatory conditions, therefore its role in 
disease pathogenesis is often questioned.  
An important group of autoantibodies in rheumatoid arthritis targets modified 
proteins, with anti-citrullinated protein antibodies (ACPA) being the most well-
characterized. These antibodies recognize a variety of proteins or peptides in which the 
amino acid arginine is modified into a citrulline through a posttranslational 
modification process mediated by Peptidyl Arginine Deiminase (PAD) enzymes. PAD 
enzymes are normally present inside cells and can be activated by high calcium levels 
when cells, such as neutrophils, undergo apoptosis, an event readily occurring during 
inflammation (2). PAD enzymes that are transported to the outside of cells can 
citrullinate the extracellular matrix and in doing so can create targets for ACPA. 
Citrullinated proteins can be found in a variety of inflamed tissues, including the 
synovial tissue of rheumatoid arthritis patients (3, 4). ACPA can recognize many 
citrullinated proteins such as vimentin, filaggrin, and fibrinogen. Because fibrinogen 
and vimentin are also present in the extracellular matrix of the synovium, these 
proteins are often considered as important target antigens for ACPA (5). 
ACPA show a very high specificity for rheumatoid arthritis, and are present in the 
majority (~70%) of rheumatoid arthritis patients (6, 7). Since their discovery ACPA are 
mainly used as diagnostic marker. However, it is now becoming increasingly clear that 
ACPA might also play a functional role in the pathology of rheumatoid arthritis. Several 
observations underlie this notion. ACPA can be observed already years before the 
onset of symptoms, and rarely develop after onset of clinical manifestation of 
rheumatoid arthritis (8, 9). The latter indicates that it is not likely that ACPA are a 
consequence of the inflammation present in rheumatoid arthritis patients. ACPA+ and 
ACPA- patients differ considerably with respect to the underlying genetic and 
environmental risk factors, suggesting that rheumatoid arthritis consists of two 
different disease entities: ACPA+ and ACPA- rheumatoid arthritis (10-13). Furthermore, 
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ACPA+ and ACPA- rheumatoid arthritis patients have a different disease course with 
ACPA+ patients having a more progressive disease, characterized by increased 
radiological joint damage and worse disease activity scores (9, 14). These findings 
suggest that ACPA contribute to disease pathogenesis. When ACPA antibodies are 
adoptively transferred into mice with a low-level synovial inflammation caused by anti-
collagen antibodies, ACPA (reactive with citrullinated fibrinogen or collagen II) could 
enhance arthritis, implicating their direct involvement in the inflammatory process (15, 
16).  
Other autoantibodies present in rheumatoid arthritis patients include antibodies 
directed against carbamylated proteins, or anti-Carbamylated Protein Antibodies (anti-
CarP), another autoantibody directed towards modified proteins. Like ACPA, Anti -CarP 
are present before disease onset and associate with disease severity in (ACPA -
negative) rheumatoid arthritis patients, and could potentially contribute to disease 
pathogenesis (17). 
TOLL LIKE RECEPTOR LIGANDS 
Toll like receptor (TLR) activation is another important pathway for immune activation 
in rheumatoid arthritis. Although TLR are particularly known for their role in protection 
against pathogens, through their recognition of pathogen associated molecular 
patterns, endogenous ligands have been reported to trigger these receptors as well. 
Such endogenous ligands are present in conditions of stress or tissue damage, and 
often are intracellular molecules that can be either passively or act ively released upon 
cell death. As rheumatoid arthritis, like other inflammatory conditions, is related to 
tissue destruction, cell death and the associated presence of endogenous TLR ligands is 
a common feature in synovium of patients. Several examples have been described of 
damage associated endogenous TLR ligands present in synovium, including HMGB1, 
heat shock proteins, tenascin c, and fibronectin (18-22). These endogenous ligands are 
thought to contribute to the chronicity of inflammation, as they can activate TLRs, 
inducing an inflammatory response, further tissue and cellular damage, and thereby 
the sustained release of damage associated TLR ligands. 
Next to damage-associated TLR ligands, cell death can also lead to release of PAD 
enzymes into the extracellular environment, leading to generation of citrullinated 
proteins, including fibrinogen. Citrullinated fibrinogen, one of the antigens recognized 
by ACPA, was shown to trigger TLR-4 (23). Therefore, chronic inflammation is often 
related to release or generation of TLR ligands, leading to a self -amplifying 
inflammatory loop (Fig. 1). 
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T HELPER CELLS 
The strong genetic association of the HLA region with disease susceptibility suggests 
the involvement of T helper cells in the etiology of rheumatoid arthritis. The 
association to HLA-DR alleles is not completely understood, but is specifically related to 
the ACPA response and could therefore be attributed to the helper function of T cells 
by which they can drive autoantibody responses by B cells (13). However, T cells 
themselves may also exert pathogenic effects, for example through their production of 
cytokines. Initially, Th1 cells, producing IFNγ and TNFɑ were thought to drive the 
immune response in rheumatoid arthritis. Since discovery of a wide variety of T helper 
cell subsets, Th17 cells (producing IL-17) have been proposed as the most relevant 
subset of T cells in relation to arthritis, although their putative role in - or contribution 
to the pathogenesis of rheumatoid arthritis in humans is unclear (24). 
CYTOKINES AND CHEMOKINES: INFLAMMATORY MEDIATORS 
The importance of proinflammatory cytokines in the pathogenesis of rheumatoid 
arthritis is well established. The development of biologic agents that target various 
immune mediators has dramatically improved the patient prognosis in the past 
decades, and most of these biologicals target cytokines or cytokine receptors. 
Established and approved therapies for rheumatoid arthritis block cytokine responses 
to TNF and IL-6 (25). Cytokines are produced in response to immune cell activation, 
and can activate cells in an autocrine, paracrine or systemic manner, leading to gene 
transcription of other cytokines, MMPs and other proinflammatory molecules. Thereby 
they contribute to the self-amplifying loop of immune activation. The cytokines 
mentioned above have a variety of target cells and functions, thereby able to tri gger 
tissue inflammation, cartilage destruction, bone erosion and angiogenesis.  
ACTIVATION OF MAST CELLS IN RHEUMATOID ARTHRITIS 
The mast cell is a potent immune cell from the myeloid lineage and is well -known for its 
granules containing inflammatory mediators which can be rapidly released upon 
activation. Mast cells reside at interfaces with the external environment, where they act 
as first line of defense against invading pathogens, such as parasites and bacteria. In 
addition, mast cells play an important role in allergic diseases (26). As there is overlap in 
the mechanisms involved in hypersensitivity in allergy and autoimmune diseases, a role 
for mast cells in autoimmune disease has long been postulated. Several clinical findings 
support an active role of mast cells in rheumatoid arthritis pathogenesis, and suggest 
that mast cells are activated in the synovium of rheumatoid arthritis patients.  
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MAST CELL HYPERPLASIA IN SYNOVIUM 
It has been shown that increased numbers of mast cells are present in synovium of 
rheumatoid arthritis patients, with numbers up to 5% of the total cell number in 
synovium (27, 28). Increased mast cell numbers, or so-called mast cell hyperplasia, is a 
hallmark of multiple autoimmune diseases. Growth factors and cytokines in synovial 
tissue, such as stem cell factor, the critical growth factor for mast cell survival, as well 
as IL-3 and IL-4 are present in synovial tissue of rheumatoid arthritis patients. These 
mediators can induce proliferation of mast cells, whereas in addition, stem cell factor 
and TGFβ have been shown to induce recruitment of mast cells (29), suggesting that 
the accumulation of mast cells in synovium may be the consequence of an ongoing 
inflammatory response mediating mast cell expansion through increased recruitment 
and proliferation. 
In addition to the accumulation of mast cells, it has been reported that the proportion 
of different mast cell subsets is changed in the synovium of rheumatoid ar thritis 
patients. Two main subsets of mast cells exist based on the expression of proteases, 
divided in tryptase-only positive cells (MCT) and tryptase−chymase double-positive 
cells (MCTC). Whereas normal synovium mainly contains MCTC cells, early 
inflammation in rheumatoid arthritis is associated with a selective expansion of MCT, 
followed by increases of MCTC in established or chronic disease (29-31). These changes 
are often correlated with clinical characteristics; MCT numbers in early disease 
associate with inflammation, whereas the MCTC numbers in chronic disease associate 
with tissue remodeling features, which may underlie active involvement of both 
subsets in different pathological processes. 
MAST CELL MEDIATORS IN SYNOVIAL TISSUE OR FLUID 
Mast cells produce a range of mediators, through three major pathways of secretion. 
First of all, they are characterized by presence of intracellular granules, containing 
preformed mediators such as histamine, proteases, proteoglycans, and heparin, which 
are rapidly released upon degranulation. Certain activation pathways can induce the 
release of lipid-derived mediators, produced from arachidonic acid, such as 
leukotrienes and prostaglandins. Finally, mast cell activation induces gene 
transcription, leading to de novo synthesis of cytokines, chemokines and growth 
factors, which can be released within several hours of activation. 
Although most of de novo-produced cytokines are not mast cell-specific, several 
preformed granule proteins are more or less specifically expressed by mast cells, 
including the mast cell specific proteases tryptase and chymase. Both histamine and 
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tryptase are elevated in synovial fluid of rheumatoid arthr itis patients likely reflecting 
local mast cell activation (28, 32-34). Furthermore, mast cells have been reported to be 
the main IL-17-positive cells in the inflammatory joint of rheumatoid arthritis and 
spondyloarthropathy patients (35). As discussed below, several of these mediators can 
contribute significantly to inflammation in the joint.  
MAST CELL ACTIVATION PATHWAYS IN RHEUMATOID ARTHRITIS 
Mast cells are most well-known because of their role in IgE-mediated immune responses 
as they express the high affinity FcεRI, and therefore have originally mainly been 
considered for their role in allergic diseases. However, the importance of mast cells in 
IgE-independent responses has been appreciated in the last decades, and has led to 
increased understanding of mast cell function in a variety of immune responses, 
including autoimmune disease. 
Mast cell activation by autoantibodies 
Depending on their specific isotype, antibodies can exert immune activation by binding 
to cellular Fc receptors and activation of complement. Because various isotypes of 
ACPA (IgG, IgA, IgM) have been previously demonstrated, ACPA are, in principle, able 
to activate the immune system via both pathways (36). The potential of ACPA to 
activate complement has been shown in vitro. ACPA bound to immobilized antigen 
activated the complement system, via both the classical and alternative pathways (37). 
These pathways can activate mast cells, for examples through the cleavage product 
C5a. It has been shown in mice that C5aR activation of synovial mast cells is essential 
for the induction of arthritis (38). However, in humans, it is not clear whether this 
pathway contributes to autoantibody-mediated mast cell activation. 
Besides indirect activation of immune cells via complement activation, autoantibodies 
can also directly activate cells upon crosslinking of Fc receptors, in particular Fcγ 
receptors (binding IgG), Fcε receptors (IgE), and Fcα receptors (IgA). As ACPA are 
mainly present as IgM and IgG isotypes, the binding of IgG-ACPA to Fcγ receptors is 
thought to play a major role in autoantibody-mediated pathogenesis. Activating Fc 
receptors are predominantly expressed by myeloid immune cells, including mast cells. 
In mice, certain mast cell subsets, including synovial mast cells, express the activating 
FcγRIIIa (39-41), the receptor involved in arthritis induced by anti-collagen 
autoantibodies (42). Human mast cells have been shown to express FcγRIIA, whereas 
there is some controversy regarding expression of FcγRI (43-45). We have recently 
shown that human cultured mast cells could be activated by ACPA immune complexes 
in a citrulline-dependent manner (45). This activation was mediated through 
crosslinking FcγRIIA. As this receptor was expressed by synovial mast cells from all 
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patients analysed, we propose that this receptor is a major player in autoantibody-
mediated mast cell activation. 
Mast cell activation by Toll like receptor ligands 
Toll like receptors (TLRs) are expressed by a variety of immune cells, and are 
considered to act as sentinels of the immune system. As mast cells are thought to play 
an important role in protection against pathogens, their expression of TLRs has been 
studied in different cell subsets and species. Although some variation is present in 
expression of these receptors, mast cells generally express a wide variety of TLRs, and 
triggering of TLR by pathogen associated molecular patterns induces activation of mast 
cells (46-49). Importantly, mast cells also express those TLRs that are thought to 
mediate responses to endogenous ligands released in inflammatory conditions. The 
main receptors involved in such responses are TLR-2, TLR-4 and endosomal TLRs which 
sense nucleic acids (20, 50). 
We have recently shown that human mast cells indeed respond to HSP70, an 
endogenous ligand for TLR-4, which is present in rheumatoid arthritis synovium (45). 
Another endogenous TLR ligand, the extra domain A of fibronectin, can induce joint 
inflammation in mice in a mast cell- and TLR4-dependent manner (18), suggesting that 
this pathway of mast cell activation can contribute to pathogenic responses in 
rheumatoid arthritis. 
Mast cell activation by cytokines 
As described above, several cytokines or growth factors are involved in survival and 
expansion of mast cells in synovium. In addition, cytokines can activate mast cells 
directly. Such cytokines include IL-3, IL-4, IL-5, and IL-33, each of which are increased in 
synovial tissue or fluid of rheumatoid arthritis patients. However, stimulation of mast 
cells with cytokines alone usually mediates mainly proliferation with only a low level of 
activation. Importantly, the cytokine environment can play an important role in priming 
of mast cell responses to other triggers (51). IL-33 has been shown to enhance arthritis in 
a mast cell-dependent manner (52), suggesting that activation or priming of mast cells by 
cytokines can significantly alter inflammatory responses in the joint.  
Mast cell-T cell interactions 
The interaction between mast cells and T helper cells has been explored in recent years. 
In both human and mouse, mast cells have been shown to present antigens to CD4
+
 T 
cells, thereby enhancing T cell responses with the possibility of skewing specific T helper 
subsets as well (53-55). Besides antigen presentation, mast cell-derived cytokines can 
also induce T cell activation (56). 
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Although we have recently shown that the interaction between T helper cells and mast 
cells does not only activate T cells, but can also change mast cell phenotype, the exact 
influence of T cells on mast cell function has been studied sparsely (57). Whereas 
regulatory T cells can inhibit mast cell activation, the effect of T cells involved in 
rheumatoid arthritis, such as Th17 cells, is not known (58, 59). However, these cell types 
are likely to interact and it is tempting to speculate that such an interaction contributes 
to pathogenesis of rheumatoid arthritis. A recent study indeed suggested that mast cells 
can regulate T cell responses in an arthritis mouse model, by inducing CD4
+
 T cell 
expansion and Th1 and Th17 cytokine secretion (60). 
CHRONIC INFLAMMATION MEDIATED BY A COMPLEX INTERPLAY OF MULTIPLE PATHWAYS 
As rheumatoid arthritis is characterized by the activation of multiple immune 
pathways, these pathways are likely to interact. For example, it has been shown for 
different types of myeloid cells that activation through TLRs synergizes with triggering 
of Fc receptors (45, 61, 62). As mast cells can be activated by different cytokines, 
several studies have investigated the interaction between cytokine- and FcεRI-
mediated activation. These studies have shown increased degranulation and cytokine 
production when mast cells are exposed to combined triggers of e.g. IL -3, IL-4 and IL-
33 with FcεRI crosslinking (63-66). Whereas these studies are important for 
understanding of the role of cytokines in allergic responses, Fcγ receptors, as 
compared to FcεRI, are probably more important for mast cell activation in rheumatoid 
arthritis. 
In this context, IL-33 was shown to enhance immune complex mediated mast cell 
responses through Fc γ receptors (67). In addition, we have studied the interaction of 
Toll Like receptor triggering on Fcγ receptor mediated mast cell activation, and shown 
that this greatly enhanced cytokine production by human mast cells (45). Importantly, 
we also showed this interaction was present in an antigen-specific system using ACPA 
autoantibodies and endogenous TLR ligands present in synovium. 
Such a synergy between TLR or cytokines and Fc receptor responsiveness likely 
represents a physiological function of the immune system to mount an enhanced 
response when antibodies are produced after the first encounter of a pathogen (68). 
Whereas this is conceivably highly beneficial when a pathogen needs to be eliminated, 
such responses in an autoimmune setting can drive chronic inflammation, because it 
can lead to further release of modified self-antigens and TLR ligands (Fig. 1). Therefore, 
synergy in mast cell responses may contribute to chronicity of rheumatoid arthritis.  
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Figure 1. Chronic inflammation in rheumatoid arthritis is amplified by mast cells. Damage associated Toll 
Like Receptor (TLR) ligands, cytokines and citrullinated proteins are all implicated in rheumatoid arthritis 
pathogenesis and are released upon inflammation, in particular in association with cell death. Both have 
been shown to activate mast cells: citrullinated proteins can form immune complexes with ACPA 
autoantibodies, and activate mast cells through Fcγ receptors; endogenous ligands can activate mast cells 
through TLRs; various cytokines can activate mast cells. In the environment of the inflamed joint, all of 
these triggers are present at the same time, and together lead to synergy in mast cell activation. This 
synergy leads to enhanced tissue inflammation, in particular neutrophil influx, leading to cell death in the 
tissue. This cell death can lead to an amplification loop by generating more endogenous TLR ligands and 
citrullinated proteins. 
MAST CELL EFFECTOR FUNCTIONS IN RHEUMATOID ARTHRITIS 
Mast cells are well-known for their potent and quick effector functions, such as present 
during allergic reactions. However, as tissue-resident cells, their physiological role is 
thought to be protection against pathogens, as well as to contribute to wound healing (69). 
Therefore, it is not surprising that they also contribute to these processes during 
autoimmune responses. 
MAST CELL-MEDIATED TISSUE INFLAMMATION 
During certain bacterial infections, mast cells can orchestrate a local inflammatory 
response by rapidly increasing vascular permeability and releasing chemokines. Thereby 
they contribute to the recruitment of neutrophils and other immune cells, ultimately 
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also characterized by accumulation of immune cells. Whereas the synovial lining mainly 
contains monocytes/macrophages and T cells, synovial fluid is the site to which 
neutrophils are recruited. In humans, it has been shown that neutrophil chemoattraction 
to the synovial fluid is mainly mediated by IL-8, a cytokine produced (although not 
exclusively) by mast cells in response to ACPA autoantibodies and TLR ligands (45, 71, 
72). In mice, mast cell-derived TNF and leukotriene B4 can both mediate neutrophil 
recruitment as well (73-76). In addition, histamine can increase vascular permeability, 
thereby augmenting neutrophil recruitment (Fig. 2A) (77). These and other mast cell-
derived chemokines can also induce recruitment of T cells and monocytes, although 
evidence indicating that this also occurs in the context of autoimmunity is scarce. Growth 
factors for neutrophils and macrophages, such as GM-CSF and G-CSF are also produced 
by mast cells, suggesting that besides inducing cellular infiltration, mast cells may also 
contribute to survival of these cell subsets. 
CROSSTALK BETWEEN SYNOVIAL FIBROBLASTS AND MAST CELLS 
An important consequence of the chronic tissue inflammation present in rheumat oid 
arthritis is activation of synovial fibroblasts, also called fibroblast-like synoviocytes, the 
main stromal cell type of the synovium. Activation of synoviocytes in rheumatoid 
arthritis leads to their proliferation and reduced apoptosis, secretion of c ytokines and 
chemokines and invasiveness, whereby synoviocytes invade the underlying 
cartilage/collagen tissue (78) Synovial fibroblasts can be activated by multiple 
pathways, including TLR activation, and cytokines (79). Cytokines implicated in this 
process are TNFɑ, IL-1, and IL-17 (80, 81). Mast cells can produce each of these 
cytokines, thereby potentially contributing to activation of synovial fibroblasts ( Fig. 2B). 
In addition, other mast cell mediators, such as histamine and tryptase have been 
shown to induce activation and inhibition of apoptosis in synovial fibroblasts cells as 
well (82, 83) Likewise, interaction between synovial fibroblasts can also lead to bi -
directional crosstalk, whereby fibroblasts recruit and activate mast cells, for example 
through stem cell factor and IL-33 (52) 
TISSUE REMODELING SUSTAINED BY MAST CELLS 
Tissue inflammation and activation of fibroblasts goes hand-in-hand with various tissue 
remodeling processes, characterized by angiogenesis, breakdown of cartilage and bone 
erosion. Angiogenesis occurs mainly in the synovial lining of the joint, where rapid-
growing fibroblasts and infiltrating immune cells require increased amounts of nutrients 
and oxygen supplied through the blood. Angiogenesis is mediated by growth factors such 
as VEGF and FGF, and angiogenic cytokines such as IL-8, TNF and GM-CSF, but can also be 
mediated by mast cell granule-derived mediators such as heparin, tryptase and chymase 
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(Fig. 2C) (84-87). Mast cells are often found in close proximity to blood vessels, and their 
numbers are often associated with angiogenesis, especially in the context of tumors and 
wound healing (88, 89). Although no functional data are available on the direct role of 
mast cells in synovial angiogenesis, their secretion profile suggests that they may 
contribute this process. 
 
Figure 2. Mast cell contribution to pathogenic processes in rheumatoid arthritis. (A) Activated mast 
cells can amplify tissue inflammation through several mechanisms. They increase vascular 
permeability through release of histamine, leading to increased recruitment of immune cells. In 
particular, neutrophils are recruited into synovial fluid by chemokines such as IL -8, TNFα, and 
leukotrienes, whereas monocytes and T cells are recruited to the synovial tissue through chemokines 
such as TNF, CCL2, and CCL5. (B) Mast cells in synovium have a bidirectional interaction with 
fibroblasts, whereby fibroblasts can activate mast cells through growth factors and cytokines (SCF, IL -
33), and activated mast cells in turn can activate synovial fibroblasts. Mast cell degranulation can  
induce proliferation of fibroblasts by histamine and tryptase, and cytokine production by mast cells 
(TNFα, IL-1, IL-17) can led to activation of synovial fibroblasts. Together, this crosstalk can induce 
fibroblasts invading into the underlying cartilage tissue. (C) Mast cell-derived cytokines and proteases 
can contribute to increased angiogenesis,a process required for the increased metabolic demand in 
inflamed tissue. Furthermore, various mast cell proteases can lead to extracellular MMP cleavage, 
leading to their activation, a crucial process in the breakdown of cartilage. 
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The two main destructive processes in rheumatoid arthritis are cartilage breakdown and 
bone erosion. Synovial fibroblasts, next to chondrocytes have been implicated in cartilage 
breakdown. Both cell types secrete matrix degrading enzymes such as matrix 
metalloproteinases (MMPs) (90). These enzymes can break down extracellular matrix 
proteins such as collagen, aggrecan and fibrinogen.  
An important feature of MMPs is their secretion as inactive pro-enzymes which need to be 
cleaved by other MMPs or other proteinases to become activated (91). As this cleavage 
occurs in the extracellular space, the proteases required for cleavage can be derived from 
different cellular origins. In this respect, mast cell tryptase could play a prominent role as it 
is known for its ability to activate MMPs (92, 93). In doing so, mast cells can contribute to 
loss of cartilage through activation of MMPs via secretion of tryptase (Fig. 2C). 
Osteoclast activation is the main mechanism leading to bone erosions. Although mast cells 
are not known to release RANKL, a major factor involved in osteoclast activation, mast cells 
may contribute to setting the balance in bone homeostasis. For example, patients with 
mastocytosis (systemic mast cell hyperplasia) exhibit features of accelerated bone 
turnover, possibly through a direct effect of histamine on osteoclasts (94, 95). 
In summary, mast cells can secrete a variety of mediators which are implicated in many of 
the basic pathogenic hallmarks of rheumatoid arthritis. 
MOUSE MODELS FOR ARTHRITIS AND MAST CELL INVOLVEMENT 
ARTHRITIS MOUSE MODELS 
Insight in the contribution of mast cells to pathogenesis of rheumatoid arthritis has 
also been obtained using models of experimental arthritis.  
The first study to show an important role for mast cells in arthritis was performed in 
mice deficient in kit signaling, KitWKitW-v mice. In this study, experimental arthritis, 
induced by K/BxN serum transfer, was completely abolished in the absence of mast 
cells. Transfer of cultured bone marrow derived wild-type mast cells to mast cell 
deficient mice restored the incidence of arthritis after K/BxN serum transfer, indicating 
a direct effector function of mast cells in the development of arthritis (96). The critical 
role of mast cells for development of arthritis in this model has boosted the 
recognition of mast cells as a non-redundant cell in the development of autoimmune 
disease. 
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However, the findings from this study have been recently challenged in different 
models (Table 1). First of all, KitW-Sh/KitW-Sh mice, another mast cell deficient mouse 
due to defect kit signaling, were able to develop arthritis after passive transfer of anti -
collagen type II antibodies (97). In addition, KitWKitW-v mice had normal arthritis 
development in the collagen induced arthritis model (98). Unlike neutropenic 
KitWKitW-v mice, KitW−sh/W−sh mice have a baseline pro-inflammatory phenotype, 
including neutrophilia (99, 100). Therefore, these confounding results have sometimes 
been attributed to the neutrophilia in KitW−sh/W−sh mice, which renders them 
insensitive to mast cell-mediated neutrophil recruitment, a critical event in early 
arthritis development (101). 
Of the mast cell deficient mouse models independent of kit, two models have been 
used to study arthritis. In one study, the Cpa3Cre/+ mice, which are mast cell deficient, 
were fully susceptible to the induction of serum-induced arthritis and clinical scores, 
histology and gene expression analysis were comparable to wild-type mice (102). 
Therefore, it was concluded that the role of mast cells in arthritis is limited. Whereas 
mast cell deficiency using Mcpt5-Cre iDTR mice did not affect serum-induced arthritis 
either, these mice experienced reduced arthritis upon immunization with collagen (60), 
suggesting that further research is needed to increase our understanding of these 
discrepancies. 
Despite these contradictory findings using mice with a complete mast cell deficiency, 
additional evidence for mast cell-mediated pathogenesis in arthritis comes from 
studies using mice deficient in mast cell-specific proteases, such as chymase or 
tryptase. Mice deficient in mMCP4, the homologue of human chymase, develop less 
severe arthritis upon collagen induced arthritis (103). Mice which are deficient in either 
tryptase mMCP6 and/or -7, especially in combination with heparin-deficiency, display a 
reduced severity of adjuvant-induced arthritis and K/BxN induced arthritis (for mMCP6 
deficiency) (104, 105). In addition, mast cell-specific (Mcpt5-Cre-mediated) deficiency 
in A20, a regulatory molecule, leads to increased mast cell activation, thereby 
exacerbating collagen induced arthritis (106). 
As most of these mouse models contain a single deficiency in a mast cell-specific 
mediator, and are therefore not associated with any other defects such as the kit 
mutant mice, these studies provide compelling evidence for mast cell involvement in 
arthritis, despite the contrasting data obtained with mast cell deficient mouse models. 
Therefore, more research is needed to increase our understanding of the role of mast  
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Table 1. Overview of experimental arthritis in MC-deficient or MC protease-deficient mice. 
Mouse strain Deficiency Arthritis model Outcome Refs 
Mast cell deficiency 
KitWKitW-v 
(W/Wv) 




  CIA No effect of mast cell deficiency 98 
KitW-Sh/KitW-Sh SCF-receptor mutation α-collagen type II 
antibody transfer 
No effect of mast cell deficiency 97 
Cpa3-Cre  
(cre-master) 
Cre-mediated tocxicity K/BxN No effect of mast cell deficiency 102 
Mast cell protease-deficiency 






K/BxN Reduced arthritis 105 
  mBSA/IL-1β Reduced arthritis 104 
Mast cell-conditional knockout 
Mcpt5Cre 
A20Fl/Fl 
A20 CIA Exacerbated arthritis 106 
Pharmacological mast cell inhibition 
Cromolyn (not mast cell specific) CIA Reduced arthritis 109 
mBSA: methylated bovine serum albumin; CIA: collagen-induced arthritis; K/BxN: SCF: stem cell factor.  
PHARMACOLOGICAL INHIBITION OF MAST CELLS 
As several lines of evidence suggest a role for mast cells in rheumatoid arthritis, 
intervention with mast cell activation could potentially form novel therapies. The drug 
cromolyn is clinically used as a treatment for asthma patients. The exact mechanism of 
cromolyn in not completely understood, but it is described to prevent the release of mast 
cell specific mediators like histamine from rat peritoneal cells (107). Cromolyn is described 
as a mast cell stabilizing agent and is used frequently in mouse studies. The effect of 
cromolyn as a prolactive on CIA was investigated in DBA/1 mice. A lower clinical score and 
radiographic score were observed compared to non-treated mice, when cromolyn was 
administered when first symptoms of clinical arthritis became evident (108). In addition, it 
was shown that intra-articular treatment of cromolyn or salbutamol prevented 
angiogenesis, pannus formation and joint destruction in mice (109).  
Recently however, the specificity of cromolyn and the sensitivity of different types of mast 
cells to cromolyn in mice is under debate (110). Also, the specificity of salbutamol can be 
questioned since it has also inhibits the secretion of pro-inflammatory cytokines by 
macrophages and T cells (109). Therefore, development of mast cell-specific therapeutics is 
needed to establish the exact role of mast cells in rheumatoid arthritis. 
248  |  CHAPTER 11 
CONCLUSIONS 
Rheumatoid arthritis is a complex autoimmune disease caused by environmental and 
genetic interactions leading to a chronic activation of many (immune) cells in the synovial 
tissue. The pathology of rheumatoid arthritis involves multiple activation pathways and 
interactions between a variety of cell types with arthritogenic functions leading to the 
progression of joint destruction. 
Mast cells can also be found in rheumatoid arthritis tissue, which indicates a possible role 
for this potent cell in the disease pathology. Many in vivo arthritis studies in mice have 
aimed to clarify the precise role of mast cells. However, since mouse models do not fully 
reflect the disease process and as some models for mast cell deficiency have additional 
non-mast cell defects, it is difficult to assess the specific role of mast cells on disease 
pathogenesis in vivo. 
Nevertheless, mast cells have the capacity to respond to a wide range of activating ligands 
in synovium and their effector functions likely reflect their potential role in pathogenesis of 
rheumatoid arthritis. 
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ABSTRACT 
In this Review we focus on the initiation of autoantibody production and autoantibody 
pathogenicity, with a special emphasis on the targeted antigens. Release of intracellular 
antigens due to excessive cell death or to ineffective clearance of apoptotic debris, 
modification of self-antigens during inflammatory responses, and molecular mimicry 
contribute to the initiation of autoantibody production.  
We hypothesize that those autoreactive B cells that survive and produce pathogenic 
autoantibodies have specificity for self-antigens that are TLR ligands. Such B cells 
experience both B cell receptor (BCR) activation and TLR engagement, leading to an escape 
from tolerance. Moreover, the autoantibodies they produce form immune complexes that 
can activate myeloid cells and thereby establish the proinflammatory milieu that further 
negates tolerance mechanisms of both B and T cells. 
INTRODUCTION  
The first autoantibodies were discovered in the late 1940s, when both antinuclear 
antibodies (ANAs) and rheumatoid factors (RFs) were described as serum factors that could 
bind nuclear antigens and immunoglobulins, respectively (1, 2). ANA and RF were 
recognized as diagnostic features of systemic lupus erythematosus (SLE) or RA, 
respectively, and as contributors to disease pathogenesis. It is now becoming increasingly 
clear that autoantibodies play a pivotal role in the pathogenesis of many diseases and that 
autoantibodies mediate both systemic inflammation and tissue injury (3). 
Here we focus mainly on the autoantibodies associated with the autoimmune diseases SLE 
and RA, and we discuss the recent developments on the generation of autoreactivity and 
the contribution of these antibodies to disease pathogenesis. We propose a model in which 
autoreactive B cells escape from tolerance because they bind TLR ligands and undergo 
clonal expansion because of continuous exposure to antigen. Furthermore, the generation 
of immune complexes containing TLR ligands leads to systemic inflammation through the 
activation of innate immune cells. This systemic inflammation is part of the disease process 
and further impairs tolerance mechanisms. While we cite data from studies of SLE and RA 
to support this paradigm, we believe the model has broader applications. 
CENTRAL VERSUS PERIPHERAL TOLERANCE DEFECTS  
During B cell development in the BM, autoreactivity is prevented through receptor 
editing, apoptosis, and induction of anergy in B cells expressing an autoreactive B cell 
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receptor (BCR). When immature B cells express surface IgM, recognition of a self-
antigen in the BM can induce these processes. Transitional B cells emerging from the 
BM continue to mature in the spleen, where additional tolerance mechanisms are in 
place. The exact mechanisms in this peripheral compartment are not fully understood, 
but they require ligand recognition by the BCR, similar to the tolerance checkpoints in 
the BM (4).  
After this stage, mature naive B cells can be activated upon antigen recognition, 
allowing them to enter the germinal center (GC). The GC is a site of rapid clonal 
expansion of B cells, affinity maturation, class switching, and differentiation to memory 
B cells or plasma cells. A unique feature of GC-matured B cells is that they have 
undergone extensive somatic mutation of the antibody genes. As somatic 
hypermutation can give rise to de novo autoreactivity as well as enhance affinity of 
existing autoreactive B cells, additional tolerance checkpoints in the post -GC 
compartment have been suggested to effectively prevent autoreactivity in memory B 
cells and plasma cells, through either apoptosis or receptor editing (5, 6). 
The ability to sequence and clone Ig genes from individual B cells has opened the 
opportunity to study these tolerance checkpoints in health and disease. The results 
from such studies using B cells from healthy individuals suggest that a high number of 
autoreactive B cells is generated in the BM and that sequential tolerance checkpoints 
lead to a gradual decrease in autoreactivity as the B cells mature (7). 
The presence of autoreactive B cells in healthy individuals indicates that central 
tolerance is not sufficient to remove all autoreactive B cells with self -targeting BCRs. 
Indeed, it is well-established that both the B1 subset and marginal zone B subset 
contain high numbers of autoreactive B cells, and in animal models B cells from these 
subsets can give rise to pathogenic autoreactivity (8-10). Although defects in early B 
cell tolerance have been found in patients with autoimmune disease (11, 12), current 
data suggest that most of their autoreactive B cells are derived from non-autoreactive 
precursors. Autoantibodies derived from memory B cells in systemic autoimmune 
disease are often class-switched and highly somatically mutated, which suggests that 
they have been involved in GC reactions (13-19). Memory B cells making anti-DNA 
antibodies and anticitrullinated protein antibodies (ACPAs) in patients with 
autoimmune disease are thought to be derived from non-autoreactive precursors 
because back-mutation of their somatic mutations to germline sequences removes 
their autoreactivity (17, 18). Furthermore, although naive polyreactive B cells can 
recognize citrullinated proteins or DNA and therefore could give rise to ACPAs and anti -
DNA–producing plasma cells, the affinity of ACPAs and anti-DNA antibodies from naive 
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B cells is greatly reduced compared with antibodies in patient serum, suggesting that 
these naive B cells have undergone affinity maturation before developing into plasma 
cells (11, 18). While sequence analyses of autoantibodies have thus far only been 
performed for a limited number of patients and access to plasma cells is limited by the 
unavailability of BM samples, there is consistent evidence that many autoreactive B 
cells in autoimmune disease mature in the GC. 
Taken together, these data suggest that defects in central and early peripheral 
tolerance checkpoints are present in autoimmune disease patients, but the defects in 
early tolerance checkpoints do not necessarily lead to the generation of pathogenic 
autoantibodies. As studies point to an important role of somatic hypermutation during 
GC reactions as a source of autoreactivity, post-GC checkpoints are likely defective in 
patients with autoimmune disease, but our understanding of these checkpoints is 
limited. 
T CELL HELP FOR AUTOANTIBODY PRODUCTION  
Development of high-affinity antibodies requires cognate B cell/T cell interactions to 
initiate and sustain the GC. Somatically mutated autoantibodies in autoimmune disease 
are thought to be derived through T cell–dependent pathways, especially because the 
presence of autoantibodies is often correlated with the presence of specific HLA alleles 
(20, 21). However, at present little is known about the specificity of T helper cells that 
are able to stimulate autoantibody-producing B cells. 
The most direct pathway for T cell helper function is for T cells to recognize the same 
antigen as the B cells. In RA, one of the genetic risk HLA alleles, HLA-DRB1*0401, has 
recently been associated with presentation of citrullinated peptides, allowing fo r 
activation of citrulline-specific T cells (22). These T cells may engage in direct antigen-
specific interactions with ACPA-producing B cells when citrullinated antigens are 
internalized through BCR-dependent recognition. However, the T cell specificities 
involved in the activation of other autoreactive B cells, such as DNA-reactive B cells, 
are not known. Some studies suggest that the epitopes for B cells and T cells do not 
necessarily need to be the same. For example, B cells can internalize multimolecular 
complexes through BCR-mediated recognition and can then process peptides from 
different proteins present in the complex. This internalization of multimolecular 
complexes clearly enables processing of nucleoproteins capable of binding DNA in 
lupus-prone mice and SLE patients (23-26). 
T cell help for autoantibody-producing B cells can also originate from T cell responses 
to foreign antigens through molecular mimicry between viral or bacterial antigens and 
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self-antigens (27-30). Activation of non-autoreactive T cells by foreign antigens can 
lead to activation of B cells that recognize the foreign antigen but also cross-react with 
a self-antigen (31). It is hypothesized that such activation can lead to selection and 
maturation of high-affinity self-reactive B cells. 
In addition to the typical GC response, class switching and somatic hypermutation can 
also occur outside of the classical GCs. In several autoimmune diseases, ectopic 
lymphoid structures can develop, usually in the target organ, such as the synovial 
tissue in RA or the kidney in SLE. These structures closely resemble the GC with the 
presence of B/T lymphoid clusters that include T follicular helper cells and follicular 
dendritic cells. Ectopic lymphoid organs are often associated with the production of 
high levels of autoantibodies, suggesting that local activation of these cells can 
contribute to T cell–dependent B cell differentiation, as in the GC (32, 33). 
TARGET ANTIGENS FOR AUTOANTIBODIES  
Autoantibodies can be directed against a variety of molecules, such as nucleic acids, 
lipids, and proteins, and these target antigens can be located in the nucleus or 
cytoplasm, on the cell surface, or in the extracellular milieu. When analyzing 
autoantibodies in the most common systemic autoimmune diseases, it is striking that 
most of them target ubiquitously expressed intracellular molecules (Table 1).  
Among these, ANAs, a group of heterogeneous antibodies targeting multiple distinct 
nuclear components, are the most common. The molecules recognized by ANAs are 
normally present in the nucleus and therefore are not accessible to antibodies or B cells. 
It is only in conditions of cell death that nuclear contents are released into the 
extracellular environment. 
RA can be considered an exception, as the autoantibodies in RA do not generally target 
intracellular molecules. The classical example is RF, which recognizes the Fc portion of 
IgG, an abundant protein in serum. Another important group of autoantibodies in RA 
targets modified proteins, with ACPAs being the best characterized. ACPAs show a very 
high specificity in clinical diagnostics for RA and are present in the majority of patients 
with RA. These antibodies recognize a variety of proteins such as fibrinogen or fibrin, 
vimentin, type II collagen, α-enolase, and histones that have undergone a 
posttranslational modification in which citrulline is substituted for arginine (34, 35). Most 
of these antigenic citrullinated antigens are extracellular proteins, although intracellular 
citrullinated proteins have also been identified as targets of ACPAs. To date, it is 
unknown whether intracellular or extracellular citrullinated antigens are the main driver 
of the ACPA response. 
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Table 1. Autoantibody recognition in systemic autoimmune disease. 
Antigen location Antibody Antigen Disease PRR 
Nuclear Anti-Ro (SS-a) Ro-RNP SLE, SS TLR7 
 Anti-La (SS-b) La antigen SLE, SS TLR7 
 Anti-Sm Small nuclear RNP SLE TLR7 
 Anti-dsDNA dsDNA SLE TLR9 
 Anti-histone Histones SLE TLR2 and 
TLR4 
 Anti-Scl-70 Topoisomerase I SSc  
 Anti-centromere Centromere SSc  
Cytoplasmic/ 
mitochondrial 
ANCA Myeloperoxidase (p-ANCA) and 
proteinase 3 (c-ANCA) 
Vasculitis, WG  
 ACA Cardiolipin APS, SLE NLRP3 
Modified ACPA Citrullinated proteins RA TLR4 
proteins Anti-Carp Carbamylated proteins RA  
Extracellular RF RF (IgG) RA  
 Lupus anticoagulant Phospholipids APS TLR4? 
 ɑ3 Chain of basement 
membrane collagen 
(type IV collagen) 
ɑ3 Chain of basement 
membrane collagen (type IV 
collagen) 
GPS  
ACA: anti-cardiolipin antibodies; ACPA: anti-citrullinated protein antibodies; ANCA: anti-neutrophil cytoplasm 
antibodies; APS: anti-phopholipid syndrome; GPS: Goodpasture’s syndrome; PRR: pattern recognition receptor; 
RA: rheumatoid arthritis; RF: rheumatoid factor; RNP: ribonucleoproteins; SLE: systemic lupus erythematosus; 
SS: Sjögren’s syndrome; SSc: systemic sclerosis; TLR: toll-like receptor; WG: Wegener’s granulomatosus. 
B CELL PROPAGATION IN RESPONSE TO SELF-ANTIGEN OR FOREIGN ANTIGEN  
The intracellular location of many autoantibody targets raises the question of how 
these antigens can drive clonal expansion, a process that requires the recognition of 
antigens through the BCR, which occurs in the extracellular space. 
Two main hypotheses exist that can explain how autoantibodies arise that recognize 
intracellular self-antigens (Figure 1A). The first theory proposes that apoptosis plays an 
important role as a source of nuclear and cytoplasmic self-antigens. During this process 
of programmed cell death, apoptotic blebs appear on the cell surface and 
microparticles can be released from the cell, both of which contain several cytoplasmic 
and nuclear components. These include several of the intracellular antigens recognized 
by autoantibodies, such as histones, dsDNA, RNA, ribonucleoproteins (RNPs), and 
myeloperoxidase and proteinase 3 in neutrophils (36-39).  
Furthermore, the process of apoptosis induces several modifications in the nucleus, 
including histone citrullination and acetylation, which can be recognized by 
autoantibodies in RA and SLE, respectively (40, 41). Apoptotic blebs are normally 
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quickly engulfed by phagocytes to prevent immune activation (42); however, a failure 
to do this, due either to a genetic defect in one of the apoptosis clearance pathways 
(as often seen in autoimmune disease) or to excessive release of these blebs due to 
inflammation, allows for the sustained presence of these self -antigens in the 




Figure 1. Mechanisms for autoantibody production: apoptosis, antigen modification, and cross -
reactivity. Three models can explain the recognition of intracellular antigens by autoantibodies. (A) 
Cell death through apoptosis or necrosis leads to extracellular exposure of intracellular self-antigens 
through release of intracellular contents into the extracellular environment, formation of apoptosis 
blebs, or NETosis. If clearance mechanisms are insufficient, there may be recognition of these 
antigens by B cells and autoantibody production. (B) Modification of self-antigen generates 
neoantigens, to which B cells have not been tolerized. (C) Autoantibody production arises from 
responses to foreign antigens, which cross-react with self-antigens. 
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Another pathway for propagation of autoantibody responses toward intracellular 
antigens is through cross-reactivity with extracellular antigens. An example of such 
cross-reactivity is anti-dsDNA antibodies in SLE, which have been shown to recognize 
antigens in the glomerular basement membrane, where these autoantibodies can 
deposit (44-47). While the binding of some anti-dsDNA antibodies to glomeruli 
depends on the presence of nucleosomes containing DNA on the glomerular 
membrane, the contribution of cross-reactivity to renal pathology has also been 
demonstrated (48, 49).  
In RA, ACPAs can target both intracellular and extracellular citrullinated antigens that 
arise during an inflammatory response (Figure 1B) (34, 35, 50). It has not been formally 
shown, but it is likely that the citrulline epitopes on different antigens form the basis 
for cross-reactivity between intra- and extracellular antigens. In cardiomyopathy, 
autoantibodies targeting cardiac myosin, an intracellular antigen, have been shown to 
cross-react with the β-adrenergic receptor, thereby inducing stimulation of 
cardiomyocytes. These findings suggest that cross-reactivity between intra- and 
extracellular antigens can drive clonal expansion. 
Similarly, cross-reactivity between foreign antigens and self-antigens can drive the 
expansion of autoreactive B cells (Figure 1C). Several autoantibodies exhibit such cross-
reactivity: dsDNA autoantibodies cross-react with pneumococcal bacteria and Epstein-
Barr virus (29, 45) and anti-neutrophil cytoplasm antibodies (ANCAs) recognize the 
bacterial adhesin FimH (28). However, this cross-reactivity between foreign antigens 
and intracellular self-antigens still requires the release of intracellular antigens through 
apoptosis or cross-reactivity to surface antigens in order for autoantibodies to bind and 
exert their pathogenic activity. We speculate that B cells with BCRs that recognize only 
intracellular antigens will propagate less well than those that cross-react with more 
ubiquitous cell surface or extracellular antigens. Therefore, the basis for clonal 
expansion of many autoreactive B cells can be found in their cross-reactivity. 
TLR RECOGNITION AND ITS ROLE IN ESCAPE FROM TOLERANCE  
Many antigens recognized by autoantibodies are able to trigger pattern recognition 
receptor (PRRs), including TLRs and Nod-Like receptors (NLRs). These receptors are 
listed in Table 1 and include DNA, RNA, citrullinated fibrinogen, cardiac myosin, 
cardiolipin, and oxidated phospholipids (51-56). 
B cells express several TLRs for nucleic acids, including TLR7 and TLR9. Engagement of 
these TLRs activates B cells. Notably, many antigens recognized by autoantibodies are 
ligands for B cell TLRs (Table 1), suggesting a role for TLR recognition in the breakdown 
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of tolerance against these antigens. Indeed, mice deficient in TLR7, TLR9, or th e TLR-
associated signaling adaptor MyD88 are partially protected against development of 
ANAs and lupus-like symptoms (57-60). This protection derives from the effects that 
TLR ligation has on reducing B cell tolerance. 
Combined BCR and TLR ligation by nuclear antigens has been shown to induce a 
synergistic signaling response, mediated by colocalization of TLR9 and antigen 
internalized through BCR (61-63). Thus, self-antigens able to activate endosomal TLRs 
and BCRs will induce robust activation in B cells. Some studies suggest that TLR 
activation of immature B cells can dysregulate central tolerance pathways (64-66). We 
hypothesize that TLR ligation might also explain the failure of peripheral tolerance in 
autoimmune disease. Several studies show increased TLR expression and function in 
activated or memory B cells compared with immature B cells, allowing for robust 
activation through TLR in the GC (67-70). As tolerance in the GC is thought to be driven 
by a survival advantage through affinity-driven selection, combined BCR/TLR ligation in 
the GC may facilitate positive selection and escape from tolerance. 
 
 
Figure 2. Proposed role of PRR 
activation and cross-reactivity in 
expansion of autoreactive B cells 
and their effector functions. (A) 
Self-antigens that bind PRRs can 
activate B cells. We hypothesize 
that the combined recognition of 
self-antigens by BCRs and PRRs is 
required for tolerance escape in 
autoreactive B cells. (B) B cells 
require recognition of antigen 
through their BCR for clonal 
expansion. As most 
autoantibodies recognize 
intracellular self-antigens, cross-
reactivity to cell surface or 
extracellular molecules enhances 
clonal expansion and 
differentiation into memory and 
plasma cells. 
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TLR ENGAGEMENT AND T CELL-INDEPENDENT B CELL ACTIVATION  
Increased levels of the cytokine B cell–activating factor of the tumor necrosis factor 
family (BAFF) and TLR activation have been implicated in T cell–independent activation 
of autoreactive B cells (60, 71). In vitro, increased TLR activation and BAFF levels have 
been shown to trigger activation-induced cytidine deaminase expression, which also 
induces somatic hypermutation and class switching in naive B cells (72). Another study 
showed that neutrophil-derived cytokines including BAFF can induce somatic 
hypermutation and class switching in marginal zone B cells (73). Furthermore, several 
studies showed that TLR activation can directly instigate IgG class switching and T cell–
independent plasma cell differentiation, thereby possibly circumventing the 
requirement for T cell help in the peripheral compartment (57, 74, 75). 
It is not clear whether these T cell–independent B cell activation pathways are 
sufficient to induce the levels of somatic hypermutation that are observed in 
autoreactive IgG
+
 memory B cells. Importantly, TLR activation and T cell help might 
interact to induce somatic mutation. TLR activation of B cells can enhance antigen 
presentation and increase surface expression of co-stimulatory molecules, which will 
facilitate non–antigen-specific interaction with T cells (76, 77). Therefore, TLR 
activation can enhance somatic mutations in T cell–dependent or –independent B cell 
responses. 
Together, these data support an important role for TLR activation in the development 
of autoantibody responses, especially when activated in combination with BCRs. B cells 
with BCR specificity for a TLR ligand may be enabled to escape tolerance mechanisms. 
If such a BCR binds a ubiquitous antigen, such as a cell membrane or extracellular 
antigen, clonal expansion occurs, with affinity maturation and differentiation to a 
plasma cell (Figure 2, A and B). 
PATHOGENICITY OF AUTOANTIBODIES  
The pathogenicity of autoantibodies has been extensively debated. Proof of 
pathogenicity is derived from the ability of autoantibodies to induce cellular damage or 
immune activation in vitro or to passively transfer autoimmune disease in animal 
models, as well as the effectiveness of B cell–targeting therapies. Although such 
evidence is not established in all autoimmune diseases, the most common systemic 
autoantibodies, such as ANAs and ACPAs, are considered pathogenic.  
Pathogenicity has been most thoroughly studied in mouse models with lupus-like 
disease. Several studies have shown that passive transfer of anti-DNA antibodies or 
expression of autoreactive transgenic BCRs can cause inflammation in the kidneys, 
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although not all antibodies have equal capacity to do so (78, 79). In contrast, only 
limited evidence of the pathogenicity of ACPAs or RF is present in mouse models of 
arthritis. This may be due to the absence of these autoantibodies in most mouse 
models; however, when ACPAs are adoptively transferred into mice with low-level 
inflammation caused by anti-collagen antibodies, ACPAs enhances arthritis, directly 
implicating them in the inflammatory process in the joint (80, 81). 
AUTOANTIBODY EFFECTOR FUNCTIONS  
The effector functions that are employed by autoantibodies resemble those of 
antibodies in general and are therefore largely dependent on their isotype. Specific 
autoantibody isotypes are present in different diseases, with IgA antibodies present in 
antiphospholipid syndrome and IgE autoantibodies present in SLE (82-84). IgM and IgG 
autoantibodies are the most abundant. IgM autoantibodies are also present in healthy 
individuals and are therefore often considered to be less pathogenic (85). IgM is a 
potent activator of the complement component 1, q subcomponent (C1q), which has 
recently been shown to inhibit TLR activation by acting as a ligand for the inhibitory 
leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), suggesting that IgM 
might inhibit immune effector responses (86). In support of this model are experiments 
that showed that an inability to secrete IgM in B cells leads to IgG autoantibody 
production in mice (87). 
A major pathway for immune activation and tissue damage for systemic autoantibodies 
is through formation of immune complexes. In situ immune complexes form when 
antigen is present at specific sites within tissues. Different monoclonal anti-DNA 
antibodies have distinct patterns of renal deposition, depending on their specificity and 
cross-reactivity (45). Although RA is associated with the presence of circulating 
immune complexes, the disease is mainly limited to the joints. This is thought to arise 
in part from preferential binding of antibodies to citrullinated proteins present in the 
synovium (88). 
Immune complexes formed in situ can activate the complement system and Fc 
receptors, leading to tissue inflammation and damage. Complement activation by 
autoantibodies has been shown to occur through both classical and alternative 
pathways (89, 90) and can lead to direct cell lysis and damage as well as recruitment of 
leukocytes to further enhance inflammatory responses. Complement-mediated cell 
lysis has also been shown to serve as a source of antigen, such as DNA, RNP, and 
citrullinated proteins (91). 
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Activating Fc receptors are expressed by a variety of cells, particularly by immune cells 
of the myeloid lineage. Autoantibodies have been shown to activate these immune 
cells through FcγR-dependent pathways (92-94). In vivo, FcγR-deficient mice often 
show decreased autoimmunity (95, 96). The capacity of IgG to activate Fc receptors 
contributes to their increased pathogenicity compared with IgM autoantibodies. 
However, IgM-RF was recently shown to enhance FcγR-dependent activation by ACPAs, 
demonstrating that isotypes other than IgG can contribute to pathogenesis (97). 
CLINICAL EVIDENCE FOR AUTOANTIBODY PATHOGENESIS  
Most autoantibodies are present years before disease onset and thus are not merely a 
consequence of inflammation (98-100). Furthermore, for ACPAs, there is evidence for 
epitope spreading, affinity maturation, isotype switching, and glycosylation changes 
before clinical symptoms start. Each of these changes is associated with greater 
pathogenic potential (101-105).  
In addition to the changes in the intrinsic properties of autoantibodies before disease 
onset, the target organ can also become susceptible to autoantibody deposition or 
binding. This is in accordance with the multiple-hit theory of autoimmunity, in which 
genetic and environmental factors induce an initial break in tolerance leading to 
production of autoantibodies. A “second hit” is needed for the antibody to exert 
pathogenic effects and to sustain the inflammatory cascade of the autoimmune 
response. This phenomenon is perhaps most clearly illustrated in myositis, in which the 
autoantibodies bind regenerating myocytes and thus sustain a cycle of injury and 
regeneration (106). 
CHRONIC INFLAMMATION  
As stated above, many autoantibodies target ubiquitously expressed intracellular 
molecules. For antibodies to bind these targets, these antigens need to be released to 
the extracellular environment, where antibodies or immune complexes are deposited. 
As the self-antigens are ubiquitously present, autoantibody effector mechanisms fail to 
eliminate the antigen, causing inflammatory injury to tissues that leads to additional 
release of these intracellular antigens. This process causes a vicious cycle wherein e ach 
disease flare can initiate further autoantibody production and tissue injury (107-109).  
Furthermore, combined TLR- and Fc receptor–mediated activation of myeloid cells 
often leads to an enhanced inflammatory response that is thought to contribute to the  
chronicity of inflammation (51, 94, 110, 111). Therefore, those self-antigens that can 
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most potently activate B cells because they are TLR ligands may also potently enhance 
pathogenic inflammatory responses (Figure 3). 
 
Figure 3. The role of PRR activation by self-
antigens in autoantibody pathogenesis. 
During autoimmune responses, 
inflammation can lead to cell death and 
release of endogenous PRR or TLR ligands. 
When recognized by autoantibodies, these 
ligands can activate myeloid immune cells 
through both Fc receptors and PRRs, 
leading to an enhanced inflammatory 
response. This response, in turn, can lead 
to tissue destruction and release of ligands 
for PRRs and autoantibodies, which further 
amplifies the chronic inflammatory 
response. 
CONCLUSIONS  
A break in tolerance against self-antigens or modified self-antigens can lead to the 
production of autoantibodies. Such a breach in tolerance can originate from a lack of 
clearance of apoptotic debris, inflammation-mediated modification of self-antigen, or 
cross-reactivity between foreign and self-antigens. Some autoantibodies cross-react 
between an intracellular antigen that is a TLR ligand and cell surface or extracellular 
antigen, allowing for continued B cell activation and autoantibody-mediated injury.  
After initiation of autoantibody production, inflammation may cause release of 
intracellular or modified self-antigens, leading to antibody effector function and 
instigation of clinical symptoms as well as to the propagation of the autoreactive B cell 
clones. These pathogenic processes are mainly mediated by IgG autoantibodies, 
although other isotypes may contribute. TLRs play an important role during both 
initiation and pathogenesis of autoantibody responses, as they can recognize several 
self-antigens such as alarmins. TLR activation can enhance the initiation of 
autoantibody responses and can synergize with Fc-mediated effector functions. We 
speculate that those autoreactive B cells that can escape tolerance and expand and 
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differentiate in response to antigen have BCRs that bind antigens that associate with or 
are TLR ligands. Reactivity with abundant cell surface or extracellular antigens permits 
the clonal expansion and survival of these B cells once inflammation has subsided. 
Furthermore, this cross-reactivity may contribute to their pathogenicity. 
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ABSTRACT 
Most current therapies for the autoimmune diseases systemic lupus erythematosus (SLE) 
and rheumatoid arthritis (RA), as well as many of the drugs in the therapeutic pipeline, 
reduce the autoimmune inflammatory process but lead to a general immunosuppression. 
The goal of the next generation of therapies should be to reduce autoimmunity while at the 
same time maintaining immunocompetence. We propose three approaches for 
accomplishing this goal: (i) modulate antigen presentation to the adaptive immune system, 
(ii) alter B cell selection in the germinal center and (iii) use decoy antigens to prevent the 
formation of proinflammatory immune complexes.  
These approaches are based on recent advances in the field: We now appreciate the role of 
dendritic cell function in autoimmune disease and the  importance of citrullinated proteins 
as neoantigens in RA. There is also new recognition that most pathogenic autoantibodies 
are produced by B cells that have matured within the germinal center and that immune 
complexes in both diseases contain ligands for toll like receptors.  We propose that 
treatments that target these newly revealed aspects of RA and SLE will decrease systemic 
inflammation without immunocompromising patients. 
INTRODUCTION 
Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune 
diseases that affect approximately 0.1 and 1 % of the population, respectively.  Because 
individuals in early to mid adulthood are affected by these diseases, their associated 
morbidity constitutes a considerable economic burden and diminishes quality of life over 
decades. Moreover, both diseases are associated with early death. Although the prognosis 
for these diseases has improved substantially over the past decades, overall outcome 
remains inadequate.  Even while on a therapeutic regimen, most patients continue to be 
symptomatic, and current treatments produce undesirable immunosuppression. For these 
reasons, there is a number of novel therapeutics under development. Hopefully, some of 
these will demonstrate dramatic benefit and low toxicity. Here, we propose concepts for 
therapy that we believe are closely aligned with disease pathogenesis. 
In considering the next generation of therapeutic regimens, it is important to consider the 
full spectrum of therapeutic goals.  Certainly, we need to protect against irreversible tissue 
damage, primarily in the kidney and brain in SLE, and in joints in RA.  We also need to 
prevent the accelerated atherosclerosis that occurs in both SLE and RA and which is 
believed to be consequent to an ongoing systemic inflammation, which remains active 
 
 
THERAPEUTICS TO BLOCK AUTOANTIBODY INITIATION AND PROPAGATION IN SLE  AND RA  |  279 
 13 
despite current treatments. We also need to maintain immunocompetence while 
suppressing autoreactivity and systemic inflammation. Ultimately, an ideal therapy would 
effect sufficient immunomodulation that patients experienced a prolonged disease-free, 
drug-free existence, despite their genetic predisposition to disease.  
One important therapeutic question is: When do we intervene? In principle, it would be 
best to intervene at a preclinical stage of disease when there is evidence of abnormal 
immune activation, but no clinical disease and no detectable target organ injury. This would 
obviate the need to understand the nature of tissue injury and the contribution of tissue-
resident cells to organ damage. Preventive strategies for RA are currently being tested in a 
clinical trial but they may necessitate treating individuals who may never develop disease 
with potentially toxic agents. For example, first degree relatives of autoimmune patients 
can exhibit elevated titers of disease-associated autoantibodies or aberrant cytokine 
profiles, but most will never develop disease. Individuals with anti-citrullinated protein 
antibodies (ACPA) who present with painful joints (arthralgia) or undifferentiated arthritis, 
however, have a high risk of RA. For these people, immunomodulation might prevent full-
blown disease. 
Treatment after the onset of clinical symptoms needs to ameliorate disease by inhibiting 
tissue injury, reducing active inflammation and maintaining prolonged immune inactivity in 
lymphoid tissue. Strategies designed to reduce organ damage would differ considerably 
from treatments that induce immune quiescence.  Moreover, their use would be 
intermittent, at times of tissue inflammation but not during the prolonged periods of 
systemic inflammation that are thought to contribute to accelerated cardiovascular 
disease. In contrast, therapeutics that decreases ongoing activation of autoreactive cells 
when target organ inflammatory is under control could reduce systemic inflammation 
without suppressing immunity against pathogens, and prevent acute exacerbations and 
further organ damage.  
To successfully modulate immune responses in SLE and RA, we must understand what 
cellular interactions or molecular pathways are aberrantly regulated in these diseases. 
Gene expression analyses based on genome wide association studies (GWAS) suggest that 
dendritic cell (DC) and B cell intrinsic pathways may be dysregulated in SLE, and T cell 
intrinsic pathways dysregulated in RA (1).  Nonetheless, each disease is promoted by an 
aberrant repertoire of adaptive immune cells, triggered, we propose, by altered antigen 
presentation and abnormal B cell selection in the germinal center (GC). Disease activity is 
sustained, in part, by the pro-inflammatory properties of the disease-specific immune 
complexes. We suggest that these pathways of disease initiation and propagation will be 
the targets of next generation therapies.  
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Should we explore antigen-specific therapeutic interventions or more global immune 
modulation? The answer may depend on the disease. In SLE, there are diverse 
autoantibodies and the T cell autospecificities have not been clearly defined. Thus, we may 
not yet have adequate knowledge of the pathogenic T and B cells in this disease, and 
targeting cells specific for one or two antigens may not be sufficient. Thus, we favor a 
global immuno-modulatory therapeutic approach for SLE. In RA, it may be time to explore 
antigen-specific therapy targeted to citrullinated proteins. Although ACPA are present in 
only 70% of patients, they clearly contribute to systemic inflammation and to tissue 
damage. 
INITIATION OF AUTOIMMUNITY 
DCs are key controllers of immune responses that present both self and foreign 
antigens to T cells in either a tolerogenic or immunogenic fashion, thereby delicately 
balancing immune activation and tolerance (2). As SLE and RA are both associated with 
autoantibodies produced through T cell – B cell collaboration, the DC is thought to play 
a major role in the initiation of such responses. The regulatory function of DCs is 
affected by environmental cues such as the microbiome, prior pathogen exposure and 
cytokines. Thus, mature DCs are stimulated by pattern recognition receptors to 
upregulate co-stimulatory molecule expression and drive effector T cell responses 
against pathogens, while immature DCs or DCs exposed to apoptotic cells normally 
induce T cell anergy or promote regulatory T cells (Treg) differentiation through 
secretio -10 (3, 4). Therefore, the activation and 
differentiation pathways of autoreactive T cells depend on the exact nature of DC 
activation and presentation of self peptides. Treatments that inhibit DC activation or 
change the peptides presented by HLA class II molecules could represent new avenues 
to prevent the initiation of autoimmunity.  
MODULATING DC ACTIVATION. 
A variety of receptors, including pattern recognition receptors, complement receptors, and 
Fc receptors can modulate activation of DCs by self antigen (5, 6). DCs express several 
inhibitory receptors, including LAIR1, a recently identified receptor for the complement 
component C1q (7). C1q deficiency is a monogenic risk factor for SLE development (8), and 
low levels of C1q correlate with increased disease activity (9). C1q prevents autoreactivity 
in at least two ways. It acts as an opsonin of apoptotic cells to facilitate clearance of cell 
debris, and it regulates DC maturation and cytokine production (10, 11). C1q blocks DC 
differentiation from monocytes through LAIR1 (7). Monocyte-derived DCs are 
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immunogenic; after stimulation, they express high levels of co-stimulatory molecules and 
secrete proinflammatory cytokines, which determine T effector cell phenotype (12). 
Monocytes from SLE patients show accelerated differentiation (13). C1q also inhibits 
activation of conventional DCs (cDCs) and plasmacytoid DCs (pDCs) by preventing the 
engagement of endosomal toll like receptors (TLRs)by immune complexes that contain TLR 
ligands (14).  
Thus, C1q and C1q-like agonists could be potent therapeutics to  prevent activation of 
monocytes, cDCs and pDCs, thereby reducing the proinflammatory, proimmunogenic 
milieu in autoimmune patients. Additional strategies to modulate activation of DCs may 
emerge through studies of the microbiome and pathogen-induced immune deviation (15-
17), but the data are not yet sufficient to enable the design of therapeutics. 
 
 
Figure 1. Targets for next-generation therapeutics: DC–T cell interactions. C1q or other ligands for inhibitory 
receptors on DCs can modulate DC activation by blocking the up-regulation of costimulatory molecules and 
cytokine production (top red arrow), modulating T cell phenotype and activation. Altering the levels or 
activity of IRF4, Blimp-1, and cathepsin S (bottom red arrow) could change the peptides presented by DCs 
through HLA, modulating T cell specificity.  
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DC ANTIGEN PRESENTATION (MODULATING T CELL REPERTOIRE). 
SLE and especially RA have a strong association with certain HLA-DR risk alleles, suggesting 
that presentation of particular antigens to CD4+ T cells are crucial components of the 
initiation of autoreactive responses (18).  Transcription factors IRF4 and Blimp-1 and the 
lysosomal protease cathepsin S normally participate in the process of antigen presentation 
(19). Cathepsin S degrades the MHC class II invariant chain to allow peptide loading to the 
MHC II molecules in antigen presenting cells (20, 21). Cathepsin S also degrades endo-
lysosomal antigens, shaping the spectrum of peptides presented on DCs (22, 23). As 
cathepsin S has both positive and negative effects on T cell selection in the thymus and the 
periphery, its abundance needs to be tightly controlled (24). For example, too much 
cathepsin S in the thymus can destroy immunodominant epitopes of self antigens, leading 
to escape of autoreactive T cells from negative selection (25). Low Blimp-1 levels in DCs, as 
occurs in individuals with the SLE Blimp-1 risk allele, can lead to elevated cathepsin S (26). A 
therapeutic agent that diminishes autoantigen presentation and autoreactive T cell 
differentiation by modulating levels of Blimp-1, IRF4 or cathepsin S could be an effective 
strategy against autoimmunity that would not result in global immunosuppression. This 
approach could be effective even without knowing the self peptides that drive autoreactive 
T cells in SLE.  
Antigen presentation of specific peptides not only initiates autoreactive T cell responses; it 
also contributes to the production of autoantibodies. This role in autoantibody generation 
is evidenced by the fact that patients with ACPA+ and ACPA- RA tend to have different HLA 
class II risk alleles, and recently citrulline-specific effector T cells were shown to be present 
in those individuals carrying the HLA risk allele associated with ACPA+ RA (27, 28). 
(Citrulline-specific T cells are also present in healthy individuals, but there these CD4+ T 
cells exhibit a Treg phenotype. In RA patients, citrulline-specific T cells have a 
proinflammatory phenotype, suggesting that additional genetic or environmental risk 
factors allow these T cells to differentiate to effector cells in the periphery where 
inflammation induces the citrullination of proteins.  
Numerous intracellular and extracellular proteins undergo post translational citrullination, 
with extracellular proteins undergoing citullination primarily in an inflammatory milieu.  The 
exact citrullinated epitopes that activate T cells in RA has only recently begun to be 
revealed. More knowledge on the processing and presentation of citrullinated antigens in 
the thymus and periphery is needed before we can design ways to modulate the T cell 
repertoire in RA patients by inhibiting presentation of citrullinated antigens to CD4+ T cells. 
Even now, however, we might consider decreasing the formation of citrullinated proteins 
by interfering with the expression or function of the peptidylarginine deiminases (PAD) that 
catalyze citrulline formation, especially PAD4, which is found in inflammatory synovium. 
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PROPAGATION OF AUTOIMMUNITY 
Although autoreactive B cells can be directly activated by self-antigens, B cell survival and 
the generation of memory B cells and long-lived plasma cells in the GC are promoted by 
proinflammatory cytokines from immunogenic DCs and require help from T follicular help 
(Tfh) cells (29). Autoantibody-containing immune complexes feed forward to 
inflammatory responses by activating complement receptors and Fc receptors on DCs 
and other innate immune cells (30). Furthermore, immune complexes deposited on 
follicular DCs could serve as a self-antigen reservoir that sustains autoreactive GC 
reactions (31). Interventions that can break down this detrimental feedback mechanism 
will be a part of the future therapeutic armamentarium for SLE and RA. 
 
Figure 2. Targets for next-generation therapeutics: GC reactions. The interaction of follicular T helper cells 
and B cells in the GC leads to propagation of autoimmunity. Enhancing the function of Treg cells in the 
germinal center may diminish this process. Qa1-restricted CD8+ Treg cells (red cell) and CTLA-4 expressing T 
follicular regulatory cells can inhibit these GC reactions.  
In the GC, antigen-activated B cells undergo random somatic hypermutations in 
immunoglobulin genes that can cause an increase or a decrease of affinity of B cell 
receptors. The rate of hypermutation and cell division is proportionally increased with the 
amount of antigen captured and presented by GC B cells to Tfh cells (32). Thus, B cells 
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expressing higher affinity B cell receptors are selected to expand and differentiate into 
memory B cells or long-lived plasma cells. B cells can also gain de novo self-reactivity 
through the process of hypermutation. These autoreactive B cells normally undergo 
negative selection, a result of the lack of cognate Tfh cells. But in both SLE and RA, somatic 
mutations contribute significantly to the generation of autoreactive memory B cells, 
suggesting that they interacted with Tfh cells in a GC response (33, 34).  
Autoreactive B and T cells are normally suppressed by regulatory cells. The regulatory cell 
population is highly heterogeneous, including Foxp3+ CD4 Treg, Qa-1 restricted CD8 Treg 
cells and IL-10- and IL-35-producing regulatory B cells (35-37). Even the CD4 Tregs are 
comprised of functionally diverse subsets that selectively regulate Th1, Th2 or Th17 
responses (38, 39). Therefore, the enhancement of a specific subset of regulatory cells in 
SLE or RA patients may suppress certain GC reactions without globally affecting immunity. 
For example, Qa-1 is specifically expressed by Tfh cells, and Qa-1 restricted CD8 Tregs 
inhibit spontaneous GC reactions by targeting autoreactive Tfh cells (40). Reduced numbers 
and dysfunctional CD4 Tregs have been reported in SLE and RA patients (41, 42).  
Whether other regulatory cells are perturbed in SLE or RA patients has not been well 
studied. More effort is required to develop agents that boost a specific population of 
regulatory cells and maintain their function in chronic inflammatory condition in SLE and RA 
patients.  One specific Treg subset found in GCs --- T follicular regulatory cells (Tfr) --- inhibit 
Tfh differentiation and GC B cell responses; their inhibition of Tfh requires expression of 
CTLA-4 (43, 44). CTLA-4-Ig fusion proteins (abatacept), which block CD28 binding to CD80 
and CD86 and thus preventing second signal for T cell activation, have been successfully 
used to treat RA (45). Abatacept has not been able to prevent flares in SLE patients; 
howeverthis may be because SLE patients already have increased serum levels of soluble 
CTLA-4.  Moreover, a major B cell tolerance checkpoint is in the GC where  a specifically 
targeted CTLA-4 agonist may boost Tfr function and suppress autoreactivity in GC B cell 
responses in SLE.  
NEUTRALIZATION OF AUTOANTIBODIES 
Because autoantibodies are thought to be critical for the pathogenesis of SLE and RA 
through their generation of immune complexes, another way to neutralize the 
proinflammatory effects of those complexes without affecting the immunocompetence of 
patients would be the use of decoy antigens.  
In SLE, anti-DNA antibodies contribute to kidney disease and neurotoxicity by through their 
cross-reactivity to glomeruli and neurons. Moreover, the DNA-containing immune 
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complexes can activate TLRs and thereby in turn activate myeloid cells and permit DNA-
reactive B cells to escape tolerance mechanisms (46). We have developed a small molecule 
peptidomimetic that prevents the anti-DNA antibody from binding to target organs and 
from activating TLR 9 (47, 48). Such mimetics are ideal agents to treat autoimmunity as 
they specifically suppress autoantibody-mediated tissue injury and autoantibody-mediated 
systemic inflammation, without inhibiting immunity against pathogens. 
In RA, citrullination is a central event in the pathogenesis of ACPA+ RA, contributing to 
both T- and B-cell activation, and induction of chronic inflammation through formation 
of ACPA immune complexes, which can activate Fc receptors and TLR4 (49, 50).   
Figure 3. Targets for next-
generation therapeutics: 
Autoantibody neutralization. 
Autoantibodies induce a 
chronic cycle of events 
leading to cell and tissue 
damage, either through 
direct effects on tissue or 
through formation of 
immune complexes. Decoy 
antigens can inhibit each of 
these processes by reducing 
antibody binding in tissues, 
inhibiting formation of 
immune complexes, and 





The use of decoy antigens for citrullinated peptides in RA could reduce activation of 
myeloid cells, thereby directly reducing inflammatory responses in the joint.  Activation 
of myeloid cells by ACPA can lead to cell death and release of PAD enzymes or citrullinated 
proteins in the joint (51, 52). This drives an incessant cycle of antigen recognition, immune 
activation, and further release of PAD enzymes and creation of citrullinated antigens in the 
joint. Decoy antigens mightn block the formation of inflammatory ACPA immune 
complexes, thereby preventing myeloid cell activation. In addition, ACPA-producing 
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plasmablasts are continuously generated in the joint, suggesting that B cells are activated 
to undergo terminal differentiation to plasma cells by joint-localized citrullinated antigens. 
Decoy antigens could compete with citrullinated antigens for binding to the B cell receptor; 
by inhibiting crosslinking of the B cell receptor, these decoys could block B cell activation as 
well as prevent generation of autoantibody producing plasma cells. 
Citrullinated proteins also occur in atherosclerotic plaques (53). Therefore, prevention of 
ACPA binding to citrullinated targets may reduce the atherosclerotic complications of 
chronic inflammation in RA patients, in addition to decreasing acute inflammatory 
responses in the joint.  
PRECISION MEDICINE 
In both SLE and RA, patients vary in the exact constellation of signs and symptoms that 
they present, likely reflecting differences in underlying genetic risk and pathogenic 
pathways. Therefore, the approaches presented here should be applied in a patient-
specific manner. For example, modulation of DC activation and antigen presentation 
may be most useful in SLE patients with a Blimp-1 risk allele, and modulation of the 
processing of citrullinated antigens in RA may be most effective in those harboring the 
HLA shared epitope alleles.  
As more is learned of autoimmune disease pathogenesis, our ability to modulate the 
immune response will become more refined. The approaches suggested here represent 
a starting point.  Modulation of antigen presentation and the GC response will 
interfere with key events in the induction of autoimmunity.  Employing decoy antigens 
can lessen the proinflammatory milieu. Agents that can be used in these strategies are 
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AIMS 
This thesis focuses on the understanding of mast cell (and basophil) functions, with a 
special emphasis on the role of mast cells in autoimmune disease. Here, I will discuss the 
findings of this thesis, based on the specific aims: 
1. To characterize the interaction between innate and Fc receptor triggers on mast 
cell and basophil function 
2. To analyze the interaction between mast cells and CD4
+
 T cells 
3. To understand the function of mast cells in chronic inflammation 
INTERACTION BETWEEN INNATE & ADAPTIVE IMMUNITY 
In the immune system, mast cells are considered to be involved in both innate and 
adaptive immunity. Their rapid degranulation makes them one of the first cells to 
respond in innate immune responses, whereas their expression of Fc receptors makes 
them important effector cells in antibody-mediated adaptive responses. However, these 
responses are often considered separately, and not much is known about the interaction 
between innate and adaptive immune triggers, which are often present, as discussed 
below.  
In the first part of this thesis, I aimed at understanding the interaction between triggers 
of the innate immune system in combination with Fc receptor triggering. In chapters 2, 4, 
and 5, I showed that interactions of both FcεRI and FcγRIIA with TLR ligands induced 
synergy in mast cell and basophil activation. This interaction was characterized by a 
marked increase in cytokine secretion, without affecting Fc receptor-mediated 
degranulation.  
Although the magnitude of the response was largely increased when TLR ligands and Fc 
receptor triggers were present at the same time, the specificity of the response remained 
tightly regulated. In particular, the cytokine profile was highly dependent on the TLR 
ligand that was present, in both basophils and mast cells.  
Although we did not investigate the mechanism of synergy, some findings suggest that 
the enhanced cytokine production was mediated through interaction of the TLR and Fc 
receptor signaling pathways. The synergy remained present when mast cells or basophils 
were treated with brefeldin A to block the transport of proteins from the Golgi system to 
the cell surface or extracellular environment (Chapter 2 and unpublished observations). 
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This suggests that the synergy did not depend on upregulation of surface receptors or 
secreted mediators.  
In human monocytes and dendritic cells, combined triggering of FcγRIIA and TLR was 
shown to induce synergy in transcription levels of several cytokines, but the exact 
signaling pathways leading to the synergy are not known (1, 2). A study in murine mast 
cells investigated the phosphorylation events downstream of TLR and Fc receptors upon 
combined triggering of these receptors and showed that activation of the JNK kinase 
pathway was enhanced upon combined triggering of these receptors (3). Many of the 
upstream molecules of the JNK kinase pathway induced by TLR activation (JNK1, MKK4, 
TAK1, IRAK1, IRAK2, MyD88, TRAM, and TRIF)(4) or Fc receptor triggering (BTK, Syk) are 
expressed by human mast cells, at least at the mRNA level (Chapter 5 and unpublished 
observations). Therefore, a similar synergy in JNK kinase activation upon activation 
through TLR and Fc receptors may be underlying the synergy we observed.  
As discussed below, the synergy in mast cell activation upon combined triggering of TLR 
and Fc receptors has important implications for both protective immunity as well as 
hypersensitivity reactions, such as during allergy or autoimmunity. 
TLR AND FC RECEPTOR ACTIVATION IN RESPONSES TO PATHOGENS 
The synergy observed upon TLR and Fc receptor triggering reflects a memory response, 
which is usually characterized by a shorter response time and an enhanced magnitude of 
the immune response after specific antibodies have been generated (5). After primary 
responses to pathogens, antibodies and T cells can contribute to increased resistance to 
secondary or chronic infections, and it is this enhanced responsiveness of the immune 
system that forms the basis for vaccination (Figure 1).  
As discussed in the introduction of this thesis, mast cells have been shown to play an 
important role in the immune response against a variety of pathogens, including bacteria, 
parasites and viruses. However, only few studies have evaluated the role of mast cells in 
recall responses against pathogens, when specific antibodies have been formed.  
In the case of bacteria, IgG antibodies are most often generated after primary infection. 
IgG immune complex mediated reactions upon passive antibody transfer in the mouse 
are dependent on mast cells, in particular through FcγRIII (6).
 
The effect of mast cells in 
such reactions is mainly to recruit neutrophils, eosinophils and other immune cells to the 
site of antigen exposure. Eosinophil recruitment in a model of passive cutaneou s 
anaphylaxis was augmented by pretreatment with LPS, suggesting that enhanced mast 
cell responses in presence of TLR ligands and immune complexes may lead to enhanced 
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protective responses against bacteria (7). In addition, neutrophil recruitment upon 
Helicobacter infection in vaccinated mice was largely reduced in mast cell -deficient 
animals (8, 9). The findings of this thesis are in line with these observations, showing that 
the production of several cytokines and chemokines, known to recruit and activate 
neutrophils and eosinophils, were markedly enhanced in the presence of  combined TLR 
and Fc receptor activation.  
In the case of parasites, most evidences suggest a dominant role for IgE in protection, 
although other IgA and IgG isotypes have been postulated to play a protective role as 
well (10-12). In mice, protective immunity, such as induced via vaccination, is IgE-
dependent (13, 14), and in humans, levels of parasite-specific IgE are correlated with 
resistance to parasitic infection (15-18). Interestingly, a recent study showed that 
opsonized parasites could be directly killed in vitro by human mast cell-derived tryptase, 
through the formation of a so-called degranulation synapse (19).  
In addition to specific antibodies able to enhance mast cell responses during recall 
immunity, IgE bound to FcεRI can be crosslinked non-specifically by an S mansoni egg 
antigen and HIV antigen gp120 (20, 21). Therefore, the synergy observed between TLR 




Figure 1. Synergy between TLR and Fc receptors can contribute to protective immunity against pathogens. 
Pathogens such as bacteria, parasites and viruses can be recognized by antibodies during secondary 
responses. These antibodies can trigger mast cell activation. When PAMPs from the pathogens trigger TLR 
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Pathogen-specific responses 
Importantly, we observed cytokine-specific responses, depending on the TLR that was 
triggered (Chapters 4 and 5), suggesting that the type of TLR-trigger (which typically 
depends on the type of pathogen encountered) can fine-tune the response mode of mast 
cells (Figure 2). There is a remarkable resemblance of the cytokines that were induced by 
specific TLRs in mast cells with their putative protective role for particular pathogens in 
vivo. For example, TLR-2 and -4 are mostly known for their involvement in bacterial and 
parasitic infection (22-25). Ligands for these TLRs in mast cells induced a cytokine profile 
characterized by production of GM-CSF, IL-5, IL-13, and MIP-1ɑ. These cytokines may 
contribute to anti-bacterial immunity; IL-8 and MIP-1ɑ are particularly known to induce 
recruitment and activation of neutrophils, an important mechanism for the first line of 
defense against extracellular bacteria (26-28). IL-5 and IL-13, in turn, are potent 
contributors to the clearance of parasites, through induction of eosinophil activation, 
mucus production and worm expulsion (29-31). 
Some of the cytokines involved in mast cell-mediated protection against bacteria in mice 
were not observed upon triggering of bacteria-associated TLRs in human mast cells. 
These include TNF-ɑ, CXCL1, CXCL2, IL-4 and IL-6 (8, 27, 32, 33). However, for several of 
these cytokines produced by murine mast cells, their production by their human 
counterparts is not commonly observed (34). Furthermore, the functions of these 
cytokines in bacterial infections largely overlap with the cytokines we observed, 
suggesting that human mast cells may serve a similar function be it through production 
of different cytokines. 
In contrast, ligands which are associated with viruses, induced a different cytokine 
profile, which is more associated with recruitment and activation of T cells and NK cells, 
such as through production of MCP-1, MIP-1β (Chapter 4 and unpublished observations). 
Recruitment of T cells and NK cells by mast cells has been shown to contribute to anti -
viral immunity in mice (35-37). Other cytokines produced by mast cells in response to the 
TLR-8 ligand ssRNA (Eotaxin, GRO-ɑ, TNF-ɑ) are associated to recruitment and activation 
of eosinophils and neutrophils. Although this process may not be generally appreciated in 
the context of viral infection, several studies now suggest that eosinophils can play an 
important role in viral infection, especially during pulmonary infections (38-40). 
Eosinophils can secrete RNAses and cationic granule products, which are known to 
degrade single stranded RNA (TLR-8 ligand) (41-43). Neutrophils can also contribute to 
anti-viral immunity, for example through secretion of antiviral peptides, formation of 
NETs, and phagocytosis of infected cells (44-46). These results therefore suggest that 
mast cell-derived cytokines in response to viral TLR ligands may contribute to antiviral 
immunity through their effects of both innate and adaptive immune cells. 
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Figure 2. Pathogen-specific responses mediated through triggering of specific TLRs. The type of pathogen 
can fine-tune the response mode of mast cells. Bacterial and parasitic TLR ligands, through production of 
specific cytokines in response to triggering of TLR-2 and -4, can induce mucus production and recruitment 
of granulocytes to the site of infection. In contrast, mast cell-derived cytokines in response to viral TLR 
ligands are associated with recruitment of T cells and NK cells. 
Differential responses determined by the type of TLR have been previously described for 
different types of dendritic cells and monocytes (47-49), suggesting a model where 
triggering of different TLRs in multiple cell types shape the immune response against 
different pathogens. In Chapter 2, I described a similar phenomenon for basophils, where 
the TLRs associated with bacteria and parasites were able to induce type 2 cytokines, IL-4 
and IL-13, whereas the TLRs associated with viruses induced secretion of RANTES, 
suggesting that both mast cells and basophils may contribute to skewing of the immune 
system to pathogen-specific responses. The specific role of mast cells and basophils seems 
to be the skewing of type 2 immunity and recruitment of neutrophils and eosinophils, 
thereby complementing protective responses induced by DCs and other cell types. The 
further enhancement of these TLR-specific responses by mast cells and basophils in the 
presence of Fc receptor triggering, suggests that mast cells and basophils may be potent 
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TLR AND FC RECEPTOR ACTIVATION IN ALLERGY 
Besides the role of TLR ligation in pathogen-specific immunity, a role for TLRs has been 
implicated in allergy as well. For example, viral and bacterial infections have been 
associated with asthma exacerbations (50, 51). Furthermore, chronic allergy may lead to 
secretion of endogenous TLR ligands (52), and some allergens have been shown to 
contain TLR ligands (53, 54). The results described in this thesis suggest that both 
basophils and mast cell allergic responses are significantly enhanced in the presence of 
TLR ligands.  
Allergy is usually hallmarked by two important processes. The sensitization phase takes 
place first, where Th2 and IgE responses against the allergen are initiated. During an 
allergic reaction, the immune system is triggered by re-exposure to the allergen. This 
effector phase consists of an FcεRI-dependent acute reaction, and a more prolonged 
reaction (late-phase reaction) caused by cytokines and inflammatory infiltrates.  
TLR ligands during allergic sensitization 
During the sensitization phase, allergen-specific Th2 responses are primed. Although 
dendritic cells are required as antigen presenting cells, they usually do not produce IL-4, a 
cytokine that is necessary for Th2 priming (55). It is unclear which cell type provides these 
early innate type 2 cytokines, but basophils may contribute to this process, in addition to 
innate lymphoid cells or naïve T cells (56, 57). Indeed, basophils were shown to enhance 
Th2 responses upon house dust mite inhalation in mice (58). 
The effect of TLR ligands, in particular endotoxin, has been studied in the context of allergic 
sensitization, although contradicting results have been obtained (59). Several studies show 
that exposure to endotoxin or pathogens (such as in rural areas) is associated with a lower 
prevalence of allergy (60-62). Furthermore, some studies in mice showed that exposure to 
LPS can reduce allergic sensitization (63), presumably by inducing Th1 responses as a 
consequence of IL-12 production by dendritic cells in response to LPS (59, 64, 65). In 
contrast, one study showed that a low level of endotoxin is required to mount a robust Th2 
response against allergens, and several studies showed that TLR-4 is required for allergic 
sensitization (58, 66, 67). 
As I showed in this thesis, TLR ligands were able to induce IL-4 production by basophils, 
thereby providing a link between innate responses and Th2 immunity such as required for 
allergic sensitization. TLR ligands alone only led to a low level of IL-4, which in itself was not 
sufficient to induce Th2 skewing. However, TLR ligands together with protease allergens 
may be able to induce a more robust IL-4 production by basophils (68), thereby potentially 
contributing to allergic sensitization.  
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TLR ligands during the effector phase of allergic reactions 
In contrast to contradicting studies on the role of TLR ligation during allergic 
sensitization, much more is known about the enhancement of allergic responses by 
pathogens during the effector phase.  Many studies suggest that pulmonary infections, 
with either virus or bacteria, are associated with asthma exacerbations (50, 51), In 
allergic individuals, challenges with combined endotoxin and allergen induced a 
synergy in neutrophil and eosinophil recruitment to the nasal tissue, or increased 
wheal and flare reactions in the skin, depending on the tissue where the challeng e took 
place (69, 70), In experimental asthma in rodents, LPS enhanced eosinophilic airway 
inflammation (66, 71). The latter was dependent on TLR-4 expression by mast cells.  
Interestingly, we observed a significant enhancement of cytokine production by mast 
cells upon combined TLR-4  and FcεRI triggering, in particular those cytokines that are 
known for their role in recruitment and activation of neutrophils and eosinophils  (71-
73). Our results further suggest that basophils are an important source of IL -4 when 
triggered through TLRs and FcεRI, in line with findings in both human and mouse that 
basophils are the main source of IL-4 during viral infections and allergen challenge (74-
76).  
Therefore, synergy between TLRs and FcεRI triggering may significantly contribute to 
allergic reactions, mainly through their actions on basophils  and mast cells during the 
effector phase of allergic responses (Figure 3). 
TLR AND FC RECEPTOR ACTIVATION IN AUTOIMMUNITY 
As described in chapter 12, many autoantibodies have specificity for TLR ligands, and 
we propose that this plays a role in the initiation of autoantibody responses, as 
triggering of TLRs in B cells is thought to mediate tolerance escape. Furthermore, the 
tissue damage that is associated with chronic inflammation in autoimmune disease 
often leads to release of endogenous TLR ligands, so-called DAMPs (77-81).  
Many studies have suggested a role for TLR signaling in the initiation of autoimmune 
responses, either through its effect on autoantibody production, or through enhancing 
autoreactive Th cell responses (82-89). Knockout animals for TLRs or MyD88 have often 
reduced autoreactive T cell responses, and such responses are aggravated when 
immunization is done in the presence of TLR agonists or pathogens (90). In vivo, a few 
studies suggest that TLR ligands can enhance inflammatory responses mediated by 
autoantibodies. TLR-4 signaling was shown to contribute significantly to thrombosis 
mediated by anti-phospholipid antibodies (91). The use of a TLR-4 antagonist after 
induction of collagen-induced arthritis led to a reduction in arthritis, suggesting a 
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contribution of TLR-4 to the inflammatory response mediated by Th cells and 
autoantibodies (92). In addition, both TLR-2 and TLR-4 deficiency led to reduced arthritis 
symptoms in passive serum-transfer induced arthritis (K/BxN) (93, 94). 
 
Figure 3. Enhancement of allergic responses through triggering of TLR by pathogens or allergens. Allergic 
exacerbations are associated with the presence of viral or bacterial infections. In addition, some allergens 
have been suggested to directly trigger TLRs. When TLR ligands derived from these pathogens or allergens 
are present at the same time as the allergen to which mast cells and basophils are sensitized, synergy in the 
production of cytokines and chemokines occurs, thereby leading to enhancement of allergic symptoms.  
We proposed in chapter 11-13, that TLR ligation may contribute to autoantibody-induced 
chronic inflammation, through their synergistic action on myeloid cells, including mast cells. 
Although the functional role of mast cells during autoantibody-mediated autoimmune 
disease is not yet clear, we were able to show for the first time that human mast cells can 
be activated by anti-citrullinated protein antibodies. The synergy observed when the 
activation by autoantibodies was combined with TLR ligands present in synovium of RA 
patients suggests that mast cells can significantly contribute to inflammatory responses in 
RA (Figure 4).  
IL-33 AS IMMUNOMODULATORY CYTOKINE DURING ANTIBODY-MEDIATED RESPONSES 
Whereas TLR-mediated activation of mast cells and basophils can generally lead to 
enhanced inflammatory responses, IL-33 is associated with modulatory effects, in particular 
through their interaction with monocytes. IL-33 specifically enhanced the production of 
type 2 cytokines (IL-5, IL-13, IL-10) induced by IgG immune complexes in mast cells. In 
basophils, IL-33 enhanced IL-4 and histamine release induced by FcεRI triggering. This led 













300  |  CHAPTER 14 
 
Figure 4. Enhancement of autoimmune responses through triggering of TLR and autoantibodies. 
Autoimmune disease is often associated with the presence of endogenous DAMPs, released as a 
consequence of tissue damage. Self-antigens against which autoantibodies are produced are also often 
recognized by TLRs. Combined activation of mast cells through TLR and Fc receptors during autoimmune 
responses can enhance their cytokine production, thereby leading to enhanced inflammation.  
The reason why IL-33 may have dual roles in allergy and autoimmune disease may lie in its 
ability to specifically drive the release of type 2 cytokines while inhibiting TNF-ɑ by 
monocytes. As described above, allergy is driven largely by type 2 cytokines, IL-4, IL-5 and 
IL-13.  
Therefore, enhancement of the production of these cytokines by basophils and mast cells 
may contribute to allergic symptoms. In particular mast cell-derived IL-13 has been shown 
to contribute to airway hyperresponsiveness in response to IL-33, although IL-13 derived 
from innate lymphoid cells is likely representing an additional important source of IL-13 as 
well (95-98). Although studies in mice confirm the regulatory action of basophils on the 
monocyte/macrophage lineage (99, 100), the strong enhancement of type 2 cytokines by 
IL-33 directly on basophils and mast cells may dominate these immunomodulatory effects, 
thereby enhancing allergic inflammation. 
In autoimmunity, different effects have been observed with IL-33. Several studies showed a 
reduction in autoreactive responses, for example through reducing autoreactive Th17 
responses or through induction of alternatively activated macrophages (101-104). In 
contrast, IL-33 was shown to exacerbate disease in most, but not all, mouse models of 
arthritis (105-109). Interestingly, IVIg was shown to upregulate IL-33, and, via the release of 
IL-4 by basophils, induced alternatively activated macrophages, thereby reducing 
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The results of this thesis suggest that IL-33 can have both pro-inflammatory and anti-
inflammatory actions through mast cells and basophils, by enhancing Th2 immune 
responses and at the same time reducing monocyte-mediated inflammation. This dual role 
may explain why contrasting results are obtained on the role of IL-33 in autoimmune 
disease. 
T CELL INTERACTIONS 
The second part of this thesis focused on the interaction between mast cells and CD4
+
 T 
cells. I showed that human mast cells can contribute to T cell activation, through antigen 
presentation, co-stimulation, and expansion of Th17 cells (Chapters 7-9). 
The antigen presenting capacity of mast cells is an area of debate (112). Several recent 
studies, including the results of this thesis suggest that human mast cells can function as 
antigen presenting cells and can provide co-stimulation to T cells (Figure 5) (113, 114). In 
mice, antigen presentation by mast cells can induce activation of memory Th cells, but 
not, or only poorly, of naïve CD4
+
 T cells, suggesting that mast cells are probably mostly 
involved in activation of memory CD4
+
 T cell responses (115). The results of this thesis 
support this hypothesis. First of all, although HLA class II expressing mast cells were 
present in tonsil, their frequency and expression levels of HLA class II are low, in 
particular compared to that of professional antigen presenting cells, such as dendritic 
cells. Furthermore, we found that human mast cells do not produce any of the cytokines 
required for skewing of naïve CD4
+
 T cells into classical Th cell subsets, such as IL-4, IL-12, 
or IL-23 (116), in line with their inability to induce skewing of naïve Th cells (Chapter 9). 
In some studies, protein antigen processing and presentation by mast cells was more 
efficient when the protein was complexed with IgG or IgE antibodies, suggesting 
enhanced antigen presentation during memory responses (117-119). Together, these 
findings suggests that mast cells probably do not represent a major cell population 
involved in the priming of naïve CD4
+
 T cells in lymphoid organs.  
Although the contribution of antigen presentation by mast cells has not been directly 
addressed in vivo, a number of studies have studied the role of mast cells in modulating T 
cell responses. First of all, many studies have shown that mast cells can direct the lymph 
node hypertrophy and migration and activation of both T cells and dendritic cells, for 
example through releasing exosomes containing TNF (in mice) (120-124). This process 
occurs for example in response to infection, but may also play a role in allergic reactions  
(125-130). 
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In contrast to these studies suggesting an activating role of mast cells in T cell responses, 
several studies have also suggested a role for mast cells in perpetuation of Treg 
responses (124, 131, 132). This effect is most often mediated through mast cell-derived 
IL-10 (133-136). Interestingly, a vast number of studies have shown that Tregs can also 
regulate mast cell-mediated responses, such as during anaphylaxis, suggesting a 
bidirectional crosstalk between T cells and mast cells in peripheral tissues (137-141). Not 
much is known about the effect of conventional T cells on mast cell function, although 
our studies indicated that T cells can modulate mast cell phenotype inducing 
upregulation of HLA class II.  
In addition to their role as accessory cell in priming of CD4
+
 T cell responses by dendritic 
cells, and their role in activating Treg cells, mast cells may play a role in the promotion of 
proinflammatory Th cell responses. This has been studied in particular in the context of 
autoimmunity. In EAE, a mouse model of multiple sclerosis, mast cells were required for 
activation of adoptively transferred T cells (142). In line with this, both total and collagen-
specific Th17 cells were reduced in mast cell deficient mice upon induction of collagen-
induced arthritis (143). What determines this balance between promoting 
proinflammatory Th cells or Treg cells is not clear, but it seems to be influenced mostly 
by the inflammatory context; e.g. infection versus tolerance (144). In agreement with 
this, one study showed that mast cells can convert Treg into Th17 cells during 
autoimmune disease (EAE) in mice, suggesting that mast cells can alter T cell phenotype 
when tolerance breaks (145).  
 
Figure 5. Mast cells interactions with CD4+ T cells lead to T cell activation and Th17 expansion. The results of 
this thesis show that human mast cells can directly activate T cells by providing all 3 signals required for T 
cell effector function: 1) Antigen presentation through HLA class II; 2) Co-stimulation, through a CD28-
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Importantly, our study showed that mast cells could specifically expand Th17 cells when 
they were activated through TLR or Fc receptors. Both chronic allergy and autoimmunity 
are often associated with Th17 cell responses, which are thought to contribute to 
disease, through neutrophil recruitment as well as tissue-specific effects (146-153). Our 
findings of Th17 cell expansion upon Fc receptor triggering of mast cells provides a 
potential link between antibody-mediated inflammation and pathogenic Th17 responses. 
These results together suggest that human mast cells have the complete molecular 
makeup to induce robust T cell activation, and when activated can drive the expansion of 
Th17 cells. 
CHRONIC INFLAMMATION 
Although the role of specific receptors such as TLRs and Fc receptors in chronic 
inflammation become increasingly known, there is a limited understanding of the 
behavior of immune cells during chronic inflammation. In chapter 10, we attempted to 
gain understanding of the function of mast cells in chronic Fc receptor mediated 
responses. We hypothesized that repeated activation through FcεRI could lead to mast 
cell-intrinsic changes reflecting what happens during chronic Fc receptor activation in 
tissue. We observed several changes in mast cell phenotype and function, which were 
correlated to gene expression in chronic allergy. These changes modified mast cell 
function, by increasing their expression of molecules involved in antigen processing and 
presentation, increasing their responsiveness to TLR stimulation, and increased 
expression and production of chemokines (Figure 6).  
CHEMOTAXIS 
Although some of the secreted molecules involved in acute IgE-mediated mast cell 
responses were downregulated, mast cells remained fully able to degranulate, and had 
increased expression of several chemokines, including CCL18 (Table 1). The chemokines 
that were upregulated are mostly involved in recruitment of T cells and granulocytes. As 
infiltration of these cell types can lead to local inflammation, epitope spreading and 
tissue remodeling, this suggests that mast cells, by retaining or even increasing their 
chemotactic capacity, may contribute to chronic inflammation by sustaining local 
leukocyte infiltration. 
Interestingly, CCL18, the most highly upregulated gene, is specifically upregulated in 
chronic inflammatory conditions, such as different forms of chronic allergy and chronic 
autoimmune diseases (154-156). There is no mouse homologue of this chemokine, 
therefore its role in vivo has been difficult to establish. CCL18 has been mainly shown to 
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play a role in chemotaxis, in particular that of naïve T cells and memory Th2 cells  (157-
160).  
These results suggest that the chemotactic function of mast cells changes during chronic 
inflammatory stimulation, and can induce several pro-inflammatory effects including 
persistent recruitment of granulocytes and T cells. 
 
Table 1. Chemokines specifically upregulated after repeated stimulation of mast cells through FcεRI 
Gene Receptor Cell types recruited 
CCL5 CCR1, CCR3, CCR5 T cells, eosinophils, basophils 
CCL7 CCR1, CCR2, CCR3 Monocytes 
CCL18 CCR8 T cells (Th2) 
CCL24 CCR3 Eosinophils, resting T cells 
CXCL1 CXCR2>CXCR1 Neutrophils 
CXCL2 CXCR2 Granulocytes 
CXCL5 CXCR2 Neutrophils 
CCL5 CCR1, CCR3, CCR5 T cells, eosinophils, basophils 
CCL7 CCR1, CCR2, CCR3 Monocytes 
CCL18 CCR8 T cells (Th2) 
CCL24 CCR3 Eosinophils, resting T cells 
Data obtained from gene expression analysis as shown in Chapter 10; information about chemokine receptors 
and recruited cell types were obtained from Zlotnik et al. (161) 
T CELL ACTIVATION 
After repeated Fc receptor triggering of mast cells, we also observed enhanced 
expression of several genes involved in antigen processing and presentation. As 
described in the part about mast cell-T cell interactions, we showed that human mast 
cells can function as antigen presenting cells, and that these results therefore may 
have important implications for the capacity of mast cells to activate CD4
+
 T cells. CD4
+
 
T cells play an important role in chronic inflammation, for example through driving the 
production of allergen-specific antibodies or autoantibodies (162-165). 
Although not much is known about the exact antigen processing pathways in mast 
cells, repeated triggering through Fc receptors induced upregulated expression of HLA 
class II molecules, costimulatory molecules (e.g. CD86), and cathepsins S. Therefore, 
our results suggest that mast cells may have increased capacity for antigen 
presentation during chronic Fc receptor-mediated inflammation, thereby potentially 
contributing to T cell activation in the local tissue environment.  
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TLR RESPONSES 
Another important function of mast cells that was enhanced after repeated stimulation 
through Fc receptors was their response to bacteria. This enhancement was 
characterized by upregulated expression of several TLRs, and we were also able to 
show increased cytokine production in response to LPS, a prototype TLR-4 ligand.  
Activation of TLRs is thought to initiate a positive feedback loop of inflammation 
through inducing tissue and cellular damage thereby leading to sustained release of 
endogenous TLR ligands (80, 81). Interestingly, those TLRs most well-known for their 
involvement in responses to DAMPs, TLR-2 and -4, were upregulated in mast cells after 
repeated Fc receptor triggering (166). Macrophages in synovium of RA patients were 
also found to exhibit increased expression of TLR-2 and -4, suggesting that 
upregulation of TLRs may be a common mechanism in different myeloid cell types 
during chronic inflammation (167).  
Given the importance of TLRs in the response to endogenous DAMPs, these findings 
suggests that TLR responses may be enhanced during chronic antibody-mediated 
responses and that this enhanced TLR responsiveness by mast cells may contribute to 
this positive feedback loop during chronic inflammation. 
TISSUE REMODELING 
Chronic inflammation is often characterized by tissue remodeling, leading to long-term, 
irreversible changes in tissue homeostasis. Possibly the most striking example is 
rheumatoid arthritis, where loss of bone and cartilage are characteristics of such tissue 
remodeling. 
One of the biological pathways significantly upregulated in mast cells after repeated Fc 
receptor triggering was wound healing, a process closely related to tissue remodeling, 
and involving several different processes including coagulation, inflammation, 
angiogenesis, and tissue regeneration. We observed upregulated gene expression of 
several tissue-remodeling enzymes and extracellular structural proteins (MMP25, 
osteopontin, and possibly PADI4) allowing for a direct influence of mast cells on tissue 
homeostasis (168-171). 
In addition to these direct effects, mast cells have been shown to have indirect effects as 
well, such as through activation of stromal cells, and cleavage of pro-MMP enzymes 
secreted by other cell types (172-174). For example, CCL18, although most well-known 
for its chemotactic functions, has also been shown to induce fibroblast activation and 
collagen production (175). In addition, besides its role in bone metabolism, osteopontin 
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is associated with a variety of effects associated with tissue repair and fibrosis, 
presumably through its effect on fibroblasts, epithelial cells and macrophages (176-179).  
Importantly, although we used an in vitro model of mast cell activation, several changes 
observed were linked to gene expression in chronic inflammatory conditions. For 
example, both CCL18, osteopontin are highly upregulated in asthma and allergy, and 
were associated with markers of tissue remodeling in several chronic inflammatory 
diseases (180-189). These molecules were also found to be expressed by mast cells in 
such chronic inflammatory diseases when analysed ex vivo (180, 190). Therefore, our 
results show that mast cells upregulate several molecules involved in tissue remodeling 
after repeated Fc receptor triggering, suggesting that mast cells can significantly 
contribute to chronic inflammation through modulation of tissue homeostasis.  
RESOLUTION OF INFLAMMATION 
Inflammatory responses are tightly regulated to prevent tissue damage. When the 
inflammatory stimulus is eliminated, a resolution phase is initiated, characterized by 
phagocytosis of apoptotic neutrophils, the production of pro-resolving lipid mediators 
and anti-inflammatory molecules, as well as removal of tissue debris (191-193).  
Repeated stimulation of mast cells led to several changes that could potentially 
contribute to resolution of inflammation. First of all, we observed a dampening of the 
acute mast cell responses, such as several cytokines and chemokines. Furthermore, the 
gene expression of several regulatory molecules was upregulated. These include a 
number of inhibitory receptors (LAIR1, LILRB2, LILRB3, and VSTM1). These and other ITIM 
motif-bearing inhibitory receptors have been shown to potently inhibit mast cell 
responses through FcεRI (194-198). Therefore, upregulation of these receptors may 
contribute to dampening of mast cell responses. In addition, heme oxygenase-1 (HO-1, 
HMOX1), a molecule with anti-inflammatory capacities, was upregulated in mast cells 
after repeated activation. HO-1 is most well-known as a stress-induced molecule that can 
suppress activation of myeloid cells (199-201). Not much is known about the role of HO-1 
in mast cells, but molecules that can upregulate expression of HO-1 diminished mast cell 
activation, suggesting an immunoregulatory role of HO-1 in mast cells as well (202, 203).  
Together, these results suggest that in addition to enhanced proinflammatory responses, 
mast cells also initiate an anti-inflammatory program, characterized by upregulation of 
immunoregulatory molecules, which could contribute to tissue protection. However, our 
results also show, that when antigen cannot be removed, therefore leading to repeated 
or continuous stimulation of mast cells through Fc receptors, proinflammatory effects 
may dominate over these anti-inflammatory mechanisms. 
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Figure 6. Potential roles of mast cells in chronic antibody-mediated inflammation. Upon repeated Fc 
receptor triggering, we observed changes in several processes related to chronic inflammation: 1) 
upregulation of inhibitory receptors, potentially contributing to resolution of inflammation; 2) enhanced 
antigen processing and presentation through HLA class II; 3) changes in production of chemokines; 4) 
enhanced TLR responses; 5) upregulation of tissue-remodeling enzymes.  
IMPLICATIONS FOR AUTOIMMUNE DISEASE 
Autoimmune diseases are characterized by immune responses during which the 
inflammatory stimulus (self-antigen) cannot be eliminated, leading to chronic 
inflammation. Our results suggest that mast cells can significantly contribute to chronic 
inflammation after repeated Fc receptor triggering, through changes in chemotaxis, 
enhancing T cell activation, upregulating their responsiveness to DAMPs, and 
upregulation of molecules involved in tissue remodeling. As we only studied FcεRI, it is 
unknown whether similar processes are upregulated upon repeated triggering of FcγRs in 
mast cells, which would be highly important in the context of autoimmunity. However, 
the mast cell response to triggering through FcεRI and FcγRIIA overlap considerably, 
suggesting similar responses may occur upon repeated stimulation of mast cells with IgG 
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upregulated in mast cells after repeated FcεRI stimulation, has also been found in 
increased levels of expression in synovium of RA patients, suggesting that this molecule 
may be upregulated in mast cells during chronic autoimmune disease as well (204-206). 
Even more interesting, synovial fluid levels of CCL18 were associated with levels of RF, 
one of the autoantibodies in RA, suggesting that repeated Fc receptor activation as 
observed in mast cells can present a novel pathway for secretion of CCL18 in response to 
autoantibodies (207). Other molecules upregulated in mast cells after repeated Fc 
receptor triggering (such as osteopontin) are also associated with autoimmune disease 
and autoantibodies (208, 209). Therefore, these studies may provide more insight into 
the role of Fc receptor activation during chronic autoimmune disease.  
IMPLICATIONS FOR THERAPY OF CHRONIC INFLAMMATORY DISEASES 
In chapter 13, we postulated several novel therapeutic approaches for the treatment of 
autoimmune diseases. As several pathogenic mechanisms overlap between autoimmune 
disease and chronic allergy, similar strategies may be employed for both types of 
diseases. Here, I will discuss the implications of these therapies for mast ce ll-mediated 
responses during chronic inflammation. 
We described therapeutic targets that could influence the interaction between dendritic 
cells and T cells. Whereas dendritic cells are often viewed as the most potent antigen 
presenting cells, the second part of this thesis showed that mast cells can also function as 
antigen presenting cells and can specifically enhance Th17 responses, an effect of mast 
cells that was also shown in vivo in an mouse arthritis model (143). Furthermore, several 
molecules involved in antigen processing and presentation had increased gene 
expression in our in vitro model of chronic inflammation, suggesting that chronic 
inflammatory responses could further enhance T cell activation by mast cells. Therefore, 
strategies to modulate APC-T cell interactions could inhibit T cell activation by mast cells 
as well.  
First of all, we proposed to modulate activation of antigen presenting cells (dendritic cells 
and monocytes) by C1q or C1q-like agonists through its effect on LAIR1. In monocytes 
and dendritic cells, C1q has been shown to inhibit cytokine secretion and maturation, 
thereby potentially decreasing T cell activation or skewing by cytokines (210, 211). 
Human mast cells also express LAIR1, but the effect of C1q and the functional 
consequences of ligation of LAIR1 in mast cells has not been studied (212). However, it is 
conceivable that LAIR1 could modulate mast cell function in a similar manner as that of 
monocytes and dendritic cells, allowing for inhibition of mast cell activation through 
LAIR1 as therapeutic targets. As mast cell activation was shown to specifically enhance 
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Th17 cell expansion, inhibition of mast cells using C1q has the potential to modulate 
chronic inflammatory diseases through its effect on Th17 responses.  
Another therapeutic target that we identified to influence T cell activation in 
autoimmune disease was through inhibition of the presentation of self -antigens to 
autoreactive T cells by modulation of the levels of Blimp-1, IRF4 or cathepsin S in 
dendritic cells. Although the expression or function of Blimp-1 or IRF4 in mast cells is not 
established, we observed increased gene expression of cathepsin S in mast cells after 
repeated stimulation through Fc receptors. Cathepsin S in mast cells has been shown to 
be involved in processing of granule proteases, but its role in antigen processing has not 
been studied (213). However, given its central role in antigen processing in other cell 
types, inhibitors of cathepsin S may potentially modulate antigen processing by mast cells 
during chronic inflammatory conditions. 
This thesis further shows that co-stimulation of T cells by mast cells is B7/CD28-
independent. Although blockade of CD28 co-stimulation by CTLA4-Ig (Abatacept) is an 
effective treatment for autoimmune diseases, inhibition of T cell activation with this 
therapy is not complete (214-217).  Furthermore, memory Th17 cells, an important T cell 
subset in various chronic inflammatory diseases, have been shown to be resistant to 
inhibition by CTLA-4-Ig, and a recent study indeed showed that treatment of RA patients 
with CTLA-4-Ig most potently inhibited Th1 responses and had no effect on Th17 cells  
(218, 219). This is interesting as we showed that mast cells specifically enhance Th17 
responses, and that T cell co-stimulation by mast cells was independent of B7/CD28. 
Therefore, blocking the interaction of antigen presenting cells and Th17 cells requires 
additional blockade besides B7/CD28, and inhibiting the interaction between mast cells 
and CD4
+
 T cells could potentially contribute to reducing Th17 cells. More research into 
the exact pathways that mediate T cell co-stimulation by mast cells may further 
contribute to inhibition of T cell activation in chronic inflammatory conditions.  
Another therapeutic strategy that could affect mast cell-mediated responses is the use of 
decoy antigens. We proposed in chapter 13 that the use of decoy antigens can reduce 
the chronicity of inflammatory responses by neutralization of autoantibodies. As 
reviewed in chapter 12, autoantibodies often target ubiquitously expressed intracellular 
molecules, which need to be released to the extracellular environment, to allow for 
binding by autoantibodies. This process can initiate inflammatory responses leading to 
tissue damage. Inflammation is sustained as the tissue damage can lead to additional 
release of self-antigen and DAMPs, which further activate myeloid cells and B cells, 
thereby creating a vicious cycle of tissue damage and autoantibody production. Decoy 
antigens can bind autoreactive B cell receptors and secreted antibodies, and should be 
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designed in such as way that they do not trigger TLRs. They can thereby block activation 
of B cells as well as myeloid cells, and can inhibit tissue damage employed by immune 
complexes.  
Although this strategy would not target mast cells specifically, they are an important 
target cell type in chronic inflammatory responses, as mast cells express only activating 
Fc receptors (in most tissues), and as they can release inflammatory cytokines as well as 
tissue modifying enzymes. We showed in this thesis that combined triggering through Fc 
receptors and TLR in mast cells can greatly enhance their cytokine release. Furthermore, 
repeated Fc receptor triggering augmented their responsiveness to TLR ligands. 
Therefore, blocking of Fc receptor activation in mast cells using decoy antigens has the 
potential to greatly reduce mast cell activation, also indirectly by reducing their response 
to DAMPs. Furthermore, repeated Fc receptor triggering led to a modulation of the mast 
cell response mode, characterized by upregulation of the expression of many genes 
involved in chronic inflammation, and it is likely that such effects are present in other cell 
types as well. Therefore, blocking Fc receptor activation might prevent the long-term 
effects of chronic activation on a cellular level, thereby breaking the vicious cycle of 
antibody-mediated inflammation. 
In conclusion, in this thesis I showed that mast cells can significantly contribute to 
chronic inflammation through their activation by Fc receptors and TLRs, as well as their 
interaction with CD4
+
 T cells, thereby increasing our understanding of their role in allergy 
and autoimmunity and providing several therapeutic targets to prevent mast cell -
mediated immune responses.  
REFERENCES 
1. Vogelpoel LT, Hansen IS, Rispens T et al., Fc 
gamma receptor-TLR cross-talk elicits pro-
inflammatory cytokine production by human M2 
macrophages. Nat Commun 5, 5444 (2014). 
2. den Dunnen J, Vogelpoel LT, Wypych T et al., 
IgG opsonization of bacteria promotes Th17 
responses via synergy between TLRs and 
FcgammaRIIa in human dendritic cells. Blood 120, 
112-21 (2012). 
3. Qiao H, Andrade MV, Lisboa FA, Morgan K, 
Beaven MA, FcepsilonR1 and toll-like receptors 
mediate synergistic signals to markedly augment 
production of inflammatory cytokines in murine 
mast cells. Blood 107, 610-8 (2006). 
4. O'Neill LA, Golenbock D, Bowie AG, The 
history of Toll-like receptors - redefining innate 
immunity. Nat Rev Immunol 13, 453-60 (2013). 
5. Abraham SN, St John AL, Mast cell-
orchestrated immunity to pathogens. Nat Rev 
Immunol 10, 440-52 (2010). 
6. Sylvestre DL, Ravetch JV, A dominant role for 
mast cell Fc receptors in the Arthus reaction. 
Immunity 5, 387-90 (1996). 
 
 
SUMMARY & DISCUSSION  |  311 
 14 
7. Macari DM, Teixeira MM, Hellewell PG, 
Priming of eosinophil recruitment in vivo by LPS 
pretreatment. J Immunol 157, 1684-92 (1996). 
8. Ding H, Nedrud JG, Wershil B et al., Partial 
protection against Helicobacter pylori in the absence 
of mast cells in mice. Infect Immun 77, 5543-50 
(2009). 
9. Velin D, Bachmann D, Bouzourene H, Michetti 
P, Mast cells are critical mediators of vaccine-
induced Helicobacter clearance in the mouse model. 
Gastroenterology 129, 142-55 (2005). 
10. Khalife J, Dunne DW, Richardson BA et al., 
Functional role of human IgG subclasses in 
eosinophil-mediated killing of schistosomula of 
Schistosoma mansoni. J Immunol 142, 4422-7 
(1989). 
11. Gaze S, Driguez P, Pearson MS et al., An 
immunomics approach to schistosome antigen 
discovery: antibody signatures of naturally resistant 
and chronically infected individuals from endemic 
areas. PLoS Pathog 10, e1004033 (2014). 
12. Grzych JM, Grezel D, Xu CB et al., IgA 
antibodies to a protective antigen in human 
Schistosomiasis mansoni. J Immunol 150, 527-35 
(1993). 
13. Abraham D, Leon O, Schnyder-Candrian S et 
al., Immunoglobulin E and eosinophil-dependent 
protective immunity to larval Onchocerca volvulus in 
mice immunized with irradiated larvae. Infect Immun 
72, 810-7 (2004). 
14. Gurish MF, Bryce PJ, Tao H et al., IgE enhances 
parasite clearance and regulates mast cell responses 
in mice infected with Trichinella spiralis. J Immunol 
172, 1139-45 (2004). 
15. Faulkner H, Turner J, Kamgno J et al., Age- and 
infection intensity-dependent cytokine and antibody 
production in human trichuriasis: the importance of 
IgE. J Infect Dis 185, 665-72 (2002). 
16. Rihet P, Demeure CE, Bourgois A, Prata A, 
Dessein AJ, Evidence for an association between 
human resistance to Schistosoma mansoni and high 
anti-larval IgE levels. Eur J Immunol 21, 2679-86 
(1991). 
17. Hagan P, Blumenthal UJ, Dunn D, Simpson AJ, 
Wilkins HA, Human IgE, IgG4 and resistance to 
reinfection with Schistosoma haematobium. Nature 
349, 243-5 (1991). 
18. Jiz M, Friedman JF, Leenstra T et al., 
Immunoglobulin E (IgE) responses to paramyosin 
predict resistance to reinfection with Schistosoma 
japonicum and are attenuated by IgG4. Infect Immun 
77, 2051-8 (2009). 
19. Joulia R, Gaudenzio N, Rodrigues M et al., 
Mast cells form antibody-dependent degranulatory 
synapse for dedicated secretion and defence. Nat 
Commun 6, 6174 (2015). 
20. Schramm G, Mohrs K, Wodrich M et al., 
Cutting edge: IPSE/alpha-1, a glycoprotein from 
Schistosoma mansoni eggs, induces IgE-dependent, 
antigen-independent IL-4 production by murine 
basophils in vivo. J Immunol 178, 6023-7 (2007). 
21. Patella V, Florio G, Petraroli A, Marone G, HIV-
1 gp120 induces IL-4 and IL-13 release from human 
Fc epsilon RI+ cells through interaction with the VH3 
region of IgE. J Immunol 164, 589-95 (2000). 
22. van der Kleij D, Latz E, Brouwers JF et al., A 
novel host-parasite lipid cross-talk. Schistosomal 
lyso-phosphatidylserine activates toll-like receptor 2 
and affects immune polarization. J Biol Chem 277, 
48122-9 (2002). 
23. Goodridge HS, Marshall FA, Else KJ et al., 
Immunomodulation via novel use of TLR4 by the 
filarial nematode phosphorylcholine-containing 
secreted product, ES-62. J Immunol 174, 284-93 
(2005). 
24. Thomas PG, Carter MR, Atochina O et al., 
Maturation of dendritic cell 2 phenotype by a 
helminth glycan uses a Toll-like receptor 4-
dependent mechanism. J Immunol 171, 5837-41 
(2003). 
25. Akira S, Uematsu S, Takeuchi O, Pathogen 
recognition and innate immunity. Cell 124, 783-801 
(2006). 
26. Urban CF, Lourido S, Zychlinsky A, How do 
microbes evade neutrophil killing? Cell Microbiol 8, 
1687-96 (2006). 
312  |  CHAPTER 14 
27. Sutherland RE, Olsen JS, McKinstry A, Villalta 
SA, Wolters PJ, Mast cell IL-6 improves survival from 
Klebsiella pneumonia and sepsis by enhancing 
neutrophil killing. J Immunol 181, 5598-605 (2008). 
28. Malaviya R, Ikeda T, Ross E, Abraham SN, Mast 
cell modulation of neutrophil influx and bacterial 
clearance at sites of infection through TNF-alpha. 
Nature 381, 77-80 (1996). 
29. Sakamoto Y, Hiromatsu K, Ishiwata K et al., 
Chronic intestinal nematode infection induces Stat6-
independent interleukin-5 production and causes 
eosinophilic inflammatory responses in mice. 
Immunology 112, 615-23 (2004). 
30. Le Goff L, Loke P, Ali HF, Taylor DW, Allen JE, 
Interleukin-5 is essential for vaccine-mediated 
immunity but not innate resistance to a filarial 
parasite. Infect Immun 68, 2513-7 (2000). 
31. Oeser K, Schwartz C, Voehringer D, 
Conditional IL-4/IL-13-deficient mice reveal a critical 
role of innate immune cells for protective immunity 
against gastrointestinal helminths. Mucosal 
Immunol,  (2014). 
32. De Filippo K, Dudeck A, Hasenberg M et al., 
Mast cell and macrophage chemokines CXCL1/CXCL2 
control the early stage of neutrophil recruitment 
during tissue inflammation. Blood 121, 4930-7 
(2013). 
33. Rodriguez AR, Yu JJ, Guentzel MN et al., Mast 
cell TLR2 signaling is crucial for effective killing of 
Francisella tularensis. J Immunol 188, 5604-11 
(2012). 
34. Bischoff SC, Role of mast cells in allergic and 
non-allergic immune responses: comparison of 
human and murine data. Nat Rev Immunol 7, 93-104 
(2007). 
35. Orinska Z, Bulanova E, Budagian V et al., TLR3-
induced activation of mast cells modulates CD8+ T-
cell recruitment. Blood 106, 978-87 (2005). 
36. St John AL, Rathore AP, Yap H et al., Immune 
surveillance by mast cells during dengue infection 
promotes natural killer (NK) and NKT-cell 
recruitment and viral clearance. Proc Natl Acad Sci U 
S A 108, 9190-5 (2011). 
37. Burke SM, Issekutz TB, Mohan K et al., Human 
mast cell activation with virus-associated stimuli 
leads to the selective chemotaxis of natural killer 
cells by a CXCL8-dependent mechanism. Blood 111, 
5467-76 (2008). 
38. Su YC, Townsend D, Herrero LJ et al., Dual 
proinflammatory and antiviral properties of 
pulmonary eosinophils in respiratory syncytial virus 
vaccine-enhanced disease. J Virol 89, 1564-78 
(2015). 
39. Percopo CM, Dyer KD, Ochkur SI et al., 
Activated mouse eosinophils protect against lethal 
respiratory virus infection. Blood 123, 743-52 (2014). 
40. Phipps S, Lam CE, Mahalingam S et al., 
Eosinophils contribute to innate antiviral immunity 
and promote clearance of respiratory syncytial virus. 
Blood 110, 1578-86 (2007). 
41. Domachowske JB, Dyer KD, Adams AG, Leto 
TL, Rosenberg HF, Eosinophil cationic protein/RNase 
3 is another RNase A-family ribonuclease with direct 
antiviral activity. Nucleic Acids Res 26, 3358-63 
(1998). 
42. Domachowske JB, Dyer KD, Bonville CA, 
Rosenberg HF, Recombinant human eosinophil-
derived neurotoxin/RNase 2 functions as an effective 
antiviral agent against respiratory syncytial virus. J 
Infect Dis 177, 1458-64 (1998). 
43. Rugeles MT, Trubey CM, Bedoya VI et al., 
Ribonuclease is partly responsible for the HIV-1 
inhibitory effect activated by HLA alloantigen 
recognition. AIDS 17, 481-6 (2003). 
44. Tripathi S, White MR, Hartshorn KL, The 
amazing innate immune response to influenza A 
virus infection. Innate Immun 21, 73-98 (2015). 
45. Saitoh T, Komano J, Saitoh Y et al., Neutrophil 
extracellular traps mediate a host defense response 
to human immunodeficiency virus-1. Cell Host 
Microbe 12, 109-16 (2012). 
46. Hashimoto Y, Moki T, Takizawa T, Shiratsuchi 
A, Nakanishi Y, Evidence for phagocytosis of 
influenza virus-infected, apoptotic cells by 
neutrophils and macrophages in mice. J Immunol 
178, 2448-57 (2007). 
 
 
SUMMARY & DISCUSSION  |  313 
 14 
47. Kadowaki N, Ho S, Antonenko S et al., Subsets 
of human dendritic cell precursors express different 
toll-like receptors and respond to different microbial 
antigens. J Exp Med 194, 863-9 (2001). 
48. Jarrossay D, Napolitani G, Colonna M, Sallusto 
F, Lanzavecchia A, Specialization and 
complementarity in microbial molecule recognition 
by human myeloid and plasmacytoid dendritic cells. 
Eur J Immunol 31, 3388-93 (2001). 
49. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, 
Lanzavecchia A, Selected Toll-like receptor agonist 
combinations synergistically trigger a T helper type 
1-polarizing program in dendritic cells. Nat Immunol 
6, 769-76 (2005). 
50. Message SD, Laza-Stanca V, Mallia P et al., 
Rhinovirus-induced lower respiratory illness is 
increased in asthma and related to virus load and 
Th1/2 cytokine and IL-10 production. Proc Natl Acad 
Sci U S A 105, 13562-7 (2008). 
51. Sykes A, Johnston SL, Etiology of asthma 
exacerbations. J Allergy Clin Immunol 122, 685-8 
(2008). 
52. Willart MA, Lambrecht BN, The danger within: 
endogenous danger signals, atopy and asthma. Clin 
Exp Allergy 39, 12-9 (2009). 
53. Michel O, Kips J, Duchateau J et al., Severity of 
asthma is related to endotoxin in house dust. Am J 
Respir Crit Care Med 154, 1641-6 (1996). 
54. Trompette A, Divanovic S, Visintin A et al., 
Allergenicity resulting from functional mimicry of a 
Toll-like receptor complex protein. Nature 457, 585-
8 (2009). 
55. Zhu J, Yamane H, Paul WE, Differentiation of 
effector CD4 T cell populations (*). Annu Rev 
Immunol 28, 445-89 (2010). 
56. Liang G, Barker T, Xie Z et al., Naive T cells 
sense the cysteine protease allergen papain through 
protease-activated receptor 2 and propel TH2 
immunity. J Allergy Clin Immunol 129, 1377-86 e13 
(2012). 
57. Halim TY, Steer CA, Matha L et al., Group 2 
innate lymphoid cells are critical for the initiation of 
adaptive T helper 2 cell-mediated allergic lung 
inflammation. Immunity 40, 425-35 (2014). 
58. Hammad H, Plantinga M, Deswarte K et al., 
Inflammatory dendritic cells--not basophils--are 
necessary and sufficient for induction of Th2 
immunity to inhaled house dust mite allergen. J Exp 
Med 207, 2097-111 (2010). 
59. Liu AH, Endotoxin exposure in allergy and 
asthma: reconciling a paradox. J Allergy Clin Immunol 
109, 379-92 (2002). 
60. Matricardi PM, Rosmini F, Riondino S et al., 
Exposure to foodborne and orofecal microbes versus 
airborne viruses in relation to atopy and allergic 
asthma: epidemiological study. BMJ 320, 412-7 
(2000). 
61. Riedler J, Braun-Fahrlander C, Eder W et al., 
Exposure to farming in early life and development of 
asthma and allergy: a cross-sectional survey. Lancet 
358, 1129-33 (2001). 
62. Gereda JE, Leung DY, Thatayatikom A et al., 
Relation between house-dust endotoxin exposure, 
type 1 T-cell development, and allergen sensitisation 
in infants at high risk of asthma. Lancet 355, 1680-3 
(2000). 
63. Tulic MK, Wale JL, Holt PG, Sly PD, 
Modification of the inflammatory response to 
allergen challenge after exposure to bacterial 
lipopolysaccharide. Am J Respir Cell Mol Biol 22, 604-
12 (2000). 
64. Langenkamp A, Messi M, Lanzavecchia A, 
Sallusto F, Kinetics of dendritic cell activation: impact 
on priming of TH1, TH2 and nonpolarized T cells. Nat 
Immunol 1, 311-6 (2000). 
65. Manetti R, Parronchi P, Giudizi MG et al., 
Natural killer cell stimulatory factor (interleukin 12 
[IL-12]) induces T helper type 1 (Th1)-specific 
immune responses and inhibits the development of 
IL-4-producing Th cells. J Exp Med 177, 1199-204 
(1993). 
66. Eisenbarth SC, Piggott DA, Huleatt JW et al., 
Lipopolysaccharide-enhanced, toll-like receptor 4-
dependent T helper cell type 2 responses to inhaled 
antigen. J Exp Med 196, 1645-51 (2002). 
314  |  CHAPTER 14 
67. Schmidt M, Raghavan B, Muller V et al., 
Crucial role for human Toll-like receptor 4 in the 
development of contact allergy to nickel. Nat 
Immunol 11, 814-9 (2010). 
68. Rosenstein RK, Bezbradica JS, Yu S, Medzhitov 
R, Signaling pathways activated by a protease 
allergen in basophils. Proc Natl Acad Sci U S A 111, 
E4963-71 (2014). 
69. Eldridge MW, Peden DB, Allergen provocation 
augments endotoxin-induced nasal inflammation in 
subjects with atopic asthma. J Allergy Clin Immunol 
105, 475-81 (2000). 
70. Michel O, Ginanni R, Le Bon B, Duchateau J, 
Effect of endotoxin contamination on the antigenic 
skin test response. Ann Allergy 66, 39-42 (1991). 
71. Nigo YI, Yamashita M, Hirahara K et al., 
Regulation of allergic airway inflammation through 
Toll-like receptor 4-mediated modification of mast 
cell function. Proc Natl Acad Sci U S A 103, 2286-91 
(2006). 
72. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, 
Young IG, Interleukin 5 deficiency abolishes 
eosinophilia, airways hyperreactivity, and lung 
damage in a mouse asthma model. J Exp Med 183, 
195-201 (1996). 
73. Weber FC, Nemeth T, Csepregi JZ et al., 
Neutrophils are required for both the sensitization 
and elicitation phase of contact hypersensitivity. J 
Exp Med 212, 15-22 (2015). 
74. Moore ML, Newcomb DC, Parekh VV et al., 
STAT1 negatively regulates lung basophil IL-4 
expression induced by respiratory syncytial virus 
infection. J Immunol 183, 2016-26 (2009). 
75. Schroeder JT, Lichtenstein LM, Roche EM, Xiao 
H, Liu MC, IL-4 production by human basophils found 
in the lung following segmental allergen challenge. J 
Allergy Clin Immunol 107, 265-71 (2001). 
76. Mukai K, Matsuoka K, Taya C et al., Basophils 
play a critical role in the development of IgE-
mediated chronic allergic inflammation 
independently of T cells and mast cells. Immunity 23, 
191-202 (2005). 
77. Seong SY, Matzinger P, Hydrophobicity: an 
ancient damage-associated molecular pattern that 
initiates innate immune responses. Nat Rev Immunol 
4, 469-78 (2004). 
78. Chen CJ, Kono H, Golenbock D et al., 
Identification of a key pathway required for the 
sterile inflammatory response triggered by dying 
cells. Nat Med 13, 851-6 (2007). 
79. Gondokaryono SP, Ushio H, Niyonsaba F et al., 
The extra domain A of fibronectin stimulates murine 
mast cells via toll-like receptor 4. J Leukoc Biol 82, 
657-65 (2007). 
80. Midwood K, Sacre S, Piccinini AM et al., 
Tenascin-C is an endogenous activator of Toll-like 
receptor 4 that is essential for maintaining 
inflammation in arthritic joint disease. Nat Med 15, 
774-80 (2009). 
81. Piccinini AM, Midwood KS, DAMPening 
inflammation by modulating TLR signalling. 
Mediators Inflamm 2010,  (2010). 
82. Reynolds JM, Martinez GJ, Chung Y, Dong C, 
Toll-like receptor 4 signaling in T cells promotes 
autoimmune inflammation. Proc Natl Acad Sci U S A 
109, 13064-9 (2012). 
83. Shi G, Vistica BP, Nugent LF et al., Differential 
involvement of Th1 and Th17 in pathogenic 
autoimmune processes triggered by different TLR 
ligands. J Immunol 191, 415-23 (2013). 
84. Viglianti GA, Lau CM, Hanley TM et al., 
Activation of autoreactive B cells by CpG dsDNA. 
Immunity 19, 837-47 (2003). 
85. Ehlers M, Fukuyama H, McGaha TL, Aderem A, 
Ravetch JV, TLR9/MyD88 signaling is required for 
class switching to pathogenic IgG2a and 2b 
autoantibodies in SLE. J Exp Med 203, 553-61 (2006). 
86. Christensen SR, Shupe J, Nickerson K et al., 
Toll-like receptor 7 and TLR9 dictate autoantibody 
specificity and have opposing inflammatory and 
regulatory roles in a murine model of lupus. 
Immunity 25, 417-28 (2006). 
87. Lau CM, Broughton C, Tabor AS et al., RNA-
associated autoantigens activate B cells by combined 
 
 
SUMMARY & DISCUSSION  |  315 
 14 
B cell antigen receptor/Toll-like receptor 7 
engagement. J Exp Med 202, 1171-7 (2005). 
88. Chaturvedi A, Dorward D, Pierce SK, The B cell 
receptor governs the subcellular location of Toll-like 
receptor 9 leading to hyperresponses to DNA-
containing antigens. Immunity 28, 799-809 (2008). 
89. Reynolds JM, Pappu BP, Peng J et al., Toll-like 
receptor 2 signaling in CD4(+) T lymphocytes 
promotes T helper 17 responses and regulates the 
pathogenesis of autoimmune disease. Immunity 32, 
692-702 (2010). 
90. Mills KH, TLR-dependent T cell activation in 
autoimmunity. Nat Rev Immunol 11, 807-22 (2011). 
91. Pierangeli SS, Vega-Ostertag ME, Raschi E et 
al., Toll-like receptor and antiphospholipid mediated 
thrombosis: in vivo studies. Ann Rheum Dis 66, 1327-
33 (2007). 
92. Abdollahi-Roodsaz S, Joosten LA, Roelofs MF 
et al., Inhibition of Toll-like receptor 4 breaks the 
inflammatory loop in autoimmune destructive 
arthritis. Arthritis Rheum 56, 2957-67 (2007). 
93. Abdollahi-Roodsaz S, Koenders MI, Walgreen 
B et al., Toll-like receptor 2 controls acute immune 
complex-driven arthritis in mice by regulating the 
inhibitory Fcgamma receptor IIB. Arthritis Rheum 65, 
2583-93 (2013). 
94. Kim HS, Chung DH, TLR4-mediated IL-12 
production enhances IFN-gamma and IL-1beta 
production, which inhibits TGF-beta production and 
promotes antibody-induced joint inflammation. 
Arthritis Res Ther 14, R210 (2012). 
95. Kaur D, Gomez E, Doe C et al., IL-33 drives 
airway hyper-responsiveness through IL-13-
mediated mast cell: airway smooth muscle crosstalk. 
Allergy,  (2015). 
96. Nagarkar DR, Ramirez-Carrozzi V, Choy DF et 
al., IL-13 mediates IL-33-dependent mast cell and 
type 2 innate lymphoid cell effects on bronchial 
epithelial cells. J Allergy Clin Immunol,  (2015). 
97. Sjoberg LC, Gregory JA, Dahlen SE, Nilsson GP, 
Adner M, Interleukin-33 exacerbates allergic 
bronchoconstriction in the mice via activation of 
mast cells. Allergy,  (2015). 
98. Christianson CA, Goplen NP, Zafar I et al., 
Persistence of asthma requires multiple feedback 
circuits involving type 2 innate lymphoid cells and IL-
33. J Allergy Clin Immunol,  (2015). 
99. Van Dyken SJ, Locksley RM, Interleukin-4- and 
interleukin-13-mediated alternatively activated 
macrophages: roles in homeostasis and disease. 
Annu Rev Immunol 31, 317-43 (2013). 
100. Egawa M, Mukai K, Yoshikawa S et al., 
Inflammatory monocytes recruited to allergic skin 
acquire an anti-inflammatory M2 phenotype via 
basophil-derived interleukin-4. Immunity 38, 570-80 
(2013). 
101. Barbour M, Allan D, Xu H et al., IL-33 
attenuates the development of experimental 
autoimmune uveitis. Eur J Immunol 44, 3320-9 
(2014). 
102. Milovanovic M, Volarevic V, Ljujic B et al., 
Deletion of IL-33R (ST2) abrogates resistance to EAE 
in BALB/C mice by enhancing polarization of APC to 
inflammatory phenotype. PLoS One 7, e45225 
(2012). 
103. Jiang HR, Milovanovic M, Allan D et al., IL-33 
attenuates EAE by suppressing IL-17 and IFN-gamma 
production and inducing alternatively activated 
macrophages. Eur J Immunol 42, 1804-14 (2012). 
104. Zaiss MM, Kurowska-Stolarska M, Bohm C et 
al., IL-33 shifts the balance from osteoclast to 
alternatively activated macrophage differentiation 
and protects from TNF-alpha-mediated bone loss. J 
Immunol 186, 6097-105 (2011). 
105. Xu D, Jiang HR, Kewin P et al., IL-33 
exacerbates antigen-induced arthritis by activating 
mast cells. Proc Natl Acad Sci U S A 105, 10913-8 
(2008). 
106. Palmer G, Talabot-Ayer D, Lamacchia C et al., 
Inhibition of interleukin-33 signaling attenuates the 
severity of experimental arthritis. Arthritis Rheum 
60, 738-49 (2009). 
107. Leung BP, Xu D, Culshaw S, McInnes IB, Liew 
FY, A novel therapy of murine collagen-induced 
arthritis with soluble T1/ST2. J Immunol 173, 145-50 
(2004). 
316  |  CHAPTER 14 
108. Xu D, Jiang HR, Li Y et al., IL-33 exacerbates 
autoantibody-induced arthritis. J Immunol 184, 
2620-6 (2010). 
109. Martin P, Talabot-Ayer D, Seemayer CA et al., 
Disease severity in K/BxN serum transfer-induced 
arthritis is not affected by IL-33 deficiency. Arthritis 
Res Ther 15, R13 (2013). 
110. Anthony RM, Kobayashi T, Wermeling F, 
Ravetch JV, Intravenous gammaglobulin suppresses 
inflammation through a novel T(H)2 pathway. Nature 
475, 110-3 (2011). 
111. Tjon AS, van Gent R, Jaadar H et al., 
Intravenous immunoglobulin treatment in humans 
suppresses dendritic cell function via stimulation of 
IL-4 and IL-13 production. J Immunol 192, 5625-34 
(2014). 
112. Kambayashi T, Laufer TM, Atypical MHC class 
II-expressing antigen-presenting cells: can anything 
replace a dendritic cell? Nat Rev Immunol 14, 719-30 
(2014). 
113. Kashiwakura J, Yokoi H, Saito H, Okayama Y, T 
cell proliferation by direct cross-talk between OX40 
ligand on human mast cells and OX40 on human T 
cells: comparison of gene expression profiles 
between human tonsillar and lung-cultured mast 
cells. J Immunol 173, 5247-57 (2004). 
114. Malaviya R, Twesten NJ, Ross EA, Abraham SN, 
Pfeifer JD, Mast cells process bacterial Ags through a 
phagocytic route for class I MHC presentation to T 
cells. J Immunol 156, 1490-6 (1996). 
115. Kambayashi T, Allenspach EJ, Chang JT et al., 
Inducible MHC class II expression by mast cells 
supports effector and regulatory T cell activation. J 
Immunol 182, 4686-95 (2009). 
116. Banchereau J, Steinman RM, Dendritic cells 
and the control of immunity. Nature 392, 245-52 
(1998). 
117. Gaudenzio N, Espagnolle N, Mars LT et al., 
Cell-cell cooperation at the T helper cell/mast cell 
immunological synapse. Blood 114, 4979-88 (2009). 
118. Gong J, Yang NS, Croft M et al., The antigen 
presentation function of bone marrow-derived mast 
cells is spatiotemporally restricted to a subset 
expressing high levels of cell surface FcepsilonRI and 
MHC II. BMC Immunol 11, 34 (2010). 
119. Kambayashi T, Baranski JD, Baker RG et al., 
Indirect involvement of allergen-captured mast cells 
in antigen presentation. Blood 111, 1489-96 (2008). 
120. Suto H, Nakae S, Kakurai M et al., Mast cell-
associated TNF promotes dendritic cell migration. J 
Immunol 176, 4102-12 (2006). 
121. Nakae S, Suto H, Kakurai M et al., Mast cells 
enhance T cell activation: Importance of mast cell-
derived TNF. Proc Natl Acad Sci U S A 102, 6467-72 
(2005). 
122. Kunder CA, St John AL, Li G et al., Mast cell-
derived particles deliver peripheral signals to remote 
lymph nodes. J Exp Med 206, 2455-67 (2009). 
123. McLachlan JB, Hart JP, Pizzo SV et al., Mast 
cell-derived tumor necrosis factor induces 
hypertrophy of draining lymph nodes during 
infection. Nat Immunol 4, 1199-205 (2003). 
124. de Vries VC, Pino-Lagos K, Nowak EC et al., 
Mast cells condition dendritic cells to mediate 
allograft tolerance. Immunity 35, 550-61 (2011). 
125. Maurer M, Lopez Kostka S, Siebenhaar F et al., 
Skin mast cells control T cell-dependent host 
defense in Leishmania major infections. FASEB J 20, 
2460-7 (2006). 
126. Reuter S, Dehzad N, Martin H et al., Mast cells 
induce migration of dendritic cells in a murine model 
of acute allergic airway disease. Int Arch Allergy 
Immunol 151, 214-22 (2010). 
127. Guermonprez P, Helft J, Claser C et al., 
Inflammatory Flt3l is essential to mobilize dendritic 
cells and for T cell responses during Plasmodium 
infection. Nat Med 19, 730-8 (2013). 
128. Shelburne CP, Nakano H, St John AL et al., 
Mast cells augment adaptive immunity by 
orchestrating dendritic cell trafficking through 
infected tissues. Cell Host Microbe 6, 331-42 (2009). 
129. Otsuka A, Kubo M, Honda T et al., 
Requirement of interaction between mast cells and 
skin dendritic cells to establish contact 
hypersensitivity. PLoS One 6, e25538 (2011). 
 
 
SUMMARY & DISCUSSION  |  317 
 14 
130. Jawdat DM, Rowden G, Marshall JS, Mast cells 
have a pivotal role in TNF-independent lymph node 
hypertrophy and the mobilization of Langerhans 
cells in response to bacterial peptidoglycan. J 
Immunol 177, 1755-62 (2006). 
131. Nowak EC, de Vries VC, Wasiuk A et al., 
Tryptophan hydroxylase-1 regulates immune 
tolerance and inflammation. J Exp Med 209, 2127-35 
(2012). 
132. Lu LF, Lind EF, Gondek DC et al., Mast cells are 
essential intermediaries in regulatory T-cell 
tolerance. Nature 442, 997-1002 (2006). 
133. Chacon-Salinas R, Limon-Flores AY, Chavez-
Blanco AD, Gonzalez-Estrada A, Ullrich SE, Mast cell-
derived IL-10 suppresses germinal center formation 
by affecting T follicular helper cell function. J 
Immunol 186, 25-31 (2011). 
134. Gan PY, Summers SA, Ooi JD et al., Mast cells 
contribute to peripheral tolerance and attenuate 
autoimmune vasculitis. J Am Soc Nephrol 23, 1955-
66 (2012). 
135. Chan CY, St John AL, Abraham SN, Mast cell 
interleukin-10 drives localized tolerance in chronic 
bladder infection. Immunity 38, 349-59 (2013). 
136. Depinay N, Hacini F, Beghdadi W, Peronet R, 
Mecheri S, Mast cell-dependent down-regulation of 
antigen-specific immune responses by mosquito 
bites. J Immunol 176, 4141-6 (2006). 
137. Gri G, Piconese S, Frossi B et al., CD4+CD25+ 
regulatory T cells suppress mast cell degranulation 
and allergic responses through OX40-OX40L 
interaction. Immunity 29, 771-81 (2008). 
138. Kashyap M, Thornton AM, Norton SK et al., 
Cutting edge: CD4 T cell-mast cell interactions alter 
IgE receptor expression and signaling. J Immunol 
180, 2039-43 (2008). 
139. Frossi B, D'Inca F, Crivellato E et al., Single-cell 
dynamics of mast cell-CD4+ CD25+ regulatory T cell 
interactions. Eur J Immunol 41, 1872-82 (2011). 
140. Su W, Fan H, Chen M et al., Induced CD4+ 
forkhead box protein-positive T cells inhibit mast cell 
function and established contact hypersensitivity 
through TGF-beta1. J Allergy Clin Immunol 130, 444-
52 e7 (2012). 
141. Ganeshan K, Bryce PJ, Regulatory T cells 
enhance mast cell production of IL-6 via surface-
bound TGF-beta. J Immunol 188, 594-603 (2012). 
142. Gregory GD, Robbie-Ryan M, Secor VH, 
Sabatino JJ, Jr., Brown MA, Mast cells are required 
for optimal autoreactive T cell responses in a murine 
model of multiple sclerosis. Eur J Immunol 35, 3478-
86 (2005). 
143. Schubert N, Dudeck J, Liu P et al., Mast cells 
promote T cell driven antigen-induced arthritis 
despite being dispensable in T cell bypassing 
antibody-induced arthritis. Arthritis Rheumatol,  
(2014). 
144. Forward NA, Furlong SJ, Yang Y, Lin TJ, Hoskin 
DW, Mast cells down-regulate CD4+CD25+ T 
regulatory cell suppressor function via histamine H1 
receptor interaction. J Immunol 183, 3014-22 (2009). 
145. Piconese S, Gri G, Tripodo C et al., Mast cells 
counteract regulatory T-cell suppression through 
interleukin-6 and OX40/OX40L axis toward Th17-cell 
differentiation. Blood 114, 2639-48 (2009). 
146. Nakae S, Saijo S, Horai R et al., IL-17 
production from activated T cells is required for the 
spontaneous development of destructive arthritis in 
mice deficient in IL-1 receptor antagonist. Proc Natl 
Acad Sci U S A 100, 5986-90 (2003). 
147. Nakae S, Nambu A, Sudo K, Iwakura Y, 
Suppression of immune induction of collagen-
induced arthritis in IL-17-deficient mice. J Immunol 
171, 6173-7 (2003). 
148. Nakae S, Komiyama Y, Nambu A et al., 
Antigen-specific T cell sensitization is impaired in IL-
17-deficient mice, causing suppression of allergic 
cellular and humoral responses. Immunity 17, 375-
87 (2002). 
149. Batten M, Li J, Yi S et al., Interleukin 27 limits 
autoimmune encephalomyelitis by suppressing the 
development of interleukin 17-producing T cells. Nat 
Immunol 7, 929-36 (2006). 
150. Molet S, Hamid Q, Davoine F et al., IL-17 is 
increased in asthmatic airways and induces human 
318  |  CHAPTER 14 
bronchial fibroblasts to produce cytokines. J Allergy 
Clin Immunol 108, 430-8 (2001). 
151. Wilson RH, Whitehead GS, Nakano H et al., 
Allergic sensitization through the airway primes 
Th17-dependent neutrophilia and airway 
hyperresponsiveness. Am J Respir Crit Care Med 180, 
720-30 (2009). 
152. Cosmi L, Liotta F, Maggi E, Romagnani S, 
Annunziato F, Th17 cells: new players in asthma 
pathogenesis. Allergy 66, 989-98 (2011). 
153. Patel DD, Lee DM, Kolbinger F, Antoni C, Effect 
of IL-17A blockade with secukinumab in autoimmune 
diseases. Ann Rheum Dis 72 Suppl 2, ii116-23 (2013). 
154. Kodera M, Hasegawa M, Komura K et al., 
Serum pulmonary and activation-regulated 
chemokine/CCL18 levels in patients with systemic 
sclerosis: a sensitive indicator of active pulmonary 
fibrosis. Arthritis Rheum 52, 2889-96 (2005). 
155. Xanthou G, Polihronis M, Tzioufas AG et al., 
"Lymphoid" chemokine messenger RNA expression 
by epithelial cells in the chronic inflammatory lesion 
of the salivary glands of Sjogren's syndrome 
patients: possible participation in lymphoid structure 
formation. Arthritis Rheum 44, 408-18 (2001). 
156. Schutyser E, Richmond A, Van Damme J, 
Involvement of CC chemokine ligand 18 (CCL18) in 
normal and pathological processes. J Leukoc Biol 78, 
14-26 (2005). 
157. Adema GJ, Hartgers F, Verstraten R et al., A 
dendritic-cell-derived C-C chemokine that 
preferentially attracts naive T cells. Nature 387, 713-
7 (1997). 
158. Gunther C, Bello-Fernandez C, Kopp T et al., 
CCL18 is expressed in atopic dermatitis and mediates 
skin homing of human memory T cells. J Immunol 
174, 1723-8 (2005). 
159. Islam SA, Ling MF, Leung J, Shreffler WG, 
Luster AD, Identification of human CCR8 as a CCL18 
receptor. J Exp Med 210, 1889-98 (2013). 
160. de Nadai P, Charbonnier AS, Chenivesse C et 
al., Involvement of CCL18 in allergic asthma. J 
Immunol 176, 6286-93 (2006). 
161. Zlotnik A, Yoshie O, Chemokines: a new 
classification system and their role in immunity. 
Immunity 12, 121-7 (2000). 
162. Tsai S, Santamaria P, MHC Class II 
Polymorphisms, Autoreactive T-Cells, and 
Autoimmunity. Front Immunol 4, 321 (2013). 
163. Irigoyen P, Lee AT, Wener MH et al., 
Regulation of anti-cyclic citrullinated peptide 
antibodies in rheumatoid arthritis: contrasting 
effects of HLA-DR3 and the shared epitope alleles. 
Arthritis Rheum 52, 3813-8 (2005). 
164. van Heemst J, Jansen DT, Polydorides S et al., 
Crossreactivity to vinculin and microbes provides a 
molecular basis for HLA-based protection against 
rheumatoid arthritis. Nat Commun 6, 6681 (2015). 
165. Kontakioti E, Domvri K, Papakosta D, Daniilidis 
M, HLA and asthma phenotypes/endotypes: a 
review. Hum Immunol 75, 930-9 (2014). 
166. McCormack WJ, Parker AE, O'Neill LA, Toll-like 
receptors and NOD-like receptors in rheumatic 
diseases. Arthritis Res Ther 11, 243 (2009). 
167. Huang Q, Ma Y, Adebayo A, Pope RM, 
Increased macrophage activation mediated through 
toll-like receptors in rheumatoid arthritis. Arthritis 
Rheum 56, 2192-201 (2007). 
168. English WR, Velasco G, Stracke JO, Knauper V, 
Murphy G, Catalytic activities of membrane-type 6 
matrix metalloproteinase (MMP25). FEBS Lett 491, 
137-42 (2001). 
169. Chang X, Zhao Y, Wang Y, Chen Y, Yan X, 
Screening citrullinated proteins in synovial tissues of 
rheumatoid arthritis using 2-dimensional western 
blotting. J Rheumatol 40, 219-27 (2013). 
170. Wegner N, Lundberg K, Kinloch A et al., 
Autoimmunity to specific citrullinated proteins gives 
the first clues to the etiology of rheumatoid arthritis. 
Immunol Rev 233, 34-54 (2010). 
171. Wang KX, Denhardt DT, Osteopontin: role in 
immune regulation and stress responses. Cytokine 
Growth Factor Rev 19, 333-45 (2008). 
172. Magarinos NJ, Bryant KJ, Fosang AJ et al., Mast 
cell-restricted, tetramer-forming tryptases induce 
 
 
SUMMARY & DISCUSSION  |  319 
 14 
aggrecanolysis in articular cartilage by activating 
matrix metalloproteinase-3 and -13 zymogens. J 
Immunol 191, 1404-12 (2013). 
173. Van Wart HE, Birkedal-Hansen H, The cysteine 
switch: a principle of regulation of metalloproteinase 
activity with potential applicability to the entire 
matrix metalloproteinase gene family. Proc Natl 
Acad Sci U S A 87, 5578-82 (1990). 
174. Zenmyo M, Hiraoka K, Komiya S, Morimatsu 
M, Sasaguri Y, Histamine-stimulated production of 
matrix metalloproteinase 1 by human rheumatoid 
synovial fibroblasts is mediated by histamine H1-
receptors. Virchows Arch 427, 437-44 (1995). 
175. Atamas SP, Luzina IG, Choi J et al., Pulmonary 
and activation-regulated chemokine stimulates 
collagen production in lung fibroblasts. Am J Respir 
Cell Mol Biol 29, 743-9 (2003). 
176. Bulfone-Paus S, Paus R, Osteopontin as a new 
player in mast cell biology. Eur J Immunol 38, 338-41 
(2008). 
177. Denhardt DT, Noda M, O'Regan AW, Pavlin D, 
Berman JS, Osteopontin as a means to cope with 
environmental insults: regulation of inflammation, 
tissue remodeling, and cell survival. J Clin Invest 107, 
1055-61 (2001). 
178. Mori R, Shaw TJ, Martin P, Molecular 
mechanisms linking wound inflammation and 
fibrosis: knockdown of osteopontin leads to rapid 
repair and reduced scarring. J Exp Med 205, 43-51 
(2008). 
179. Berman JS, Serlin D, Li X et al., Altered 
bleomycin-induced lung fibrosis in osteopontin-
deficient mice. Am J Physiol Lung Cell Mol Physiol 
286, L1311-8 (2004). 
180. Samitas K, Zervas E, Vittorakis S et al., 
Osteopontin expression and relation to disease 
severity in human asthma. Eur Respir J 37, 331-41 
(2011). 
181. Xanthou G, Alissafi T, Semitekolou M et al., 
Osteopontin has a crucial role in allergic airway 
disease through regulation of dendritic cell subsets. 
Nat Med 13, 570-8 (2007). 
182. Simoes DC, Xanthou G, Petrochilou K et al., 
Osteopontin deficiency protects against airway 
remodeling and hyperresponsiveness in chronic 
asthma. Am J Respir Crit Care Med 179, 894-902 
(2009). 
183. Hon KL, Ching GK, Ng PC, Leung TF, Exploring 
CCL18, eczema severity and atopy. Pediatr Allergy 
Immunol 22, 704-7 (2011). 
184. Kollert F, Binder M, Probst C et al., CCL18 -- 
potential biomarker of fibroinflammatory activity in 
chronic periaortitis. J Rheumatol 39, 1407-12 (2012). 
185. Kim HB, Kim CK, Iijima K, Kobayashi T, Kita H, 
Protein microarray analysis in patients with asthma: 
elevation of the chemokine PARC/CCL18 in sputum. 
Chest 135, 295-302 (2009). 
186. Prasse A, Pechkovsky DV, Toews GB et al., 
CCL18 as an indicator of pulmonary fibrotic activity 
in idiopathic interstitial pneumonias and systemic 
sclerosis. Arthritis Rheum 56, 1685-93 (2007). 
187. Yang IV, Tomfohr J, Singh J et al., The clinical 
and environmental determinants of airway 
transcriptional profiles in allergic asthma. Am J 
Respir Crit Care Med 185, 620-7 (2012). 
188. Gavala ML, Kelly EA, Esnault S et al., 
Segmental allergen challenge enhances chitinase 
activity and levels of CCL18 in mild atopic asthma. 
Clin Exp Allergy 43, 187-97 (2013). 
189. Blumenthal MN, Zhong W, Miller M et al., 
Serum metalloproteinase leukolysin (MMP-25/MT-
6): a potential metabolic marker for atopy-
associated inflammation. Clin Exp Allergy 40, 859-66 
(2010). 
190. Peterson S, Poposki JA, Nagarkar DR et al., 
Increased expression of CC chemokine ligand 18 in 
patients with chronic rhinosinusitis with nasal 
polyps. J Allergy Clin Immunol 129, 119-27 e1-9 
(2012). 
191. Perez DA, Vago JP, Athayde RM et al., 
Switching off key signaling survival molecules to 
switch on the resolution of inflammation. Mediators 
Inflamm 2014, 829851 (2014). 
320  |  CHAPTER 14 
192. Buckley CD, Gilroy DW, Serhan CN, Stockinger 
B, Tak PP, The resolution of inflammation. Nat Rev 
Immunol 13, 59-66 (2013). 
193. Serhan CN, Dalli J, Karamnov S et al., 
Macrophage proresolving mediator maresin 1 
stimulates tissue regeneration and controls pain. 
FASEB J 26, 1755-65 (2012). 
194. Lebbink RJ, de Ruiter T, Verbrugge A, Bril WS, 
Meyaard L, The mouse homologue of the leukocyte-
associated Ig-like receptor-1 is an inhibitory receptor 
that recruits Src homology region 2-containing 
protein tyrosine phosphatase (SHP)-2, but not SHP-1. 
J Immunol 172, 5535-43 (2004). 
195. Steevels TA, Lebbink RJ, Westerlaken GH, 
Coffer PJ, Meyaard L, Signal inhibitory receptor on 
leukocytes-1 is a novel functional inhibitory immune 
receptor expressed on human phagocytes. J 
Immunol 184, 4741-8 (2010). 
196. Masuda A, Nakamura A, Maeda T, Sakamoto 
Y, Takai T, Cis binding between inhibitory receptors 
and MHC class I can regulate mast cell activation. J 
Exp Med 204, 907-20 (2007). 
197. Hitomi K, Tahara-Hanaoka S, Someya S et al., 
An immunoglobulin-like receptor, Allergin-1, inhibits 
immunoglobulin E-mediated immediate 
hypersensitivity reactions. Nat Immunol 11, 601-7 
(2010). 
198. Nakahashi-Oda C, Tahara-Hanaoka S, Shoji M 
et al., Apoptotic cells suppress mast cell 
inflammatory responses via the CD300a 
immunoreceptor. J Exp Med 209, 1493-503 (2012). 
199. Yachie A, Niida Y, Wada T et al., Oxidative 
stress causes enhanced endothelial cell injury in 
human heme oxygenase-1 deficiency. J Clin Invest 
103, 129-35 (1999). 
200. Tzima S, Victoratos P, Kranidioti K, Alexiou M, 
Kollias G, Myeloid heme oxygenase-1 regulates 
innate immunity and autoimmunity by modulating 
IFN-beta production. J Exp Med 206, 1167-79 (2009). 
201. Lee TS, Chau LY, Heme oxygenase-1 mediates 
the anti-inflammatory effect of interleukin-10 in 
mice. Nat Med 8, 240-6 (2002). 
202. Takamiya R, Murakami M, Kajimura M et al., 
Stabilization of mast cells by heme oxygenase-1: an 
anti-inflammatory role. Am J Physiol Heart Circ 
Physiol 283, H861-70 (2002). 
203. Ma YY, Yang MQ, Wang CF, Ding J, Li JY, 
Inhibiting mast cell degranulation by HO-1 affects 
dendritic cell maturation in vitro. Inflamm Res 63, 
527-37 (2014). 
204. Takayasu A, Miyabe Y, Yokoyama W et al., 
CCL18 activates fibroblast-like synoviocytes in 
patients with rheumatoid arthritis. J Rheumatol 40, 
1026-8 (2013). 
205. Iwamoto T, Okamoto H, Toyama Y, Momohara 
S, Molecular aspects of rheumatoid arthritis: 
chemokines in the joints of patients. FEBS J 275, 
4448-55 (2008). 
206. van Lieshout AW, Fransen J, Flendrie M et al., 
Circulating levels of the chemokine CCL18 but not 
CXCL16 are elevated and correlate with disease 
activity in rheumatoid arthritis. Ann Rheum Dis 66, 
1334-8 (2007). 
207. Momohara S, Okamoto H, Iwamoto T et al., 
High CCL18/PARC expression in articular cartilage 
and synovial tissue of patients with rheumatoid 
arthritis. J Rheumatol 34, 266-71 (2007). 
208. Zhang F, Luo W, Li Y, Gao S, Lei G, Role of 
osteopontin in rheumatoid arthritis. Rheumatol Int 
35, 589-95 (2015). 
209. Gazal S, Sacre K, Allanore Y et al., 
Identification of secreted phosphoprotein 1 gene as 
a new rheumatoid arthritis susceptibility gene. Ann 
Rheum Dis 74, e19 (2015). 
210. Son M, Santiago-Schwarz F, Al-Abed Y, 
Diamond B, C1q limits dendritic cell differentiation 
and activation by engaging LAIR-1. Proc Natl Acad Sci 
U S A 109, E3160-7 (2012). 
211. Son M, Diamond B, C1q-Mediated Repression 
of Human Monocytes Is Regulated by Leukocyte-
Associated Ig-Like Receptor 1 (LAIR-1). Mol Med 20, 
559-68 (2015). 
212. Florian S, Sonneck K, Czerny M et al., 
Detection of novel leukocyte differentiation antigens 
 
 
SUMMARY & DISCUSSION  |  321 
 14 
on basophils and mast cells by HLDA8 antibodies. 
Allergy 61, 1054-62 (2006). 
213. Henningsson F, Wolters P, Chapman HA, 
Caughey GH, Pejler G, Mast cell cathepsins C and S 
control levels of carboxypeptidase A and the 
chymase, mouse mast cell protease 5. Biol Chem 
384, 1527-31 (2003). 
214. Maxwell L, Singh JA, Abatacept for rheumatoid 
arthritis. Cochrane Database Syst Rev, CD007277 
(2009). 
215. Emery P, Burmester GR, Bykerk VP et al., 
Evaluating drug-free remission with abatacept in 
early rheumatoid arthritis: results from the phase 
3b, multicentre, randomised, active-controlled 
AVERT study of 24 months, with a 12-month, 
double-blind treatment period. Ann Rheum Dis 74, 
19-26 (2015). 
216. Gottenberg JE, Ravaud P, Cantagrel A et al., 
Positivity for anti-cyclic citrullinated peptide is 
associated with a better response to abatacept: data 
from the 'Orencia and Rheumatoid Arthritis' registry. 
Ann Rheum Dis 71, 1815-9 (2012). 
217. Pieper J, Herrath J, Raghavan S et al., CTLA4-Ig 
(abatacept) therapy modulates T cell effector 
functions in autoantibody-positive rheumatoid 
arthritis patients. BMC Immunol 14, 34 (2013). 
218. Riella LV, Sayegh MH, T-cell co-stimulatory 
blockade in transplantation: two steps forward one 
step back! Expert Opin Biol Ther 13, 1557-68 (2013). 
219. Bouguermouh S, Fortin G, Baba N, Rubio M, 
Sarfati M, CD28 co-stimulation down regulates Th17 







324  |  CHAPTER 15 
NEDERLANDSE SAMENVATTING 
Mestcellen zijn onderdeel van het afweersysteem, en zijn het meest bekend vanwege 
de rol die ze spelen in allergie. Tijdens een acute allergische reactie kunnen mestcellen 
degranuleren, het proces waarbij ze hun granules, vol met stoffen die een 
afweerreactie kunnen induceren, binnen enkele seconden kunnen uitscheiden. Het is 
deze functie van mestcellen dat maakt dat ze een beruchte reputatie hebben. Echter, 
er is nog weinig bekend over de functie van mestcellen buiten de degranulatie om. In 
de laatste jaren is het steeds meer duidelijk geworden dat mestcellen ook een rol 
spelen in andere afweerreacties, zoals tijdens chronische allergie en auto-
immuunziekten. In dit proefschrift hebben we de functie van mestcellen tijdens deze 
reacties onderzocht. 
ACTIVATIE VAN MESTCELLEN VIA HET AANGEBOREN EN AANGELEERDE AFWEERSYSTEEM 
Toll like receptoren (TLR) zijn moleculen die aanwezig zijn in immuuncellen en werken 
als een sensor voor de aanwezigheid van pathogenen zoals bacteriën en virussen. Als 
een TLR wordt geactiveerd kan dit een afweerreactie opwekken. In het eerste deel van 
dit proefschrift hebben we de functie onderzocht van TLR in mestcellen en een ander 
celtype dat betrokken is bij allergie, de basofiel. In Hoofdstuk 2, 4, en 5 laten we zien 
dat zowel mestcellen als basofielen TLR tot expressie brengen, en dat stimulatie van 
deze receptoren tot activatie van mestcellen en basofielen leidt.  
Activatie van TLR door pathogenen is een aangeboren eigenschap van het 
afweersysteem. Wanneer iemand echter herhaaldelijk geïnfecteerd raakt met 
hetzelfde pathogeen leidt dit normaal gesproken tot een snellere en betere 
afweerreactie, doordat het aangeleerde afweersysteem een specifieke reactie voor dat 
pathogeen heeft opgebouwd. Deze bescherming bestaat onder andere uit de productie 
van antilichamen. Antilichamen kunnen via stimulatie van Fc receptoren ervoor zorgen 
dat cellen van het afweersysteem het pathogeen direct kunnen herkennen en daardoor 
een snelle afweerreactie kunnen initieren om het pathogeen uit te schakelen. 
Mestcellen brengen verschillende Fc receptoren tot expressie, zoals FcRI, de receptor 
voor IgE antilichamen, en FcRIIA, een receptor voor IgG antilichamen. In Hoofdstuk 2, 
4, en 5 vroegen wij ons daarom af of de afweerreactie van mestcellen en basofielen 
verandert als TLR en Fc receptoren tegelijkertijd geactiveerd worden. We hebben laten 
zien dat de activatie van mestcellen en basofielen sterk verhoogd is onder deze 
omstandigheden. De mestcellen en basofielen produceerden veel grotere 
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hoeveelheden cytokines en chemokines. Deze signaalstoffen staan bekend om hun 
functie om andere immuuncellen te recruteren en activeren en zo een afweerreactie in 
gang te zetten. Deze synergie in productie van cytokines kan hierdoor bijdragen aan 
een betere bescherming tegen pathogenen.  
Er is echter ook een andere kant aan dit mechanisme. Zowel TLR als antilichamen 
spelen namelijk ook een rol bij allergie en auto-immuunziekten. Allergie wordt meestal 
veroorzaakt door IgE antilichamen die een allergeen herkennen. Allergenen zijn 
eiwitten die overgevoeligheid kunnen veroorzaken. Als een allergisch persoon wordt 
blootgesteld aan het allergeen leidt dit tot degranulatie van mestcellen en basofielen 
en wordt zo een allergische reactie in gang gezet. Infectie kan een allergische reactie 
verergeren, maar het mechanisme waardoor dit gebeurt is niet bekend. In Hoofdstuk 2 
en 4 laten we zien dat de activatie van mestcellen en basofielen door TLR en allergeen 
leidt tot een versterkte activatie en daardoor kan bijdragen aan verhoogde allergische 
reacties tijdens infecties. 
Naast het verhogen van allergische reacties, spelen TLR en antilichamen ook een rol bij 
auto-immuunziekten zoals reumatoïde artritis (RA). In RA patiënten worden vaak 
antilichamen gevonden die lichaamseigen eiwitten kunnen herkennen. De antilichamen 
die gecitrullineerde eiwitten (ACPA) herkennen hebben een sterke associatie met de 
ontwikkeling van RA. Daarnaast leidt de chronische ontstekingsreactie bij auto-
immuunziekten tot uitscheiding van endogene moleculen die TLR kunnen activeren. 
Over de activatie van mestcellen tijdens auto-immuunziekten is nog niet veel bekend. 
Daarom hebben we in Hoofdstuk 5 eerst bestudeerd of mestcellen ook geactiveerd 
kunnen raken door auto-antilichamen. We hebben laten zien dat mestcellen in het 
onstoken gewricht FcRIIA tot expressie brengen, en dat mestcellen geactiveerd 
kunnen worden door ACPA als ze gecitrullineerd antigeen herkennen. In de 
aanwezigheid van endogene TLR liganden wordt de activatie van mestcellen door ACPA 
versterkt en wij veronderstellen daarom dat het effect van zowel auto-antilichamen 
alsmede TLR op de mestcellen kan bijdragen aan chronische ontsteking bij auto-
immuunziekten. 
Dat de interactie tussen het aangeboren en aangeleerde afweersysteem ook een 
regulerend effect op het afweersysteem kan hebben laten we zien in Hoofdstuk 3 en 6. 
Hier bestudeerden we het effect van het cytokine IL-33 op mestcel- en basofiel-
activatie. IL-33 is een cytokine dat gerelateerd is met activatie en inhibitie van het 
afweersysteem, en in verhoogde hoeveelheden voorkomt bij zowel allergie als RA. We 
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hebben het effect bestudeerd van activatie van mestcellen en basofielen door IL -33 in 
combinatie met het activeren van FcRI en FcRIIA. Dit leidt bij beide celtypes to 
activatie en productie van cytokines en andere moleculen. Echter, deze uitgescheiden 
cytokines zorgden voor inhibitie van de activatie van monocyten, en ander type 
immuuncel. Dit laat zien dat de activatie van het afweersysteem complex is en dat de 
interactie tussen het aangeboren en aangeleerde afweersysteem tot zowel activatie als 
inhibitie kan leiden. 
We kunnen op basis van deze studies concluderen dat de activatie van mestcellen en 
basofielen via receptoren van het aangeboren afweersysteem versterkt wordt door 
receptoren van het aangeleerde afweersysteem. De mestcellen en basofielen kunnen 
zo bijdragen aan ontstekingsreacties bij allergie en autoafweerziekten, waarbij de 
specifieke afweerreactie die wordt geinitieerd vooral bepaald wordt door de 
receptoren van het aangeboren afweersysteem. 
MESTCELLEN SPELEN EEN ROL IN ACTIVATIE VAN T CELLEN EN EXPANSIE VAN TH17 CELLEN 
T cellen zijn cellen van het aangeleerde afweersysteem. Deze cellen kunnen peptiden 
herkennen van lichaamsvreemde eiwitten door middel van hun T cel receptor. CD4
+
 T 
cellen herkennen alleen peptiden als ze gepresenteerd worden door HLA klasse II 
moleculen, die tot expressie komen op zogenaamde antigeen presenterende cellen. 
Wanneer CD4
+
 T cellen geactiveerd worden gaan ze cytokines produceren en vindt 
celdeling plaats. De cytokines die CD4
+
 T cellen produceren kunnen andere cellen van 
het afweersysteem reguleren en zo bepalen welke  specifieke afweerreactie 
plaatsvindt. De herkenning van peptide door HLA klasse II noemen we ook wel signaal 
1. Daarnaast hebben T cellen nog andere signalen nodig; co-stimulatie noemen we 
signaal 2. Hierbij is er een interactie tussen receptoren op de T cel met costimulatoire 
moleculen op de antigeen presenterende cel. Deze interactie verhoogd de 
signaaltransductie van de T cel receptor, en is benodigd voor volledige T cel activatie. 
Signaal 3 vindt plaats door middel van specifieke cytokines die worden geproduceerd 
door antigeen presenterende cellen. Deze cytokines kunnen vervolgens de specifieke 
cytokine respons van de T cellen reguleren, dit wordt het “skewen” of “sturen” van T 
cellen genoemd.  
Over de interactie tussen mestcellen en T cellen is, met name in de mens, nog niet veel 
bekend. In Hoofdstuk 7 en 8 hebben we eerst onderzocht of mestcellen ook kunnen 
functioneren als antigeen presenterende cellen. We hebben in Hoofdstuk 7 laten zien 
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dat mestcellen HLA klasse II tot expressie brengen en peptide en eiwit kunnen 
presenteren aan CD4
+
 T cellen (signaal 1). In Hoofdstuk 8 hebben we onderzocht of de 
mestcellen ook co-stimulatie kunnen geven aan CD4
+
 T cellen. Met deze studie hebben 
we laten zien dat mestcellen een sterk co-stimulatie signaal aan de T cellen kunnen 
geven, en dat deze co-stimulatie niet door de klassieke costimulatie via CD28 wordt 
gemedieerd.   
In Hoofdstuk 9 hebben we onderzocht of mestcellen ook een effect hebben op het 
skewen of sturen van T cellen. Activatie van mestcellen leidt tot specifieke expansie 
van Th17 cellen, T cellen die het cytokine IL-17 produceren. We hebben laten zien dat 
het cytokine IL-1beta geproduceerd door mestcellen voornamelijk verantwoordelijk 
was voor dit effect.  
Deze studies laten zien dat mestcellen een rol kunnen spelen in het initiëren van 
aangeleerde afweerreacties, door activatie van T cellen en expansie van Th17 cellen.  
Th17 cellen spelen een rol bij de bescherming tegen extracellulaire pathogenen zoals 
bacteriën en schimmels, and onze resultaten suggereren daarom dat mestcel activatie 
kan bijdragen tot betere bescherming tegen zulke pathogenen. De Th17 cellen worden 
echter ook geassocieerd met auto-immuunziekten en sommige allergiën, en zo kan T 
cel activatie door mestcellen ook schadelijke effecten hebben. 
DE ROL VAN MESTCELLEN TIJDENS CHRONISCHE ONTSTEKING 
Chronische ontsteking speelt een belangrijke rol bij verschillende chronische ziektes, 
zoals chronisch allergiën en auto-immuunziekten. In Hoofdstuk  11 en 12 beschrijven 
we hoe de samenwerking tussen TLR en antilichamen kunnen bijdragen aan de 
chroniciteit van auto-immuunziekten zoals RA en Systemische lupus erythematosus 
(SLE). De antilichamen die een rol spelen in auto-immuunziekten kunnen namelijk vaak 
antigenen herkennen die tegelijkertijd TLR kunnen activeren. Zoals we in deel 1 van dit 
proefschrift hebben laten zien kan dit ertoe leiden dat mestcellen, alsmede andere 
immuuncellen, sterk geactiveerd worden door de combinatie van TLR liganden en 
antilichamen tijdens auto-immuunziekten. 
Hoewel er steeds meer duidelijk wordt over de verschillende receptoren die een rol 
spelen bij chronisch ontsteking, is er nog weinig bekend over de veranderingen die 
immuuncellen ondergaan in de context van een chronische activatie van het 
afweersysteem. In Hoofdstuk 10 hebben we daarom onderzocht hoe de functie van 
mestcellen verandert als er een herhaaldelijke activatie plaatsvindt via FcεRI. Onze 
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hypothese was dat herhaaldelijke activatie via FcεRI zou kunnen leiden tot intrinsieke 
veranderingen in de mestcel die reflecteren wat er gebeurt tijdens chronisch 
ontsteking. De resultaten van deze studie lieten zien dat er verscheidene 
veranderingen in het phenotype en de functie van mestcellen plaatsvonden, en dat 
deze veranderingen waren gerelateerd aan veranderingen in weefsel van patiënten 
met chronische allergie. Dit bevestigt onze hypothese en suggereert dat herhaaldelijke 
activatie van het afweersysteem via Fc receptoren kan bijdragen aan veranderingen in 
weefsel tijdens chronische ontsteking. 
CONCLUSIES EN KLINISCHE IMPLICATIES 
In  Hoofdstuk 13 beschrijven we hoe we kunnen komen tot een nieuwe therapeutische 
aanpak van auto-immuunziekten. Het doel van nieuwe therapeutische strategiën zou 
moeten liggen in het aanpakken van de chronische activatie van het afweersysteem 
zonder daarbij het totale afweersysteem te onderdrukken en daarbij het risico op 
infecties te verhogen. Auto-immuunziekten zijn getypeerd door een samenspel van 
vele verschillende immuuncellen en vereisen daarom een aanpak van verschillende 
onderdelen van het afweersysteem. Hoewel de studies in dit proefschrift met name 
verricht zijn met mestcellen en basofielen, zijn meerdere van deze processen ook 
gevonden in andere cellen van het myeloide afweersysteem en zijn de mechanismes 
dus breder toepasbaar.  
We hebben de volgende strategiën geidentificeerd die kunnen bijdragen aan de 
ontwikkeling van nieuwe behandelingen voor auto-immuunziekten: 1) modulatie van 
antigeen presentatie aan cellen van het aangeleerde afweersysteem; 2) veranderen 
van de B cel selectie in de germinal centers; en 3) het gebruik van decoy antigeen om 
te de formatie van pro-inflammatoire immuuncomplexen te voorkomen. De resultaten 
van dit proefschrift suggereren dat met name de eerste en derde strategie de bijdrage 
van mestcellen aan chronische ontsteking kunnen verminderen. 
Samenvattend, in dit proefschrift hebben we laten zien dat mestcellen een significante 
bijdrage kunnen leveren aan chronische ontsteking door middel van activatie via Fc 
receptoren en TLR, alsmede door hun interactie met CD4
+
 T cellen. Deze studies 
dragen daarom bij aan ons begrip van de rol van mestcellen in allergie en auto-
immuunziekten en kunnen bijdragen aan de ontwikkeling van nieuwe 
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